Subjects With Specific Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Musculoskeletal and connective tissue disorders	**155**	**(14.3)**
Muscle spasms	7	(0.6)
Muscle tightness	2	(0.2)
Musculoskeletal chest pain	1	(0.1)
Musculoskeletal pain	9	(0.8)
Musculoskeletal stiffness	6	(0.6)
Myalgia	7	(0.6)
Neck pain	4	(0.4)
Nodal osteoarthritis	1	(0.1)
Osteoarthritis	8	(0.7)
Osteoporosis	3	(0.3)
Pain in extremity	10	(0.9)
Periarthritis	11	(1.0)
Periostitis	1	(0.1)
Plantar fasciitis	1	(0.1)
Spinal osteoarthritis	6	(0.6)
Spondylolisthesis	1	(0.1)
Spondylolysis	1	(0.1)
Synovial cyst	2	(0.2)
Temporomandibular joint syndrome	1	(0.1)
Tendonitis	1	(0.1)
Tenosynovitis	4	(0.4)
Trigger finger	5	(0.5)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**17**	**(1.6)**

Confidential

Subjects With Specific Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**17**	**(1.6)**
Breast cancer	1	(0.1)
Colon adenoma	1	(0.1)
Colon cancer	2	(0.2)
Gastric cancer	1	(0.1)
Haemangioma of liver	2	(0.2)
Hypopharyngeal cancer	1	(0.1)
Liposarcoma	1	(0.1)
Lung neoplasm malignant	1	(0.1)
Neoplasm skin	1	(0.1)
Oral neoplasm benign	1	(0.1)
Prostate cancer	1	(0.1)
Pyogenic granuloma	1	(0.1)
Thyroid adenoma	1	(0.1)
Tongue neoplasm malignant stage unspecified	1	(0.1)
Transitional cell carcinoma	1	(0.1)
Uterine leiomyoma	1	(0.1)
Nervous system disorders	**50**	**(4.6)**
Carotid artery stenosis	1	(0.1)
Carpal tunnel syndrome	1	(0.1)
Cerebral infarction	1	(0.1)
Cervicobrachial syndrome	1	(0.1)
Diabetic neuropathy	3	(0.3)
Dizziness	5	(0.5)

C Confidential

Subjects With Specific Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Nervous system disorders	**50**	**(4.6)**
Dizziness postural	1	(0.1)
Headache	22	(2.0)
Hemiparesis	1	(0.1)
Hypoaesthesia	5	(0.5)
IVth nerve paralysis	1	(0.1)
Intercostal neuralgia	1	(0.1)
Neuralgia	1	(0.1)
Paraesthesia	1	(0.1)
Post herpetic neuralgia	1	(0.1)
Presyncope	1	(0.1)
Sciatica	3	(0.3)
Subarachnoid haemorrhage	1	(0.1)
Syncope	1	(0.1)
VIIth nerve paralysis	1	(0.1)
Psychiatric disorders	**9**	**(0.8)**
Insomnia	8	(0.7)
Listless	1	(0.1)
Renal and urinary disorders	**16**	**(1.5)**
Calculus urinary	1	(0.1)
Haematuria	1	(0.1)
Hypertonic bladder	1	(0.1)
Micturition disorder	1	(0.1)

Confidential

Subjects With Specific Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Renal and urinary disorders	**16**	**(1.5)**
Nephrolithiasis	4	(0.4)
Nocturia	2	(0.2)
Pollakiuria	2	(0.2)
Renal cyst	4	(0.4)
Renal impairment	1	(0.1)
Reproductive system and breast disorders	**11**	**(1.0)**
Adenomyosis	1	(0.1)
Atrophic vulvovaginitis	1	(0.1)
Benign prostatic hyperplasia	2	(0.2)
Dysmenorrhoea	1	(0.1)
Gynaecomastia	1	(0.1)
Menstruation irregular	1	(0.1)
Nipple swelling	1	(0.1)
Ovarian cyst	1	(0.1)
Prostatitis	1	(0.1)
Pruritus genital	1	(0.1)
Respiratory, thoracic and mediastinal disorders	**64**	**(5.9)**
Asthma	4	(0.4)
Chronic obstructive pulmonary disease	1	(0.1)
Cough	10	(0.9)
Dyspnoea exertional	1	(0.1)
Emphysema	1	(0.1)

Confidential

Subjects With Specific Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Respiratory, thoracic and mediastinal disorders	**64**	**(5.9)**
Epistaxis	3	(0.3)
Hyperventilation	1	(0.1)
Nasal septum deviation	1	(0.1)
Oropharyngeal pain	2	(0.2)
Respiratory tract inflammation	2	(0.2)
Rhinitis allergic	6	(0.6)
Rhinitis hypertrophic	1	(0.1)
Rhinorrhoea	1	(0.1)
Sleep apnoea syndrome	1	(0.1)
Upper respiratory tract inflammation	33	(3.0)
Skin and subcutaneous tissue disorders	**101**	**(9.3)**
Acne	1	(0.1)
Alopecia areata	1	(0.1)
Asteatosis	1	(0.1)
Dermal cyst	3	(0.3)
Dermatitis	7	(0.6)
Dermatitis allergic	5	(0.5)
Dermatitis contact	12	(1.1)
Drug eruption	2	(0.2)
Dry skin	3	(0.3)
Dyshidrotic eczema	1	(0.1)
Eczema	26	(2.4)
Eczema asteatotic	2	(0.2)

C Confidential

Subjects With Specific Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Skin and subcutaneous tissue disorders	**101**	**(9.3)**
Erythema	1	(0.1)
Erythema multiforme	1	(0.1)
Haemorrhage subcutaneous	1	(0.1)
Hyperkeratosis	2	(0.2)
Melanosis	1	(0.1)
Miliaria	1	(0.1)
Nail bed bleeding	1	(0.1)
Nail discolouration	1	(0.1)
Pruritus	6	(0.6)
Pruritus generalised	2	(0.2)
Psoriasis	1	(0.1)
Purpura	1	(0.1)
Rash	8	(0.7)
Rash pruritic	1	(0.1)
Skin fissures	1	(0.1)
Skin ulcer	1	(0.1)
Urticaria	10	(0.9)
Xeroderma	2	(0.2)
Vascular disorders	**23**	**(2.1)**
Aortic aneurysm	1	(0.1)
Aortic thrombosis	1	(0.1)
Arteriosclerosis	3	(0.3)
Essential hypertension	1	(0.1)

Confidential

Subjects With Specific Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Vascular disorders	**23**	**(2.1)**
Hypertension	15	(1.4)
Hypotension	1	(0.1)
Peripheral arterial occlusive disease	1	(0.1)
Peripheral vascular disorder	1	(0.1)
Vascular calcification	1	(0.1)

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

For P006 base study (P006-00), MK-3102 25 mg for 12 weeks data was included and, for the extension study (P006-13), MK-3102 0.25 mg/MK-3102 25 mg, MK-3102 1 mg/MK-3102 25 mg, MK-3102 3 mg/MK-3102 25 mg, MK-3102 10 mg/MK-3102 25 mg and MK-3102 25 mg/MK-3102 25 mg for 66 weeks data were included.　For P015 double-blind period (Phase A), MK-3102 25 mg for 24 weeks data was included and for the extension period (Phase B), Placebo/ MK-3102 25 mg and MK-3102 25 mg/MK-3102 25 mg for 28 weeks data were included. For P020 double-blind period (Phase A), MK-3102 25 mg for 24 weeks data was included and for the extension period (Phase B), Placebo/ MK-3102 25 mg, Sitagliptin/MK-3102 25 mg and MK-3102 25 mg/MK-3102 25 mg for 28 weeks data were included.

In P020, rescue therapy was not allowed during study.

Confidential

付録 2.7.4: 13　　副作用の発現率
（いずれかの投与群で発現率>0%）
（長期投与時の日本人併合解析対象集団、P006-00、P006-13、P015、P020）
（レスキュー治療開始後のデータを除く）

Confidential

Subjects With Drug-Related Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Subjects in population	1,084	
with one or more drug related adverse events	73	(6.7)
with no drug related adverse events	1,011	(93.3)
Cardiac disorders	**4**	**(0.4)**
Atrial fibrillation	1	(0.1)
Bundle branch block right	1	(0.1)
Supraventricular extrasystoles	1	(0.1)
Tachycardia paroxysmal	1	(0.1)
Ventricular extrasystoles	1	(0.1)
Eye disorders	**1**	**(0.1)**
Cataract	1	(0.1)
Gastrointestinal disorders	**22**	**(2.0)**
Abdominal discomfort	2	(0.2)
Abdominal pain	1	(0.1)
Abdominal pain upper	1	(0.1)
Cheilitis	1	(0.1)
Constipation	8	(0.7)
Diarrhoea	5	(0.5)
Gastric polyps	1	(0.1)
Gastritis	1	(0.1)
Gastritis atrophic	1	(0.1)
Gastrooesophageal reflux disease	2	(0.2)

C Confidential

Subjects With Drug-Related Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Gastrointestinal disorders	**22**	**(2.0)**
Nausea	2	(0.2)
Vomiting	1	(0.1)
General disorders and administration site conditions	**2**	**(0.2)**
Chest pain	1	(0.1)
Malaise	1	(0.1)
Hepatobiliary disorders	**2**	**(0.2)**
Hepatic function abnormal	2	(0.2)
Infections and infestations	**2**	**(0.2)**
Influenza	1	(0.1)
Upper respiratory tract infection	1	(0.1)
Investigations	**16**	**(1.5)**
Alanine aminotransferase increased	5	(0.5)
Albumin urine present	2	(0.2)
Aspartate aminotransferase increased	2	(0.2)
Blood alkaline phosphatase increased	1	(0.1)
Blood cholesterol increased	1	(0.1)
Blood creatinine increased	1	(0.1)
Blood glucose increased	5	(0.5)
Blood triglycerides increased	1	(0.1)
Blood uric acid increased	2	(0.2)

C Confidential

Subjects With Drug-Related Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Investigations	**16**	**(1.5)**
Blood urine present	1	(0.1)
Glycosylated haemoglobin increased	3	(0.3)
Urine albumin/creatinine ratio increased	2	(0.2)
White blood cell count increased	1	(0.1)
Metabolism and nutrition disorders	**16**	**(1.5)**
Hypoglycaemia	16	(1.5)
Musculoskeletal and connective tissue disorders	**1**	**(0.1)**
Muscle spasms	1	(0.1)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**1**	**(0.1)**
Prostate cancer	1	(0.1)
Nervous system disorders	**2**	**(0.2)**
Headache	1	(0.1)
VIIth nerve paralysis	1	(0.1)
Renal and urinary disorders	**1**	**(0.1)**
Nocturia	1	(0.1)
Reproductive system and breast disorders	**2**	**(0.2)**
Menstruation irregular	1	(0.1)
Ovarian cyst	1	(0.1)

Confidential

Subjects With Drug-Related Adverse Events (Incidence > 0% in One or More Treatment Groups)
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Excluding Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Skin and subcutaneous tissue disorders	**12**	**(1.1)**
Dermatitis	1	(0.1)
Drug eruption	1	(0.1)
Eczema	5	(0.5)
Erythema multiforme	1	(0.1)
Pruritus generalised	1	(0.1)
Purpura	1	(0.1)
Rash	1	(0.1)
Rash pruritic	1	(0.1)

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

For P006 base study (P006-00), MK-3102 25 mg for 12 weeks data was included and, for the extension study (P006-13), MK-3102 0.25 mg/MK-3102 25 mg, MK-3102 1 mg/MK-3102 25 mg, MK-3102 3 mg/MK-3102 25 mg, MK-3102 10 mg/MK-3102 25 mg and MK-3102 25 mg/MK-3102 25 mg for 66 weeks data were included. For P015 double-blind period (Phase A), MK-3102 25 mg for 24 weeks data was included and for the extension period (Phase B), Placebo/ MK-3102 25 mg and MK-3102 25 mg/MK-3102 25 mg for 28 weeks data were included. For P020 double-blind period (Phase A), MK-3102 25 mg for 24 weeks data was included and for the extension period (Phase B), Placebo/ MK-3102 25 mg, Sitagliptin/MK-3102 25 mg and MK-3102 25 mg/MK-3102 25 mg for 28 weeks data were included.

In P020, rescue therapy was not allowed during study.

Confidential

付録 2.7.4: 14　　有害事象の要約
（長期投与時の日本人併合解析対象集団、P006-00、P006-13、P015、P020）
（レスキュー治療開始後のデータを含む）

Confidential

Adverse Event Summary
Pooled Japanese Subjects (P006, P015, P020) [Double-Blind and Extension Periods]
(Including Data after Glycemic Rescue)
(ASaT)

	MK-3102 25 mg	
	n	(%)
Subjects in population	1,084	
with one or more adverse events	735	(67.8)
with no adverse event	349	(32.2)
with drug-related† adverse events	75	(6.9)
with serious adverse events	37	(3.4)
with serious drug-related adverse events	1	(0.1)
who died	1	(0.1)
discontinued‡ due to an adverse event	26	(2.4)
discontinued due to a drug-related adverse event	7	(0.6)
discontinued due to a serious adverse event	12	(1.1)
discontinued due to a serious drug-related adverse event	0	(0.0)

† Determined by the investigator to be related to the drug.

‡ Study medication withdrawn.

Confidential

付録 2.7.4: 15　　臨床検査値の PDLC に該当した被験者の割合
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P006-00）

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Hemoglobin (g/dL)			
Last value with a decrease >= 1.5 gm/dL ‡			
Placebo	111	3 (2.7)	
MK-3102 0.25 mg	111	2 (1.8)	-0.9
MK-3102 1 mg	114	1 (0.9)	-1.8
MK-3102 3 mg	113	2 (1.8)	-0.9
MK-3102 10 mg	114	3 (2.6)	-0.1
MK-3102 25 mg	112	3 (2.7)	-0.0
WBC Count (10^3/microL)			
One value with a decrease >= 50% and value < LLN			
Placebo	111	0 (0.0)	
MK-3102 0.25 mg	111	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	113	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	112	0 (0.0)	0.0
Last value with a decrease >= 50% and value < LLN			
Placebo	111	0 (0.0)	
MK-3102 0.25 mg	111	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	113	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	112	0 (0.0)	0.0
One value with an increase >= 20% and value > ULN			
Placebo	111	1 (0.9)	
MK-3102 0.25 mg	111	4 (3.6)	2.7 (-1.7, 8.1)
MK-3102 1 mg	114	3 (2.6)	1.7 (-2.6, 6.7)
MK-3102 3 mg	113	1 (0.9)	-0.0 (-4.1, 4.0)
MK-3102 10 mg	114	2 (1.8)	0.9 (-3.3, 5.4)
MK-3102 25 mg	112	5 (4.5)	3.6 (-0.9, 9.3)
Last value with an increase >= 20% and value > ULN			
Placebo	111	0 (0.0)	

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
MK-3102 0.25 mg	111	1 (0.9)	0.9 (-2.5, 4.9)
MK-3102 1 mg	114	2 (1.8)	1.8 (-1.6, 6.2)
MK-3102 3 mg	113	1 (0.9)	0.9 (-2.5, 4.9)
MK-3102 10 mg	114	2 (1.8)	1.8 (-1.6, 6.2)
MK-3102 25 mg	112	4 (3.6)	3.6 (0.2, 8.8)
Neutrophil Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
Placebo	111	4 (3.6)	
MK-3102 0.25 mg	111	1 (0.9)	-2.7 (-8.1, 1.7)
MK-3102 1 mg	114	1 (0.9)	-2.7 (-8.1, 1.6)
MK-3102 3 mg	113	0 (0.0)	-3.6 (-8.9, -0.2)
MK-3102 10 mg	114	0 (0.0)	-3.6 (-8.9, -0.3)
MK-3102 25 mg	112	2 (1.8)	-1.8 (-7.4, 3.1)
Last value with a decrease >= 20% and value < LLN			
Placebo	111	1 (0.9)	
MK-3102 0.25 mg	111	0 (0.0)	-0.9
MK-3102 1 mg	114	1 (0.9)	-0.0
MK-3102 3 mg	113	0 (0.0)	-0.9
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	112	2 (1.8)	0.9
One value with an increase >= 20% and value > ULN			
Placebo	111	1 (0.9)	
MK-3102 0.25 mg	111	4 (3.6)	2.7 (-1.7, 8.1)
MK-3102 1 mg	114	2 (1.8)	0.9 (-3.3, 5.4)
MK-3102 3 mg	113	1 (0.9)	-0.0 (-4.1, 4.0)
MK-3102 10 mg	114	2 (1.8)	0.9 (-3.3, 5.4)
MK-3102 25 mg	112	4 (3.6)	2.7 (-1.7, 8.1)
Last value with an increase >= 20% and value > ULN			
Placebo	111	1 (0.9)	
MK-3102 0.25 mg	111	0 (0.0)	-0.9
MK-3102 1 mg	114	1 (0.9)	-0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters Excluding Data After Glycemic Rescue (APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 3 mg	113	1 (0.9)	-0.0
MK-3102 10 mg	114	2 (1.8)	0.9
MK-3102 25 mg	112	3 (2.7)	1.8
Lymphocyte Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
Placebo	111	1 (0.9)	
MK-3102 0.25 mg	111	1 (0.9)	0.0
MK-3102 1 mg	114	0 (0.0)	-0.9
MK-3102 3 mg	113	1 (0.9)	-0.0
MK-3102 10 mg	114	1 (0.9)	-0.0
MK-3102 25 mg	112	1 (0.9)	-0.0
Last value with a decrease >= 20% and value < LLN			
Placebo	111	1 (0.9)	
MK-3102 0.25 mg	111	0 (0.0)	-0.9
MK-3102 1 mg	114	0 (0.0)	-0.9
MK-3102 3 mg	113	1 (0.9)	-0.0
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	112	1 (0.9)	-0.0
One value with an increase >= 20% and value > ULN			
Placebo	111	2 (1.8)	
MK-3102 0.25 mg	111	4 (3.6)	1.8 (-3.2, 7.3)
MK-3102 1 mg	114	0 (0.0)	-1.8 (-6.3, 1.5)
MK-3102 3 mg	113	3 (2.7)	0.9 (-4.0, 6.0)
MK-3102 10 mg	114	4 (3.5)	1.7 (-3.3, 7.1)
MK-3102 25 mg	112	2 (1.8)	-0.0 (-4.8, 4.7)
Last value with an increase >= 20% and value > ULN			
Placebo	111	2 (1.8)	
MK-3102 0.25 mg	111	1 (0.9)	-0.9
MK-3102 1 mg	114	0 (0.0)	-1.8
MK-3102 3 mg	113	3 (2.7)	0.9
MK-3102 10 mg	114	2 (1.8)	-0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
MK-3102 25 mg	112	2 (1.8)	-0.0
Platelet Count (10^3/microL)			
One value with a decrease >= 25% and value < LLN			
Placebo	110	0 (0.0)	
MK-3102 0.25 mg	111	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	111	0 (0.0)	0.0
MK-3102 10 mg	112	0 (0.0)	0.0
MK-3102 25 mg	110	0 (0.0)	0.0
Last value with a decrease >= 25% and value < LLN			
Placebo	110	0 (0.0)	
MK-3102 0.25 mg	111	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	111	0 (0.0)	0.0
MK-3102 10 mg	112	0 (0.0)	0.0
MK-3102 25 mg	110	0 (0.0)	0.0
One value with an increase >= 100% and value > ULN			
Placebo	110	0 (0.0)	
MK-3102 0.25 mg	111	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	111	0 (0.0)	0.0
MK-3102 10 mg	112	0 (0.0)	0.0
MK-3102 25 mg	110	0 (0.0)	0.0
Last value with an increase >= 100% and value > ULN			
Placebo	110	0 (0.0)	
MK-3102 0.25 mg	111	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	111	0 (0.0)	0.0
MK-3102 10 mg	112	0 (0.0)	0.0
MK-3102 25 mg	110	0 (0.0)	0.0
BUN (mg/dL)			
Last value with an increase >= 50% and value > ULN			

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
Placebo	113	2 (1.8)	
MK-3102 0.25 mg	113	1 (0.9)	-0.9
MK-3102 1 mg	114	1 (0.9)	-0.9
MK-3102 3 mg	114	1 (0.9)	-0.9
MK-3102 10 mg	114	3 (2.6)	0.9
MK-3102 25 mg	114	1 (0.9)	-0.9
Serum Creatine Kinase (IU/L)			
One value > 5xULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	1 (0.9)	0.9
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	1 (0.9)	0.9
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	2 (1.8)	1.8
Last value > 5xULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 10xULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	1 (0.9)	0.9
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	1 (0.9)	0.9
Last value > 10xULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Serum Creatinine (mg/dL)			
Last value with an increase >= 0.3 mg/dL			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	2 (1.8)	0.9
MK-3102 1 mg	114	1 (0.9)	-0.0
MK-3102 3 mg	114	3 (2.6)	1.7
MK-3102 10 mg	114	2 (1.8)	0.9
MK-3102 25 mg	114	0 (0.0)	-0.9
Total Bilirubin (mg/dL)			
One value > 2xULN			
Placebo	113	2 (1.8)	
MK-3102 0.25 mg	113	0 (0.0)	-1.8
MK-3102 1 mg	114	0 (0.0)	-1.8
MK-3102 3 mg	114	0 (0.0)	-1.8
MK-3102 10 mg	114	0 (0.0)	-1.8
MK-3102 25 mg	114	0 (0.0)	-1.8
Last value > 2xULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	0 (0.0)	-0.9
MK-3102 1 mg	114	0 (0.0)	-0.9
MK-3102 3 mg	114	0 (0.0)	-0.9
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	114	0 (0.0)	-0.9
AST (IU/L)			
One value > 3×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	1 (0.9)	0.9

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 3×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 5×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 5×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 10×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value > 10×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 20×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 20×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
ALT (IU/L)			
One value > 3×ULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	1 (0.9)	0.0
MK-3102 1 mg	114	1 (0.9)	-0.0
MK-3102 3 mg	114	1 (0.9)	-0.0
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	114	0 (0.0)	-0.9
Last value > 3×ULN			
Placebo	113	0 (0.0)	

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 5×ULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	0 (0.0)	-0.9
MK-3102 1 mg	114	0 (0.0)	-0.9
MK-3102 3 mg	114	0 (0.0)	-0.9
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	114	0 (0.0)	-0.9
Last value > 5×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 10×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 10×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 20×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 20×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
AST (IU/L) or ALT (IU/L)			
One value > 3×ULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	1 (0.9)	0.0
MK-3102 1 mg	114	1 (0.9)	-0.0
MK-3102 3 mg	114	2 (1.8)	0.9
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	114	0 (0.0)	-0.9
One value > 5×ULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	0 (0.0)	-0.9
MK-3102 1 mg	114	0 (0.0)	-0.9
MK-3102 3 mg	114	0 (0.0)	-0.9
MK-3102 10 mg	114	0 (0.0)	-0.9

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters Excluding Data After Glycemic Rescue (APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	114	0 (0.0)	-0.9
One value > 10×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
One value > 20×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 3×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 5×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 10×ULN			

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value > 20×ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST > 3*ULN or ALT > 3*ULN) with Bilirubin > 2*ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value meeting (AST > 3*ULN or ALT > 3*ULN) with Bilirubin > 2*ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
Placebo	113	2 (1.8)	
MK-3102 0.25 mg	113	2 (1.8)	0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 1 mg	114	1 (0.9)	-0.9
MK-3102 3 mg	114	1 (0.9)	-0.9
MK-3102 10 mg	114	0 (0.0)	-1.8
MK-3102 25 mg	114	1 (0.9)	-0.9
Last value > 1.5×ULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	1 (0.9)	0.0
MK-3102 1 mg	114	1 (0.9)	-0.0
MK-3102 3 mg	114	1 (0.9)	-0.0
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	114	0 (0.0)	-0.9
Serum Uric Acid (mg/dL)			
One value with an increase >= 50% and value > ULN			
Placebo	113	3 (2.7)	
MK-3102 0.25 mg	113	1 (0.9)	-1.8
MK-3102 1 mg	114	0 (0.0)	-2.7
MK-3102 3 mg	114	2 (1.8)	-0.9
MK-3102 10 mg	114	1 (0.9)	-1.8
MK-3102 25 mg	114	1 (0.9)	-1.8
Last value with an increase >= 50% and value > ULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	1 (0.9)	0.0
MK-3102 1 mg	114	0 (0.0)	-0.9
MK-3102 3 mg	114	1 (0.9)	-0.0
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	114	0 (0.0)	-0.9
Serum Sodium (mEq/L)			
Last value with a decrease >= 10 mEq/L and value < LLN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value with an increase >= 10 mEq/L and value > ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Serum Potassium (mEq/L)			
Last value with a decrease >= 1.0 mEq/L and value < LLN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Last value with an increase >= 1.0 mEq/L and value > ULN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	1 (0.9)	0.9
MK-3102 1 mg	114	0 (0.0)	0.0
MK-3102 3 mg	114	1 (0.9)	0.9
MK-3102 10 mg	114	0 (0.0)	0.0
MK-3102 25 mg	114	0 (0.0)	0.0
Serum Calcium (mg/dL)			
Last value with an increase >= 1.0 mg/dL and value > ULN			
Placebo	113	1 (0.9)	
MK-3102 0.25 mg	113	0 (0.0)	-0.9
MK-3102 1 mg	114	0 (0.0)	-0.9
MK-3102 3 mg	114	0 (0.0)	-0.9
MK-3102 10 mg	114	0 (0.0)	-0.9
MK-3102 25 mg	114	0 (0.0)	-0.9

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(APaT)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with a decrease >= 1.0 mg/dL and value < LLN			
Placebo	113	0 (0.0)	
MK-3102 0.25 mg	113	0 (0.0)	0.0
MK-3102 1 mg	114	1 (0.9)	0.9
MK-3102 3 mg	114	0 (0.0)	0.0
MK-3102 10 mg	114	2 (1.8)	1.8
MK-3102 25 mg	114	2 (1.8)	1.8
QTc (milliseconds)			
Last value >= 500 msec			
Placebo	104	0 (0.0)	
MK-3102 0.25 mg	102	0 (0.0)	0.0
MK-3102 1 mg	106	0 (0.0)	0.0
MK-3102 3 mg	101	0 (0.0)	0.0
MK-3102 10 mg	101	0 (0.0)	0.0
MK-3102 25 mg	100	0 (0.0)	0.0
Last value with an increase >= 30 msec and value > gender specific ULN			
Placebo	94	2 (2.1)	
MK-3102 0.25 mg	98	3 (3.1)	0.9 (-4.7, 6.8)
MK-3102 1 mg	100	2 (2.0)	-0.1 (-5.7, 5.1)
MK-3102 3 mg	92	1 (1.1)	-1.0 (-6.5, 4.0)
MK-3102 10 mg	93	3 (3.2)	1.1 (-4.6, 7.2)
MK-3102 25 mg	89	4 (4.5)	2.4 (-3.5, 9.2)
Last value with an increase >= 60 msec and value > gender specific ULN			
Placebo	94	0 (0.0)	
MK-3102 0.25 mg	98	0 (0.0)	0.0
MK-3102 1 mg	100	0 (0.0)	0.0
MK-3102 3 mg	92	0 (0.0)	0.0
MK-3102 10 mg	93	0 (0.0)	0.0
MK-3102 25 mg	89	0 (0.0)	0.0

† Based on Miettinen & Nurminen method. The 95% CI was computed only for those endpoints with at least 4 patients having events in one or more treatment groups.

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 12.

N = Patients in population

C Confidential

付録 2.7.4: 16　　臨床検査値の PDLC に該当した被験者の割合
（安全性解析対象集団）
（P020、プラセボ対照期）

Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Hemoglobin (g/dL)			
Last value with a decrease >= 1.5 g/dL ‡			
MK-3102 25 mg	166	6 (3.6)	-2.5 (-10.2, 2.8)
Sitagliptin 50 mg	164	10 (6.1)	0.0 (-7.9, 6.0)
Placebo	82	5 (6.1)	
WBC Count (10^3/microL)			
One value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	166	1 (0.6)	-0.6
Sitagliptin 50 mg	164	0 (0.0)	-1.2
Placebo	82	1 (1.2)	
Last value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	166	1 (0.6)	0.6
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	166	8 (4.8)	3.6 (-2.1, 8.2)
Sitagliptin 50 mg	164	5 (3.0)	1.8 (-3.7, 6.0)
Placebo	82	1 (1.2)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	166	3 (1.8)	1.8
Sitagliptin 50 mg	164	3 (1.8)	1.8
Placebo	82	0 (0.0)	
Neutrophil Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	166	4 (2.4)	1.2 (-4.3, 5.0)
Sitagliptin 50 mg	164	3 (1.8)	0.6 (-4.9, 4.2)
Placebo	82	1 (1.2)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	166	2 (1.2)	1.2
Sitagliptin 50 mg	164	1 (0.6)	0.6
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	166	9 (5.4)	5.4 (0.8, 10.0)
Sitagliptin 50 mg	164	4 (2.4)	2.4 (-2.1, 6.1)
Placebo	82	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	166	3 (1.8)	1.8
Sitagliptin 50 mg	164	2 (1.2)	1.2
Placebo	82	0 (0.0)	
Lymphocyte Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	166	1 (0.6)	-0.6
Sitagliptin 50 mg	164	1 (0.6)	-0.6
Placebo	82	1 (1.2)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	166	1 (0.6)	0.6
Sitagliptin 50 mg	164	1 (0.6)	0.6
Placebo	82	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Platelet Count (10^3/microL)			
One value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	166	1 (0.6)	0.6
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value with an increase >= 100% and value > ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value with an increase >= 100% and value > ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
BUN (mg/dL)			
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	166	0 (0.0)	-1.2
Sitagliptin 50 mg	164	3 (1.8)	0.6
Placebo	82	1 (1.2)	
Serum Creatine Kinase (IU/L)			
One value with an increase > 5×ULN			
MK-3102 25 mg	166	2 (1.2)	1.2
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value with an increase > 5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value with an increase > 10×ULN			
MK-3102 25 mg	166	1 (0.6)	0.6
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase > 10×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Serum Creatinine (mg/dL)			
Last value with an increase >= 0.3 mg/dL			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Total Bilirubin (mg/dL)			
One value >= 2×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value >= 2×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
AST (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value > 5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
One value > 5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
AST (IU/L) or ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
One value > 5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
MK-3102 25 mg	166	0 (0.0)	-1.2
Sitagliptin 50 mg	164	0 (0.0)	-1.2
Placebo	82	1 (1.2)	
Last value > 1.5×ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Serum Uric Acid (mg/dL)			
One value with an increase >= 50% and value > ULN			
MK-3102 25 mg	166	2 (1.2)	1.2
Sitagliptin 50 mg	164	1 (0.6)	0.6
Placebo	82	0 (0.0)	
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	166	1 (0.6)	0.6
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Serum Sodium (mEq/L)			
Last value with a decrease >= 10 mEq/L and value < LLN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase >= 10 mEq/L and value > ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Serum Potassium (mEq/L)			
Last value with a decrease >= 1.0 mEq/L and value < LLN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value with an increase >= 1.0 mEq/L and value > ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Serum Calcium (mg/dL)			
Last value with an increase >= 1.0 mg/dL and value > ULN			
MK-3102 25 mg	166	1 (0.6)	0.6
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
Last value with a decrease >= 1.0 mg/dL and value < LLN			
MK-3102 25 mg	166	1 (0.6)	0.6
Sitagliptin 50 mg	164	0 (0.0)	0.0
Placebo	82	0 (0.0)	
QTc (milliseconds)			
Last value >= 500 msec			
MK-3102 25 mg	166	0 (0.0)	-1.2
Sitagliptin 50 mg	164	0 (0.0)	-1.2
Placebo	82	1 (1.2)	
Last value with an increase >= 30 msec and value > gender specific ULN			
MK-3102 25 mg	166	2 (1.2)	-2.5 (-9.1, 1.3)
Sitagliptin 50 mg	164	4 (2.4)	-1.2 (-8.0, 3.2)
Placebo	82	3 (3.7)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase >= 60 msec and value > gender specific ULN			
MK-3102 25 mg	166	0 (0.0)	0.0
Sitagliptin 50 mg	164	1 (0.6)	0.6
Placebo	82	0 (0.0)	

† Based on Miettinen & Nurminen method. The 95% CI was computed only for those endpoints with at least 4 subjects having events in one or more treatment groups.

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 24.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

付録 2.7.4: 17　　臨床検査値のベースラインからの変化量（安全性解析対象集団）（P020、プラセボ対照期）

C Confidential

Summary of Change From Baseline by Week in RBC (10^6/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	4.81 (0.42)	-	-	-	-
Sitagliptin 50 mg	164	4.83 (0.43)	-	-	-	-
Placebo	82	4.78 (0.45)	-	-	-	-
Week 4						
MK-3102 25 mg	166	4.81 (0.42)	4.77 (0.44)	-0.04 (0.01)	-0.05	-0.51 to 0.56
Sitagliptin 50 mg	164	4.83 (0.43)	4.78 (0.41)	-0.05 (0.01)	-0.04	-0.55 to 0.57
Placebo	82	4.78 (0.45)	4.78 (0.44)	-0.00 (0.02)	-0.02	-0.67 to 0.43
Week 8						
MK-3102 25 mg	165	4.81 (0.42)	4.78 (0.43)	-0.02 (0.01)	-0.01	-0.59 to 0.38
Sitagliptin 50 mg	161	4.83 (0.43)	4.82 (0.44)	-0.01 (0.02)	-0.01	-0.41 to 0.81
Placebo	82	4.78 (0.45)	4.78 (0.43)	-0.00 (0.02)	-0.01	-0.50 to 0.53
Week 12						
MK-3102 25 mg	165	4.81 (0.42)	4.79 (0.46)	-0.02 (0.02)	0.00	-0.70 to 0.48
Sitagliptin 50 mg	161	4.83 (0.43)	4.81 (0.43)	-0.03 (0.02)	-0.04	-0.56 to 0.64
Placebo	82	4.78 (0.45)	4.76 (0.43)	-0.02 (0.02)	-0.05	-0.56 to 0.78
Week 24						
MK-3102 25 mg	163	4.81 (0.42)	4.70 (0.43)	-0.11 (0.02)	-0.11	-0.78 to 0.41
Sitagliptin 50 mg	161	4.83 (0.43)	4.74 (0.41)	-0.10 (0.02)	-0.08	-0.79 to 0.77
Placebo	80	4.78 (0.46)	4.71 (0.44)	-0.07 (0.03)	-0.04	-0.95 to 0.44

C Confidential

Summary of Change From Baseline by Week in Hemoglobin (gm/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	14.68 (1.39)	-	-	-	-
Sitagliptin 50 mg	164	14.76 (1.31)	-	-	-	-
Placebo	82	14.70 (1.44)	-	-	-	-
Week 4						
MK-3102 25 mg	166	14.68 (1.39)	14.53 (1.39)	-0.14 (0.05)	-0.20	-1.70 to 1.60
Sitagliptin 50 mg	164	14.76 (1.31)	14.59 (1.24)	-0.17 (0.04)	-0.20	-1.90 to 1.90
Placebo	82	14.70 (1.44)	14.63 (1.40)	-0.07 (0.07)	-0.05	-2.20 to 1.50
Week 8						
MK-3102 25 mg	165	14.66 (1.38)	14.58 (1.33)	-0.09 (0.05)	-0.10	-1.90 to 2.20
Sitagliptin 50 mg	161	14.77 (1.32)	14.71 (1.34)	-0.06 (0.05)	-0.10	-1.20 to 2.50
Placebo	82	14.70 (1.44)	14.64 (1.38)	-0.06 (0.07)	-0.10	-1.40 to 1.80
Week 12						
MK-3102 25 mg	165	14.66 (1.38)	14.58 (1.42)	-0.08 (0.05)	0.00	-1.90 to 1.80
Sitagliptin 50 mg	161	14.77 (1.32)	14.63 (1.30)	-0.14 (0.05)	-0.20	-1.80 to 2.00
Placebo	82	14.70 (1.44)	14.59 (1.41)	-0.11 (0.07)	-0.20	-1.70 to 2.00
Week 24						
MK-3102 25 mg	163	14.67 (1.39)	14.34 (1.34)	-0.32 (0.05)	-0.40	-2.60 to 2.40
Sitagliptin 50 mg	161	14.77 (1.32)	14.43 (1.23)	-0.34 (0.05)	-0.30	-2.10 to 3.10
Placebo	80	14.71 (1.45)	14.43 (1.47)	-0.29 (0.07)	-0.20	-2.30 to 1.00

C Confidential

Summary of Change From Baseline by Week in Hematocrit (%) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	44.67 (3.65)	-	-	-	-
Sitagliptin 50 mg	164	44.87 (3.61)	-	-	-	-
Placebo	82	44.65 (3.76)	-	-	-	-
Week 4						
MK-3102 25 mg	166	44.67 (3.65)	44.51 (3.72)	-0.16 (0.13)	-0.40	-5.00 to 4.90
Sitagliptin 50 mg	164	44.87 (3.61)	44.53 (3.42)	-0.34 (0.14)	-0.30	-5.30 to 4.90
Placebo	82	44.65 (3.76)	44.59 (3.61)	-0.06 (0.22)	0.00	-5.40 to 4.30
Week 8						
MK-3102 25 mg	165	44.64 (3.63)	44.60 (3.62)	-0.03 (0.14)	0.10	-6.00 to 5.70
Sitagliptin 50 mg	161	44.88 (3.64)	44.93 (3.69)	0.04 (0.15)	0.00	-4.00 to 7.60
Placebo	82	44.65 (3.76)	44.60 (3.64)	-0.04 (0.22)	0.00	-3.70 to 5.70
Week 12						
MK-3102 25 mg	165	44.64 (3.63)	44.73 (3.93)	0.09 (0.15)	0.30	-6.60 to 5.40
Sitagliptin 50 mg	161	44.88 (3.64)	44.75 (3.65)	-0.14 (0.14)	-0.10	-4.50 to 6.20
Placebo	82	44.65 (3.76)	44.52 (3.65)	-0.12 (0.21)	-0.45	-3.80 to 6.90
Week 24						
MK-3102 25 mg	163	44.65 (3.66)	43.45 (3.66)	-1.19 (0.16)	-1.20	-6.20 to 5.40
Sitagliptin 50 mg	161	44.88 (3.64)	43.61 (3.38)	-1.27 (0.16)	-1.10	-7.20 to 7.10
Placebo	80	44.68 (3.80)	43.67 (3.77)	-1.01 (0.25)	-0.65	-7.80 to 4.00

Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	32.83 (0.97)	-	-	-	-
Sitagliptin 50 mg	164	32.89 (0.79)	-	-	-	-
Placebo	82	32.90 (0.97)	-	-	-	-
Week 4						
MK-3102 25 mg	166	32.83 (0.97)	32.63 (0.96)	-0.20 (0.04)	-0.20	-1.90 to 1.10
Sitagliptin 50 mg	164	32.89 (0.79)	32.76 (0.77)	-0.13 (0.04)	-0.10	-1.70 to 1.40
Placebo	82	32.90 (0.97)	32.78 (0.96)	-0.12 (0.06)	-0.10	-1.40 to 1.10
Week 8						
MK-3102 25 mg	165	32.83 (0.97)	32.66 (0.89)	-0.17 (0.04)	-0.10	-1.70 to 1.00
Sitagliptin 50 mg	161	32.90 (0.79)	32.74 (0.85)	-0.17 (0.04)	-0.20	-1.80 to 1.70
Placebo	82	32.90 (0.97)	32.79 (0.91)	-0.11 (0.06)	-0.10	-1.30 to 1.00
Week 12						
MK-3102 25 mg	165	32.83 (0.97)	32.58 (0.91)	-0.24 (0.04)	-0.30	-2.10 to 1.20
Sitagliptin 50 mg	161	32.90 (0.79)	32.70 (0.82)	-0.21 (0.05)	-0.20	-2.00 to 2.10
Placebo	82	32.90 (0.97)	32.74 (0.92)	-0.16 (0.07)	-0.10	-1.50 to 1.30
Week 24						
MK-3102 25 mg	163	32.83 (0.97)	32.99 (0.99)	0.16 (0.06)	0.10	-1.60 to 3.10
Sitagliptin 50 mg	161	32.90 (0.79)	33.09 (0.89)	0.19 (0.06)	0.20	-1.50 to 2.10
Placebo	80	32.91 (0.98)	33.01 (1.08)	0.10 (0.08)	0.10	-1.90 to 1.70

C Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular Volume (fL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	93.02 (4.83)	-	-	-	-
Sitagliptin 50 mg	164	93.03 (4.54)	-	-	-	-
Placebo	82	93.60 (4.56)	-	-	-	-
Week 4						
MK-3102 25 mg	166	93.02 (4.83)	93.44 (4.85)	0.43 (0.10)	0.40	-3.00 to 4.90
Sitagliptin 50 mg	164	93.03 (4.54)	93.27 (4.62)	0.24 (0.08)	0.20	-3.70 to 4.00
Placebo	82	93.60 (4.56)	93.55 (4.97)	-0.05 (0.13)	0.00	-2.80 to 3.90
Week 8						
MK-3102 25 mg	165	92.99 (4.83)	93.40 (4.73)	0.41 (0.12)	0.40	-3.70 to 6.20
Sitagliptin 50 mg	161	93.02 (4.56)	93.32 (4.67)	0.30 (0.10)	0.20	-3.00 to 5.40
Placebo	82	93.60 (4.56)	93.57 (4.76)	-0.03 (0.14)	-0.30	-3.70 to 3.70
Week 12						
MK-3102 25 mg	165	92.99 (4.83)	93.51 (4.78)	0.52 (0.14)	0.50	-4.00 to 8.80
Sitagliptin 50 mg	161	93.02 (4.56)	93.29 (4.66)	0.26 (0.12)	0.30	-3.60 to 4.20
Placebo	82	93.60 (4.56)	93.71 (4.87)	0.11 (0.18)	0.15	-4.20 to 4.10
Week 24						
MK-3102 25 mg	163	92.93 (4.79)	92.58 (4.66)	-0.35 (0.19)	-0.60	-4.40 to 12.00
Sitagliptin 50 mg	161	93.02 (4.56)	92.24 (4.74)	-0.78 (0.14)	-0.80	-5.60 to 4.40
Placebo	80	93.60 (4.60)	92.95 (5.20)	-0.65 (0.23)	-0.10	-5.80 to 3.20

C Confidential

Summary of Change From Baseline by Week in Platelet (10^3/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	233.10 (52.34)	-	-	-	-
Sitagliptin 50 mg	164	238.55 (54.65)	-	-	-	-
Placebo	82	240.27 (66.59)	-	-	-	-
Week 4						
MK-3102 25 mg	166	233.10 (52.34)	232.08 (51.87)	-1.02 (1.92)	-0.50	-80.00 to 83.00
Sitagliptin 50 mg	164	238.55 (54.65)	234.66 (49.15)	-3.89 (2.12)	-2.00	-139.00 to 72.00
Placebo	82	240.27 (66.59)	238.33 (62.83)	-1.94 (2.62)	-4.00	-101.00 to 61.00
Week 8						
MK-3102 25 mg	165	233.59 (52.13)	228.62 (50.25)	-4.96 (1.75)	-6.00	-75.00 to 96.00
Sitagliptin 50 mg	161	237.88 (54.74)	233.06 (51.18)	-4.82 (2.29)	-4.00	-175.00 to 82.00
Placebo	82	240.27 (66.59)	235.52 (60.20)	-4.74 (2.82)	-3.50	-102.00 to 96.00
Week 12						
MK-3102 25 mg	165	233.59 (52.13)	228.62 (49.91)	-4.97 (1.92)	-5.00	-87.00 to 84.00
Sitagliptin 50 mg	161	237.88 (54.74)	231.75 (50.50)	-6.13 (2.46)	-5.00	-176.00 to 76.00
Placebo	82	240.27 (66.59)	239.41 (64.00)	-0.85 (2.99)	0.50	-94.00 to 71.00
Week 24						
MK-3102 25 mg	163	233.43 (52.31)	222.59 (48.15)	-10.84 (1.83)	-10.00	-112.00 to 54.00
Sitagliptin 50 mg	161	237.88 (54.74)	229.24 (50.58)	-8.64 (2.58)	-9.00	-180.00 to 90.00
Placebo	80	241.30 (67.00)	233.75 (61.63)	-7.55 (2.79)	-5.50	-112.00 to 47.00

C Confidential

Summary of Change From Baseline by Week in WBC (cells/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	5487.35 (1607.45)	-	-	-	-
Sitagliptin 50 mg	164	5904.88 (1751.42)	-	-	-	-
Placebo	82	5834.15 (1874.01)	-	-	-	-
Week 4						
MK-3102 25 mg	166	5487.35 (1607.45)	5806.02 (1833.71)	318.67 (81.31)	300.00	-2500.00 to 5400.00
Sitagliptin 50 mg	164	5904.88 (1751.42)	6062.20 (1798.54)	157.32 (81.90)	100.00	-5100.00 to 4700.00
Placebo	82	5834.15 (1874.01)	5848.78 (1590.11)	14.63 (119.84)	0.00	-3200.00 to 3700.00
Week 8						
MK-3102 25 mg	165	5488.48 (1612.28)	5839.39 (1518.81)	350.91 (73.67)	400.00	-4200.00 to 2600.00
Sitagliptin 50 mg	161	5875.78 (1752.49)	6013.66 (1678.82)	137.89 (81.71)	100.00	-5100.00 to 3100.00
Placebo	82	5834.15 (1874.01)	5795.12 (1456.44)	-39.02 (131.49)	200.00	-4800.00 to 1900.00
Week 12						
MK-3102 25 mg	165	5488.48 (1612.28)	5849.09 (1843.96)	360.61 (105.91)	300.00	-2400.00 to 12000.00
Sitagliptin 50 mg	161	5875.78 (1752.49)	5986.34 (1656.56)	110.56 (86.81)	0.00	-4800.00 to 3800.00
Placebo	82	5834.15 (1874.01)	5696.34 (1691.26)	-137.80 (134.09)	-50.00	-4300.00 to 3100.00
Week 24						
MK-3102 25 mg	163	5496.32 (1620.39)	5789.57 (1897.29)	293.25 (90.20)	300.00	-3400.00 to 4700.00
Sitagliptin 50 mg	161	5875.78 (1752.49)	6010.56 (1625.06)	134.78 (92.63)	100.00	-5400.00 to 6500.00
Placebo	80	5827.50 (1867.44)	5802.50 (1474.25)	-25.00 (127.59)	0.00	-4200.00 to 2200.00

Confidential

Summary of Change From Baseline by Week in Neutrophils (cells/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	3236.32 (1284.25)	-	-	-	-
Sitagliptin 50 mg	164	3429.62 (1331.31)	-	-	-	-
Placebo	82	3486.16 (1512.07)	-	-	-	-
Week 4						
MK-3102 25 mg	166	3236.32 (1284.25)	3502.72 (1551.98)	266.40 (78.24)	178.40	-2207.30 to 5446.80
Sitagliptin 50 mg	164	3429.62 (1331.31)	3597.09 (1373.28)	167.47 (77.51)	141.35	-6472.80 to 3951.20
Placebo	82	3486.16 (1512.07)	3393.34 (1283.26)	-92.82 (103.12)	-48.80	-3024.00 to 2350.40
Week 8						
MK-3102 25 mg	165	3236.89 (1288.13)	3484.07 (1195.15)	247.18 (65.64)	311.50	-3710.40 to 2549.20
Sitagliptin 50 mg	161	3408.68 (1327.68)	3528.07 (1282.72)	119.38 (74.42)	135.00	-6292.40 to 2817.60
Placebo	82	3486.16 (1512.07)	3291.88 (1104.31)	-194.28 (116.94)	2.50	-4697.10 to 1564.90
Week 12						
MK-3102 25 mg	165	3236.89 (1288.13)	3520.36 (1523.79)	283.48 (95.47)	230.40	-2621.40 to 10736.10
Sitagliptin 50 mg	161	3408.68 (1327.68)	3497.31 (1274.73)	88.63 (76.16)	106.90	-6085.20 to 3467.40
Placebo	82	3486.16 (1512.07)	3273.56 (1283.95)	-212.60 (116.86)	-121.10	-4070.20 to 2600.40
Week 24						
MK-3102 25 mg	163	3246.08 (1293.04)	3505.59 (1549.86)	259.50 (82.41)	200.00	-2950.80 to 4842.30
Sitagliptin 50 mg	161	3408.68 (1327.68)	3593.88 (1287.21)	185.19 (82.57)	155.20	-6275.60 to 6101.40
Placebo	80	3474.19 (1504.77)	3381.04 (1164.33)	-93.15 (121.68)	41.00	-4066.20 to 2537.70

Confidential

Summary of Change From Baseline by Week in Lymphocytes (cells/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	1785.21 (537.45)	-	-	-	-
Sitagliptin 50 mg	164	1957.29 (686.13)	-	-	-	-
Placebo	82	1812.89 (481.22)	-	-	-	-
Week 4						
MK-3102 25 mg	166	1785.21 (537.45)	1806.23 (488.62)	21.01 (25.22)	14.70	-1234.50 to 929.70
Sitagliptin 50 mg	164	1957.29 (686.13)	1916.59 (654.12)	-40.70 (27.41)	-14.70	-1314.60 to 1236.00
Placebo	82	1812.89 (481.22)	1916.27 (539.33)	103.39 (34.03)	74.85	-697.20 to 1059.90
Week 8						
MK-3102 25 mg	165	1785.21 (539.08)	1836.03 (508.89)	50.82 (24.46)	87.20	-1173.80 to 811.70
Sitagliptin 50 mg	161	1949.98 (685.55)	1933.15 (615.34)	-16.82 (27.08)	-35.60	-1568.70 to 1217.90
Placebo	82	1812.89 (481.22)	1970.24 (561.22)	157.36 (36.43)	156.00	-458.20 to 1104.30
Week 12						
MK-3102 25 mg	165	1785.21 (539.08)	1813.48 (529.95)	28.27 (25.80)	20.60	-1295.00 to 851.60
Sitagliptin 50 mg	161	1949.98 (685.55)	1935.12 (592.27)	-14.85 (29.96)	-29.20	-1608.00 to 1305.20
Placebo	82	1812.89 (481.22)	1899.94 (513.75)	87.06 (33.90)	99.35	-546.30 to 952.80
Week 24						
MK-3102 25 mg	163	1782.44 (541.81)	1782.97 (513.24)	0.53 (23.85)	13.40	-879.80 to 1067.40
Sitagliptin 50 mg	161	1949.98 (685.55)	1883.08 (635.01)	-66.90 (29.79)	-48.00	-1656.60 to 1219.40
Placebo	80	1816.55 (483.78)	1901.47 (541.12)	84.92 (31.42)	64.30	-626.00 to 803.00

Confidential

Summary of Change From Baseline by Week in Monocytes (cells/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	280.72 (82.85)	-	-	-	-
Sitagliptin 50 mg	164	308.64 (106.25)	-	-	-	-
Placebo	82	314.70 (105.36)	-	-	-	-
Week 4						
MK-3102 25 mg	166	280.72 (82.85)	307.62 (95.29)	26.89 (5.10)	27.10	-196.40 to 335.20
Sitagliptin 50 mg	164	308.64 (106.25)	339.46 (120.46)	30.82 (6.15)	21.80	-199.00 to 274.60
Placebo	82	314.70 (105.36)	315.94 (96.49)	1.24 (8.43)	3.50	-360.30 to 203.20
Week 8						
MK-3102 25 mg	165	280.85 (83.08)	316.98 (90.53)	36.13 (5.43)	39.40	-156.10 to 261.70
Sitagliptin 50 mg	161	307.24 (106.19)	336.95 (110.04)	29.71 (5.67)	23.60	-176.60 to 235.40
Placebo	82	314.70 (105.36)	314.34 (93.72)	-0.36 (9.27)	-3.80	-361.50 to 251.10
Week 12						
MK-3102 25 mg	165	280.85 (83.08)	318.08 (114.73)	37.23 (8.24)	28.80	-175.20 to 1034.40
Sitagliptin 50 mg	161	307.24 (106.19)	335.03 (124.50)	27.79 (6.40)	27.00	-148.60 to 467.50
Placebo	82	314.70 (105.36)	304.06 (100.70)	-10.64 (9.02)	-3.00	-343.50 to 219.20
Week 24						
MK-3102 25 mg	163	281.66 (83.27)	309.06 (97.82)	27.40 (5.69)	28.00	-143.20 to 232.70
Sitagliptin 50 mg	161	307.24 (106.19)	329.74 (106.83)	22.51 (6.04)	20.00	-150.00 to 219.80
Placebo	80	313.93 (105.02)	305.49 (99.39)	-8.43 (9.74)	-8.25	-312.50 to 297.00

Confidential

Summary of Change From Baseline by Week in Eosinophils (cells/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	152.20 (97.79)	-	-	-	-
Sitagliptin 50 mg	164	173.21 (123.06)	-	-	-	-
Placebo	82	184.70 (133.31)	-	-	-	-
Week 4						
MK-3102 25 mg	166	152.20 (97.79)	156.48 (102.94)	4.28 (4.40)	-1.00	-128.00 to 253.30
Sitagliptin 50 mg	164	173.21 (123.06)	175.04 (123.79)	1.83 (5.02)	-0.15	-343.50 to 189.60
Placebo	82	184.70 (133.31)	187.13 (120.93)	2.43 (7.99)	0.45	-188.60 to 265.70
Week 8						
MK-3102 25 mg	165	152.51 (98.01)	166.79 (112.85)	14.28 (6.23)	-0.50	-177.80 to 644.70
Sitagliptin 50 mg	161	173.68 (124.11)	179.67 (129.73)	5.99 (6.17)	0.70	-346.90 to 397.30
Placebo	82	184.70 (133.31)	181.55 (111.95)	-3.15 (8.92)	2.20	-427.80 to 252.00
Week 12						
MK-3102 25 mg	165	152.51 (98.01)	163.06 (113.70)	10.55 (5.52)	-0.30	-153.30 to 373.80
Sitagliptin 50 mg	161	173.68 (124.11)	182.38 (117.79)	8.70 (6.30)	5.50	-409.70 to 270.00
Placebo	82	184.70 (133.31)	182.56 (117.77)	-2.15 (9.21)	9.20	-242.60 to 393.90
Week 24						
MK-3102 25 mg	163	153.09 (98.43)	159.16 (101.35)	6.07 (5.84)	0.00	-201.90 to 391.60
Sitagliptin 50 mg	161	173.68 (124.11)	169.77 (113.21)	-3.91 (5.41)	0.00	-279.90 to 164.00
Placebo	80	186.71 (134.08)	180.07 (126.68)	-6.63 (9.68)	-5.95	-317.10 to 348.00

Confidential

Summary of Change From Baseline by Week in Basophils (cells/microL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	32.89 (17.82)	-	-	-	-
Sitagliptin 50 mg	164	36.12 (20.83)	-	-	-	-
Placebo	82	35.70 (23.34)	-	-	-	-
Week 4						
MK-3102 25 mg	166	32.89 (17.82)	32.98 (18.57)	0.09 (1.21)	-1.00	-45.90 to 51.50
Sitagliptin 50 mg	164	36.12 (20.83)	34.02 (20.01)	-2.10 (1.22)	-0.75	-56.00 to 52.30
Placebo	82	35.70 (23.34)	36.10 (22.34)	0.40 (1.57)	1.50	-50.00 to 32.60
Week 8						
MK-3102 25 mg	165	33.03 (17.79)	35.52 (18.75)	2.50 (1.20)	1.40	-51.30 to 47.40
Sitagliptin 50 mg	161	36.20 (21.00)	35.83 (20.88)	-0.37 (1.21)	0.20	-38.60 to 40.00
Placebo	82	35.70 (23.34)	37.10 (24.30)	1.41 (1.68)	0.80	-43.00 to 41.60
Week 12						
MK-3102 25 mg	165	33.03 (17.79)	34.11 (18.20)	1.08 (1.14)	0.40	-56.50 to 40.80
Sitagliptin 50 mg	161	36.20 (21.00)	36.50 (22.44)	0.30 (1.23)	-0.40	-62.30 to 55.70
Placebo	82	35.70 (23.34)	36.21 (23.70)	0.52 (1.98)	0.40	-63.50 to 62.20
Week 24						
MK-3102 25 mg	163	33.05 (17.90)	32.79 (16.79)	-0.26 (1.09)	-0.30	-46.30 to 45.20
Sitagliptin 50 mg	161	36.20 (21.00)	34.09 (19.41)	-2.11 (1.07)	-0.80	-42.50 to 41.20
Placebo	80	36.13 (23.46)	34.43 (23.07)	-1.71 (1.74)	-0.25	-41.80 to 36.20

Confidential

Summary of Change From Baseline by Week in Protein (gm/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	7.28 (0.47)	-	-	-	-
Sitagliptin 50 mg	164	7.34 (0.48)	-	-	-	-
Placebo	82	7.25 (0.42)	-	-	-	-
Week 4						
MK-3102 25 mg	166	7.28 (0.47)	7.28 (0.41)	-0.00 (0.03)	0.00	-2.60 to 1.00
Sitagliptin 50 mg	164	7.34 (0.48)	7.31 (0.39)	-0.03 (0.03)	0.00	-1.20 to 0.90
Placebo	82	7.25 (0.42)	7.24 (0.39)	-0.01 (0.04)	-0.05	-0.80 to 0.80
Week 8						
MK-3102 25 mg	165	7.28 (0.47)	7.31 (0.39)	0.04 (0.03)	0.00	-2.70 to 1.00
Sitagliptin 50 mg	161	7.34 (0.49)	7.40 (0.40)	0.06 (0.03)	0.10	-1.20 to 1.40
Placebo	82	7.25 (0.42)	7.25 (0.44)	0.00 (0.04)	-0.10	-1.10 to 1.10
Week 12						
MK-3102 25 mg	165	7.28 (0.47)	7.31 (0.36)	0.03 (0.03)	0.10	-2.60 to 1.20
Sitagliptin 50 mg	161	7.34 (0.49)	7.31 (0.42)	-0.03 (0.03)	0.00	-1.30 to 1.10
Placebo	82	7.25 (0.42)	7.22 (0.38)	-0.03 (0.04)	0.00	-1.10 to 0.70
Week 24						
MK-3102 25 mg	163	7.28 (0.47)	7.24 (0.36)	-0.04 (0.03)	0.00	-2.50 to 0.90
Sitagliptin 50 mg	161	7.34 (0.49)	7.27 (0.38)	-0.07 (0.03)	-0.10	-1.40 to 1.40
Placebo	80	7.24 (0.40)	7.15 (0.42)	-0.09 (0.04)	-0.10	-1.20 to 0.70

C Confidential

Summary of Change From Baseline by Week in Albumin (gm/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	4.44 (0.26)	-	-	-	-
Sitagliptin 50 mg	164	4.44 (0.26)	-	-	-	-
Placebo	82	4.39 (0.23)	-	-	-	-
Week 4						
MK-3102 25 mg	166	4.44 (0.26)	4.44 (0.26)	-0.00 (0.02)	0.00	-0.80 to 0.80
Sitagliptin 50 mg	164	4.44 (0.26)	4.42 (0.24)	-0.03 (0.02)	0.00	-0.60 to 0.60
Placebo	82	4.39 (0.23)	4.40 (0.23)	0.01 (0.02)	0.00	-0.60 to 0.50
Week 8						
MK-3102 25 mg	165	4.44 (0.26)	4.45 (0.24)	0.01 (0.02)	0.00	-0.70 to 0.60
Sitagliptin 50 mg	161	4.44 (0.26)	4.46 (0.24)	0.02 (0.02)	0.00	-0.70 to 0.80
Placebo	82	4.39 (0.23)	4.40 (0.22)	0.01 (0.02)	0.00	-0.70 to 0.70
Week 12						
MK-3102 25 mg	165	4.44 (0.26)	4.43 (0.24)	-0.01 (0.02)	0.00	-0.70 to 0.70
Sitagliptin 50 mg	161	4.44 (0.26)	4.40 (0.23)	-0.04 (0.02)	0.00	-0.80 to 0.50
Placebo	82	4.39 (0.23)	4.37 (0.22)	-0.02 (0.02)	0.00	-0.80 to 0.50
Week 24						
MK-3102 25 mg	163	4.44 (0.26)	4.40 (0.23)	-0.03 (0.02)	0.00	-0.80 to 0.60
Sitagliptin 50 mg	161	4.44 (0.26)	4.39 (0.24)	-0.05 (0.02)	-0.10	-0.80 to 0.60
Placebo	80	4.38 (0.22)	4.35 (0.23)	-0.04 (0.02)	-0.10	-0.70 to 0.60

C Confidential

Summary of Change From Baseline by Week in Bilirubin (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	0.68 (0.24)	-	-	-	-
Sitagliptin 50 mg	164	0.65 (0.26)	-	-	-	-
Placebo	82	0.73 (0.27)	-	-	-	-
Week 4						
MK-3102 25 mg	166	0.68 (0.24)	0.71 (0.27)	0.03 (0.02)	0.00	-0.70 to 1.50
Sitagliptin 50 mg	164	0.65 (0.26)	0.69 (0.25)	0.04 (0.02)	0.00	-0.90 to 0.90
Placebo	82	0.73 (0.27)	0.73 (0.28)	-0.00 (0.02)	0.00	-0.50 to 0.40
Week 8						
MK-3102 25 mg	165	0.67 (0.24)	0.71 (0.23)	0.04 (0.02)	0.00	-1.00 to 0.70
Sitagliptin 50 mg	161	0.65 (0.26)	0.69 (0.23)	0.04 (0.02)	0.00	-0.70 to 0.90
Placebo	82	0.73 (0.27)	0.78 (0.29)	0.05 (0.02)	0.10	-0.40 to 0.70
Week 12						
MK-3102 25 mg	165	0.67 (0.24)	0.70 (0.24)	0.03 (0.01)	0.00	-0.50 to 0.40
Sitagliptin 50 mg	161	0.65 (0.26)	0.66 (0.24)	0.02 (0.02)	0.00	-0.80 to 1.00
Placebo	82	0.73 (0.27)	0.79 (0.29)	0.06 (0.02)	0.10	-0.60 to 0.50
Week 24						
MK-3102 25 mg	163	0.67 (0.24)	0.71 (0.24)	0.04 (0.02)	0.10	-0.60 to 0.50
Sitagliptin 50 mg	161	0.65 (0.26)	0.70 (0.26)	0.05 (0.02)	0.00	-0.60 to 0.70
Placebo	80	0.73 (0.27)	0.77 (0.30)	0.04 (0.02)	0.05	-0.40 to 0.70

Confidential

Summary of Change From Baseline by Week in Aspartate Aminotransferase (IU/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	23.15 (9.34)	-	-	-	-
Sitagliptin 50 mg	164	22.21 (7.18)	-	-	-	-
Placebo	82	21.30 (7.31)	-	-	-	-
Week 4						
MK-3102 25 mg	166	23.15 (9.34)	23.02 (10.50)	-0.13 (0.72)	0.00	-70.00 to 66.00
Sitagliptin 50 mg	164	22.21 (7.18)	21.63 (6.54)	-0.57 (0.33)	0.00	-18.00 to 10.00
Placebo	82	21.30 (7.31)	21.59 (7.94)	0.28 (0.68)	0.50	-27.00 to 26.00
Week 8						
MK-3102 25 mg	165	23.15 (9.37)	22.33 (7.91)	-0.82 (0.60)	-1.00	-73.00 to 14.00
Sitagliptin 50 mg	161	22.26 (7.23)	21.35 (7.08)	-0.91 (0.36)	-1.00	-20.00 to 16.00
Placebo	82	21.30 (7.31)	20.94 (7.70)	-0.37 (0.65)	0.00	-27.00 to 26.00
Week 12						
MK-3102 25 mg	165	23.15 (9.37)	22.48 (7.96)	-0.67 (0.66)	0.00	-68.00 to 27.00
Sitagliptin 50 mg	161	22.26 (7.23)	22.09 (8.18)	-0.17 (0.41)	0.00	-16.00 to 23.00
Placebo	82	21.30 (7.31)	20.82 (6.28)	-0.49 (0.66)	0.00	-24.00 to 16.00
Week 24						
MK-3102 25 mg	163	23.15 (9.37)	22.67 (9.84)	-0.48 (0.79)	-1.00	-69.00 to 56.00
Sitagliptin 50 mg	161	22.26 (7.23)	22.84 (9.48)	0.58 (0.55)	0.00	-18.00 to 40.00
Placebo	80	21.30 (7.33)	19.83 (6.02)	-1.48 (0.66)	-1.50	-28.00 to 10.00

Confidential

Summary of Change From Baseline by Week in Alanine Aminotransferase (IU/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	25.78 (12.73)	-	-	-	-
Sitagliptin 50 mg	164	26.09 (12.25)	-	-	-	-
Placebo	82	24.82 (12.70)	-	-	-	-
Week 4						
MK-3102 25 mg	166	25.78 (12.73)	24.71 (13.48)	-1.07 (0.59)	-1.00	-34.00 to 33.00
Sitagliptin 50 mg	164	26.09 (12.25)	23.73 (11.19)	-2.36 (0.50)	-2.00	-26.00 to 18.00
Placebo	82	24.82 (12.70)	24.20 (11.76)	-0.62 (1.20)	0.00	-53.00 to 61.00
Week 8						
MK-3102 25 mg	165	25.79 (12.77)	24.22 (13.52)	-1.57 (0.62)	-1.00	-37.00 to 22.00
Sitagliptin 50 mg	161	26.27 (12.28)	23.63 (11.21)	-2.64 (0.53)	-2.00	-33.00 to 21.00
Placebo	82	24.82 (12.70)	22.04 (10.58)	-2.78 (0.95)	-2.00	-52.00 to 14.00
Week 12						
MK-3102 25 mg	165	25.79 (12.77)	24.07 (13.17)	-1.72 (0.67)	-2.00	-37.00 to 36.00
Sitagliptin 50 mg	161	26.27 (12.28)	24.05 (11.77)	-2.22 (0.59)	-1.00	-38.00 to 19.00
Placebo	82	24.82 (12.70)	22.90 (10.62)	-1.91 (1.06)	-1.00	-42.00 to 22.00
Week 24						
MK-3102 25 mg	163	25.85 (12.79)	24.34 (13.71)	-1.51 (0.85)	-2.00	-39.00 to 49.00
Sitagliptin 50 mg	161	26.27 (12.28)	25.24 (14.07)	-1.04 (0.78)	-1.00	-43.00 to 48.00
Placebo	80	24.93 (12.79)	20.68 (8.68)	-4.25 (1.14)	-2.50	-55.00 to 22.00

Confidential

Summary of Change From Baseline by Week in Gamma Glutamyl Transferase (IU/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	42.83 (41.15)	-	-	-	-
Sitagliptin 50 mg	164	43.47 (37.16)	-	-	-	-
Placebo	82	41.94 (34.09)	-	-	-	-
Week 4						
MK-3102 25 mg	166	42.83 (41.15)	42.82 (44.81)	-0.01 (1.45)	-1.00	-75.00 to 123.00
Sitagliptin 50 mg	164	43.47 (37.16)	40.84 (37.65)	-2.63 (1.34)	-2.00	-65.00 to 158.00
Placebo	82	41.94 (34.09)	42.91 (37.23)	0.98 (1.62)	0.00	-54.00 to 53.00
Week 8						
MK-3102 25 mg	165	42.93 (41.25)	41.73 (37.93)	-1.19 (1.27)	-1.00	-110.00 to 72.00
Sitagliptin 50 mg	161	43.86 (37.39)	41.46 (37.90)	-2.40 (0.88)	-2.00	-40.00 to 87.00
Placebo	82	41.94 (34.09)	39.30 (37.50)	-2.63 (2.00)	-2.00	-63.00 to 101.00
Week 12						
MK-3102 25 mg	165	42.93 (41.25)	40.70 (33.75)	-2.22 (1.78)	-1.00	-134.00 to 114.00
Sitagliptin 50 mg	161	43.86 (37.39)	42.32 (42.04)	-1.54 (1.35)	-2.00	-63.00 to 150.00
Placebo	82	41.94 (34.09)	40.79 (37.67)	-1.15 (1.68)	-1.00	-71.00 to 67.00
Week 24						
MK-3102 25 mg	163	43.09 (41.44)	45.23 (44.28)	2.14 (2.37)	0.00	-107.00 to 272.00
Sitagliptin 50 mg	161	43.86 (37.39)	41.42 (34.23)	-2.44 (1.11)	-1.00	-99.00 to 39.00
Placebo	80	42.39 (34.37)	38.63 (33.47)	-3.76 (1.53)	-2.00	-86.00 to 41.00

Confidential

Summary of Change From Baseline by Week in Alkaline Phosphatase (IU/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	237.77 (72.01)	-	-	-	-
Sitagliptin 50 mg	164	247.62 (69.35)	-	-	-	-
Placebo	82	248.89 (68.90)	-	-	-	-
Week 4						
MK-3102 25 mg	166	237.77 (72.01)	228.69 (64.79)	-9.08 (2.37)	-10.00	-119.00 to 121.00
Sitagliptin 50 mg	164	247.62 (69.35)	232.28 (62.55)	-15.34 (1.76)	-14.00	-80.00 to 38.00
Placebo	82	248.89 (68.90)	250.24 (77.38)	1.35 (3.99)	-1.50	-148.00 to 163.00
Week 8						
MK-3102 25 mg	165	238.10 (72.11)	222.71 (63.09)	-15.39 (2.35)	-14.00	-133.00 to 91.00
Sitagliptin 50 mg	161	246.87 (68.14)	227.72 (60.40)	-19.15 (1.97)	-19.00	-101.00 to 102.00
Placebo	82	248.89 (68.90)	239.41 (67.50)	-9.48 (2.71)	-8.50	-95.00 to 50.00
Week 12						
MK-3102 25 mg	165	238.10 (72.11)	218.79 (60.60)	-19.31 (2.46)	-17.00	-143.00 to 50.00
Sitagliptin 50 mg	161	246.87 (68.14)	223.64 (60.92)	-23.23 (2.22)	-23.00	-107.00 to 129.00
Placebo	82	248.89 (68.90)	243.66 (71.79)	-5.23 (4.26)	-10.00	-98.00 to 206.00
Week 24						
MK-3102 25 mg	163	237.72 (72.47)	215.45 (60.04)	-22.27 (3.01)	-19.00	-185.00 to 189.00
Sitagliptin 50 mg	161	246.87 (68.14)	217.37 (59.21)	-29.50 (2.18)	-27.00	-109.00 to 45.00
Placebo	80	246.59 (66.68)	236.19 (63.24)	-10.40 (4.41)	-8.00	-132.00 to 145.00

Confidential

Summary of Change From Baseline by Week in Lactate Dehydrogenase (IU/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	184.58 (86.63)	-	-	-	-
Sitagliptin 50 mg	164	170.73 (28.40)	-	-	-	-
Placebo	82	169.06 (27.81)	-	-	-	-
Week 4						
MK-3102 25 mg	166	184.58 (86.63)	180.40 (34.24)	-4.18 (6.84)	4.50	-1063.00 to 250.00
Sitagliptin 50 mg	164	170.73 (28.40)	172.85 (29.17)	2.12 (1.54)	2.00	-58.00 to 109.00
Placebo	82	169.06 (27.81)	173.05 (30.38)	3.99 (1.83)	4.00	-46.00 to 50.00
Week 8						
MK-3102 25 mg	165	184.70 (86.88)	178.75 (31.06)	-5.96 (6.67)	2.00	-1056.00 to 45.00
Sitagliptin 50 mg	161	170.45 (28.34)	174.61 (26.98)	4.16 (1.36)	4.00	-62.00 to 56.00
Placebo	82	169.06 (27.81)	170.21 (29.24)	1.15 (1.51)	0.00	-37.00 to 34.00
Week 12						
MK-3102 25 mg	165	184.70 (86.88)	181.03 (30.61)	-3.67 (6.76)	2.00	-1060.00 to 73.00
Sitagliptin 50 mg	161	170.45 (28.34)	174.66 (29.89)	4.21 (1.38)	5.00	-44.00 to 94.00
Placebo	82	169.06 (27.81)	170.38 (26.39)	1.32 (1.81)	1.00	-50.00 to 45.00
Week 24						
MK-3102 25 mg	163	185.16 (87.30)	180.32 (31.54)	-4.84 (6.83)	2.00	-1061.00 to 74.00
Sitagliptin 50 mg	161	170.45 (28.34)	171.98 (29.26)	1.53 (1.50)	2.00	-58.00 to 59.00
Placebo	80	168.64 (28.02)	168.28 (28.99)	-0.36 (1.82)	-1.00	-58.00 to 45.00

C Confidential

Summary of Change From Baseline by Week in Creatine Kinase (IU/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	114.22 (65.74)	-	-	-	-
Sitagliptin 50 mg	164	108.99 (65.51)	-	-	-	-
Placebo	82	100.24 (66.54)	-	-	-	-
Week 4						
MK-3102 25 mg	166	114.22 (65.74)	119.34 (90.04)	5.12 (5.57)	2.00	-202.00 to 702.00
Sitagliptin 50 mg	164	108.99 (65.51)	109.23 (54.69)	0.24 (4.72)	1.50	-404.00 to 317.00
Placebo	82	100.24 (66.54)	96.57 (45.49)	-3.67 (6.49)	0.00	-438.00 to 81.00
Week 8						
MK-3102 25 mg	165	114.05 (65.91)	117.06 (78.38)	3.01 (4.15)	1.00	-189.00 to 414.00
Sitagliptin 50 mg	161	109.04 (66.01)	109.19 (54.86)	0.14 (4.79)	3.00	-405.00 to 283.00
Placebo	82	100.24 (66.54)	101.68 (49.07)	1.44 (7.18)	3.00	-430.00 to 173.00
Week 12						
MK-3102 25 mg	165	114.05 (65.91)	119.01 (78.53)	4.96 (5.20)	2.00	-175.00 to 583.00
Sitagliptin 50 mg	161	109.04 (66.01)	111.66 (49.28)	2.62 (4.59)	5.00	-421.00 to 128.00
Placebo	82	100.24 (66.54)	97.12 (43.49)	-3.12 (6.90)	4.50	-453.00 to 100.00
Week 24						
MK-3102 25 mg	163	114.75 (66.00)	127.61 (81.27)	12.85 (5.26)	6.00	-169.00 to 382.00
Sitagliptin 50 mg	161	109.04 (66.01)	114.06 (70.75)	5.02 (6.10)	3.00	-405.00 to 473.00
Placebo	80	100.69 (66.99)	114.58 (107.55)	13.89 (12.09)	3.00	-278.00 to 849.00

Confidential

Summary of Change From Baseline by Week in Blood Urea Nitrogen (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	13.79 (2.95)	-	-	-	-
Sitagliptin 50 mg	164	14.25 (3.38)	-	-	-	-
Placebo	82	13.69 (3.59)	-	-	-	-
Week 4						
MK-3102 25 mg	166	13.79 (2.95)	14.09 (3.33)	0.30 (0.19)	0.20	-7.50 to 8.50
Sitagliptin 50 mg	164	14.25 (3.38)	14.26 (3.85)	0.01 (0.20)	-0.05	-8.30 to 8.80
Placebo	82	13.69 (3.59)	13.55 (3.66)	-0.14 (0.31)	-0.40	-8.10 to 5.70
Week 8						
MK-3102 25 mg	165	13.77 (2.94)	14.26 (3.31)	0.49 (0.20)	0.30	-8.10 to 10.20
Sitagliptin 50 mg	161	14.26 (3.39)	14.40 (3.52)	0.14 (0.22)	0.20	-10.10 to 8.00
Placebo	82	13.69 (3.59)	13.37 (3.63)	-0.32 (0.29)	-0.40	-7.00 to 6.30
Week 12						
MK-3102 25 mg	165	13.77 (2.94)	14.00 (3.13)	0.24 (0.21)	0.00	-7.40 to 8.80
Sitagliptin 50 mg	161	14.26 (3.39)	14.10 (3.62)	-0.15 (0.22)	-0.40	-8.60 to 9.10
Placebo	82	13.69 (3.59)	13.50 (3.70)	-0.19 (0.32)	0.20	-7.60 to 7.90
Week 24						
MK-3102 25 mg	163	13.80 (2.94)	14.02 (3.53)	0.23 (0.23)	0.00	-8.30 to 8.10
Sitagliptin 50 mg	161	14.26 (3.39)	14.35 (3.68)	0.10 (0.24)	0.00	-8.00 to 9.60
Placebo	80	13.63 (3.60)	13.93 (4.20)	0.31 (0.34)	-0.30	-7.70 to 7.90

C Confidential

Summary of Change From Baseline by Week in Creatinine (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	0.70 (0.15)	-	-	-	-
Sitagliptin 50 mg	164	0.72 (0.16)	-	-	-	-
Placebo	82	0.72 (0.16)	-	-	-	-
Week 4						
MK-3102 25 mg	166	0.70 (0.15)	0.71 (0.15)	0.01 (0.00)	0.01	-0.18 to 0.18
Sitagliptin 50 mg	164	0.72 (0.16)	0.73 (0.16)	0.01 (0.00)	0.01	-0.13 to 0.17
Placebo	82	0.72 (0.16)	0.71 (0.17)	-0.00 (0.01)	0.00	-0.17 to 0.17
Week 8						
MK-3102 25 mg	165	0.70 (0.15)	0.71 (0.15)	0.01 (0.00)	0.01	-0.23 to 0.20
Sitagliptin 50 mg	161	0.72 (0.16)	0.73 (0.17)	0.01 (0.00)	0.01	-0.12 to 0.21
Placebo	82	0.72 (0.16)	0.71 (0.16)	-0.01 (0.01)	-0.01	-0.15 to 0.12
Week 12						
MK-3102 25 mg	165	0.70 (0.15)	0.70 (0.15)	0.01 (0.00)	0.01	-0.15 to 0.26
Sitagliptin 50 mg	161	0.72 (0.16)	0.73 (0.17)	0.01 (0.00)	0.00	-0.12 to 0.20
Placebo	82	0.72 (0.16)	0.70 (0.16)	-0.02 (0.01)	-0.03	-0.18 to 0.12
Week 24						
MK-3102 25 mg	163	0.70 (0.15)	0.70 (0.16)	0.01 (0.00)	0.01	-0.14 to 0.21
Sitagliptin 50 mg	161	0.72 (0.16)	0.74 (0.16)	0.01 (0.01)	0.01	-0.19 to 0.27
Placebo	80	0.72 (0.16)	0.71 (0.16)	-0.01 (0.01)	-0.02	-0.15 to 0.16

C Confidential

Summary of Change From Baseline by Week in Urate (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	4.94 (1.20)	-	-	-	-
Sitagliptin 50 mg	164	5.00 (1.19)	-	-	-	-
Placebo	82	4.70 (0.97)	-	-	-	-
Week 4						
MK-3102 25 mg	166	4.94 (1.20)	5.14 (1.24)	0.20 (0.05)	0.20	-1.40 to 2.50
Sitagliptin 50 mg	164	5.00 (1.19)	5.24 (1.18)	0.24 (0.05)	0.20	-2.10 to 1.70
Placebo	82	4.70 (0.97)	4.83 (1.01)	0.13 (0.06)	0.10	-1.20 to 1.20
Week 8						
MK-3102 25 mg	165	4.93 (1.20)	5.26 (1.33)	0.33 (0.05)	0.30	-1.50 to 3.10
Sitagliptin 50 mg	161	4.99 (1.19)	5.34 (1.26)	0.35 (0.05)	0.30	-2.20 to 2.90
Placebo	82	4.70 (0.97)	4.77 (0.99)	0.07 (0.06)	0.10	-1.20 to 1.30
Week 12						
MK-3102 25 mg	165	4.93 (1.20)	5.23 (1.26)	0.30 (0.04)	0.30	-1.30 to 1.80
Sitagliptin 50 mg	161	4.99 (1.19)	5.30 (1.16)	0.31 (0.05)	0.30	-2.50 to 2.10
Placebo	82	4.70 (0.97)	4.89 (1.07)	0.19 (0.07)	0.15	-1.50 to 2.40
Week 24						
MK-3102 25 mg	163	4.93 (1.20)	5.24 (1.36)	0.32 (0.05)	0.30	-1.20 to 3.20
Sitagliptin 50 mg	161	4.99 (1.19)	5.41 (1.28)	0.42 (0.06)	0.40	-2.30 to 2.20
Placebo	80	4.73 (0.96)	4.93 (1.05)	0.20 (0.07)	0.15	-2.40 to 1.90

C Confidential

Summary of Change From Baseline by Week in Sodium (mEq/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	140.45 (2.10)	-	-	-	-
Sitagliptin 50 mg	164	140.32 (1.67)	-	-	-	-
Placebo	82	140.18 (1.77)	-	-	-	-
Week 4						
MK-3102 25 mg	166	140.45 (2.10)	140.88 (1.75)	0.43 (0.14)	0.00	-3.00 to 8.00
Sitagliptin 50 mg	164	140.32 (1.67)	140.74 (1.79)	0.42 (0.12)	0.00	-3.00 to 5.00
Placebo	82	140.18 (1.77)	140.55 (1.85)	0.37 (0.16)	0.00	-3.00 to 4.00
Week 8						
MK-3102 25 mg	165	140.44 (2.10)	140.81 (1.86)	0.37 (0.15)	0.00	-4.00 to 10.00
Sitagliptin 50 mg	161	140.31 (1.68)	140.88 (1.95)	0.57 (0.12)	1.00	-4.00 to 5.00
Placebo	82	140.18 (1.77)	140.66 (1.87)	0.48 (0.18)	0.00	-3.00 to 6.00
Week 12						
MK-3102 25 mg	165	140.44 (2.10)	140.98 (1.73)	0.54 (0.14)	1.00	-4.00 to 9.00
Sitagliptin 50 mg	161	140.31 (1.68)	140.86 (1.76)	0.55 (0.13)	1.00	-3.00 to 5.00
Placebo	82	140.18 (1.77)	140.65 (2.00)	0.46 (0.17)	0.00	-3.00 to 6.00
Week 24						
MK-3102 25 mg	163	140.43 (2.09)	140.93 (1.80)	0.50 (0.15)	0.00	-4.00 to 9.00
Sitagliptin 50 mg	161	140.31 (1.68)	140.81 (1.97)	0.50 (0.14)	1.00	-7.00 to 6.00
Placebo	80	140.16 (1.79)	140.21 (1.97)	0.05 (0.19)	0.00	-5.00 to 4.00

Confidential

Summary of Change From Baseline by Week in Potassium (mEq/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	4.35 (0.70)	-	-	-	-
Sitagliptin 50 mg	164	4.27 (0.37)	-	-	-	-
Placebo	82	4.18 (0.31)	-	-	-	-
Week 4						
MK-3102 25 mg	166	4.35 (0.70)	4.36 (0.34)	0.00 (0.05)	0.00	-7.60 to 1.30
Sitagliptin 50 mg	164	4.27 (0.37)	4.32 (0.33)	0.05 (0.03)	0.10	-0.90 to 0.90
Placebo	82	4.18 (0.31)	4.23 (0.29)	0.05 (0.03)	0.05	-0.70 to 0.70
Week 8						
MK-3102 25 mg	165	4.35 (0.71)	4.34 (0.34)	-0.02 (0.05)	0.00	-7.40 to 1.00
Sitagliptin 50 mg	161	4.27 (0.37)	4.35 (0.31)	0.08 (0.03)	0.10	-0.90 to 0.90
Placebo	82	4.18 (0.31)	4.20 (0.27)	0.02 (0.03)	0.00	-0.50 to 0.90
Week 12						
MK-3102 25 mg	165	4.35 (0.71)	4.35 (0.38)	-0.00 (0.05)	0.00	-7.30 to 1.30
Sitagliptin 50 mg	161	4.27 (0.37)	4.32 (0.32)	0.05 (0.03)	0.00	-0.80 to 1.20
Placebo	82	4.18 (0.31)	4.22 (0.28)	0.04 (0.04)	0.00	-0.70 to 1.00
Week 24						
MK-3102 25 mg	163	4.35 (0.71)	4.19 (0.31)	-0.16 (0.05)	-0.10	-7.40 to 0.70
Sitagliptin 50 mg	161	4.27 (0.37)	4.20 (0.32)	-0.08 (0.03)	0.00	-1.10 to 0.70
Placebo	80	4.19 (0.29)	4.11 (0.25)	-0.09 (0.03)	-0.10	-0.70 to 0.90

Confidential

Summary of Change From Baseline by Week in Chloride (mEQ/L) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	101.22 (2.31)	-	-	-	-
Sitagliptin 50 mg	164	101.06 (2.40)	-	-	-	-
Placebo	82	100.82 (2.01)	-	-	-	-
Week 4						
MK-3102 25 mg	166	101.22 (2.31)	102.08 (2.20)	0.86 (0.17)	1.00	-5.00 to 7.00
Sitagliptin 50 mg	164	101.06 (2.40)	101.92 (2.23)	0.86 (0.16)	1.00	-4.00 to 7.00
Placebo	82	100.82 (2.01)	101.27 (1.89)	0.45 (0.20)	0.50	-3.00 to 4.00
Week 8						
MK-3102 25 mg	165	101.23 (2.31)	101.88 (2.20)	0.65 (0.18)	0.00	-5.00 to 7.00
Sitagliptin 50 mg	161	101.06 (2.42)	101.81 (2.71)	0.75 (0.18)	1.00	-5.00 to 10.00
Placebo	82	100.82 (2.01)	101.60 (2.18)	0.78 (0.23)	1.00	-3.00 to 5.00
Week 12						
MK-3102 25 mg	165	101.23 (2.31)	102.16 (2.35)	0.93 (0.18)	1.00	-6.00 to 8.00
Sitagliptin 50 mg	161	101.06 (2.42)	102.25 (2.53)	1.19 (0.18)	1.00	-4.00 to 8.00
Placebo	82	100.82 (2.01)	101.63 (2.17)	0.82 (0.21)	1.00	-3.00 to 7.00
Week 24						
MK-3102 25 mg	163	101.25 (2.30)	102.74 (2.30)	1.49 (0.18)	2.00	-6.00 to 7.00
Sitagliptin 50 mg	161	101.06 (2.42)	102.64 (2.57)	1.58 (0.21)	2.00	-8.00 to 8.00
Placebo	80	100.86 (2.00)	102.10 (2.33)	1.24 (0.26)	1.00	-4.00 to 8.00

Confidential

Summary of Change From Baseline by Week in Calcium (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	9.20 (0.39)	-	-	-	-
Sitagliptin 50 mg	164	9.19 (0.31)	-	-	-	-
Placebo	82	9.12 (0.34)	-	-	-	-
Week 4						
MK-3102 25 mg	166	9.20 (0.39)	9.22 (0.37)	0.01 (0.03)	0.00	-0.80 to 1.50
Sitagliptin 50 mg	164	9.19 (0.31)	9.18 (0.32)	-0.01 (0.02)	0.00	-0.70 to 0.70
Placebo	82	9.12 (0.34)	9.19 (0.32)	0.07 (0.03)	0.10	-0.90 to 0.60
Week 8						
MK-3102 25 mg	165	9.20 (0.39)	9.24 (0.37)	0.04 (0.03)	0.00	-0.90 to 1.30
Sitagliptin 50 mg	161	9.19 (0.31)	9.23 (0.36)	0.04 (0.02)	0.00	-0.70 to 0.90
Placebo	82	9.12 (0.34)	9.16 (0.34)	0.03 (0.03)	0.10	-0.90 to 0.60
Week 12						
MK-3102 25 mg	165	9.20 (0.39)	9.18 (0.37)	-0.03 (0.03)	0.00	-1.10 to 1.50
Sitagliptin 50 mg	161	9.19 (0.31)	9.12 (0.32)	-0.07 (0.02)	-0.10	-0.80 to 0.60
Placebo	82	9.12 (0.34)	9.13 (0.30)	0.00 (0.03)	0.00	-0.90 to 0.70
Week 24						
MK-3102 25 mg	163	9.20 (0.39)	9.09 (0.37)	-0.10 (0.03)	-0.10	-1.30 to 1.50
Sitagliptin 50 mg	161	9.19 (0.31)	9.04 (0.31)	-0.15 (0.02)	-0.10	-0.90 to 0.60
Placebo	80	9.12 (0.35)	9.01 (0.31)	-0.11 (0.03)	-0.10	-0.90 to 0.60

C Confidential

Summary of Change From Baseline by Week in Phosphate (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	3.48 (0.47)	-	-	-	-
Sitagliptin 50 mg	164	3.46 (0.49)	-	-	-	-
Placebo	82	3.37 (0.41)	-	-	-	-
Week 4						
MK-3102 25 mg	166	3.48 (0.47)	3.36 (0.47)	-0.12 (0.03)	-0.10	-2.00 to 1.20
Sitagliptin 50 mg	164	3.46 (0.49)	3.39 (0.48)	-0.07 (0.03)	-0.10	-1.00 to 0.90
Placebo	82	3.37 (0.41)	3.33 (0.42)	-0.04 (0.04)	0.00	-0.80 to 1.10
Week 8						
MK-3102 25 mg	165	3.48 (0.47)	3.41 (0.45)	-0.07 (0.03)	-0.10	-2.20 to 0.80
Sitagliptin 50 mg	161	3.46 (0.49)	3.39 (0.46)	-0.08 (0.03)	0.00	-0.80 to 0.80
Placebo	82	3.37 (0.41)	3.39 (0.47)	0.02 (0.05)	0.00	-0.80 to 1.90
Week 12						
MK-3102 25 mg	165	3.48 (0.47)	3.40 (0.45)	-0.08 (0.03)	-0.10	-2.20 to 0.90
Sitagliptin 50 mg	161	3.46 (0.49)	3.36 (0.48)	-0.10 (0.03)	-0.10	-1.20 to 0.80
Placebo	82	3.37 (0.41)	3.33 (0.43)	-0.04 (0.04)	0.00	-1.20 to 0.80
Week 24						
MK-3102 25 mg	163	3.48 (0.47)	3.39 (0.47)	-0.09 (0.03)	0.00	-2.20 to 1.10
Sitagliptin 50 mg	161	3.46 (0.49)	3.35 (0.47)	-0.11 (0.03)	-0.10	-1.00 to 0.90
Placebo	80	3.38 (0.40)	3.36 (0.46)	-0.02 (0.04)	0.00	-1.00 to 0.80

Confidential

Summary of Change From Baseline by Week in Total Cholesterol (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	210.25 (34.03)	-	-	-	-
Sitagliptin 50 mg	164	208.37 (35.31)	-	-	-	-
Placebo	82	205.16 (26.30)	-	-	-	-
Week 4						
MK-3102 25 mg	166	210.25 (34.03)	205.33 (32.67)	-4.93 (1.72)	-3.00	-111.00 to 88.00
Sitagliptin 50 mg	164	208.37 (35.31)	204.15 (34.92)	-4.22 (1.67)	-5.00	-82.00 to 48.00
Placebo	82	205.16 (26.30)	204.07 (30.65)	-1.09 (2.04)	-3.00	-64.00 to 48.00
Week 12						
MK-3102 25 mg	165	210.05 (34.04)	206.56 (34.49)	-3.50 (2.08)	-3.00	-94.00 to 127.00
Sitagliptin 50 mg	161	208.82 (35.33)	203.43 (34.45)	-5.39 (1.72)	-5.00	-71.00 to 50.00
Placebo	82	205.16 (26.30)	202.00 (25.30)	-3.16 (2.16)	-3.00	-50.00 to 40.00
Week 24						
MK-3102 25 mg	163	210.04 (34.25)	198.78 (30.11)	-11.26 (1.88)	-8.00	-87.00 to 51.00
Sitagliptin 50 mg	161	208.82 (35.33)	198.22 (32.67)	-10.60 (1.81)	-8.00	-97.00 to 47.00
Placebo	80	205.38 (26.58)	195.16 (28.75)	-10.21 (2.38)	-11.00	-60.00 to 53.00

C Confidential

Summary of Change From Baseline by Week in HDL Cholesterol (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	59.31 (15.31)	-	-	-	-
Sitagliptin 50 mg	164	56.57 (13.46)	-	-	-	-
Placebo	82	58.50 (13.76)	-	-	-	-
Week 4						
MK-3102 25 mg	166	59.31 (15.31)	58.08 (14.30)	-1.23 (0.60)	-2.00	-47.00 to 29.00
Sitagliptin 50 mg	164	56.57 (13.46)	55.18 (13.14)	-1.39 (0.50)	-1.00	-23.00 to 14.00
Placebo	82	58.50 (13.76)	57.30 (14.20)	-1.20 (0.75)	-1.00	-22.00 to 23.00
Week 12						
MK-3102 25 mg	165	59.25 (15.34)	57.68 (13.40)	-1.56 (0.58)	-1.00	-37.00 to 21.00
Sitagliptin 50 mg	161	56.52 (12.94)	54.94 (12.19)	-1.58 (0.58)	-1.00	-21.00 to 21.00
Placebo	82	58.50 (13.76)	56.88 (13.47)	-1.62 (0.76)	-2.00	-20.00 to 20.00
Week 24						
MK-3102 25 mg	163	59.25 (15.43)	55.63 (13.33)	-3.61 (0.55)	-3.00	-24.00 to 29.00
Sitagliptin 50 mg	161	56.52 (12.94)	52.22 (11.75)	-4.30 (0.60)	-4.00	-40.00 to 17.00
Placebo	80	58.01 (13.53)	53.99 (12.04)	-4.03 (0.94)	-3.50	-30.00 to 23.00

C Confidential

Summary of Change From Baseline by Week in LDL Cholesterol (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	129.68 (29.36)	-	-	-	-
Sitagliptin 50 mg	164	127.84 (30.19)	-	-	-	-
Placebo	82	126.68 (24.59)	-	-	-	-
Week 4						
MK-3102 25 mg	166	129.68 (29.36)	125.84 (27.70)	-3.84 (1.47)	-3.00	-82.00 to 69.00
Sitagliptin 50 mg	164	127.84 (30.19)	124.62 (30.21)	-3.22 (1.46)	-4.00	-63.00 to 53.00
Placebo	82	126.68 (24.59)	122.82 (29.29)	-3.87 (1.70)	-5.00	-38.00 to 49.00
Week 12						
MK-3102 25 mg	165	129.53 (29.39)	127.60 (29.70)	-1.93 (1.79)	-1.00	-75.00 to 116.00
Sitagliptin 50 mg	161	128.30 (30.21)	125.76 (30.78)	-2.53 (1.52)	-3.00	-63.00 to 49.00
Placebo	82	126.68 (24.59)	122.88 (23.53)	-3.80 (1.96)	-4.00	-43.00 to 45.00
Week 24						
MK-3102 25 mg	163	129.51 (29.56)	124.56 (26.60)	-4.95 (1.67)	-2.00	-76.00 to 49.00
Sitagliptin 50 mg	161	128.30 (30.21)	125.07 (30.78)	-3.22 (1.43)	-3.00	-47.00 to 54.00
Placebo	80	127.21 (24.66)	120.05 (26.48)	-7.16 (1.97)	-7.00	-55.00 to 36.00

C Confidential

Summary of Change From Baseline by Week in Triglycerides (mg/dL) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	121.98 (98.34)	-	-	-	-
Sitagliptin 50 mg	164	137.43 (88.20)	-	-	-	-
Placebo	82	114.13 (64.77)	-	-	-	-
Week 4						
MK-3102 25 mg	166	121.98 (98.34)	111.08 (58.58)	-10.89 (6.72)	-4.00	-962.00 to 183.00
Sitagliptin 50 mg	164	137.43 (88.20)	129.34 (84.66)	-8.09 (5.10)	-1.00	-393.00 to 386.00
Placebo	82	114.13 (64.77)	123.96 (82.68)	9.83 (4.67)	2.00	-66.00 to 180.00
Week 12						
MK-3102 25 mg	165	122.03 (98.64)	118.56 (80.63)	-3.47 (4.34)	3.00	-360.00 to 179.00
Sitagliptin 50 mg	161	138.33 (88.75)	129.24 (83.63)	-9.09 (5.48)	-2.00	-302.00 to 352.00
Placebo	82	114.13 (64.77)	120.38 (98.61)	6.24 (6.36)	3.00	-110.00 to 386.00
Week 24						
MK-3102 25 mg	163	122.48 (99.12)	114.01 (60.82)	-8.48 (6.46)	-1.00	-809.00 to 224.00
Sitagliptin 50 mg	161	138.33 (88.75)	133.79 (82.19)	-4.54 (4.63)	-1.00	-346.00 to 176.00
Placebo	80	114.95 (65.26)	131.20 (114.05)	16.25 (8.14)	4.50	-88.00 to 467.00

C Confidential

付録 2.7.4: 18　　臨床検査値の PDLC に該当した被験者の割合
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P015、プラセボ対照期）

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data After Glycemic Rescue
(ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Hemoglobin (g/dL)			
Last value with a decrease >= 1.5 gm/dL ‡			
MK-3102 25 mg	126	5 (4.0)	2.4 (-4.8, 7.7)
Placebo	63	1 (1.6)	
WBC Count (10^3/microL)			
One value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	126	4 (3.2)	-3.2 (-12.4, 2.9)
Placebo	63	4 (6.3)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	126	1 (0.8)	-0.8
Placebo	63	1 (1.6)	
Neutrophil Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	126	2 (1.6)	1.6
Placebo	63	0 (0.0)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	126	2 (1.6)	-3.2
Placebo	63	3 (4.8)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Lymphocyte Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Platelet Count (10^3/microL)			
One value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	126	0 (0.0)	-1.6
Placebo	63	1 (1.6)	
Last value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value with an increase >= 100% and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value with an increase >= 100% and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
BUN (mg/dL)			
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	126	2 (1.6)	1.6
Placebo	63	0 (0.0)	
Serum Creatine Kinase (IU/L)			
One value with an increase > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	63	0 (0.0)	
Last value with an increase > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value with an increase > 10×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value with an increase > 10×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Serum Creatinine (mg/dL)			
Last value with an increase >= 0.3 mg/dL			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Total Bilirubin (mg/dL)			
One value >= 2×ULN			
MK-3102 25 mg	126	0 (0.0)	-1.6
Placebo	63	1 (1.6)	
Last value >= 2×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
AST (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	126	1 (0.8)	0.8
Placebo	63	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 10×ULN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
AST (IU/L) or ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	126	1 (0.8)	0.8
Placebo	63	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	63	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
MK-3102 25 mg	126	1 (0.8)	-0.8
Placebo	63	1 (1.6)	
Last value > 1.5×ULN			
MK-3102 25 mg	126	0 (0.0)	-1.6
Placebo	63	1 (1.6)	
Serum Uric Acid (mg/dL)			
One value with an increase >= 50% and value > ULN			
MK-3102 25 mg	126	2 (1.6)	1.6
Placebo	63	0 (0.0)	
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	126	1 (0.8)	0.8
Placebo	63	0 (0.0)	
Serum Sodium (mEq/L)			
Last value with a decrease >= 10 mEq/L and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase >= 10 mEq/L and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Serum Potassium (mEq/L)			
Last value with a decrease >= 1.0 mEq/L and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value with an increase >= 1.0 mEq/L and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Serum Calcium (mg/dL)			
Last value with an increase >= 1.0 mg/dL and value > ULN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
Last value with a decrease >= 1.0 mg/dL and value < LLN			
MK-3102 25 mg	126	0 (0.0)	0.0
Placebo	63	0 (0.0)	
QTc (milliseconds)			
Last value >= 500 msec			
MK-3102 25 mg	124	1 (0.8)	0.8
Placebo	63	0 (0.0)	
Last value with an increase >= 30 msec and value > gender specific ULN			
MK-3102 25 mg	124	4 (3.2)	1.6 (-5.5, 6.7)
Placebo	63	1 (1.6)	
Last value with an increase >= 60 msec and value > gender specific ULN			
MK-3102 25 mg	124	1 (0.8)	0.8
Placebo	63	0 (0.0)	

† Based on Miettinen & Nurminen method. The 95% CI was computed only for those endpoints with at least 4 subjects having events in one or more treatment groups.

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 24.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Hemoglobin (g/dL)			
Last value with a decrease >= 1.5 gm/dL ‡			
MK-3102 25 mg	65	3 (4.6)	4.6
Placebo	34	0 (0.0)	
WBC Count (10^3/microL)			
One value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	2 (3.1)	3.1
Placebo	34	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Neutrophil Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	-2.9
Placebo	34	1 (2.9)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Lymphocyte Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Platelet Count (10^3/microL)			
One value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase >= 100% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 100% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
BUN (mg/dL)			
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	65	1 (1.5)	-1.4
Placebo	34	1 (2.9)	
Serum Creatine Kinase (IU/L)			
One value with an increase > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	34	0 (0.0)	
Last value with an increase > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Creatinine (mg/dL)			
Last value with an increase >= 0.3 mg/dL			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Total Bilirubin (mg/dL)			
One value >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	-5.9
Placebo	34	2 (5.9)	
Last value >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	-2.9
Placebo	34	1 (2.9)	
AST (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 10×ULN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
AST (IU/L) or ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	34	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 1.5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Uric Acid (mg/dL)			
One value with an increase >= 50% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Sodium (mEq/L)			
Last value with a decrease >= 10 mEq/L and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase >= 10 mEq/L and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Potassium (mEq/L)			
Last value with a decrease >= 1.0 mEq/L and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 1.0 mEq/L and value > ULN			
MK-3102 25 mg	65	2 (3.1)	3.1
Placebo	34	0 (0.0)	
Serum Calcium (mg/dL)			
Last value with an increase >= 1.0 mg/dL and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with a decrease >= 1.0 mg/dL and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
QTc (milliseconds)			
Last value >= 500 msec			
MK-3102 25 mg	64	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 30 msec and value > gender specific ULN			
MK-3102 25 mg	64	2 (3.1)	3.1
Placebo	34	0 (0.0)	
Last value with an increase >= 60 msec and value > gender specific ULN			
MK-3102 25 mg	64	0 (0.0)	0.0
Placebo	34	0 (0.0)	

† Based on Miettinen & Nurminen method. The 95% CI was computed only for those endpoints with at least 4 subjects having events in one or more treatment groups.

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 24.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Biguanides (BGs)
Excluding Data After Glycemic Rescue
(ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Hemoglobin (g/dL)			
Last value with a decrease >= 1.5 gm/dL ‡			
MK-3102 25 mg	66	1 (1.5)	-4.5
Placebo	33	2 (6.1)	
WBC Count (10^3/microL)			
One value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	66	3 (4.5)	1.5
Placebo	33	1 (3.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
Neutrophil Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	66	4 (6.1)	3.0 (-9.8, 12.2)
Placebo	33	1 (3.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Lymphocyte Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Biguanides (BGs)
Excluding Data After Glycemic Rescue
(ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Platelet Count (10^3/microL)			
One value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
Last value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value with an increase >= 100% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	-3.0
Placebo	33	1 (3.0)	
Last value with an increase >= 100% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
BUN (mg/dL)			
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Serum Creatine Kinase (IU/L)			
One value with an increase > 5×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	33	0 (0.0)	
Last value with an increase > 5×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value with an increase > 10×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with an increase > 10×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Serum Creatinine (mg/dL)			
Last value with an increase >= 0.3 mg/dL			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Total Bilirubin (mg/dL)			
One value >= 2×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value >= 2×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
AST (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value > 5×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value > 10×ULN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
AST (IU/L) or ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	66	1 (1.5)	1.5
Placebo	33	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	33	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value > 1.5×ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Serum Uric Acid (mg/dL)			
One value with an increase >= 50% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Serum Sodium (mEq/L)			
Last value with a decrease >= 10 mEq/L and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase >= 10 mEq/L and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Serum Potassium (mEq/L)			
Last value with a decrease >= 1.0 mEq/L and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with an increase >= 1.0 mEq/L and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Serum Calcium (mg/dL)			
Last value with an increase >= 1.0 mg/dL and value > ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with a decrease >= 1.0 mg/dL and value < LLN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
QTc (milliseconds)			
Last value >= 500 msec			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	
Last value with an increase >= 30 msec and value > gender specific ULN			
MK-3102 25 mg	66	4 (6.1)	6.1 (-4.7, 14.6)
Placebo	33	0 (0.0)	
Last value with an increase >= 60 msec and value > gender specific ULN			
MK-3102 25 mg	66	0 (0.0)	0.0
Placebo	33	0 (0.0)	

† Based on Miettinen & Nurminen method. The 95% CI was computed only for those endpoints with at least 4 subjects having events in one or more treatment groups.

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 24.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Hemoglobin (g/dL)			
Last value with a decrease >= 1.5 gm/dL ‡			
MK-3102 25 mg	65	5 (7.7)	7.7 (-2.8, 16.8)
Placebo	34	0 (0.0)	
WBC Count (10^3/microL)			
One value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	4 (6.2)	3.2 (-9.4, 12.5)
Placebo	34	1 (2.9)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Neutrophil Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	-2.9
Placebo	34	1 (2.9)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	-2.9
Placebo	34	1 (2.9)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	2 (3.1)	0.1
Placebo	34	1 (2.9)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Lymphocyte Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	65	2 (3.1)	3.1
Placebo	34	0 (0.0)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Platelet Count (10^3/microL)			
One value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	65	1 (1.5)	-1.4
Placebo	34	1 (2.9)	
Last value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase >= 100% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 100% and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
BUN (mg/dL)			
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Serum Creatine Kinase (IU/L)			
One value with an increase > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	34	0 (0.0)	
Last value with an increase > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value with an increase > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Creatinine (mg/dL)			
Last value with an increase >= 0.3 mg/dL			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Total Bilirubin (mg/dL)			
One value >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
AST (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 10×ULN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
AST (IU/L) or ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	34	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Last value > 1.5×ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Uric Acid (mg/dL)			
One value with an increase >= 50% and value > ULN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Serum Sodium (mEq/L)			
Last value with a decrease >= 10 mEq/L and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase >= 10 mEq/L and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Potassium (mEq/L)			
Last value with a decrease >= 1.0 mEq/L and value < LLN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 1.0 mEq/L and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Serum Calcium (mg/dL)			
Last value with an increase >= 1.0 mg/dL and value > ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with a decrease >= 1.0 mg/dL and value < LLN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
QTc (milliseconds)			
Last value >= 500 msec			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	
Last value with an increase >= 30 msec and value > gender specific ULN			
MK-3102 25 mg	65	1 (1.5)	1.5
Placebo	34	0 (0.0)	
Last value with an increase >= 60 msec and value > gender specific ULN			
MK-3102 25 mg	65	0 (0.0)	0.0
Placebo	34	0 (0.0)	

† Based on Miettinen & Nurminen method. The 95% CI was computed only for those endpoints with at least 4 subjects having events in one or more treatment groups.

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 24.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
Hemoglobin (g/dL)			
Last value with a decrease >= 1.5 gm/dL [‡]			
MK-3102 25 mg	67	3 (4.5)	-1.8
Placebo	32	2 (6.3)	
WBC Count (10^3/microL)			
One value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value with a decrease >= 50% and value < LLN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	67	3 (4.5)	-1.8
Placebo	32	2 (6.3)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	67	0 (0.0)	-3.1
Placebo	32	1 (3.1)	
Neutrophil Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	67	0 (0.0)	-3.1
Placebo	32	1 (3.1)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	67	2 (3.0)	-3.3
Placebo	32	2 (6.3)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	67	0 (0.0)	-3.1
Placebo	32	1 (3.1)	
Lymphocyte Count (10^3/microL)			
One value with a decrease >= 20% and value < LLN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value with a decrease >= 20% and value < LLN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value with an increase >= 20% and value > ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value with an increase >= 20% and value > ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Platelet Count (10^3/microL)			
One value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	67	1 (1.5)	-1.6
Placebo	32	1 (3.1)	
Last value with a decrease >= 25% and value < LLN			
MK-3102 25 mg	67	0 (0.0)	-3.1
Placebo	32	1 (3.1)	
One value with an increase >= 100% and value > ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value with an increase >= 100% and value > ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
BUN (mg/dL)			
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	67	1 (1.5)	1.5
Placebo	32	0 (0.0)	
Serum Creatine Kinase (IU/L)			
One value with an increase > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
Placebo	32	0 (0.0)	
Last value with an increase > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value with an increase > 10×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value with an increase > 10×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Serum Creatinine (mg/dL)			
Last value with an increase >= 0.3 mg/dL			
MK-3102 25 mg	67	1 (1.5)	1.5
Placebo	32	0 (0.0)	
Total Bilirubin (mg/dL)			
One value >= 2×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value >= 2×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
AST (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
Last value > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 10×ULN			

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI[†])
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
AST (IU/L) or ALT (IU/L)			
One value >= 3×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 10×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
One value > 20×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value >= 3×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Placebo	32	0 (0.0)	
Last value > 10×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 20×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value > 1.5×ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Serum Uric Acid (mg/dL)			
One value with an increase >= 50% and value > ULN			
MK-3102 25 mg	67	1 (1.5)	1.5
Placebo	32	0 (0.0)	
Last value with an increase >= 50% and value > ULN			
MK-3102 25 mg	67	1 (1.5)	1.5
Placebo	32	0 (0.0)	
Serum Sodium (mEq/L)			
Last value with a decrease >= 10 mEq/L and value < LLN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Week 0 to Week 24)

	N	n (%)	Difference in % vs. Placebo Estimate (95% CI†)
Last value with an increase >= 10 mEq/L and value > ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Serum Potassium (mEq/L)			
Last value with a decrease >= 1.0 mEq/L and value < LLN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value with an increase >= 1.0 mEq/L and value > ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Serum Calcium (mg/dL)			
Last value with an increase >= 1.0 mg/dL and value > ULN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
Last value with a decrease >= 1.0 mg/dL and value < LLN			
MK-3102 25 mg	67	0 (0.0)	0.0
Placebo	32	0 (0.0)	
QTc (milliseconds)			
Last value >= 500 msec			
MK-3102 25 mg	67	2 (3.0)	3.0
Placebo	31	0 (0.0)	
Last value with an increase >= 30 msec and value > gender specific ULN			
MK-3102 25 mg	67	4 (6.0)	6.0 (-5.4, 14.4)
Placebo	31	0 (0.0)	
Last value with an increase >= 60 msec and value > gender specific ULN			
MK-3102 25 mg	67	1 (1.5)	1.5
Placebo	31	0 (0.0)	

† Based on Miettinen & Nurminen method. The 95% CI was computed only for those endpoints with at least 4 subjects having events in one or more treatment groups.

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 24.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

付録 2.7.4: 19　　臨床検査値のベースラインからの変化量
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P015、プラセボ対照期）

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	4.77 (0.41)	-	-	-	-
Placebo	63	4.79 (0.46)	-	-	-	-
Week 4						
MK-3102 25 mg	126	4.77 (0.41)	4.75 (0.42)	-0.02 (0.02)	-0.04	-0.42 to 0.40
Placebo	63	4.79 (0.46)	4.84 (0.45)	0.04 (0.02)	0.03	-0.47 to 0.46
Week 8						
MK-3102 25 mg	125	4.77 (0.41)	4.74 (0.44)	-0.03 (0.02)	-0.04	-0.50 to 0.62
Placebo	63	4.79 (0.46)	4.81 (0.45)	0.02 (0.03)	0.03	-0.54 to 0.47
Week 12						
MK-3102 25 mg	124	4.77 (0.41)	4.75 (0.39)	-0.03 (0.02)	-0.00	-0.50 to 0.60
Placebo	63	4.79 (0.46)	4.80 (0.41)	0.00 (0.02)	0.01	-0.51 to 0.49
Week 24						
MK-3102 25 mg	122	4.77 (0.41)	4.68 (0.41)	-0.09 (0.02)	-0.10	-0.86 to 0.36
Placebo	62	4.79 (0.46)	4.77 (0.42)	-0.02 (0.03)	-0.02	-0.63 to 0.46

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	4.86 (0.42)	-	-	-	-
Placebo	34	4.91 (0.33)	-	-	-	-
Week 4						
MK-3102 25 mg	65	4.86 (0.42)	4.83 (0.39)	-0.03 (0.02)	0.00	-0.62 to 0.38
Placebo	34	4.91 (0.33)	4.89 (0.30)	-0.02 (0.03)	-0.04	-0.45 to 0.42
Week 8						
MK-3102 25 mg	65	4.86 (0.42)	4.84 (0.36)	-0.01 (0.02)	0.01	-0.56 to 0.40
Placebo	34	4.91 (0.33)	4.88 (0.36)	-0.03 (0.03)	-0.01	-0.42 to 0.27
Week 12						
MK-3102 25 mg	62	4.83 (0.40)	4.82 (0.40)	-0.01 (0.02)	0.00	-0.68 to 0.33
Placebo	34	4.91 (0.33)	4.92 (0.32)	0.01 (0.03)	0.00	-0.28 to 0.52
Week 24						
MK-3102 25 mg	61	4.83 (0.40)	4.77 (0.40)	-0.07 (0.03)	-0.08	-0.54 to 0.41
Placebo	31	4.89 (0.34)	4.86 (0.37)	-0.03 (0.04)	0.00	-0.42 to 0.38

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	4.78 (0.41)	-	-	-	-
Placebo	33	4.87 (0.37)	-	-	-	-
Week 4						
MK-3102 25 mg	66	4.78 (0.41)	4.76 (0.39)	-0.01 (0.02)	-0.01	-0.42 to 0.46
Placebo	33	4.87 (0.37)	4.90 (0.40)	0.03 (0.04)	0.08	-0.56 to 0.41
Week 8						
MK-3102 25 mg	66	4.78 (0.41)	4.78 (0.40)	0.00 (0.03)	0.02	-0.48 to 0.42
Placebo	33	4.87 (0.37)	4.84 (0.39)	-0.03 (0.04)	0.00	-0.59 to 0.38
Week 12						
MK-3102 25 mg	66	4.78 (0.41)	4.75 (0.39)	-0.02 (0.02)	0.01	-0.46 to 0.55
Placebo	33	4.87 (0.37)	4.88 (0.43)	0.01 (0.03)	-0.02	-0.28 to 0.42
Week 24						
MK-3102 25 mg	65	4.77 (0.41)	4.68 (0.42)	-0.09 (0.03)	-0.09	-0.52 to 0.68
Placebo	33	4.87 (0.37)	4.78 (0.39)	-0.09 (0.04)	-0.02	-0.60 to 0.24

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	4.74 (0.43)	-	-	-	-
Placebo	34	4.77 (0.42)	-	-	-	-
Week 4						
MK-3102 25 mg	65	4.74 (0.43)	4.70 (0.48)	-0.04 (0.02)	-0.03	-0.61 to 0.26
Placebo	34	4.77 (0.42)	4.74 (0.38)	-0.03 (0.02)	-0.04	-0.24 to 0.24
Week 8						
MK-3102 25 mg	65	4.74 (0.43)	4.70 (0.47)	-0.04 (0.02)	-0.02	-0.61 to 0.29
Placebo	33	4.75 (0.41)	4.73 (0.35)	-0.02 (0.03)	-0.03	-0.48 to 0.36
Week 12						
MK-3102 25 mg	64	4.74 (0.43)	4.69 (0.48)	-0.05 (0.02)	-0.06	-0.54 to 0.39
Placebo	33	4.75 (0.41)	4.71 (0.41)	-0.04 (0.03)	-0.02	-0.43 to 0.40
Week 24						
MK-3102 25 mg	63	4.74 (0.44)	4.60 (0.52)	-0.14 (0.03)	-0.12	-1.02 to 0.28
Placebo	33	4.75 (0.41)	4.67 (0.42)	-0.08 (0.03)	-0.12	-0.41 to 0.27

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	4.82 (0.47)	-	-	-	-
Placebo	32	4.79 (0.37)	-	-	-	-
Week 4						
MK-3102 25 mg	67	4.82 (0.47)	4.82 (0.46)	-0.01 (0.02)	0.02	-0.39 to 0.23
Placebo	32	4.79 (0.37)	4.76 (0.37)	-0.03 (0.03)	-0.02	-0.46 to 0.38
Week 8						
MK-3102 25 mg	67	4.82 (0.47)	4.82 (0.46)	-0.00 (0.02)	-0.02	-0.47 to 0.42
Placebo	32	4.79 (0.37)	4.76 (0.33)	-0.03 (0.04)	-0.01	-0.49 to 0.34
Week 12						
MK-3102 25 mg	67	4.82 (0.47)	4.83 (0.48)	0.01 (0.02)	0.05	-0.48 to 0.46
Placebo	30	4.79 (0.38)	4.75 (0.35)	-0.05 (0.03)	-0.07	-0.43 to 0.26
Week 24						
MK-3102 25 mg	67	4.82 (0.47)	4.76 (0.45)	-0.06 (0.03)	-0.07	-0.67 to 0.57
Placebo	29	4.78 (0.38)	4.67 (0.38)	-0.11 (0.04)	-0.07	-0.51 to 0.30

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	14.61 (1.16)	-	-	-	-
Placebo	63	14.74 (1.36)	-	-	-	-
Week 4						
MK-3102 25 mg	126	14.61 (1.16)	14.51 (1.24)	-0.09 (0.05)	-0.10	-1.40 to 1.30
Placebo	63	14.74 (1.36)	14.86 (1.32)	0.12 (0.08)	0.10	-1.70 to 1.40
Week 8						
MK-3102 25 mg	125	14.61 (1.17)	14.49 (1.32)	-0.12 (0.06)	-0.20	-1.90 to 1.90
Placebo	63	14.74 (1.36)	14.77 (1.28)	0.03 (0.09)	0.00	-1.60 to 1.50
Week 12						
MK-3102 25 mg	124	14.62 (1.17)	14.49 (1.15)	-0.13 (0.05)	-0.10	-1.40 to 2.30
Placebo	63	14.74 (1.36)	14.69 (1.15)	-0.05 (0.08)	0.10	-1.50 to 1.50
Week 24						
MK-3102 25 mg	122	14.57 (1.13)	14.24 (1.16)	-0.33 (0.06)	-0.30	-2.10 to 1.70
Placebo	62	14.72 (1.36)	14.61 (1.26)	-0.12 (0.08)	-0.10	-1.90 to 1.30

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	14.98 (1.33)	-	-	-	-
Placebo	34	14.95 (1.08)	-	-	-	-
Week 4						
MK-3102 25 mg	65	14.98 (1.33)	14.88 (1.32)	-0.11 (0.08)	-0.10	-1.90 to 1.30
Placebo	34	14.95 (1.08)	14.87 (1.12)	-0.08 (0.09)	-0.10	-1.30 to 1.60
Week 8						
MK-3102 25 mg	65	14.98 (1.33)	14.87 (1.21)	-0.12 (0.08)	-0.10	-1.90 to 1.40
Placebo	34	14.95 (1.08)	14.89 (1.27)	-0.06 (0.10)	-0.05	-1.30 to 1.10
Week 12						
MK-3102 25 mg	62	14.91 (1.28)	14.79 (1.35)	-0.12 (0.07)	0.00	-2.00 to 1.00
Placebo	34	14.95 (1.08)	14.92 (1.21)	-0.03 (0.09)	-0.10	-0.80 to 1.20
Week 24						
MK-3102 25 mg	61	14.92 (1.29)	14.63 (1.34)	-0.29 (0.08)	-0.30	-1.70 to 1.40
Placebo	31	14.91 (1.12)	14.75 (1.23)	-0.16 (0.12)	-0.10	-1.40 to 1.40

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	14.43 (1.40)	-	-	-	-
Placebo	33	14.74 (1.05)	-	-	-	-
Week 4						
MK-3102 25 mg	66	14.43 (1.40)	14.36 (1.39)	-0.07 (0.06)	-0.10	-1.20 to 1.50
Placebo	33	14.74 (1.05)	14.80 (1.11)	0.06 (0.11)	0.20	-1.70 to 1.30
Week 8						
MK-3102 25 mg	66	14.43 (1.40)	14.40 (1.46)	-0.04 (0.08)	0.00	-1.40 to 1.10
Placebo	33	14.74 (1.05)	14.62 (1.12)	-0.12 (0.12)	0.00	-1.90 to 1.00
Week 12						
MK-3102 25 mg	66	14.43 (1.40)	14.30 (1.44)	-0.13 (0.06)	-0.10	-1.50 to 0.90
Placebo	33	14.74 (1.05)	14.69 (1.24)	-0.05 (0.09)	-0.10	-0.80 to 1.10
Week 24						
MK-3102 25 mg	65	14.43 (1.41)	14.05 (1.57)	-0.38 (0.08)	-0.40	-1.80 to 2.10
Placebo	33	14.74 (1.05)	14.43 (1.09)	-0.31 (0.11)	-0.20	-1.90 to 0.70

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	14.42 (1.52)	-	-	-	-
Placebo	34	14.76 (1.31)	-	-	-	-
Week 4						
MK-3102 25 mg	65	14.42 (1.52)	14.23 (1.55)	-0.19 (0.06)	-0.10	-1.80 to 0.70
Placebo	34	14.76 (1.31)	14.61 (1.18)	-0.14 (0.08)	-0.15	-0.90 to 0.60
Week 8						
MK-3102 25 mg	65	14.42 (1.52)	14.24 (1.56)	-0.17 (0.07)	-0.10	-1.60 to 1.00
Placebo	33	14.70 (1.28)	14.60 (1.18)	-0.10 (0.10)	-0.10	-1.40 to 1.20
Week 12						
MK-3102 25 mg	64	14.41 (1.54)	14.18 (1.63)	-0.23 (0.07)	-0.25	-1.50 to 1.20
Placebo	33	14.70 (1.28)	14.58 (1.38)	-0.12 (0.11)	-0.10	-1.30 to 1.50
Week 24						
MK-3102 25 mg	63	14.43 (1.54)	13.94 (1.79)	-0.49 (0.11)	-0.40	-4.50 to 0.90
Placebo	33	14.70 (1.28)	14.37 (1.31)	-0.33 (0.08)	-0.40	-1.00 to 0.70

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	14.75 (1.45)	-	-	-	-
Placebo	32	14.55 (1.29)	-	-	-	-
Week 4						
MK-3102 25 mg	67	14.75 (1.45)	14.71 (1.35)	-0.04 (0.06)	0.00	-1.10 to 1.00
Placebo	32	14.55 (1.29)	14.43 (1.29)	-0.13 (0.10)	-0.10	-1.20 to 1.10
Week 8						
MK-3102 25 mg	67	14.75 (1.45)	14.69 (1.40)	-0.06 (0.07)	-0.10	-1.50 to 1.40
Placebo	32	14.55 (1.29)	14.43 (1.30)	-0.12 (0.10)	-0.10	-1.40 to 0.80
Week 12						
MK-3102 25 mg	67	14.75 (1.45)	14.73 (1.47)	-0.03 (0.08)	0.00	-1.40 to 1.40
Placebo	30	14.54 (1.34)	14.38 (1.39)	-0.17 (0.10)	-0.20	-1.10 to 0.80
Week 24						
MK-3102 25 mg	67	14.75 (1.45)	14.54 (1.28)	-0.22 (0.08)	-0.20	-2.20 to 1.60
Placebo	29	14.49 (1.33)	14.05 (1.41)	-0.44 (0.13)	-0.40	-1.60 to 1.20

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	44.40 (3.22)	-	-	-	-
Placebo	63	44.64 (3.83)	-	-	-	-
Week 4						
MK-3102 25 mg	126	44.40 (3.22)	44.48 (3.49)	0.09 (0.15)	0.05	-3.60 to 4.40
Placebo	63	44.64 (3.83)	45.19 (3.77)	0.55 (0.22)	0.50	-3.50 to 3.90
Week 8						
MK-3102 25 mg	125	44.42 (3.22)	44.40 (3.68)	-0.02 (0.18)	-0.10	-4.80 to 6.20
Placebo	63	44.64 (3.83)	44.99 (3.68)	0.35 (0.24)	0.20	-5.20 to 4.20
Week 12						
MK-3102 25 mg	124	44.43 (3.23)	44.35 (3.30)	-0.08 (0.16)	-0.15	-3.90 to 6.20
Placebo	63	44.64 (3.83)	44.62 (3.14)	-0.03 (0.22)	0.10	-3.70 to 3.30
Week 24						
MK-3102 25 mg	122	44.35 (3.20)	43.09 (3.27)	-1.27 (0.17)	-1.20	-6.60 to 4.10
Placebo	62	44.59 (3.84)	43.82 (3.51)	-0.77 (0.26)	-0.85	-5.70 to 3.50

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	45.18 (3.70)	-	-	-	-
Placebo	34	45.31 (3.12)	-	-	-	-
Week 4						
MK-3102 25 mg	65	45.18 (3.70)	45.08 (3.70)	-0.10 (0.24)	-0.10	-4.90 to 6.80
Placebo	34	45.31 (3.12)	45.06 (3.24)	-0.25 (0.26)	-0.40	-4.30 to 4.30
Week 8						
MK-3102 25 mg	65	45.18 (3.70)	45.18 (3.27)	0.00 (0.24)	-0.20	-5.30 to 4.40
Placebo	34	45.31 (3.12)	44.94 (3.44)	-0.38 (0.23)	-0.30	-4.00 to 1.50
Week 12						
MK-3102 25 mg	62	44.99 (3.62)	45.07 (3.72)	0.08 (0.23)	0.15	-5.70 to 5.10
Placebo	34	45.31 (3.12)	45.36 (3.33)	0.05 (0.30)	-0.45	-2.90 to 4.70
Week 24						
MK-3102 25 mg	61	45.04 (3.64)	44.32 (3.61)	-0.72 (0.27)	-0.50	-5.70 to 4.30
Placebo	31	45.07 (3.16)	44.78 (3.65)	-0.29 (0.40)	0.20	-4.60 to 3.90

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	43.98 (3.60)	-	-	-	-
Placebo	33	44.90 (2.95)	-	-	-	-
Week 4						
MK-3102 25 mg	66	43.98 (3.60)	44.03 (3.63)	0.05 (0.20)	0.20	-3.10 to 4.50
Placebo	33	44.90 (2.95)	45.08 (2.92)	0.18 (0.36)	0.30	-4.60 to 3.30
Week 8						
MK-3102 25 mg	66	43.98 (3.60)	44.08 (3.89)	0.10 (0.24)	0.10	-4.60 to 3.90
Placebo	33	44.90 (2.95)	44.71 (2.90)	-0.18 (0.41)	0.10	-5.90 to 3.80
Week 12						
MK-3102 25 mg	66	43.98 (3.60)	43.88 (3.67)	-0.11 (0.20)	-0.15	-4.00 to 3.50
Placebo	33	44.90 (2.95)	44.99 (3.34)	0.10 (0.29)	0.00	-3.40 to 3.40
Week 24						
MK-3102 25 mg	65	43.96 (3.63)	42.60 (4.15)	-1.36 (0.27)	-1.50	-5.70 to 6.50
Placebo	33	44.90 (2.95)	43.62 (2.84)	-1.28 (0.36)	-0.90	-5.40 to 2.00

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	44.36 (3.89)	-	-	-	-
Placebo	34	45.21 (3.61)	-	-	-	-
Week 4						
MK-3102 25 mg	65	44.36 (3.89)	43.91 (4.18)	-0.46 (0.20)	-0.20	-5.50 to 2.40
Placebo	34	45.21 (3.61)	44.86 (3.20)	-0.36 (0.26)	-0.45	-2.80 to 2.70
Week 8						
MK-3102 25 mg	65	44.36 (3.89)	44.10 (4.16)	-0.26 (0.23)	-0.30	-4.90 to 4.30
Placebo	33	45.07 (3.56)	44.95 (3.10)	-0.12 (0.33)	-0.20	-4.30 to 4.30
Week 12						
MK-3102 25 mg	64	44.37 (3.92)	44.00 (4.35)	-0.37 (0.21)	-0.45	-4.00 to 3.70
Placebo	33	45.07 (3.56)	44.83 (3.65)	-0.24 (0.35)	-0.70	-3.80 to 4.00
Week 24						
MK-3102 25 mg	63	44.41 (3.94)	42.78 (5.00)	-1.62 (0.32)	-1.30	-12.70 to 2.40
Placebo	33	45.07 (3.56)	43.91 (3.64)	-1.16 (0.29)	-1.30	-4.60 to 2.40

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	44.90 (4.11)	-	-	-	-
Placebo	32	44.16 (3.40)	-	-	-	-
Week 4						
MK-3102 25 mg	67	44.90 (4.11)	44.91 (3.85)	0.01 (0.18)	0.30	-3.10 to 3.30
Placebo	32	44.16 (3.40)	43.73 (3.44)	-0.42 (0.29)	-0.30	-3.70 to 2.80
Week 8						
MK-3102 25 mg	67	44.90 (4.11)	44.99 (3.84)	0.09 (0.21)	0.00	-4.50 to 4.00
Placebo	32	44.16 (3.40)	43.95 (3.33)	-0.21 (0.34)	0.10	-3.90 to 4.10
Week 12						
MK-3102 25 mg	67	44.90 (4.11)	45.15 (4.13)	0.24 (0.23)	0.50	-4.20 to 5.00
Placebo	30	44.20 (3.50)	43.79 (3.44)	-0.40 (0.33)	-0.30	-4.20 to 2.90
Week 24						
MK-3102 25 mg	67	44.90 (4.11)	44.15 (3.88)	-0.75 (0.26)	-0.80	-7.10 to 5.40
Placebo	29	44.16 (3.55)	42.86 (3.67)	-1.30 (0.44)	-1.10	-5.70 to 3.70

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	32.90 (0.84)	-	-	-	-
Placebo	63	33.00 (0.83)	-	-	-	-
Week 4						
MK-3102 25 mg	126	32.90 (0.84)	32.62 (0.77)	-0.28 (0.04)	-0.30	-1.50 to 0.80
Placebo	63	33.00 (0.83)	32.88 (0.86)	-0.12 (0.06)	-0.10	-1.10 to 0.80
Week 8						
MK-3102 25 mg	125	32.89 (0.84)	32.62 (0.87)	-0.26 (0.05)	-0.20	-1.60 to 1.40
Placebo	63	33.00 (0.83)	32.82 (0.85)	-0.18 (0.06)	-0.20	-1.40 to 0.90
Week 12						
MK-3102 25 mg	124	32.89 (0.84)	32.66 (0.87)	-0.23 (0.05)	-0.25	-1.90 to 2.60
Placebo	63	33.00 (0.83)	32.93 (0.92)	-0.07 (0.09)	-0.10	-1.50 to 1.50
Week 24						
MK-3102 25 mg	122	32.85 (0.79)	33.05 (0.91)	0.19 (0.07)	0.20	-2.10 to 1.90
Placebo	62	33.00 (0.84)	33.33 (0.96)	0.32 (0.10)	0.50	-1.30 to 2.20

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	33.15 (0.74)	-	-	-	-
Placebo	34	32.99 (0.89)	-	-	-	-
Week 4						
MK-3102 25 mg	65	33.15 (0.74)	32.99 (0.67)	-0.16 (0.07)	-0.20	-2.10 to 0.90
Placebo	34	32.99 (0.89)	33.00 (0.85)	0.01 (0.10)	0.05	-1.30 to 1.00
Week 8						
MK-3102 25 mg	65	33.15 (0.74)	32.89 (0.73)	-0.26 (0.06)	-0.30	-1.30 to 0.70
Placebo	34	32.99 (0.89)	33.13 (0.86)	0.14 (0.09)	0.15	-0.80 to 1.50
Week 12						
MK-3102 25 mg	62	33.13 (0.74)	32.80 (0.67)	-0.33 (0.06)	-0.30	-1.50 to 0.50
Placebo	34	32.99 (0.89)	32.89 (0.83)	-0.11 (0.08)	-0.05	-1.00 to 0.80
Week 24						
MK-3102 25 mg	61	33.11 (0.73)	33.00 (0.86)	-0.11 (0.07)	-0.20	-1.30 to 1.20
Placebo	31	33.07 (0.89)	32.95 (0.90)	-0.13 (0.12)	-0.10	-1.60 to 1.60

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	32.78 (0.93)	-	-	-	-
Placebo	33	32.82 (0.90)	-	-	-	-
Week 4						
MK-3102 25 mg	66	32.78 (0.93)	32.59 (0.93)	-0.19 (0.06)	-0.15	-2.20 to 0.80
Placebo	33	32.82 (0.90)	32.82 (0.79)	-0.01 (0.10)	-0.10	-1.60 to 1.40
Week 8						
MK-3102 25 mg	66	32.78 (0.93)	32.63 (0.94)	-0.15 (0.05)	-0.20	-1.00 to 0.80
Placebo	33	32.82 (0.90)	32.69 (0.95)	-0.13 (0.11)	-0.20	-1.90 to 0.90
Week 12						
MK-3102 25 mg	66	32.78 (0.93)	32.55 (1.04)	-0.23 (0.08)	-0.30	-1.80 to 2.00
Placebo	33	32.82 (0.90)	32.64 (0.86)	-0.18 (0.10)	-0.10	-1.60 to 0.80
Week 24						
MK-3102 25 mg	65	32.78 (0.93)	32.96 (1.25)	0.18 (0.11)	0.20	-2.20 to 2.30
Placebo	33	32.82 (0.90)	33.08 (0.94)	0.25 (0.14)	0.10	-1.50 to 1.70

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	32.46 (1.03)	-	-	-	-
Placebo	34	32.63 (0.78)	-	-	-	-
Week 4						
MK-3102 25 mg	65	32.46 (1.03)	32.38 (0.95)	-0.08 (0.07)	-0.10	-1.50 to 1.30
Placebo	34	32.63 (0.78)	32.56 (0.75)	-0.06 (0.08)	-0.05	-0.90 to 0.80
Week 8						
MK-3102 25 mg	65	32.46 (1.03)	32.25 (0.96)	-0.21 (0.07)	-0.20	-1.70 to 1.20
Placebo	33	32.60 (0.77)	32.45 (0.86)	-0.15 (0.08)	-0.20	-1.40 to 0.80
Week 12						
MK-3102 25 mg	64	32.45 (1.04)	32.18 (0.90)	-0.26 (0.06)	-0.30	-1.70 to 1.10
Placebo	33	32.60 (0.77)	32.48 (0.82)	-0.12 (0.09)	-0.10	-1.10 to 1.00
Week 24						
MK-3102 25 mg	63	32.45 (1.05)	32.54 (1.03)	0.09 (0.11)	0.00	-2.50 to 2.50
Placebo	33	32.60 (0.77)	32.71 (0.86)	0.11 (0.12)	-0.10	-0.90 to 1.60

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	32.84 (0.75)	-	-	-	-
Placebo	32	32.94 (1.02)	-	-	-	-
Week 4						
MK-3102 25 mg	67	32.84 (0.75)	32.75 (0.71)	-0.09 (0.06)	0.00	-1.50 to 1.40
Placebo	32	32.94 (1.02)	32.97 (0.92)	0.03 (0.08)	-0.10	-1.20 to 0.70
Week 8						
MK-3102 25 mg	67	32.84 (0.75)	32.63 (0.74)	-0.22 (0.06)	-0.20	-1.30 to 0.60
Placebo	32	32.94 (1.02)	32.81 (1.06)	-0.13 (0.10)	-0.10	-1.30 to 0.90
Week 12						
MK-3102 25 mg	67	32.84 (0.75)	32.60 (0.78)	-0.25 (0.06)	-0.30	-1.60 to 1.30
Placebo	30	32.89 (1.03)	32.79 (0.97)	-0.09 (0.09)	0.00	-1.30 to 0.90
Week 24						
MK-3102 25 mg	67	32.84 (0.75)	32.93 (0.82)	0.09 (0.09)	0.10	-2.30 to 1.50
Placebo	29	32.79 (0.91)	32.76 (1.04)	-0.03 (0.14)	-0.20	-1.60 to 1.40

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	93.29 (4.90)	-	-	-	-
Placebo	63	93.26 (3.60)	-	-	-	-
Week 4						
MK-3102 25 mg	126	93.29 (4.90)	93.89 (5.07)	0.59 (0.09)	0.65	-1.50 to 3.40
Placebo	63	93.26 (3.60)	93.57 (3.71)	0.32 (0.15)	0.20	-2.20 to 3.30
Week 8						
MK-3102 25 mg	125	93.28 (4.92)	93.86 (5.04)	0.58 (0.11)	0.50	-2.30 to 3.00
Placebo	63	93.26 (3.60)	93.62 (3.86)	0.37 (0.16)	0.20	-2.30 to 3.70
Week 12						
MK-3102 25 mg	124	93.29 (4.94)	93.60 (5.10)	0.30 (0.12)	0.50	-3.20 to 3.90
Placebo	63	93.26 (3.60)	93.21 (3.71)	-0.05 (0.24)	0.10	-4.80 to 3.70
Week 24						
MK-3102 25 mg	122	93.29 (4.97)	92.32 (5.38)	-0.97 (0.19)	-1.40	-7.30 to 10.60
Placebo	62	93.25 (3.63)	92.05 (3.70)	-1.20 (0.24)	-1.25	-4.70 to 2.70

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	93.16 (4.09)	-	-	-	-
Placebo	34	92.36 (4.14)	-	-	-	-
Week 4						
MK-3102 25 mg	65	93.16 (4.09)	93.39 (3.94)	0.24 (0.17)	0.10	-1.70 to 7.50
Placebo	34	92.36 (4.14)	92.22 (4.28)	-0.14 (0.18)	0.00	-3.30 to 2.00
Week 8						
MK-3102 25 mg	65	93.16 (4.09)	93.42 (3.98)	0.26 (0.17)	0.10	-2.40 to 6.40
Placebo	34	92.36 (4.14)	92.13 (3.91)	-0.23 (0.22)	-0.05	-2.80 to 2.80
Week 12						
MK-3102 25 mg	62	93.23 (4.12)	93.61 (4.19)	0.38 (0.19)	0.55	-2.70 to 6.20
Placebo	34	92.36 (4.14)	92.25 (3.82)	-0.11 (0.23)	-0.15	-3.10 to 3.50
Week 24						
MK-3102 25 mg	61	93.26 (4.15)	93.11 (4.12)	-0.15 (0.22)	0.20	-3.70 to 3.30
Placebo	31	92.27 (4.31)	92.28 (4.01)	0.01 (0.26)	-0.10	-2.50 to 2.90

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	92.22 (4.22)	-	-	-	-
Placebo	33	92.35 (4.50)	-	-	-	-
Week 4						
MK-3102 25 mg	66	92.22 (4.22)	92.56 (4.38)	0.34 (0.16)	0.30	-2.40 to 4.20
Placebo	33	92.35 (4.50)	92.28 (4.29)	-0.08 (0.22)	-0.10	-2.90 to 2.70
Week 8						
MK-3102 25 mg	66	92.22 (4.22)	92.37 (4.56)	0.15 (0.14)	0.10	-4.20 to 2.80
Placebo	33	92.35 (4.50)	92.51 (4.41)	0.15 (0.22)	0.20	-2.20 to 3.10
Week 12						
MK-3102 25 mg	66	92.22 (4.22)	92.42 (4.75)	0.20 (0.20)	-0.05	-5.40 to 5.10
Placebo	33	92.35 (4.50)	92.47 (4.36)	0.12 (0.25)	0.30	-2.40 to 3.80
Week 24						
MK-3102 25 mg	65	92.26 (4.25)	91.14 (4.66)	-1.12 (0.28)	-1.20	-7.30 to 5.30
Placebo	33	92.35 (4.50)	91.47 (4.18)	-0.89 (0.37)	-0.30	-5.10 to 3.00

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	93.75 (4.90)	-	-	-	-
Placebo	34	94.88 (3.75)	-	-	-	-
Week 4						
MK-3102 25 mg	65	93.75 (4.90)	93.63 (5.03)	-0.12 (0.14)	-0.10	-3.40 to 2.90
Placebo	34	94.88 (3.75)	94.78 (3.77)	-0.10 (0.21)	-0.20	-2.60 to 2.60
Week 8						
MK-3102 25 mg	65	93.75 (4.90)	93.94 (5.05)	0.19 (0.16)	0.20	-2.00 to 3.00
Placebo	33	94.95 (3.78)	95.13 (3.86)	0.18 (0.21)	0.20	-2.50 to 3.30
Week 12						
MK-3102 25 mg	64	93.77 (4.94)	94.01 (5.11)	0.24 (0.17)	0.10	-2.70 to 4.20
Placebo	33	94.95 (3.78)	95.20 (3.90)	0.25 (0.28)	0.50	-3.40 to 3.20
Week 24						
MK-3102 25 mg	63	93.83 (4.96)	93.02 (5.18)	-0.80 (0.30)	-0.90	-11.20 to 4.40
Placebo	33	94.95 (3.78)	94.11 (3.79)	-0.85 (0.31)	-0.70	-5.50 to 2.60

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	93.24 (4.65)	-	-	-	-
Placebo	32	92.31 (3.32)	-	-	-	-
Week 4						
MK-3102 25 mg	67	93.24 (4.65)	93.43 (4.60)	0.19 (0.15)	0.40	-3.30 to 4.80
Placebo	32	92.31 (3.32)	91.99 (3.65)	-0.32 (0.19)	-0.30	-2.50 to 1.80
Week 8						
MK-3102 25 mg	67	93.24 (4.65)	93.46 (4.62)	0.22 (0.17)	0.10	-2.40 to 6.40
Placebo	32	92.31 (3.32)	92.39 (3.76)	0.08 (0.24)	0.15	-3.30 to 2.70
Week 12						
MK-3102 25 mg	67	93.24 (4.65)	93.60 (4.68)	0.36 (0.18)	0.40	-3.40 to 5.50
Placebo	30	92.22 (3.40)	92.30 (3.83)	0.08 (0.27)	0.05	-3.60 to 2.30
Week 24						
MK-3102 25 mg	67	93.24 (4.65)	92.82 (4.37)	-0.42 (0.25)	-0.30	-6.10 to 5.10
Placebo	29	92.34 (3.39)	91.84 (4.31)	-0.51 (0.43)	-0.50	-6.30 to 4.40

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	227.82 (52.70)	-	-	-	-
Placebo	63	221.21 (56.35)	-	-	-	-
Week 4						
MK-3102 25 mg	126	227.82 (52.70)	226.15 (50.34)	-1.67 (2.03)	-2.00	-109.00 to 63.00
Placebo	63	221.21 (56.35)	222.32 (53.96)	1.11 (3.16)	0.00	-72.00 to 98.00
Week 8						
MK-3102 25 mg	125	227.70 (52.89)	224.82 (52.88)	-2.88 (2.21)	-4.00	-72.00 to 91.00
Placebo	63	221.21 (56.35)	219.84 (51.90)	-1.37 (2.95)	-1.00	-69.00 to 52.00
Week 12						
MK-3102 25 mg	124	227.40 (52.99)	220.59 (47.34)	-6.81 (2.11)	-6.00	-99.00 to 57.00
Placebo	63	221.21 (56.35)	219.05 (53.62)	-2.16 (3.28)	-1.00	-60.00 to 96.00
Week 24						
MK-3102 25 mg	122	228.24 (53.01)	220.11 (47.78)	-8.13 (2.51)	-7.00	-98.00 to 102.00
Placebo	62	220.23 (56.26)	215.56 (62.43)	-4.66 (3.92)	-5.00	-80.00 to 116.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	224.66 (55.40)	-	-	-	-
Placebo	34	221.26 (43.19)	-	-	-	-
Week 4						
MK-3102 25 mg	65	224.66 (55.40)	218.68 (51.12)	-5.98 (2.47)	-7.00	-63.00 to 61.00
Placebo	34	221.26 (43.19)	225.44 (41.84)	4.18 (3.50)	2.50	-40.00 to 69.00
Week 8						
MK-3102 25 mg	65	224.66 (55.40)	221.72 (52.96)	-2.94 (2.39)	-1.00	-50.00 to 52.00
Placebo	34	221.26 (43.19)	218.21 (41.16)	-3.06 (3.30)	2.00	-47.00 to 27.00
Week 12						
MK-3102 25 mg	62	226.10 (55.50)	219.29 (57.18)	-6.81 (3.17)	-10.00	-50.00 to 121.00
Placebo	34	221.26 (43.19)	220.62 (42.30)	-0.65 (3.73)	0.00	-41.00 to 68.00
Week 24						
MK-3102 25 mg	61	226.79 (55.69)	221.34 (53.74)	-5.44 (2.64)	-6.00	-61.00 to 49.00
Placebo	31	225.61 (42.54)	218.06 (41.07)	-7.55 (3.98)	-13.00	-47.00 to 48.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	238.56 (67.23)	-	-	-	-
Placebo	33	234.33 (48.89)	-	-	-	-
Week 4						
MK-3102 25 mg	66	238.56 (67.23)	233.88 (64.83)	-4.68 (3.60)	-4.00	-117.00 to 66.00
Placebo	33	234.33 (48.89)	232.33 (47.99)	-2.00 (4.26)	-1.00	-48.00 to 73.00
Week 8						
MK-3102 25 mg	66	238.56 (67.23)	234.61 (64.69)	-3.95 (3.70)	-4.00	-119.00 to 105.00
Placebo	33	234.33 (48.89)	241.85 (69.42)	7.52 (9.49)	-2.00	-48.00 to 271.00
Week 12						
MK-3102 25 mg	66	238.56 (67.23)	233.48 (65.20)	-5.08 (3.53)	-5.00	-105.00 to 73.00
Placebo	33	234.33 (48.89)	240.00 (49.56)	5.67 (4.63)	-2.00	-37.00 to 97.00
Week 24						
MK-3102 25 mg	65	239.32 (67.46)	229.74 (68.25)	-9.58 (3.42)	-6.00	-77.00 to 91.00
Placebo	33	234.33 (48.89)	229.30 (41.46)	-5.03 (4.25)	-6.00	-45.00 to 53.00

C Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	222.11 (56.70)	-	-	-	-
Placebo	34	216.15 (53.46)	-	-	-	-
Week 4						
MK-3102 25 mg	65	222.11 (56.70)	220.12 (62.62)	-1.98 (2.87)	-2.00	-64.00 to 52.00
Placebo	34	216.15 (53.46)	214.50 (48.89)	-1.65 (3.55)	-1.00	-54.00 to 46.00
Week 8						
MK-3102 25 mg	65	222.11 (56.70)	221.77 (60.09)	-0.34 (2.94)	-2.00	-49.00 to 78.00
Placebo	33	211.55 (46.95)	211.21 (46.17)	-0.33 (2.78)	1.00	-33.00 to 27.00
Week 12						
MK-3102 25 mg	64	222.70 (56.94)	225.95 (63.56)	3.25 (3.88)	0.00	-82.00 to 124.00
Placebo	33	211.55 (46.95)	208.79 (46.51)	-2.76 (2.80)	-3.00	-38.00 to 31.00
Week 24						
MK-3102 25 mg	63	220.27 (53.94)	215.86 (57.22)	-4.41 (3.73)	-4.00	-64.00 to 113.00
Placebo	33	211.55 (46.95)	207.30 (46.47)	-4.24 (2.78)	-1.00	-36.00 to 20.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	230.30 (63.81)	-	-	-	-
Placebo	32	241.03 (57.37)	-	-	-	-
Week 4						
MK-3102 25 mg	67	230.30 (63.81)	224.90 (63.05)	-5.40 (3.62)	-2.00	-179.00 to 42.00
Placebo	32	241.03 (57.37)	235.75 (51.96)	-5.28 (4.29)	-4.00	-73.00 to 51.00
Week 8						
MK-3102 25 mg	67	230.30 (63.81)	223.88 (56.80)	-6.42 (3.59)	-6.00	-164.00 to 52.00
Placebo	32	241.03 (57.37)	233.75 (58.16)	-7.28 (4.19)	-3.50	-76.00 to 36.00
Week 12						
MK-3102 25 mg	67	230.30 (63.81)	225.78 (56.58)	-4.52 (2.46)	-7.00	-72.00 to 58.00
Placebo	30	239.73 (59.04)	239.40 (69.72)	-0.33 (4.31)	-0.50	-44.00 to 55.00
Week 24						
MK-3102 25 mg	67	230.30 (63.81)	214.66 (47.73)	-15.64 (3.82)	-11.00	-177.00 to 26.00
Placebo	29	239.93 (60.07)	230.00 (62.44)	-9.93 (4.85)	-10.00	-78.00 to 59.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	5972.22 (1515.92)	-	-	-	-
Placebo	63	5453.97 (1340.66)	-	-	-	-
Week 4						
MK-3102 25 mg	126	5972.22 (1515.92)	6092.06 (1505.33)	119.84 (111.83)	100.00	-8000.00 to 4000.00
Placebo	63	5453.97 (1340.66)	5584.13 (1524.45)	130.16 (109.50)	200.00	-1900.00 to 2300.00
Week 8						
MK-3102 25 mg	125	5968.00 (1521.28)	6076.00 (1462.51)	108.00 (115.95)	200.00	-8200.00 to 3300.00
Placebo	63	5453.97 (1340.66)	5642.86 (1368.27)	188.89 (131.65)	100.00	-2400.00 to 3900.00
Week 12						
MK-3102 25 mg	124	5980.65 (1520.84)	6112.10 (1415.91)	131.45 (109.13)	200.00	-6400.00 to 3600.00
Placebo	63	5453.97 (1340.66)	5706.35 (1498.16)	252.38 (119.63)	200.00	-1800.00 to 3200.00
Week 24						
MK-3102 25 mg	122	5973.77 (1532.34)	6149.18 (1501.86)	175.41 (116.52)	200.00	-7600.00 to 2800.00
Placebo	62	5441.94 (1348.17)	5645.16 (1542.05)	203.23 (110.16)	100.00	-1600.00 to 2700.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	5604.62 (1551.25)	-	-	-	-
Placebo	34	5779.41 (1466.76)	-	-	-	-
Week 4						
MK-3102 25 mg	65	5604.62 (1551.25)	5816.92 (1503.80)	212.31 (104.98)	200.00	-1500.00 to 2800.00
Placebo	34	5779.41 (1466.76)	5591.18 (1198.32)	-188.24 (191.29)	-300.00	-4000.00 to 2400.00
Week 8						
MK-3102 25 mg	65	5604.62 (1551.25)	5963.08 (1698.86)	358.46 (129.33)	300.00	-2000.00 to 3100.00
Placebo	34	5779.41 (1466.76)	5808.82 (1319.86)	29.41 (191.00)	200.00	-4000.00 to 2600.00
Week 12						
MK-3102 25 mg	62	5609.68 (1585.56)	5898.39 (1594.82)	288.71 (124.35)	150.00	-1800.00 to 3100.00
Placebo	34	5779.41 (1466.76)	5700.00 (1232.64)	-79.41 (159.92)	50.00	-2700.00 to 1300.00
Week 24						
MK-3102 25 mg	61	5596.72 (1595.41)	5857.38 (1444.47)	260.66 (106.39)	300.00	-1500.00 to 2300.00
Placebo	31	5848.39 (1490.38)	5570.97 (1153.02)	-277.42 (200.79)	-100.00	-3700.00 to 2000.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	5986.36 (1682.20)	-	-	-	-
Placebo	33	5966.67 (1996.19)	-	-	-	-
Week 4						
MK-3102 25 mg	66	5986.36 (1682.20)	6083.33 (1718.64)	96.97 (122.31)	50.00	-2200.00 to 3800.00
Placebo	33	5966.67 (1996.19)	6290.91 (1623.15)	324.24 (207.85)	500.00	-3700.00 to 2000.00
Week 8						
MK-3102 25 mg	66	5986.36 (1682.20)	6101.52 (1626.18)	115.15 (150.70)	100.00	-2400.00 to 5800.00
Placebo	33	5966.67 (1996.19)	6133.33 (1980.64)	166.67 (191.42)	200.00	-2100.00 to 3500.00
Week 12						
MK-3102 25 mg	66	5986.36 (1682.20)	6206.06 (1620.24)	219.70 (144.97)	100.00	-2200.00 to 4000.00
Placebo	33	5966.67 (1996.19)	5909.09 (1444.03)	-57.58 (267.64)	200.00	-6100.00 to 2600.00
Week 24						
MK-3102 25 mg	65	6001.54 (1690.74)	6186.15 (1567.63)	184.62 (125.69)	200.00	-2300.00 to 3200.00
Placebo	33	5966.67 (1996.19)	6045.45 (1722.12)	78.79 (202.15)	400.00	-3800.00 to 2400.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	5940.00 (1726.43)	-	-	-	-
Placebo	34	5500.00 (1811.91)	-	-	-	-
Week 4						
MK-3102 25 mg	65	5940.00 (1726.43)	5793.85 (1591.57)	-146.15 (157.96)	100.00	-5000.00 to 4500.00
Placebo	34	5500.00 (1811.91)	5502.94 (1751.97)	2.94 (192.48)	-50.00	-3600.00 to 3300.00
Week 8						
MK-3102 25 mg	65	5940.00 (1726.43)	5852.31 (1573.42)	-87.69 (141.17)	100.00	-5100.00 to 2100.00
Placebo	33	5333.33 (1552.95)	5366.67 (1666.52)	33.33 (130.68)	100.00	-1400.00 to 1700.00
Week 12						
MK-3102 25 mg	64	5950.00 (1738.18)	5857.81 (1639.28)	-92.19 (161.01)	0.00	-6700.00 to 2600.00
Placebo	33	5333.33 (1552.95)	5357.58 (1775.53)	24.24 (189.40)	100.00	-1800.00 to 3500.00
Week 24						
MK-3102 25 mg	63	5904.76 (1713.74)	5888.89 (1529.08)	-15.87 (179.79)	200.00	-6800.00 to 3200.00
Placebo	33	5333.33 (1552.95)	5121.21 (1517.56)	-212.12 (89.27)	-200.00	-1900.00 to 700.00

C Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	5949.25 (1926.17)	-	-	-	-
Placebo	32	5668.75 (1473.52)	-	-	-	-
Week 4						
MK-3102 25 mg	67	5949.25 (1926.17)	6114.93 (1530.52)	165.67 (176.23)	200.00	-5300.00 to 4900.00
Placebo	32	5668.75 (1473.52)	5456.25 (1439.52)	-212.50 (132.42)	-150.00	-1600.00 to 1800.00
Week 8						
MK-3102 25 mg	67	5949.25 (1926.17)	5952.24 (1339.76)	2.99 (175.58)	200.00	-6500.00 to 2500.00
Placebo	32	5668.75 (1473.52)	5521.88 (1671.15)	-146.88 (204.44)	-150.00	-2700.00 to 4500.00
Week 12						
MK-3102 25 mg	67	5949.25 (1926.17)	6116.42 (1499.96)	167.16 (176.07)	200.00	-5700.00 to 3500.00
Placebo	30	5626.67 (1512.92)	5483.33 (1776.49)	-143.33 (198.60)	-200.00	-2400.00 to 3400.00
Week 24						
MK-3102 25 mg	67	5949.25 (1926.17)	6016.42 (1362.66)	67.16 (167.84)	300.00	-7000.00 to 2600.00
Placebo	29	5634.48 (1539.08)	5600.00 (1997.68)	-34.48 (268.88)	100.00	-2900.00 to 5500.00

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	3497.14 (1220.88)	-	-	-	-
Placebo	63	3183.91 (1037.25)	-	-	-	-
Week 4						
MK-3102 25 mg	126	3497.14 (1220.88)	3672.53 (1220.57)	175.39 (105.27)	112.80	-7741.80 to 4258.60
Placebo	63	3183.91 (1037.25)	3253.13 (1166.81)	69.22 (95.08)	133.50	-2039.40 to 1770.80
Week 8						
MK-3102 25 mg	125	3502.81 (1224.13)	3650.07 (1136.03)	147.27 (108.78)	169.80	-7919.20 to 3810.10
Placebo	63	3183.91 (1037.25)	3280.60 (1130.51)	96.69 (135.34)	-13.40	-2117.40 to 5585.60
Week 12						
MK-3102 25 mg	124	3510.44 (1226.11)	3618.73 (1049.67)	108.29 (99.52)	127.35	-6504.20 to 3136.80
Placebo	63	3183.91 (1037.25)	3339.68 (1179.32)	155.77 (102.98)	82.60	-1881.80 to 2807.00
Week 24						
MK-3102 25 mg	122	3505.86 (1235.02)	3682.03 (1135.28)	176.16 (107.52)	225.25	-7535.60 to 2872.80
Placebo	62	3168.36 (1038.29)	3283.70 (1214.57)	115.35 (103.81)	50.30	-1833.60 to 2491.20

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	3210.75 (1152.80)	-	-	-	-
Placebo	34	3636.49 (1278.04)	-	-	-	-
Week 4						
MK-3102 25 mg	65	3210.75 (1152.80)	3421.86 (1191.40)	211.11 (93.10)	230.20	-1016.30 to 2454.50
Placebo	34	3636.49 (1278.04)	3363.82 (1035.66)	-272.67 (182.56)	-181.45	-3745.20 to 2285.60
Week 8						
MK-3102 25 mg	65	3210.75 (1152.80)	3551.72 (1341.31)	340.96 (109.10)	251.90	-1631.80 to 2978.70
Placebo	34	3636.49 (1278.04)	3529.08 (1079.87)	-107.41 (181.53)	119.80	-3738.50 to 2230.80
Week 12						
MK-3102 25 mg	62	3201.36 (1174.48)	3443.90 (1253.74)	242.55 (91.72)	178.50	-1028.20 to 2970.60
Placebo	34	3636.49 (1278.04)	3435.36 (949.22)	-201.13 (158.02)	-44.20	-2746.80 to 1088.30
Week 24						
MK-3102 25 mg	61	3191.41 (1181.59)	3449.72 (1138.25)	258.31 (82.83)	261.00	-954.70 to 2508.40
Placebo	31	3675.54 (1291.52)	3279.49 (879.52)	-396.05 (210.84)	-297.00	-3916.90 to 1636.80

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	3570.91 (1295.52)	-	-	-	-
Placebo	33	3492.26 (1796.63)	-	-	-	-
Week 4						
MK-3102 25 mg	66	3570.91 (1295.52)	3689.54 (1329.49)	118.63 (108.02)	84.25	-2589.90 to 3239.30
Placebo	33	3492.26 (1796.63)	3682.60 (1307.08)	190.33 (194.87)	269.40	-3878.10 to 1869.40
Week 8						
MK-3102 25 mg	66	3570.91 (1295.52)	3757.89 (1277.07)	186.98 (134.64)	160.10	-2844.00 to 5335.40
Placebo	33	3492.26 (1796.63)	3615.21 (1716.71)	122.95 (198.25)	123.80	-2164.30 to 3888.50
Week 12						
MK-3102 25 mg	66	3570.91 (1295.52)	3832.02 (1343.66)	261.11 (129.70)	164.00	-2527.40 to 4043.90
Placebo	33	3492.26 (1796.63)	3408.94 (1084.85)	-83.32 (252.97)	80.70	-6499.00 to 1969.00
Week 24						
MK-3102 25 mg	65	3577.62 (1304.44)	3742.91 (1169.47)	165.29 (105.73)	168.00	-1881.40 to 2187.10
Placebo	33	3492.26 (1796.63)	3520.69 (1437.36)	28.42 (165.06)	252.60	-3079.40 to 1703.80

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	3500.32 (1312.84)	-	-	-	-
Placebo	34	3263.32 (1373.08)	-	-	-	-
Week 4						
MK-3102 25 mg	65	3500.32 (1312.84)	3448.85 (1360.24)	-51.48 (148.75)	16.50	-4816.20 to 4605.40
Placebo	34	3263.32 (1373.08)	3245.76 (1431.43)	-17.56 (184.52)	21.65	-3337.60 to 3732.90
Week 8						
MK-3102 25 mg	65	3500.32 (1312.84)	3483.64 (1231.06)	-16.69 (128.64)	122.60	-4777.20 to 1810.40
Placebo	33	3128.54 (1143.39)	3165.63 (1217.46)	37.09 (108.01)	121.90	-980.70 to 1712.10
Week 12						
MK-3102 25 mg	64	3516.18 (1316.93)	3413.66 (1170.00)	-102.52 (137.61)	30.55	-5857.70 to 2308.70
Placebo	33	3128.54 (1143.39)	3128.03 (1333.13)	-0.51 (177.94)	38.60	-1698.00 to 3771.10
Week 24						
MK-3102 25 mg	63	3486.37 (1305.55)	3477.36 (1069.85)	-9.00 (156.76)	108.00	-5822.40 to 2375.10
Placebo	33	3128.54 (1143.39)	2910.53 (1197.00)	-218.01 (98.73)	-120.70	-2027.30 to 832.00

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	3658.11 (1554.59)	-	-	-	-
Placebo	32	3203.63 (1150.46)	-	-	-	-
Week 4						
MK-3102 25 mg	67	3658.11 (1554.59)	3824.73 (1273.34)	166.62 (156.30)	135.00	-4596.40 to 4785.70
Placebo	32	3203.63 (1150.46)	3048.40 (1113.16)	-155.23 (149.25)	-165.70	-1961.60 to 2913.00
Week 8						
MK-3102 25 mg	67	3658.11 (1554.59)	3605.11 (1048.76)	-53.00 (160.13)	61.60	-6315.00 to 3119.00
Placebo	32	3203.63 (1150.46)	3152.98 (1342.04)	-50.65 (211.35)	-7.30	-2826.00 to 5196.00
Week 12						
MK-3102 25 mg	67	3658.11 (1554.59)	3727.14 (1191.02)	69.03 (151.60)	119.70	-5246.40 to 2143.10
Placebo	30	3186.22 (1186.18)	3106.80 (1446.40)	-79.42 (185.37)	-133.05	-2679.00 to 3227.80
Week 24						
MK-3102 25 mg	67	3658.11 (1554.59)	3615.98 (971.10)	-42.13 (147.43)	109.40	-6136.00 to 2010.30
Placebo	29	3197.21 (1205.62)	3253.10 (1809.41)	55.89 (252.44)	78.70	-2715.90 to 5502.20

C Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	1937.70 (557.96)	-	-	-	-
Placebo	63	1769.81 (546.15)	-	-	-	-
Week 4						
MK-3102 25 mg	126	1937.70 (557.96)	1860.70 (512.20)	-76.99 (24.83)	-40.05	-908.80 to 609.00
Placebo	63	1769.81 (546.15)	1830.91 (563.09)	61.10 (37.71)	58.50	-700.70 to 973.60
Week 8						
MK-3102 25 mg	125	1928.86 (551.29)	1873.95 (582.05)	-54.92 (30.01)	-35.80	-1324.80 to 812.70
Placebo	63	1769.81 (546.15)	1868.46 (502.62)	98.65 (49.24)	76.60	-1696.60 to 952.00
Week 12						
MK-3102 25 mg	124	1933.49 (551.08)	1931.70 (563.26)	-1.79 (27.45)	16.20	-1049.60 to 750.80
Placebo	63	1769.81 (546.15)	1860.59 (529.53)	90.78 (42.20)	133.00	-710.30 to 829.60
Week 24						
MK-3102 25 mg	122	1930.33 (553.61)	1911.33 (575.70)	-19.00 (26.26)	-36.75	-965.60 to 1051.60
Placebo	62	1776.46 (548.03)	1872.75 (552.29)	96.29 (43.36)	72.90	-643.60 to 1273.30

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	1873.02 (612.91)	-	-	-	-
Placebo	34	1685.91 (587.78)	-	-	-	-
Week 4						
MK-3102 25 mg	65	1873.02 (612.91)	1853.54 (538.93)	-19.48 (41.82)	41.60	-1272.20 to 1193.50
Placebo	34	1685.91 (587.78)	1777.47 (536.38)	91.56 (61.91)	46.10	-674.10 to 1453.60
Week 8						
MK-3102 25 mg	65	1873.02 (612.91)	1883.12 (612.55)	10.10 (52.68)	-39.60	-760.40 to 2025.70
Placebo	34	1685.91 (587.78)	1815.87 (534.65)	129.96 (56.67)	147.45	-643.40 to 1298.00
Week 12						
MK-3102 25 mg	62	1887.18 (623.43)	1898.31 (556.25)	11.13 (51.61)	27.75	-796.10 to 1768.80
Placebo	34	1685.91 (587.78)	1791.36 (504.06)	105.44 (61.78)	94.95	-623.70 to 1506.30
Week 24						
MK-3102 25 mg	61	1884.23 (628.16)	1896.50 (558.79)	12.28 (50.30)	35.80	-907.90 to 1635.00
Placebo	31	1711.37 (603.34)	1835.98 (553.59)	124.61 (63.76)	100.50	-392.70 to 1467.40

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	1873.16 (585.83)	-	-	-	-
Placebo	33	1937.92 (480.55)	-	-	-	-
Week 4						
MK-3102 25 mg	66	1873.16 (585.83)	1843.39 (540.70)	-29.77 (33.07)	-67.35	-500.00 to 636.60
Placebo	33	1937.92 (480.55)	2027.60 (514.23)	89.68 (44.54)	46.00	-472.20 to 690.20
Week 8						
MK-3102 25 mg	66	1873.16 (585.83)	1807.57 (532.15)	-65.59 (39.31)	-65.15	-800.70 to 619.60
Placebo	33	1937.92 (480.55)	1955.61 (551.89)	17.69 (48.74)	1.50	-566.60 to 591.00
Week 12						
MK-3102 25 mg	66	1873.16 (585.83)	1823.92 (583.90)	-49.23 (40.67)	-71.05	-762.00 to 1092.30
Placebo	33	1937.92 (480.55)	1955.26 (503.99)	17.35 (43.41)	-3.00	-558.30 to 610.00
Week 24						
MK-3102 25 mg	65	1879.74 (587.92)	1898.77 (530.94)	19.02 (41.26)	18.90	-785.20 to 893.40
Placebo	33	1937.92 (480.55)	1997.19 (534.31)	59.27 (60.62)	19.90	-515.60 to 877.40

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	1919.28 (560.91)	-	-	-	-
Placebo	34	1770.79 (660.47)	-	-	-	-
Week 4						
MK-3102 25 mg	65	1919.28 (560.91)	1798.91 (462.00)	-120.37 (36.65)	-87.90	-965.00 to 620.20
Placebo	34	1770.79 (660.47)	1779.25 (687.44)	8.46 (51.12)	-7.70	-504.90 to 632.70
Week 8						
MK-3102 25 mg	65	1919.28 (560.91)	1821.82 (526.72)	-97.46 (34.61)	-82.90	-870.00 to 492.60
Placebo	33	1747.78 (656.73)	1728.44 (684.57)	-19.34 (47.95)	-3.10	-746.10 to 519.20
Week 12						
MK-3102 25 mg	64	1911.75 (562.02)	1897.76 (584.70)	-13.99 (36.53)	-3.35	-796.40 to 961.50
Placebo	33	1747.78 (656.73)	1758.55 (658.84)	10.77 (43.77)	1.00	-708.60 to 508.30
Week 24						
MK-3102 25 mg	63	1901.31 (560.25)	1846.46 (595.13)	-54.85 (42.81)	8.60	-907.60 to 708.90
Placebo	33	1747.78 (656.73)	1778.62 (582.69)	30.84 (40.71)	34.40	-583.70 to 578.20

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	1788.54 (498.08)	-	-	-	-
Placebo	32	1934.79 (593.86)	-	-	-	-
Week 4						
MK-3102 25 mg	67	1788.54 (498.08)	1750.75 (494.63)	-37.79 (43.18)	27.50	-1558.50 to 631.80
Placebo	32	1934.79 (593.86)	1894.65 (581.62)	-40.14 (75.60)	36.80	-1456.20 to 804.00
Week 8						
MK-3102 25 mg	67	1788.54 (498.08)	1814.62 (465.03)	26.08 (38.39)	78.10	-1136.60 to 757.70
Placebo	32	1934.79 (593.86)	1851.66 (510.55)	-83.13 (64.99)	-53.15	-884.70 to 787.90
Week 12						
MK-3102 25 mg	67	1788.54 (498.08)	1841.65 (526.50)	53.11 (43.98)	85.20	-715.00 to 1149.50
Placebo	30	1925.19 (612.55)	1893.68 (501.51)	-31.51 (55.96)	-66.65	-943.30 to 440.40
Week 24						
MK-3102 25 mg	67	1788.54 (498.08)	1861.20 (554.96)	72.66 (41.14)	93.20	-690.00 to 778.60
Placebo	29	1925.47 (623.39)	1857.57 (473.20)	-67.90 (66.64)	-15.60	-1111.70 to 383.40

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	319.43 (99.94)	-	-	-	-
Placebo	63	300.82 (113.37)	-	-	-	-
Week 4						
MK-3102 25 mg	126	319.43 (99.94)	335.21 (112.30)	15.78 (6.72)	7.65	-208.60 to 289.20
Placebo	63	300.82 (113.37)	294.51 (86.03)	-6.32 (8.32)	-7.20	-185.40 to 138.00
Week 8						
MK-3102 25 mg	125	318.50 (99.80)	339.82 (105.03)	21.32 (7.25)	18.10	-219.70 to 265.20
Placebo	63	300.82 (113.37)	296.00 (97.58)	-4.82 (11.05)	0.30	-308.40 to 143.30
Week 12						
MK-3102 25 mg	124	319.36 (99.73)	332.81 (100.86)	13.45 (6.64)	12.85	-266.90 to 259.00
Placebo	63	300.82 (113.37)	305.44 (105.19)	4.62 (11.26)	18.00	-239.20 to 324.00
Week 24						
MK-3102 25 mg	122	319.23 (100.08)	340.12 (111.66)	20.89 (7.58)	19.80	-203.00 to 354.50
Placebo	62	297.98 (112.00)	294.76 (90.88)	-3.22 (9.44)	-1.15	-240.90 to 148.20

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	311.33 (92.63)	-	-	-	-
Placebo	34	315.14 (106.24)	-	-	-	-
Week 4						
MK-3102 25 mg	65	311.33 (92.63)	328.33 (89.14)	17.00 (10.61)	18.50	-211.70 to 289.90
Placebo	34	315.14 (106.24)	298.91 (81.06)	-16.24 (12.86)	-6.70	-245.50 to 182.40
Week 8						
MK-3102 25 mg	65	311.33 (92.63)	333.08 (98.27)	21.75 (10.11)	13.20	-191.40 to 248.90
Placebo	34	315.14 (106.24)	314.39 (90.41)	-0.75 (14.94)	1.70	-245.50 to 281.80
Week 12						
MK-3102 25 mg	62	311.92 (94.53)	337.36 (80.10)	25.44 (10.71)	26.20	-176.70 to 221.20
Placebo	34	315.14 (106.24)	322.78 (88.05)	7.64 (10.38)	5.20	-111.10 to 143.40
Week 24						
MK-3102 25 mg	61	310.84 (94.93)	310.09 (76.45)	-0.75 (10.06)	-2.10	-237.50 to 181.20
Placebo	31	317.15 (106.70)	293.76 (82.80)	-23.39 (11.82)	-23.70	-189.10 to 129.30

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	327.13 (122.85)	-	-	-	-
Placebo	33	321.32 (103.78)	-	-	-	-
Week 4						
MK-3102 25 mg	66	327.13 (122.85)	329.47 (136.23)	2.34 (9.35)	9.55	-257.60 to 209.30
Placebo	33	321.32 (103.78)	342.89 (95.10)	21.58 (15.71)	24.70	-233.00 to 175.60
Week 8						
MK-3102 25 mg	66	327.13 (122.85)	334.28 (113.67)	7.15 (11.06)	16.35	-262.80 to 364.40
Placebo	33	321.32 (103.78)	337.86 (105.38)	16.54 (15.39)	18.00	-231.90 to 156.10
Week 12						
MK-3102 25 mg	66	327.13 (122.85)	350.50 (137.30)	23.38 (10.37)	18.90	-166.70 to 234.00
Placebo	33	321.32 (103.78)	322.20 (109.25)	0.88 (16.77)	0.00	-283.50 to 316.10
Week 24						
MK-3102 25 mg	65	326.78 (123.78)	340.65 (123.20)	13.88 (9.74)	3.60	-125.70 to 284.40
Placebo	33	321.32 (103.78)	322.29 (102.85)	0.98 (14.88)	3.80	-264.10 to 143.30

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	308.44 (101.35)	-	-	-	-
Placebo	34	303.74 (96.85)	-	-	-	-
Week 4						
MK-3102 25 mg	65	308.44 (101.35)	329.06 (112.42)	20.62 (11.39)	12.80	-265.40 to 254.50
Placebo	34	303.74 (96.85)	306.26 (85.88)	2.52 (13.45)	-3.30	-209.00 to 190.30
Week 8						
MK-3102 25 mg	65	308.44 (101.35)	335.43 (111.02)	26.99 (12.26)	30.50	-305.40 to 354.50
Placebo	33	294.28 (80.83)	301.11 (90.93)	6.83 (9.81)	9.00	-90.60 to 135.50
Week 12						
MK-3102 25 mg	64	308.87 (102.09)	330.04 (108.30)	21.17 (10.94)	23.10	-224.10 to 205.80
Placebo	33	294.28 (80.83)	314.99 (125.55)	20.71 (15.56)	-8.70	-96.00 to 324.20
Week 24						
MK-3102 25 mg	63	306.65 (101.34)	337.67 (115.21)	31.02 (13.53)	29.20	-339.80 to 461.60
Placebo	33	294.28 (80.83)	274.84 (78.78)	-19.44 (9.42)	-11.50	-138.10 to 93.70

C Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	310.78 (101.73)	-	-	-	-
Placebo	32	326.80 (93.55)	-	-	-	-
Week 4						
MK-3102 25 mg	67	310.78 (101.73)	353.16 (121.01)	42.38 (10.41)	24.60	-161.70 to 264.80
Placebo	32	326.80 (93.55)	315.20 (94.79)	-11.60 (11.48)	-12.30	-110.30 to 191.40
Week 8						
MK-3102 25 mg	67	310.78 (101.73)	337.49 (103.74)	26.70 (9.43)	19.50	-130.40 to 213.00
Placebo	32	326.80 (93.55)	325.90 (114.13)	-0.89 (17.20)	-4.95	-146.20 to 297.00
Week 12						
MK-3102 25 mg	67	310.78 (101.73)	348.88 (104.27)	38.10 (8.01)	36.50	-120.80 to 184.00
Placebo	30	318.60 (87.68)	297.80 (98.35)	-20.81 (14.12)	-23.05	-187.40 to 103.80
Week 24						
MK-3102 25 mg	67	310.78 (101.73)	336.43 (104.90)	25.65 (9.18)	19.90	-210.70 to 209.60
Placebo	29	314.32 (85.98)	297.79 (85.63)	-16.53 (14.11)	-20.80	-209.00 to 125.80

C Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	183.49 (132.15)	-	-	-	-
Placebo	63	161.36 (119.20)	-	-	-	-
Week 4						
MK-3102 25 mg	126	183.49 (132.15)	186.89 (141.46)	3.41 (6.66)	1.95	-208.40 to 293.30
Placebo	63	161.36 (119.20)	168.76 (104.54)	7.40 (8.46)	2.70	-290.40 to 199.50
Week 8						
MK-3102 25 mg	125	183.34 (132.67)	191.64 (146.14)	8.30 (7.60)	-2.90	-205.20 to 627.20
Placebo	63	161.36 (119.20)	162.79 (103.50)	1.43 (8.30)	2.90	-317.90 to 182.10
Week 12						
MK-3102 25 mg	124	182.98 (133.15)	193.27 (145.16)	10.30 (7.66)	3.40	-243.40 to 327.60
Placebo	63	161.36 (119.20)	167.17 (108.86)	5.82 (9.06)	8.00	-322.80 to 140.60
Week 24						
MK-3102 25 mg	122	183.82 (134.06)	182.20 (124.75)	-1.62 (8.05)	5.10	-328.80 to 240.60
Placebo	62	162.36 (119.91)	158.95 (103.07)	-3.41 (10.96)	5.95	-471.00 to 183.60

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	173.15 (113.25)	-	-	-	-
Placebo	34	115.38 (90.08)	-	-	-	-
Week 4						
MK-3102 25 mg	65	173.15 (113.25)	178.83 (120.52)	5.69 (7.47)	-7.70	-117.00 to 208.50
Placebo	34	115.38 (90.08)	121.21 (102.85)	5.82 (8.02)	1.95	-161.00 to 111.40
Week 8						
MK-3102 25 mg	65	173.15 (113.25)	162.61 (104.44)	-10.54 (9.05)	-6.70	-208.20 to 215.10
Placebo	34	115.38 (90.08)	122.07 (105.33)	6.69 (9.77)	1.40	-162.00 to 154.00
Week 12						
MK-3102 25 mg	62	172.83 (112.47)	184.83 (147.04)	12.00 (15.05)	-2.45	-169.80 to 726.20
Placebo	34	115.38 (90.08)	119.19 (106.62)	3.80 (8.69)	-0.00	-168.00 to 148.80
Week 24						
MK-3102 25 mg	61	173.56 (113.26)	167.18 (111.50)	-6.39 (11.17)	-6.10	-249.70 to 302.40
Placebo	31	118.58 (93.25)	135.27 (115.32)	16.69 (9.11)	10.70	-120.50 to 135.60

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	178.07 (123.35)	-	-	-	-
Placebo	33	178.16 (115.63)	-	-	-	-
Week 4						
MK-3102 25 mg	66	178.07 (123.35)	183.50 (142.19)	5.43 (9.61)	1.20	-114.80 to 342.00
Placebo	33	178.16 (115.63)	200.31 (135.54)	22.15 (15.49)	23.40	-148.50 to 358.40
Week 8						
MK-3102 25 mg	66	178.07 (123.35)	167.58 (129.67)	-10.48 (6.81)	-11.30	-160.80 to 152.90
Placebo	33	178.16 (115.63)	186.79 (130.30)	8.63 (18.09)	0.00	-188.40 to 440.40
Week 12						
MK-3102 25 mg	66	178.07 (123.35)	163.32 (114.05)	-14.75 (9.58)	-7.25	-440.00 to 128.40
Placebo	33	178.16 (115.63)	185.06 (109.85)	6.90 (13.74)	8.70	-182.50 to 201.50
Week 24						
MK-3102 25 mg	65	179.89 (123.41)	168.51 (104.67)	-11.37 (7.76)	-7.50	-266.50 to 158.50
Placebo	33	178.16 (115.63)	168.62 (116.58)	-9.54 (13.76)	-0.80	-228.70 to 153.40

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	180.05 (118.37)	-	-	-	-
Placebo	34	134.37 (72.67)	-	-	-	-
Week 4						
MK-3102 25 mg	65	180.05 (118.37)	184.19 (126.92)	4.14 (6.77)	-7.00	-127.70 to 212.20
Placebo	34	134.37 (72.67)	143.58 (79.94)	9.21 (8.64)	10.05	-67.30 to 154.30
Week 8						
MK-3102 25 mg	65	180.05 (118.37)	180.38 (138.34)	0.33 (8.50)	0.30	-111.80 to 388.60
Placebo	33	135.11 (73.67)	141.91 (61.30)	6.81 (10.32)	3.80	-110.00 to 122.10
Week 12						
MK-3102 25 mg	64	180.96 (119.08)	185.89 (167.91)	4.93 (13.78)	-5.15	-137.10 to 754.90
Placebo	33	135.11 (73.67)	129.12 (50.85)	-5.98 (13.61)	-9.70	-262.50 to 138.80
Week 24						
MK-3102 25 mg	63	178.10 (117.81)	196.33 (206.86)	18.23 (20.20)	0.00	-116.00 to 1195.40
Placebo	33	135.11 (73.67)	128.97 (65.89)	-6.13 (6.70)	-7.60	-99.40 to 92.10

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	158.59 (109.81)	-	-	-	-
Placebo	32	164.67 (115.12)	-	-	-	-
Week 4						
MK-3102 25 mg	67	158.59 (109.81)	155.83 (107.36)	-2.77 (7.51)	-1.10	-174.80 to 235.20
Placebo	32	164.67 (115.12)	159.27 (127.77)	-5.40 (10.08)	-13.65	-208.90 to 171.00
Week 8						
MK-3102 25 mg	67	158.59 (109.81)	158.64 (126.85)	0.05 (11.12)	-6.90	-283.40 to 538.00
Placebo	32	164.67 (115.12)	155.61 (109.77)	-9.07 (8.76)	-4.65	-111.60 to 79.20
Week 12						
MK-3102 25 mg	67	158.59 (109.81)	164.72 (110.52)	6.13 (7.76)	12.20	-171.20 to 274.50
Placebo	30	158.52 (110.96)	151.93 (101.62)	-6.59 (9.15)	-4.35	-136.20 to 93.30
Week 24						
MK-3102 25 mg	67	158.59 (109.81)	169.42 (102.65)	10.83 (6.89)	16.40	-136.50 to 228.60
Placebo	29	159.14 (112.87)	157.19 (98.76)	-1.96 (11.75)	-5.50	-131.00 to 202.00

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	34.48 (21.49)	-	-	-	-
Placebo	63	38.07 (26.16)	-	-	-	-
Week 4						
MK-3102 25 mg	126	34.48 (21.49)	36.73 (22.26)	2.25 (1.32)	0.70	-28.30 to 60.60
Placebo	63	38.07 (26.16)	36.82 (23.44)	-1.25 (2.16)	-1.50	-74.10 to 49.10
Week 8						
MK-3102 25 mg	125	34.49 (21.57)	35.72 (22.21)	1.22 (1.20)	0.80	-33.20 to 42.60
Placebo	63	38.07 (26.16)	35.00 (22.66)	-3.06 (2.49)	-0.30	-73.30 to 41.70
Week 12						
MK-3102 25 mg	124	34.38 (21.62)	35.59 (22.24)	1.21 (1.48)	0.00	-38.00 to 91.80
Placebo	63	38.07 (26.16)	33.46 (21.21)	-4.60 (2.40)	-1.60	-93.60 to 27.90
Week 24						
MK-3102 25 mg	122	34.52 (21.75)	33.51 (21.17)	-1.01 (1.15)	0.55	-45.90 to 26.20
Placebo	62	36.78 (24.28)	35.00 (21.64)	-1.78 (2.20)	0.10	-50.30 to 67.80

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	36.37 (19.62)	-	-	-	-
Placebo	34	26.49 (20.78)	-	-	-	-
Week 4						
MK-3102 25 mg	65	36.37 (19.62)	34.35 (19.00)	-2.02 (1.83)	-0.40	-35.30 to 32.00
Placebo	34	26.49 (20.78)	29.78 (21.16)	3.29 (1.99)	0.60	-16.20 to 28.40
Week 8						
MK-3102 25 mg	65	36.37 (19.62)	32.56 (17.60)	-3.81 (1.85)	-2.30	-32.10 to 32.30
Placebo	34	26.49 (20.78)	27.41 (19.63)	0.93 (2.21)	0.50	-30.50 to 32.40
Week 12						
MK-3102 25 mg	62	36.40 (19.98)	33.99 (21.28)	-2.41 (2.01)	-1.85	-38.60 to 48.60
Placebo	34	26.49 (20.78)	31.32 (20.96)	4.83 (1.87)	4.25	-15.40 to 29.90
Week 24						
MK-3102 25 mg	61	36.68 (20.03)	33.89 (19.14)	-2.79 (1.81)	-1.80	-30.10 to 42.00
Placebo	31	25.74 (20.66)	26.46 (19.10)	0.72 (2.34)	-0.50	-20.50 to 42.60

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	37.10 (21.28)	-	-	-	-
Placebo	33	37.01 (19.68)	-	-	-	-
Week 4						
MK-3102 25 mg	66	37.10 (21.28)	37.43 (20.47)	0.33 (1.87)	-0.40	-46.80 to 51.00
Placebo	33	37.01 (19.68)	37.51 (20.91)	0.50 (2.11)	2.50	-30.00 to 23.30
Week 8						
MK-3102 25 mg	66	37.10 (21.28)	34.20 (22.39)	-2.90 (1.93)	-2.00	-45.10 to 46.30
Placebo	33	37.01 (19.68)	37.87 (21.88)	0.86 (2.69)	-0.30	-32.00 to 47.20
Week 12						
MK-3102 25 mg	66	37.10 (21.28)	36.30 (21.92)	-0.80 (1.72)	-0.90	-41.30 to 37.90
Placebo	33	37.01 (19.68)	37.62 (19.17)	0.61 (2.75)	1.30	-31.50 to 42.20
Week 24						
MK-3102 25 mg	65	37.52 (21.17)	35.31 (19.36)	-2.21 (1.85)	-1.00	-49.00 to 29.60
Placebo	33	37.01 (19.68)	36.66 (19.96)	-0.35 (3.13)	0.00	-33.00 to 47.60

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	31.91 (22.29)	-	-	-	-
Placebo	34	27.79 (15.91)	-	-	-	-
Week 4						
MK-3102 25 mg	65	31.91 (22.29)	32.84 (21.88)	0.94 (2.41)	1.00	-101.00 to 57.20
Placebo	34	27.79 (15.91)	28.09 (15.15)	0.30 (1.94)	1.35	-29.70 to 21.20
Week 8						
MK-3102 25 mg	65	31.91 (22.29)	31.04 (16.68)	-0.86 (2.12)	0.20	-102.50 to 32.80
Placebo	33	27.63 (16.13)	29.58 (18.51)	1.95 (1.94)	1.10	-21.90 to 26.80
Week 12						
MK-3102 25 mg	64	32.24 (22.30)	30.46 (20.23)	-1.78 (2.52)	-0.45	-102.00 to 46.20
Placebo	33	27.63 (16.13)	26.88 (15.67)	-0.75 (2.57)	0.80	-31.60 to 34.50
Week 24						
MK-3102 25 mg	63	32.33 (22.46)	31.07 (21.41)	-1.27 (2.29)	-1.00	-91.20 to 50.30
Placebo	33	27.63 (16.13)	28.25 (16.00)	0.62 (1.77)	0.00	-19.50 to 25.60

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	33.22 (18.45)	-	-	-	-
Placebo	32	38.87 (27.89)	-	-	-	-
Week 4						
MK-3102 25 mg	67	33.22 (18.45)	30.46 (20.37)	-2.76 (1.90)	-2.40	-51.20 to 31.20
Placebo	32	38.87 (27.89)	38.73 (28.88)	-0.13 (3.13)	0.20	-68.80 to 20.80
Week 8						
MK-3102 25 mg	67	33.22 (18.45)	36.38 (21.71)	3.16 (1.57)	1.50	-20.00 to 48.40
Placebo	32	38.87 (27.89)	35.73 (22.69)	-3.13 (3.31)	1.25	-60.20 to 30.50
Week 12						
MK-3102 25 mg	67	33.22 (18.45)	34.03 (17.88)	0.81 (1.63)	-0.40	-23.20 to 30.20
Placebo	30	38.14 (28.32)	33.13 (28.46)	-5.01 (3.11)	-1.90	-60.60 to 33.60
Week 24						
MK-3102 25 mg	67	33.22 (18.45)	33.38 (17.06)	0.16 (1.69)	0.00	-37.00 to 30.30
Placebo	29	38.33 (28.80)	34.35 (26.35)	-3.99 (3.18)	-0.40	-60.20 to 21.50

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	7.25 (0.39)	-	-	-	-
Placebo	63	7.25 (0.46)	-	-	-	-
Week 4						
MK-3102 25 mg	126	7.25 (0.39)	7.28 (0.38)	0.03 (0.03)	0.00	-0.90 to 0.90
Placebo	63	7.25 (0.46)	7.30 (0.39)	0.05 (0.04)	0.10	-0.70 to 0.60
Week 8						
MK-3102 25 mg	125	7.25 (0.39)	7.30 (0.39)	0.05 (0.03)	0.00	-0.90 to 1.40
Placebo	63	7.25 (0.46)	7.33 (0.48)	0.08 (0.04)	0.10	-0.70 to 1.10
Week 12						
MK-3102 25 mg	124	7.25 (0.40)	7.28 (0.38)	0.02 (0.03)	0.00	-0.80 to 0.90
Placebo	63	7.25 (0.46)	7.24 (0.45)	-0.02 (0.04)	0.00	-0.80 to 0.50
Week 24						
MK-3102 25 mg	122	7.26 (0.40)	7.24 (0.37)	-0.02 (0.03)	0.00	-0.90 to 1.10
Placebo	62	7.25 (0.46)	7.17 (0.42)	-0.08 (0.04)	-0.10	-0.60 to 0.70

C Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	7.33 (0.49)	-	-	-	-
Placebo	34	7.43 (0.51)	-	-	-	-
Week 4						
MK-3102 25 mg	65	7.33 (0.49)	7.37 (0.47)	0.04 (0.05)	0.00	-1.20 to 0.80
Placebo	34	7.43 (0.51)	7.47 (0.50)	0.04 (0.08)	0.00	-0.80 to 1.80
Week 8						
MK-3102 25 mg	65	7.33 (0.49)	7.41 (0.44)	0.08 (0.05)	0.10	-1.30 to 1.40
Placebo	34	7.43 (0.51)	7.42 (0.45)	-0.01 (0.05)	0.10	-0.80 to 0.50
Week 12						
MK-3102 25 mg	62	7.35 (0.48)	7.46 (0.51)	0.11 (0.05)	0.15	-1.20 to 0.70
Placebo	34	7.43 (0.51)	7.37 (0.44)	-0.06 (0.06)	-0.10	-0.80 to 0.60
Week 24						
MK-3102 25 mg	61	7.35 (0.48)	7.34 (0.48)	-0.01 (0.06)	0.00	-1.40 to 1.00
Placebo	31	7.45 (0.53)	7.35 (0.45)	-0.11 (0.07)	-0.10	-1.00 to 0.50

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	7.33 (0.37)	-	-	-	-
Placebo	33	7.39 (0.53)	-	-	-	-
Week 4						
MK-3102 25 mg	66	7.33 (0.37)	7.38 (0.42)	0.05 (0.04)	0.00	-0.60 to 1.10
Placebo	33	7.39 (0.53)	7.32 (0.47)	-0.07 (0.07)	0.00	-1.10 to 0.50
Week 8						
MK-3102 25 mg	66	7.33 (0.37)	7.41 (0.41)	0.08 (0.04)	0.10	-0.60 to 1.00
Placebo	33	7.39 (0.53)	7.32 (0.47)	-0.08 (0.08)	-0.10	-1.30 to 0.70
Week 12						
MK-3102 25 mg	66	7.33 (0.37)	7.34 (0.39)	0.02 (0.04)	0.00	-0.80 to 0.80
Placebo	33	7.39 (0.53)	7.29 (0.47)	-0.10 (0.06)	-0.10	-0.70 to 0.90
Week 24						
MK-3102 25 mg	65	7.32 (0.37)	7.28 (0.42)	-0.04 (0.04)	0.00	-1.20 to 0.70
Placebo	33	7.39 (0.53)	7.18 (0.47)	-0.21 (0.07)	-0.10	-1.10 to 0.40

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	7.35 (0.45)	-	-	-	-
Placebo	34	7.19 (0.42)	-	-	-	-
Week 4						
MK-3102 25 mg	65	7.35 (0.45)	7.32 (0.43)	-0.03 (0.04)	0.00	-0.70 to 0.80
Placebo	34	7.19 (0.42)	7.20 (0.45)	0.01 (0.06)	0.05	-0.80 to 0.80
Week 8						
MK-3102 25 mg	65	7.35 (0.45)	7.37 (0.50)	0.02 (0.05)	0.00	-0.70 to 1.00
Placebo	33	7.18 (0.43)	7.19 (0.41)	0.01 (0.05)	0.00	-0.50 to 0.90
Week 12						
MK-3102 25 mg	64	7.35 (0.45)	7.33 (0.45)	-0.02 (0.04)	-0.10	-0.80 to 1.00
Placebo	33	7.18 (0.43)	7.22 (0.41)	0.04 (0.06)	0.10	-0.60 to 0.50
Week 24						
MK-3102 25 mg	63	7.35 (0.46)	7.21 (0.42)	-0.13 (0.04)	-0.10	-0.90 to 0.70
Placebo	33	7.18 (0.43)	7.06 (0.36)	-0.12 (0.05)	0.00	-0.90 to 0.40

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	7.30 (0.40)	-	-	-	-
Placebo	32	7.26 (0.44)	-	-	-	-
Week 4						
MK-3102 25 mg	67	7.30 (0.40)	7.31 (0.34)	0.01 (0.04)	0.00	-0.70 to 0.80
Placebo	32	7.26 (0.44)	7.20 (0.39)	-0.06 (0.08)	0.00	-1.00 to 0.70
Week 8						
MK-3102 25 mg	67	7.30 (0.40)	7.34 (0.38)	0.03 (0.04)	0.00	-0.70 to 0.90
Placebo	32	7.26 (0.44)	7.19 (0.40)	-0.08 (0.08)	0.00	-0.90 to 0.80
Week 12						
MK-3102 25 mg	67	7.30 (0.40)	7.38 (0.39)	0.08 (0.05)	0.10	-0.80 to 1.10
Placebo	30	7.24 (0.44)	7.14 (0.37)	-0.09 (0.05)	-0.05	-0.80 to 0.40
Week 24						
MK-3102 25 mg	67	7.30 (0.40)	7.29 (0.37)	-0.01 (0.05)	0.00	-0.80 to 0.90
Placebo	29	7.25 (0.44)	7.03 (0.39)	-0.22 (0.08)	-0.10	-1.10 to 0.40

Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	4.39 (0.23)	-	-	-	-
Placebo	63	4.34 (0.25)	-	-	-	-
Week 4						
MK-3102 25 mg	126	4.39 (0.23)	4.40 (0.25)	0.01 (0.02)	0.00	-0.40 to 0.60
Placebo	63	4.34 (0.25)	4.39 (0.19)	0.05 (0.03)	0.10	-0.40 to 0.50
Week 8						
MK-3102 25 mg	125	4.39 (0.23)	4.39 (0.25)	0.00 (0.02)	0.00	-0.50 to 0.70
Placebo	63	4.34 (0.25)	4.41 (0.25)	0.07 (0.03)	0.10	-0.40 to 0.70
Week 12						
MK-3102 25 mg	124	4.39 (0.23)	4.39 (0.24)	-0.00 (0.02)	0.00	-0.60 to 0.50
Placebo	63	4.34 (0.25)	4.37 (0.23)	0.03 (0.02)	0.00	-0.40 to 0.40
Week 24						
MK-3102 25 mg	122	4.39 (0.23)	4.35 (0.26)	-0.04 (0.02)	0.00	-0.70 to 0.50
Placebo	62	4.34 (0.25)	4.33 (0.24)	-0.01 (0.02)	0.00	-0.30 to 0.60

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	4.50 (0.27)	-	-	-	-
Placebo	34	4.47 (0.24)	-	-	-	-
Week 4						
MK-3102 25 mg	65	4.50 (0.27)	4.51 (0.28)	0.01 (0.03)	0.00	-0.70 to 0.70
Placebo	34	4.47 (0.24)	4.49 (0.24)	0.02 (0.03)	0.10	-0.50 to 0.40
Week 8						
MK-3102 25 mg	65	4.50 (0.27)	4.53 (0.23)	0.03 (0.03)	0.00	-0.70 to 0.70
Placebo	34	4.47 (0.24)	4.47 (0.22)	-0.00 (0.03)	0.05	-0.40 to 0.40
Week 12						
MK-3102 25 mg	62	4.50 (0.27)	4.50 (0.27)	0.00 (0.03)	0.00	-0.60 to 0.60
Placebo	34	4.47 (0.24)	4.43 (0.24)	-0.04 (0.03)	0.00	-0.50 to 0.30
Week 24						
MK-3102 25 mg	61	4.51 (0.27)	4.47 (0.27)	-0.04 (0.03)	0.00	-0.70 to 0.60
Placebo	31	4.46 (0.24)	4.42 (0.20)	-0.04 (0.04)	0.00	-0.50 to 0.30

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	4.47 (0.22)	-	-	-	-
Placebo	33	4.54 (0.25)	-	-	-	-
Week 4						
MK-3102 25 mg	66	4.47 (0.22)	4.47 (0.26)	0.01 (0.03)	0.00	-0.50 to 0.70
Placebo	33	4.54 (0.25)	4.50 (0.23)	-0.04 (0.04)	0.00	-0.60 to 0.30
Week 8						
MK-3102 25 mg	66	4.47 (0.22)	4.47 (0.23)	0.00 (0.02)	0.00	-0.50 to 0.50
Placebo	33	4.54 (0.25)	4.48 (0.24)	-0.07 (0.05)	0.00	-0.80 to 0.40
Week 12						
MK-3102 25 mg	66	4.47 (0.22)	4.43 (0.22)	-0.03 (0.03)	0.00	-0.60 to 0.50
Placebo	33	4.54 (0.25)	4.48 (0.22)	-0.06 (0.04)	-0.10	-0.50 to 0.60
Week 24						
MK-3102 25 mg	65	4.46 (0.23)	4.41 (0.23)	-0.06 (0.03)	-0.10	-0.70 to 0.50
Placebo	33	4.54 (0.25)	4.45 (0.18)	-0.10 (0.05)	0.00	-0.80 to 0.30

Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	4.39 (0.27)	-	-	-	-
Placebo	34	4.40 (0.27)	-	-	-	-
Week 4						
MK-3102 25 mg	65	4.39 (0.27)	4.38 (0.28)	-0.00 (0.02)	0.00	-0.40 to 0.60
Placebo	34	4.40 (0.27)	4.38 (0.28)	-0.03 (0.04)	0.00	-0.40 to 0.50
Week 8						
MK-3102 25 mg	65	4.39 (0.27)	4.39 (0.26)	0.00 (0.03)	0.00	-0.50 to 0.60
Placebo	33	4.39 (0.27)	4.38 (0.22)	-0.01 (0.03)	0.00	-0.50 to 0.50
Week 12						
MK-3102 25 mg	64	4.39 (0.27)	4.36 (0.27)	-0.03 (0.03)	0.00	-0.60 to 0.70
Placebo	33	4.39 (0.27)	4.38 (0.28)	-0.01 (0.04)	0.00	-0.60 to 0.40
Week 24						
MK-3102 25 mg	63	4.40 (0.27)	4.32 (0.26)	-0.08 (0.02)	-0.10	-0.60 to 0.30
Placebo	33	4.39 (0.27)	4.31 (0.23)	-0.08 (0.04)	-0.10	-0.50 to 0.30

Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	4.45 (0.31)	-	-	-	-
Placebo	32	4.42 (0.25)	-	-	-	-
Week 4						
MK-3102 25 mg	67	4.45 (0.31)	4.44 (0.25)	-0.01 (0.03)	0.00	-0.50 to 0.50
Placebo	32	4.42 (0.25)	4.38 (0.26)	-0.04 (0.05)	0.00	-0.70 to 0.50
Week 8						
MK-3102 25 mg	67	4.45 (0.31)	4.42 (0.28)	-0.03 (0.02)	0.00	-0.50 to 0.40
Placebo	32	4.42 (0.25)	4.39 (0.24)	-0.03 (0.05)	0.00	-0.60 to 0.40
Week 12						
MK-3102 25 mg	67	4.45 (0.31)	4.43 (0.24)	-0.02 (0.03)	0.00	-0.60 to 0.50
Placebo	30	4.43 (0.26)	4.34 (0.24)	-0.09 (0.03)	-0.10	-0.60 to 0.30
Week 24						
MK-3102 25 mg	67	4.45 (0.31)	4.40 (0.28)	-0.05 (0.03)	-0.10	-0.60 to 0.50
Placebo	29	4.43 (0.26)	4.29 (0.25)	-0.14 (0.04)	-0.10	-0.70 to 0.20

Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	0.64 (0.22)	-	-	-	-
Placebo	63	0.69 (0.26)	-	-	-	-
Week 4						
MK-3102 25 mg	126	0.64 (0.22)	0.66 (0.22)	0.02 (0.01)	0.00	-0.40 to 0.40
Placebo	63	0.69 (0.26)	0.70 (0.22)	0.00 (0.02)	0.00	-0.60 to 0.40
Week 8						
MK-3102 25 mg	125	0.64 (0.22)	0.62 (0.21)	-0.02 (0.01)	0.00	-0.50 to 0.60
Placebo	63	0.69 (0.26)	0.74 (0.26)	0.05 (0.03)	0.10	-0.40 to 0.60
Week 12						
MK-3102 25 mg	124	0.64 (0.22)	0.63 (0.20)	-0.01 (0.02)	0.00	-0.50 to 0.50
Placebo	63	0.69 (0.26)	0.76 (0.33)	0.07 (0.03)	0.10	-0.30 to 1.10
Week 24						
MK-3102 25 mg	122	0.64 (0.22)	0.67 (0.24)	0.04 (0.02)	0.10	-0.50 to 0.50
Placebo	62	0.69 (0.26)	0.77 (0.29)	0.08 (0.02)	0.10	-0.50 to 0.50

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	0.69 (0.22)	-	-	-	-
Placebo	34	0.75 (0.41)	-	-	-	-
Week 4						
MK-3102 25 mg	65	0.69 (0.22)	0.72 (0.24)	0.04 (0.02)	0.00	-0.30 to 0.40
Placebo	34	0.75 (0.41)	0.85 (0.47)	0.10 (0.04)	0.10	-0.50 to 0.70
Week 8						
MK-3102 25 mg	65	0.69 (0.22)	0.70 (0.25)	0.02 (0.02)	0.00	-0.30 to 0.50
Placebo	34	0.75 (0.41)	0.83 (0.44)	0.08 (0.04)	0.10	-0.40 to 0.80
Week 12						
MK-3102 25 mg	62	0.69 (0.23)	0.71 (0.26)	0.02 (0.02)	0.00	-0.30 to 0.60
Placebo	34	0.75 (0.41)	0.82 (0.43)	0.06 (0.03)	0.10	-0.40 to 0.40
Week 24						
MK-3102 25 mg	61	0.69 (0.23)	0.70 (0.26)	0.02 (0.02)	0.00	-0.40 to 0.40
Placebo	31	0.77 (0.42)	0.87 (0.43)	0.10 (0.04)	0.10	-0.60 to 0.80

Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	0.62 (0.28)	-	-	-	-
Placebo	33	0.70 (0.22)	-	-	-	-
Week 4						
MK-3102 25 mg	66	0.62 (0.28)	0.65 (0.25)	0.02 (0.02)	0.00	-0.60 to 0.30
Placebo	33	0.70 (0.22)	0.81 (0.27)	0.11 (0.04)	0.10	-0.40 to 0.60
Week 8						
MK-3102 25 mg	66	0.62 (0.28)	0.68 (0.29)	0.05 (0.02)	0.05	-0.30 to 0.70
Placebo	33	0.70 (0.22)	0.79 (0.31)	0.09 (0.04)	0.10	-0.40 to 0.50
Week 12						
MK-3102 25 mg	66	0.62 (0.28)	0.69 (0.29)	0.07 (0.02)	0.10	-0.30 to 0.70
Placebo	33	0.70 (0.22)	0.76 (0.27)	0.06 (0.04)	0.10	-0.30 to 0.60
Week 24						
MK-3102 25 mg	65	0.62 (0.28)	0.67 (0.25)	0.04 (0.02)	0.00	-0.40 to 0.40
Placebo	33	0.70 (0.22)	0.83 (0.34)	0.13 (0.04)	0.10	-0.40 to 0.70

Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	0.58 (0.19)	-	-	-	-
Placebo	34	0.59 (0.15)	-	-	-	-
Week 4						
MK-3102 25 mg	65	0.58 (0.19)	0.63 (0.21)	0.05 (0.02)	0.10	-0.20 to 0.50
Placebo	34	0.59 (0.15)	0.65 (0.23)	0.06 (0.03)	0.00	-0.20 to 0.50
Week 8						
MK-3102 25 mg	65	0.58 (0.19)	0.63 (0.22)	0.05 (0.02)	0.00	-0.30 to 0.70
Placebo	33	0.59 (0.15)	0.64 (0.22)	0.05 (0.02)	0.00	-0.20 to 0.40
Week 12						
MK-3102 25 mg	64	0.58 (0.20)	0.62 (0.20)	0.03 (0.02)	0.00	-0.30 to 0.40
Placebo	33	0.59 (0.15)	0.66 (0.21)	0.07 (0.03)	0.10	-0.20 to 0.40
Week 24						
MK-3102 25 mg	63	0.59 (0.20)	0.62 (0.18)	0.03 (0.02)	0.00	-0.40 to 0.70
Placebo	33	0.59 (0.15)	0.65 (0.24)	0.06 (0.03)	0.00	-0.20 to 0.50

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	0.70 (0.26)	-	-	-	-
Placebo	32	0.67 (0.19)	-	-	-	-
Week 4						
MK-3102 25 mg	67	0.70 (0.26)	0.73 (0.31)	0.03 (0.03)	0.00	-0.50 to 0.70
Placebo	32	0.67 (0.19)	0.70 (0.22)	0.03 (0.04)	0.00	-0.60 to 0.60
Week 8						
MK-3102 25 mg	67	0.70 (0.26)	0.72 (0.30)	0.02 (0.02)	0.00	-0.40 to 0.50
Placebo	32	0.67 (0.19)	0.74 (0.24)	0.08 (0.03)	0.10	-0.40 to 0.50
Week 12						
MK-3102 25 mg	67	0.70 (0.26)	0.72 (0.30)	0.01 (0.02)	0.00	-0.40 to 0.60
Placebo	30	0.67 (0.20)	0.68 (0.21)	0.01 (0.03)	0.00	-0.40 to 0.50
Week 24						
MK-3102 25 mg	67	0.70 (0.26)	0.79 (0.35)	0.08 (0.03)	0.10	-0.40 to 1.20
Placebo	29	0.67 (0.20)	0.71 (0.20)	0.04 (0.03)	0.10	-0.50 to 0.20

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	21.79 (7.49)	-	-	-	-
Placebo	63	21.68 (6.80)	-	-	-	-
Week 4						
MK-3102 25 mg	126	21.79 (7.49)	22.16 (7.55)	0.37 (0.37)	0.00	-13.00 to 12.00
Placebo	63	21.68 (6.80)	21.98 (7.70)	0.30 (0.67)	0.00	-11.00 to 27.00
Week 8						
MK-3102 25 mg	125	21.82 (7.51)	21.57 (6.59)	-0.26 (0.47)	0.00	-20.00 to 26.00
Placebo	63	21.68 (6.80)	22.11 (8.14)	0.43 (0.62)	0.00	-11.00 to 20.00
Week 12						
MK-3102 25 mg	124	21.90 (7.50)	21.16 (5.83)	-0.73 (0.47)	-0.50	-22.00 to 15.00
Placebo	63	21.68 (6.80)	21.11 (7.10)	-0.57 (0.61)	-1.00	-15.00 to 13.00
Week 24						
MK-3102 25 mg	122	21.94 (7.55)	22.35 (8.09)	0.41 (0.51)	0.00	-23.00 to 18.00
Placebo	62	21.53 (6.75)	21.31 (6.58)	-0.23 (0.68)	0.00	-12.00 to 16.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	24.80 (11.17)	-	-	-	-
Placebo	34	23.56 (10.69)	-	-	-	-
Week 4						
MK-3102 25 mg	65	24.80 (11.17)	24.29 (9.87)	-0.51 (0.67)	-1.00	-17.00 to 18.00
Placebo	34	23.56 (10.69)	24.56 (10.54)	1.00 (1.26)	1.00	-28.00 to 17.00
Week 8						
MK-3102 25 mg	65	24.80 (11.17)	23.46 (8.52)	-1.34 (0.95)	0.00	-30.00 to 19.00
Placebo	34	23.56 (10.69)	22.47 (11.98)	-1.09 (1.28)	-1.00	-35.00 to 20.00
Week 12						
MK-3102 25 mg	62	24.66 (10.57)	22.63 (7.31)	-2.03 (0.95)	-1.00	-33.00 to 10.00
Placebo	34	23.56 (10.69)	21.29 (7.80)	-2.26 (1.20)	-2.00	-35.00 to 7.00
Week 24						
MK-3102 25 mg	61	24.26 (10.17)	24.44 (10.27)	0.18 (0.92)	0.00	-18.00 to 24.00
Placebo	31	23.77 (11.16)	23.81 (13.05)	0.03 (1.41)	0.00	-29.00 to 22.00

C Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	23.59 (9.99)	-	-	-	-
Placebo	33	26.03 (13.11)	-	-	-	-
Week 4						
MK-3102 25 mg	66	23.59 (9.99)	23.06 (8.39)	-0.53 (0.63)	0.00	-17.00 to 15.00
Placebo	33	26.03 (13.11)	26.03 (11.03)	0.00 (1.08)	1.00	-18.00 to 12.00
Week 8						
MK-3102 25 mg	66	23.59 (9.99)	22.82 (7.63)	-0.77 (0.72)	0.00	-22.00 to 11.00
Placebo	33	26.03 (13.11)	24.33 (11.75)	-1.70 (0.97)	0.00	-17.00 to 9.00
Week 12						
MK-3102 25 mg	66	23.59 (9.99)	22.39 (8.43)	-1.20 (0.79)	-1.00	-32.00 to 14.00
Placebo	33	26.03 (13.11)	22.58 (10.44)	-3.45 (1.44)	-3.00	-25.00 to 20.00
Week 24						
MK-3102 25 mg	65	23.20 (9.54)	22.55 (8.21)	-0.65 (1.04)	0.00	-29.00 to 33.00
Placebo	33	26.03 (13.11)	24.52 (11.36)	-1.52 (1.60)	0.00	-27.00 to 14.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	22.46 (7.23)	-	-	-	-
Placebo	34	21.18 (5.22)	-	-	-	-
Week 4						
MK-3102 25 mg	65	22.46 (7.23)	22.80 (7.19)	0.34 (0.56)	0.00	-15.00 to 13.00
Placebo	34	21.18 (5.22)	21.50 (5.03)	0.32 (0.55)	0.00	-5.00 to 10.00
Week 8						
MK-3102 25 mg	65	22.46 (7.23)	22.42 (7.67)	-0.05 (0.61)	0.00	-11.00 to 22.00
Placebo	33	21.33 (5.22)	21.73 (5.25)	0.39 (0.60)	0.00	-5.00 to 9.00
Week 12						
MK-3102 25 mg	64	22.22 (7.02)	22.45 (6.67)	0.23 (0.59)	0.00	-14.00 to 14.00
Placebo	33	21.33 (5.22)	21.91 (5.48)	0.58 (0.51)	1.00	-3.00 to 8.00
Week 24						
MK-3102 25 mg	63	22.22 (7.07)	22.17 (8.01)	-0.05 (0.58)	0.00	-14.00 to 18.00
Placebo	33	21.33 (5.22)	20.21 (5.15)	-1.12 (0.60)	-1.00	-8.00 to 7.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	23.57 (8.05)	-	-	-	-
Placebo	32	21.00 (7.64)	-	-	-	-
Week 4						
MK-3102 25 mg	67	23.57 (8.05)	23.00 (9.64)	-0.57 (0.70)	0.00	-15.00 to 20.00
Placebo	32	21.00 (7.64)	22.66 (11.08)	1.66 (1.31)	0.00	-13.00 to 28.00
Week 8						
MK-3102 25 mg	67	23.57 (8.05)	22.52 (7.47)	-1.04 (0.68)	-1.00	-19.00 to 19.00
Placebo	32	21.00 (7.64)	21.19 (9.81)	0.19 (0.98)	0.00	-13.00 to 17.00
Week 12						
MK-3102 25 mg	67	23.57 (8.05)	22.52 (8.14)	-1.04 (0.72)	0.00	-18.00 to 20.00
Placebo	30	20.50 (7.63)	20.40 (6.58)	-0.10 (0.71)	0.00	-8.00 to 8.00
Week 24						
MK-3102 25 mg	67	23.57 (8.05)	24.22 (11.37)	0.66 (0.92)	1.00	-16.00 to 33.00
Placebo	29	20.69 (7.70)	21.38 (10.07)	0.69 (1.05)	0.00	-8.00 to 20.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	24.52 (12.41)	-	-	-	-
Placebo	63	24.68 (11.38)	-	-	-	-
Week 4						
MK-3102 25 mg	126	24.52 (12.41)	23.94 (11.17)	-0.57 (0.55)	0.00	-28.00 to 17.00
Placebo	63	24.68 (11.38)	25.78 (15.05)	1.10 (0.91)	0.00	-13.00 to 30.00
Week 8						
MK-3102 25 mg	125	24.54 (12.46)	23.30 (11.80)	-1.23 (0.73)	-1.00	-26.00 to 50.00
Placebo	63	24.68 (11.38)	25.60 (13.47)	0.92 (0.87)	0.00	-12.00 to 26.00
Week 12						
MK-3102 25 mg	124	24.63 (12.46)	23.27 (10.86)	-1.35 (0.73)	-1.00	-30.00 to 34.00
Placebo	63	24.68 (11.38)	24.86 (13.52)	0.17 (0.97)	-1.00	-16.00 to 22.00
Week 24						
MK-3102 25 mg	122	24.60 (12.52)	23.60 (10.65)	-1.00 (0.69)	-1.50	-29.00 to 20.00
Placebo	62	24.42 (11.28)	23.84 (12.35)	-0.58 (0.99)	-1.00	-18.00 to 26.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	28.25 (15.84)	-	-	-	-
Placebo	34	26.03 (12.93)	-	-	-	-
Week 4						
MK-3102 25 mg	65	28.25 (15.84)	26.66 (15.60)	-1.58 (0.94)	-1.00	-26.00 to 31.00
Placebo	34	26.03 (12.93)	27.03 (12.00)	1.00 (1.28)	1.50	-26.00 to 18.00
Week 8						
MK-3102 25 mg	65	28.25 (15.84)	26.38 (14.25)	-1.86 (1.14)	-1.00	-31.00 to 31.00
Placebo	34	26.03 (12.93)	26.24 (15.67)	0.21 (2.06)	0.00	-36.00 to 52.00
Week 12						
MK-3102 25 mg	62	27.98 (14.95)	25.63 (12.48)	-2.35 (1.10)	-1.00	-33.00 to 14.00
Placebo	34	26.03 (12.93)	24.59 (9.76)	-1.44 (1.56)	-0.50	-42.00 to 13.00
Week 24						
MK-3102 25 mg	61	27.97 (15.07)	27.80 (16.93)	-0.16 (1.42)	-1.00	-32.00 to 42.00
Placebo	31	26.35 (13.46)	26.68 (12.79)	0.32 (1.95)	2.00	-42.00 to 20.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	26.68 (13.88)	-	-	-	-
Placebo	33	34.73 (20.60)	-	-	-	-
Week 4						
MK-3102 25 mg	66	26.68 (13.88)	24.97 (12.61)	-1.71 (0.86)	-1.00	-25.00 to 20.00
Placebo	33	34.73 (20.60)	35.33 (20.81)	0.61 (1.45)	1.00	-23.00 to 20.00
Week 8						
MK-3102 25 mg	66	26.68 (13.88)	24.80 (13.24)	-1.88 (1.04)	-1.00	-38.00 to 14.00
Placebo	33	34.73 (20.60)	31.15 (18.79)	-3.58 (1.70)	-4.00	-30.00 to 20.00
Week 12						
MK-3102 25 mg	66	26.68 (13.88)	24.47 (14.40)	-2.21 (1.05)	-1.50	-46.00 to 20.00
Placebo	33	34.73 (20.60)	28.79 (17.71)	-5.94 (2.33)	-4.00	-41.00 to 25.00
Week 24						
MK-3102 25 mg	65	25.80 (11.98)	24.55 (14.25)	-1.25 (1.50)	-1.00	-44.00 to 56.00
Placebo	33	34.73 (20.60)	31.21 (19.10)	-3.52 (2.20)	-2.00	-44.00 to 19.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	22.66 (10.20)	-	-	-	-
Placebo	34	23.00 (9.34)	-	-	-	-
Week 4						
MK-3102 25 mg	65	22.66 (10.20)	21.58 (10.33)	-1.08 (0.68)	-1.00	-17.00 to 15.00
Placebo	34	23.00 (9.34)	22.85 (9.91)	-0.15 (0.91)	-1.00	-13.00 to 12.00
Week 8						
MK-3102 25 mg	65	22.66 (10.20)	21.00 (10.03)	-1.66 (0.62)	-1.00	-20.00 to 8.00
Placebo	33	23.09 (9.47)	23.24 (10.42)	0.15 (0.82)	-1.00	-9.00 to 14.00
Week 12						
MK-3102 25 mg	64	22.36 (9.98)	21.27 (9.93)	-1.09 (0.75)	-1.00	-20.00 to 17.00
Placebo	33	23.09 (9.47)	23.24 (11.18)	0.15 (1.04)	-1.00	-10.00 to 21.00
Week 24						
MK-3102 25 mg	63	22.40 (10.05)	20.60 (10.84)	-1.79 (0.81)	-2.00	-18.00 to 24.00
Placebo	33	23.09 (9.47)	21.30 (8.55)	-1.79 (0.93)	-2.00	-18.00 to 6.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	28.81 (14.10)	-	-	-	-
Placebo	32	24.72 (9.76)	-	-	-	-
Week 4						
MK-3102 25 mg	67	28.81 (14.10)	27.79 (16.12)	-1.01 (1.07)	-2.00	-21.00 to 25.00
Placebo	32	24.72 (9.76)	27.94 (12.72)	3.22 (1.54)	1.50	-14.00 to 24.00
Week 8						
MK-3102 25 mg	67	28.81 (14.10)	26.55 (12.21)	-2.25 (1.12)	-2.00	-31.00 to 31.00
Placebo	32	24.72 (9.76)	24.69 (10.79)	-0.03 (1.27)	1.00	-25.00 to 17.00
Week 12						
MK-3102 25 mg	67	28.81 (14.10)	26.30 (13.35)	-2.51 (1.31)	-2.00	-36.00 to 42.00
Placebo	30	23.57 (8.83)	23.93 (10.00)	0.37 (1.15)	0.50	-17.00 to 14.00
Week 24						
MK-3102 25 mg	67	28.81 (14.10)	28.97 (17.78)	0.16 (1.20)	0.00	-21.00 to 39.00
Placebo	29	23.59 (8.99)	24.03 (11.12)	0.45 (1.30)	0.00	-20.00 to 17.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	45.67 (40.56)	-	-	-	-
Placebo	63	43.52 (42.33)	-	-	-	-
Week 4						
MK-3102 25 mg	126	45.67 (40.56)	43.40 (38.13)	-2.26 (1.56)	-1.00	-118.00 to 98.00
Placebo	63	43.52 (42.33)	43.35 (40.21)	-0.17 (1.28)	0.00	-62.00 to 18.00
Week 8						
MK-3102 25 mg	125	45.63 (40.72)	45.24 (50.74)	-0.39 (2.60)	-1.00	-104.00 to 222.00
Placebo	63	43.52 (42.33)	43.35 (44.71)	-0.17 (1.48)	0.00	-53.00 to 52.00
Week 12						
MK-3102 25 mg	124	45.84 (40.82)	44.24 (40.13)	-1.60 (1.64)	-1.00	-96.00 to 72.00
Placebo	63	43.52 (42.33)	46.30 (70.96)	2.78 (5.29)	0.00	-121.00 to 298.00
Week 24						
MK-3102 25 mg	122	45.86 (41.09)	45.65 (43.74)	-0.21 (2.59)	-1.00	-124.00 to 254.00
Placebo	62	43.61 (42.67)	44.97 (55.28)	1.35 (3.43)	-1.00	-108.00 to 155.00

C Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	45.58 (45.53)	-	-	-	-
Placebo	34	54.50 (42.94)	-	-	-	-
Week 4						
MK-3102 25 mg	65	45.58 (45.53)	42.92 (39.14)	-2.66 (2.30)	-1.00	-111.00 to 52.00
Placebo	34	54.50 (42.94)	53.24 (41.00)	-1.26 (1.31)	-1.00	-21.00 to 18.00
Week 8						
MK-3102 25 mg	65	45.58 (45.53)	42.38 (38.17)	-3.20 (2.27)	-1.00	-122.00 to 51.00
Placebo	34	54.50 (42.94)	50.71 (38.68)	-3.79 (2.57)	-2.00	-60.00 to 35.00
Week 12						
MK-3102 25 mg	62	45.48 (46.31)	41.19 (41.01)	-4.29 (2.63)	-1.00	-143.00 to 34.00
Placebo	34	54.50 (42.94)	52.24 (41.28)	-2.26 (2.08)	-2.00	-35.00 to 35.00
Week 24						
MK-3102 25 mg	61	44.74 (46.32)	42.11 (34.90)	-2.62 (3.08)	0.00	-149.00 to 48.00
Placebo	31	54.03 (44.81)	51.77 (39.35)	-2.26 (3.50)	0.00	-71.00 to 35.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	37.58 (23.41)	-	-	-	-
Placebo	33	47.36 (48.63)	-	-	-	-
Week 4						
MK-3102 25 mg	66	37.58 (23.41)	35.36 (23.71)	-2.21 (1.06)	-1.00	-36.00 to 26.00
Placebo	33	47.36 (48.63)	50.15 (61.32)	2.79 (3.77)	-1.00	-24.00 to 109.00
Week 8						
MK-3102 25 mg	66	37.58 (23.41)	35.56 (26.36)	-2.02 (1.49)	-1.00	-38.00 to 49.00
Placebo	33	47.36 (48.63)	45.03 (45.20)	-2.33 (3.14)	-1.00	-54.00 to 76.00
Week 12						
MK-3102 25 mg	66	37.58 (23.41)	36.08 (28.61)	-1.50 (2.15)	-2.00	-37.00 to 112.00
Placebo	33	47.36 (48.63)	40.33 (37.06)	-7.03 (2.82)	-2.00	-80.00 to 12.00
Week 24						
MK-3102 25 mg	65	37.46 (23.57)	37.57 (36.38)	0.11 (3.38)	-2.00	-39.00 to 194.00
Placebo	33	47.36 (48.63)	43.88 (44.12)	-3.48 (3.29)	-1.00	-49.00 to 68.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	36.75 (36.59)	-	-	-	-
Placebo	34	37.53 (32.42)	-	-	-	-
Week 4						
MK-3102 25 mg	65	36.75 (36.59)	34.38 (33.16)	-2.37 (0.91)	-1.00	-42.00 to 13.00
Placebo	34	37.53 (32.42)	38.85 (31.71)	1.32 (1.12)	1.00	-21.00 to 16.00
Week 8						
MK-3102 25 mg	65	36.75 (36.59)	35.08 (31.08)	-1.68 (1.91)	-1.00	-101.00 to 46.00
Placebo	33	37.85 (32.86)	38.03 (28.02)	0.18 (2.03)	0.00	-50.00 to 21.00
Week 12						
MK-3102 25 mg	64	36.77 (36.88)	32.81 (27.50)	-3.95 (3.24)	-1.00	-199.00 to 32.00
Placebo	33	37.85 (32.86)	41.64 (36.12)	3.79 (2.66)	0.00	-36.00 to 64.00
Week 24						
MK-3102 25 mg	63	37.06 (37.10)	36.17 (34.99)	-0.89 (1.85)	-1.00	-75.00 to 37.00
Placebo	33	37.85 (32.86)	39.67 (41.53)	1.82 (2.41)	0.00	-28.00 to 59.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	35.67 (24.46)	-	-	-	-
Placebo	32	34.00 (17.37)	-	-	-	-
Week 4						
MK-3102 25 mg	67	35.67 (24.46)	33.03 (20.99)	-2.64 (1.04)	-1.00	-33.00 to 21.00
Placebo	32	34.00 (17.37)	33.59 (18.53)	-0.41 (1.48)	0.00	-29.00 to 22.00
Week 8						
MK-3102 25 mg	67	35.67 (24.46)	33.51 (24.03)	-2.16 (1.16)	-1.00	-29.00 to 21.00
Placebo	32	34.00 (17.37)	31.44 (15.29)	-2.56 (1.39)	-1.00	-28.00 to 11.00
Week 12						
MK-3102 25 mg	67	35.67 (24.46)	33.64 (22.02)	-2.03 (1.20)	-1.00	-36.00 to 35.00
Placebo	30	34.00 (17.91)	30.90 (14.95)	-3.10 (1.70)	-2.00	-39.00 to 16.00
Week 24						
MK-3102 25 mg	67	35.67 (24.46)	35.81 (25.56)	0.13 (1.90)	0.00	-47.00 to 70.00
Placebo	29	33.90 (18.21)	29.79 (13.11)	-4.10 (1.96)	-2.00	-41.00 to 19.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	243.71 (72.98)	-	-	-	-
Placebo	63	238.19 (70.56)	-	-	-	-
Week 4						
MK-3102 25 mg	126	243.71 (72.98)	235.54 (68.66)	-8.17 (2.34)	-6.00	-117.00 to 77.00
Placebo	63	238.19 (70.56)	239.62 (66.60)	1.43 (2.48)	3.00	-55.00 to 64.00
Week 8						
MK-3102 25 mg	125	243.35 (73.16)	229.26 (66.32)	-14.09 (2.68)	-11.00	-144.00 to 93.00
Placebo	63	238.19 (70.56)	244.84 (77.77)	6.65 (3.42)	7.00	-51.00 to 116.00
Week 12						
MK-3102 25 mg	124	243.20 (73.44)	227.30 (64.76)	-15.90 (3.07)	-15.50	-134.00 to 108.00
Placebo	63	238.19 (70.56)	239.87 (77.31)	1.68 (3.34)	0.00	-89.00 to 88.00
Week 24						
MK-3102 25 mg	122	243.66 (73.93)	224.35 (64.49)	-19.31 (3.15)	-18.00	-169.00 to 85.00
Placebo	62	238.23 (71.14)	239.24 (84.18)	1.02 (4.72)	-0.50	-98.00 to 142.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	242.09 (66.91)	-	-	-	-
Placebo	34	241.62 (67.62)	-	-	-	-
Week 4						
MK-3102 25 mg	65	242.09 (66.91)	234.88 (62.30)	-7.22 (3.99)	-6.00	-145.00 to 117.00
Placebo	34	241.62 (67.62)	244.41 (75.58)	2.79 (4.36)	0.50	-45.00 to 92.00
Week 8						
MK-3102 25 mg	65	242.09 (66.91)	229.78 (64.30)	-12.31 (4.01)	-12.00	-136.00 to 83.00
Placebo	34	241.62 (67.62)	242.41 (72.33)	0.79 (5.36)	-2.50	-71.00 to 69.00
Week 12						
MK-3102 25 mg	62	241.81 (67.76)	227.00 (61.12)	-14.81 (3.25)	-12.00	-99.00 to 38.00
Placebo	34	241.62 (67.62)	242.38 (69.53)	0.76 (3.95)	3.00	-51.00 to 42.00
Week 24						
MK-3102 25 mg	61	241.59 (68.30)	219.20 (60.07)	-22.39 (5.42)	-18.00	-221.00 to 66.00
Placebo	31	240.55 (69.76)	239.87 (89.35)	-0.68 (6.55)	-6.00	-72.00 to 128.00

C Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	231.70 (63.93)	-	-	-	-
Placebo	33	230.97 (52.02)	-	-	-	-
Week 4						
MK-3102 25 mg	66	231.70 (63.93)	225.17 (68.25)	-6.53 (2.57)	-9.00	-50.00 to 59.00
Placebo	33	230.97 (52.02)	228.94 (56.50)	-2.03 (5.52)	-4.00	-61.00 to 125.00
Week 8						
MK-3102 25 mg	66	231.70 (63.93)	218.24 (67.83)	-13.45 (2.76)	-14.50	-57.00 to 93.00
Placebo	33	230.97 (52.02)	231.30 (64.07)	0.33 (9.46)	-1.00	-72.00 to 255.00
Week 12						
MK-3102 25 mg	66	231.70 (63.93)	217.26 (64.60)	-14.44 (2.74)	-16.50	-50.00 to 67.00
Placebo	33	230.97 (52.02)	228.15 (54.83)	-2.82 (5.63)	-7.00	-48.00 to 111.00
Week 24						
MK-3102 25 mg	65	231.55 (64.42)	213.43 (61.55)	-18.12 (2.96)	-20.00	-65.00 to 71.00
Placebo	33	230.97 (52.02)	219.03 (49.46)	-11.94 (4.48)	-11.00	-66.00 to 64.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	232.15 (60.38)	-	-	-	-
Placebo	34	228.88 (57.62)	-	-	-	-
Week 4						
MK-3102 25 mg	65	232.15 (60.38)	219.98 (62.31)	-12.17 (2.43)	-12.00	-60.00 to 39.00
Placebo	34	228.88 (57.62)	228.62 (57.89)	-0.26 (3.58)	1.00	-52.00 to 39.00
Week 8						
MK-3102 25 mg	65	232.15 (60.38)	217.46 (70.60)	-14.69 (3.96)	-19.00	-65.00 to 160.00
Placebo	33	231.36 (56.64)	233.97 (64.96)	2.61 (5.86)	2.00	-56.00 to 146.00
Week 12						
MK-3102 25 mg	64	231.31 (60.47)	215.44 (69.00)	-15.88 (3.29)	-18.50	-64.00 to 55.00
Placebo	33	231.36 (56.64)	234.45 (65.54)	3.09 (6.88)	4.00	-60.00 to 175.00
Week 24						
MK-3102 25 mg	63	231.62 (60.90)	205.75 (61.17)	-25.87 (3.30)	-24.00	-111.00 to 40.00
Placebo	33	231.36 (56.64)	224.48 (49.48)	-6.88 (3.94)	-3.00	-61.00 to 27.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	230.60 (63.06)	-	-	-	-
Placebo	32	247.09 (78.88)	-	-	-	-
Week 4						
MK-3102 25 mg	67	230.60 (63.06)	219.88 (58.00)	-10.72 (2.38)	-9.00	-85.00 to 42.00
Placebo	32	247.09 (78.88)	239.84 (76.47)	-7.25 (4.88)	-3.00	-66.00 to 50.00
Week 8						
MK-3102 25 mg	67	230.60 (63.06)	212.90 (54.05)	-17.70 (2.90)	-17.00	-73.00 to 41.00
Placebo	32	247.09 (78.88)	240.06 (79.15)	-7.03 (5.61)	-6.50	-74.00 to 64.00
Week 12						
MK-3102 25 mg	67	230.60 (63.06)	212.06 (52.19)	-18.54 (3.08)	-15.00	-97.00 to 50.00
Placebo	30	246.47 (81.49)	243.93 (86.74)	-2.53 (6.12)	-9.00	-69.00 to 86.00
Week 24						
MK-3102 25 mg	67	230.60 (63.06)	205.30 (47.01)	-25.30 (3.19)	-22.00	-113.00 to 16.00
Placebo	29	241.31 (77.80)	232.93 (89.72)	-8.38 (6.95)	-15.00	-80.00 to 76.00

Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	174.11 (32.79)	-	-	-	-
Placebo	63	174.16 (24.88)	-	-	-	-
Week 4						
MK-3102 25 mg	126	174.11 (32.79)	176.86 (30.57)	2.75 (1.78)	4.00	-78.00 to 90.00
Placebo	63	174.16 (24.88)	177.87 (30.00)	3.71 (2.46)	1.00	-32.00 to 96.00
Week 8						
MK-3102 25 mg	125	174.02 (32.90)	176.46 (29.83)	2.45 (1.70)	3.00	-70.00 to 51.00
Placebo	63	174.16 (24.88)	179.02 (30.64)	4.86 (2.13)	6.00	-43.00 to 61.00
Week 12						
MK-3102 25 mg	124	174.09 (33.02)	175.45 (28.41)	1.36 (1.67)	3.50	-72.00 to 41.00
Placebo	63	174.16 (24.88)	174.98 (24.89)	0.83 (1.88)	1.00	-34.00 to 31.00
Week 24						
MK-3102 25 mg	122	174.43 (33.18)	177.21 (34.23)	2.78 (2.19)	3.00	-83.00 to 168.00
Placebo	62	174.56 (24.87)	174.65 (28.86)	0.08 (2.47)	0.00	-48.00 to 50.00

Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	172.40 (36.03)	-	-	-	-
Placebo	34	163.03 (23.56)	-	-	-	-
Week 4						
MK-3102 25 mg	65	172.40 (36.03)	176.22 (36.71)	3.82 (2.10)	2.00	-53.00 to 38.00
Placebo	34	163.03 (23.56)	175.38 (42.84)	12.35 (5.45)	7.00	-27.00 to 146.00
Week 8						
MK-3102 25 mg	65	172.40 (36.03)	174.29 (32.39)	1.89 (2.63)	2.00	-77.00 to 50.00
Placebo	34	163.03 (23.56)	166.24 (32.43)	3.21 (3.35)	1.00	-36.00 to 84.00
Week 12						
MK-3102 25 mg	62	172.26 (35.34)	173.40 (29.24)	1.15 (2.31)	-2.00	-66.00 to 53.00
Placebo	34	163.03 (23.56)	161.24 (26.84)	-1.79 (2.63)	-1.00	-40.00 to 28.00
Week 24						
MK-3102 25 mg	61	170.72 (33.48)	175.93 (36.76)	5.21 (2.47)	1.00	-36.00 to 74.00
Placebo	31	163.68 (24.25)	164.94 (29.40)	1.26 (3.24)	2.00	-44.00 to 43.00

Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	163.85 (28.76)	-	-	-	-
Placebo	33	163.06 (30.77)	-	-	-	-
Week 4						
MK-3102 25 mg	66	163.85 (28.76)	165.53 (26.89)	1.68 (2.31)	2.50	-53.00 to 56.00
Placebo	33	163.06 (30.77)	165.36 (27.84)	2.30 (2.63)	8.00	-49.00 to 26.00
Week 8						
MK-3102 25 mg	66	163.85 (28.76)	166.48 (28.37)	2.64 (2.29)	3.50	-59.00 to 39.00
Placebo	33	163.06 (30.77)	164.91 (29.18)	1.85 (2.72)	1.00	-33.00 to 40.00
Week 12						
MK-3102 25 mg	66	163.85 (28.76)	164.71 (26.24)	0.86 (2.32)	4.50	-61.00 to 60.00
Placebo	33	163.06 (30.77)	160.12 (24.88)	-2.94 (2.63)	-1.00	-52.00 to 28.00
Week 24						
MK-3102 25 mg	65	163.45 (28.79)	164.97 (28.82)	1.52 (3.47)	1.00	-50.00 to 127.00
Placebo	33	163.06 (30.77)	160.85 (29.30)	-2.21 (2.76)	-3.00	-42.00 to 30.00

Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	188.28 (35.14)	-	-	-	-
Placebo	34	191.41 (37.99)	-	-	-	-
Week 4						
MK-3102 25 mg	65	188.28 (35.14)	193.91 (36.18)	5.63 (2.40)	5.00	-46.00 to 82.00
Placebo	34	191.41 (37.99)	198.41 (37.87)	7.00 (3.41)	6.00	-40.00 to 53.00
Week 8						
MK-3102 25 mg	65	188.28 (35.14)	196.52 (48.61)	8.25 (5.16)	4.00	-47.00 to 304.00
Placebo	33	191.67 (38.55)	198.58 (38.13)	6.91 (3.69)	4.00	-26.00 to 94.00
Week 12						
MK-3102 25 mg	64	187.73 (35.14)	195.55 (38.68)	7.81 (2.70)	11.00	-43.00 to 64.00
Placebo	33	191.67 (38.55)	198.58 (38.83)	6.91 (2.82)	6.00	-27.00 to 44.00
Week 24						
MK-3102 25 mg	63	187.83 (35.41)	192.13 (34.21)	4.30 (2.29)	4.00	-51.00 to 48.00
Placebo	33	191.67 (38.55)	191.82 (36.62)	0.15 (3.20)	-2.00	-38.00 to 35.00

Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	170.49 (30.00)	-	-	-	-
Placebo	32	172.59 (31.21)	-	-	-	-
Week 4						
MK-3102 25 mg	67	170.49 (30.00)	174.93 (34.90)	4.43 (2.21)	5.00	-38.00 to 67.00
Placebo	32	172.59 (31.21)	171.81 (31.19)	-0.78 (3.00)	-1.50	-34.00 to 36.00
Week 8						
MK-3102 25 mg	67	170.49 (30.00)	173.48 (32.30)	2.99 (1.91)	4.00	-40.00 to 34.00
Placebo	32	172.59 (31.21)	172.41 (31.34)	-0.19 (3.18)	1.00	-36.00 to 43.00
Week 12						
MK-3102 25 mg	67	170.49 (30.00)	175.99 (32.13)	5.49 (2.33)	2.00	-26.00 to 76.00
Placebo	30	172.77 (32.23)	171.03 (31.71)	-1.73 (2.61)	0.00	-40.00 to 27.00
Week 24						
MK-3102 25 mg	67	170.49 (30.00)	177.67 (40.34)	7.18 (3.38)	5.00	-41.00 to 174.00
Placebo	29	172.69 (32.79)	169.31 (35.33)	-3.38 (3.47)	-4.00	-32.00 to 39.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	104.25 (72.11)	-	-	-	-
Placebo	63	101.57 (54.08)	-	-	-	-
Week 4						
MK-3102 25 mg	126	104.25 (72.11)	104.05 (50.81)	-0.20 (5.41)	0.00	-508.00 to 150.00
Placebo	63	101.57 (54.08)	95.46 (44.01)	-6.11 (4.44)	-5.00	-144.00 to 83.00
Week 8						
MK-3102 25 mg	125	104.03 (72.36)	105.38 (64.52)	1.34 (6.12)	4.00	-438.00 to 382.00
Placebo	63	101.57 (54.08)	100.90 (56.06)	-0.67 (5.08)	-2.00	-141.00 to 100.00
Week 12						
MK-3102 25 mg	124	104.23 (72.62)	106.51 (61.98)	2.27 (5.21)	2.50	-405.00 to 237.00
Placebo	63	101.57 (54.08)	97.21 (41.91)	-4.37 (4.26)	0.00	-165.00 to 86.00
Week 24						
MK-3102 25 mg	122	104.39 (73.19)	115.48 (76.49)	11.10 (6.10)	7.50	-477.00 to 310.00
Placebo	62	100.13 (53.29)	105.82 (52.74)	5.69 (5.51)	2.50	-129.00 to 184.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	123.68 (78.63)	-	-	-	-
Placebo	34	116.56 (86.38)	-	-	-	-
Week 4						
MK-3102 25 mg	65	123.68 (78.63)	124.06 (69.52)	0.38 (7.84)	0.00	-246.00 to 210.00
Placebo	34	116.56 (86.38)	113.68 (58.06)	-2.88 (14.59)	5.50	-334.00 to 218.00
Week 8						
MK-3102 25 mg	65	123.68 (78.63)	123.11 (70.58)	-0.57 (7.61)	2.00	-212.00 to 234.00
Placebo	34	116.56 (86.38)	106.47 (63.66)	-10.09 (7.47)	-0.50	-200.00 to 58.00
Week 12						
MK-3102 25 mg	62	123.77 (79.01)	123.53 (54.73)	-0.24 (7.36)	4.00	-297.00 to 126.00
Placebo	34	116.56 (86.38)	103.18 (54.11)	-13.38 (10.74)	1.50	-250.00 to 51.00
Week 24						
MK-3102 25 mg	61	123.23 (79.55)	136.11 (94.09)	12.89 (9.28)	7.00	-157.00 to 406.00
Placebo	31	107.42 (71.50)	116.10 (76.18)	8.68 (13.31)	0.00	-207.00 to 255.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	103.76 (77.55)	-	-	-	-
Placebo	33	93.55 (35.37)	-	-	-	-
Week 4						
MK-3102 25 mg	66	103.76 (77.55)	97.82 (42.83)	-5.94 (7.34)	3.00	-317.00 to 81.00
Placebo	33	93.55 (35.37)	102.64 (46.91)	9.09 (5.65)	-2.00	-65.00 to 93.00
Week 8						
MK-3102 25 mg	66	103.76 (77.55)	104.38 (56.74)	0.62 (7.33)	7.00	-279.00 to 160.00
Placebo	33	93.55 (35.37)	94.42 (31.68)	0.88 (3.53)	2.00	-55.00 to 41.00
Week 12						
MK-3102 25 mg	66	103.76 (77.55)	101.64 (66.67)	-2.12 (6.46)	2.00	-320.00 to 137.00
Placebo	33	93.55 (35.37)	96.03 (44.95)	2.48 (4.65)	0.00	-58.00 to 79.00
Week 24						
MK-3102 25 mg	65	103.85 (78.15)	102.17 (53.63)	-1.68 (7.60)	4.00	-289.00 to 132.00
Placebo	33	93.55 (35.37)	105.55 (47.93)	12.00 (5.26)	5.00	-36.00 to 106.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	130.22 (77.60)	-	-	-	-
Placebo	34	152.97 (141.89)	-	-	-	-
Week 4						
MK-3102 25 mg	65	130.22 (77.60)	133.45 (82.17)	3.23 (6.61)	-1.00	-137.00 to 237.00
Placebo	34	152.97 (141.89)	118.24 (55.28)	-34.74 (23.18)	-2.50	-686.00 to 85.00
Week 8						
MK-3102 25 mg	65	130.22 (77.60)	130.57 (69.94)	0.35 (6.42)	5.00	-159.00 to 153.00
Placebo	33	154.94 (143.62)	125.00 (64.46)	-29.94 (23.11)	-2.00	-625.00 to 196.00
Week 12						
MK-3102 25 mg	64	131.30 (77.72)	141.33 (106.00)	10.03 (8.72)	7.50	-192.00 to 357.00
Placebo	33	154.94 (143.62)	122.73 (66.69)	-32.21 (21.78)	2.00	-611.00 to 112.00
Week 24						
MK-3102 25 mg	63	131.10 (78.32)	137.68 (83.16)	6.59 (6.86)	8.00	-144.00 to 187.00
Placebo	33	154.94 (143.62)	121.03 (63.38)	-33.91 (22.44)	-9.00	-649.00 to 152.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	126.37 (99.22)	-	-	-	-
Placebo	32	113.31 (61.12)	-	-	-	-
Week 4						
MK-3102 25 mg	67	126.37 (99.22)	120.81 (92.06)	-5.57 (10.26)	2.00	-376.00 to 209.00
Placebo	32	113.31 (61.12)	111.06 (59.02)	-2.25 (7.55)	1.00	-103.00 to 98.00
Week 8						
MK-3102 25 mg	67	126.37 (99.22)	126.63 (101.04)	0.25 (8.64)	3.00	-389.00 to 155.00
Placebo	32	113.31 (61.12)	101.16 (49.36)	-12.16 (6.72)	-9.00	-105.00 to 47.00
Week 12						
MK-3102 25 mg	67	126.37 (99.22)	118.99 (72.22)	-7.39 (10.42)	5.00	-395.00 to 259.00
Placebo	30	103.33 (43.64)	101.50 (67.05)	-1.83 (9.67)	-10.00	-82.00 to 178.00
Week 24						
MK-3102 25 mg	67	126.37 (99.22)	130.73 (95.92)	4.36 (12.29)	7.00	-389.00 to 448.00
Placebo	29	102.07 (43.85)	101.14 (51.50)	-0.93 (6.85)	-7.00	-78.00 to 115.00

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	14.54 (3.92)	-	-	-	-
Placebo	63	14.74 (3.50)	-	-	-	-
Week 4						
MK-3102 25 mg	126	14.54 (3.92)	14.71 (4.02)	0.18 (0.28)	0.20	-8.70 to 11.60
Placebo	63	14.74 (3.50)	14.84 (3.40)	0.10 (0.33)	0.30	-7.90 to 4.70
Week 8						
MK-3102 25 mg	125	14.56 (3.93)	14.69 (3.46)	0.14 (0.28)	0.10	-9.10 to 8.40
Placebo	63	14.74 (3.50)	15.18 (3.10)	0.44 (0.38)	0.10	-6.80 to 7.20
Week 12						
MK-3102 25 mg	124	14.54 (3.94)	15.16 (4.05)	0.62 (0.33)	0.70	-10.40 to 18.70
Placebo	63	14.74 (3.50)	14.64 (3.00)	-0.10 (0.40)	-0.50	-9.00 to 5.80
Week 24						
MK-3102 25 mg	122	14.58 (3.95)	15.24 (3.93)	0.66 (0.33)	1.10	-9.30 to 9.70
Placebo	62	14.73 (3.53)	14.86 (3.18)	0.13 (0.33)	-0.00	-6.00 to 5.40

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	13.09 (2.69)	-	-	-	-
Placebo	34	14.32 (3.38)	-	-	-	-
Week 4						
MK-3102 25 mg	65	13.09 (2.69)	13.41 (3.15)	0.32 (0.30)	0.30	-5.90 to 7.20
Placebo	34	14.32 (3.38)	14.28 (3.06)	-0.04 (0.51)	-0.25	-7.80 to 4.70
Week 8						
MK-3102 25 mg	65	13.09 (2.69)	13.16 (3.55)	0.07 (0.32)	0.20	-6.10 to 5.60
Placebo	34	14.32 (3.38)	13.66 (3.72)	-0.66 (0.51)	-1.65	-4.60 to 6.10
Week 12						
MK-3102 25 mg	62	13.05 (2.69)	13.03 (3.35)	-0.02 (0.30)	-0.25	-5.50 to 5.60
Placebo	34	14.32 (3.38)	14.44 (3.61)	0.11 (0.62)	0.05	-8.70 to 8.80
Week 24						
MK-3102 25 mg	61	13.07 (2.71)	13.56 (3.56)	0.49 (0.36)	0.30	-4.50 to 12.80
Placebo	31	13.98 (3.30)	14.78 (4.20)	0.80 (0.63)	0.50	-6.70 to 9.40

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	13.88 (2.92)	-	-	-	-
Placebo	33	13.94 (3.75)	-	-	-	-
Week 4						
MK-3102 25 mg	66	13.88 (2.92)	13.50 (3.24)	-0.38 (0.34)	-0.80	-6.00 to 6.40
Placebo	33	13.94 (3.75)	13.69 (3.11)	-0.25 (0.52)	-1.10	-7.60 to 5.00
Week 8						
MK-3102 25 mg	66	13.88 (2.92)	13.95 (3.56)	0.07 (0.37)	0.20	-4.80 to 9.80
Placebo	33	13.94 (3.75)	13.29 (3.40)	-0.65 (0.51)	-0.90	-8.00 to 4.40
Week 12						
MK-3102 25 mg	66	13.88 (2.92)	13.62 (3.42)	-0.26 (0.32)	-0.40	-6.30 to 7.20
Placebo	33	13.94 (3.75)	14.28 (3.61)	0.34 (0.63)	0.90	-9.40 to 9.20
Week 24						
MK-3102 25 mg	65	13.89 (2.94)	13.93 (3.69)	0.04 (0.36)	-0.30	-6.00 to 6.00
Placebo	33	13.94 (3.75)	14.65 (3.93)	0.71 (0.57)	0.60	-6.40 to 7.30

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	14.73 (4.01)	-	-	-	-
Placebo	34	15.47 (3.49)	-	-	-	-
Week 4						
MK-3102 25 mg	65	14.73 (4.01)	14.44 (3.61)	-0.29 (0.41)	-0.30	-10.80 to 7.80
Placebo	34	15.47 (3.49)	15.12 (3.73)	-0.35 (0.46)	-0.20	-6.90 to 4.90
Week 8						
MK-3102 25 mg	65	14.73 (4.01)	14.76 (3.77)	0.04 (0.36)	-0.50	-7.20 to 6.30
Placebo	33	15.59 (3.47)	15.55 (3.10)	-0.05 (0.48)	-0.30	-6.50 to 7.10
Week 12						
MK-3102 25 mg	64	14.81 (3.99)	14.55 (3.69)	-0.26 (0.37)	-0.10	-7.10 to 8.00
Placebo	33	15.59 (3.47)	15.54 (3.29)	-0.05 (0.56)	0.20	-7.50 to 6.40
Week 24						
MK-3102 25 mg	63	14.78 (4.01)	14.83 (3.99)	0.05 (0.45)	-0.10	-7.80 to 12.30
Placebo	33	15.59 (3.47)	15.16 (3.43)	-0.43 (0.57)	-0.20	-9.10 to 5.90

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	13.43 (3.55)	-	-	-	-
Placebo	32	13.63 (2.60)	-	-	-	-
Week 4						
MK-3102 25 mg	67	13.43 (3.55)	13.65 (3.46)	0.22 (0.28)	0.30	-5.10 to 6.80
Placebo	32	13.63 (2.60)	13.81 (2.98)	0.18 (0.50)	-0.85	-6.20 to 6.80
Week 8						
MK-3102 25 mg	67	13.43 (3.55)	13.24 (3.71)	-0.19 (0.28)	-0.10	-6.70 to 4.70
Placebo	32	13.63 (2.60)	13.43 (2.25)	-0.20 (0.37)	-0.35	-4.40 to 3.10
Week 12						
MK-3102 25 mg	67	13.43 (3.55)	13.80 (3.57)	0.37 (0.28)	0.30	-4.80 to 7.50
Placebo	30	13.59 (2.66)	13.42 (3.04)	-0.16 (0.41)	-0.20	-4.50 to 4.80
Week 24						
MK-3102 25 mg	67	13.43 (3.55)	14.40 (3.91)	0.97 (0.32)	0.90	-6.20 to 8.90
Placebo	29	13.60 (2.71)	13.74 (3.69)	0.14 (0.67)	-0.60	-6.10 to 8.30

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	0.75 (0.15)	-	-	-	-
Placebo	63	0.73 (0.15)	-	-	-	-
Week 4						
MK-3102 25 mg	126	0.75 (0.15)	0.76 (0.17)	0.02 (0.01)	0.01	-0.13 to 0.32
Placebo	63	0.73 (0.15)	0.74 (0.16)	0.00 (0.01)	0.01	-0.09 to 0.17
Week 8						
MK-3102 25 mg	125	0.75 (0.15)	0.76 (0.16)	0.01 (0.01)	0.01	-0.16 to 0.18
Placebo	63	0.73 (0.15)	0.73 (0.16)	-0.00 (0.01)	-0.01	-0.11 to 0.15
Week 12						
MK-3102 25 mg	124	0.75 (0.15)	0.77 (0.16)	0.02 (0.01)	0.01	-0.13 to 0.38
Placebo	63	0.73 (0.15)	0.73 (0.17)	-0.00 (0.01)	-0.01	-0.11 to 0.19
Week 24						
MK-3102 25 mg	122	0.74 (0.15)	0.77 (0.17)	0.02 (0.01)	0.01	-0.13 to 0.24
Placebo	62	0.73 (0.16)	0.74 (0.16)	0.01 (0.01)	-0.01	-0.12 to 0.13

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	0.75 (0.17)	-	-	-	-
Placebo	34	0.77 (0.17)	-	-	-	-
Week 4						
MK-3102 25 mg	65	0.75 (0.17)	0.76 (0.19)	0.00 (0.01)	0.00	-0.12 to 0.16
Placebo	34	0.77 (0.17)	0.75 (0.17)	-0.02 (0.01)	-0.01	-0.14 to 0.12
Week 8						
MK-3102 25 mg	65	0.75 (0.17)	0.76 (0.18)	0.00 (0.01)	0.00	-0.13 to 0.14
Placebo	34	0.77 (0.17)	0.74 (0.16)	-0.03 (0.01)	-0.03	-0.13 to 0.13
Week 12						
MK-3102 25 mg	62	0.75 (0.17)	0.76 (0.19)	0.01 (0.01)	0.01	-0.13 to 0.17
Placebo	34	0.77 (0.17)	0.74 (0.17)	-0.03 (0.01)	-0.02	-0.14 to 0.13
Week 24						
MK-3102 25 mg	61	0.75 (0.17)	0.75 (0.18)	-0.00 (0.01)	-0.01	-0.18 to 0.16
Placebo	31	0.77 (0.18)	0.74 (0.17)	-0.03 (0.01)	-0.04	-0.11 to 0.15

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	0.70 (0.15)	-	-	-	-
Placebo	33	0.69 (0.11)	-	-	-	-
Week 4						
MK-3102 25 mg	66	0.70 (0.15)	0.69 (0.15)	-0.00 (0.01)	-0.01	-0.12 to 0.11
Placebo	33	0.69 (0.11)	0.71 (0.14)	0.02 (0.01)	0.01	-0.08 to 0.21
Week 8						
MK-3102 25 mg	66	0.70 (0.15)	0.70 (0.14)	0.00 (0.01)	0.00	-0.13 to 0.15
Placebo	33	0.69 (0.11)	0.70 (0.13)	0.01 (0.01)	0.01	-0.10 to 0.18
Week 12						
MK-3102 25 mg	66	0.70 (0.15)	0.70 (0.15)	-0.00 (0.01)	-0.01	-0.15 to 0.16
Placebo	33	0.69 (0.11)	0.68 (0.12)	-0.01 (0.01)	-0.02	-0.12 to 0.11
Week 24						
MK-3102 25 mg	65	0.70 (0.15)	0.71 (0.15)	0.01 (0.01)	0.00	-0.17 to 0.21
Placebo	33	0.69 (0.11)	0.70 (0.13)	0.01 (0.01)	0.01	-0.09 to 0.16

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	0.74 (0.19)	-	-	-	-
Placebo	34	0.73 (0.12)	-	-	-	-
Week 4						
MK-3102 25 mg	65	0.74 (0.19)	0.75 (0.19)	0.01 (0.01)	0.01	-0.12 to 0.12
Placebo	34	0.73 (0.12)	0.71 (0.13)	-0.02 (0.01)	-0.02	-0.14 to 0.12
Week 8						
MK-3102 25 mg	65	0.74 (0.19)	0.76 (0.20)	0.02 (0.01)	0.02	-0.12 to 0.17
Placebo	33	0.73 (0.13)	0.70 (0.13)	-0.03 (0.01)	-0.03	-0.17 to 0.09
Week 12						
MK-3102 25 mg	64	0.74 (0.18)	0.75 (0.20)	0.01 (0.01)	0.01	-0.12 to 0.19
Placebo	33	0.73 (0.13)	0.70 (0.12)	-0.03 (0.01)	-0.03	-0.17 to 0.07
Week 24						
MK-3102 25 mg	63	0.74 (0.18)	0.76 (0.21)	0.01 (0.01)	0.00	-0.18 to 0.39
Placebo	33	0.73 (0.13)	0.71 (0.14)	-0.02 (0.01)	-0.02	-0.14 to 0.11

C Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	0.74 (0.17)	-	-	-	-
Placebo	32	0.73 (0.16)	-	-	-	-
Week 4						
MK-3102 25 mg	67	0.74 (0.17)	0.76 (0.17)	0.02 (0.01)	0.02	-0.18 to 0.14
Placebo	32	0.73 (0.16)	0.73 (0.15)	-0.00 (0.01)	-0.01	-0.14 to 0.07
Week 8						
MK-3102 25 mg	67	0.74 (0.17)	0.75 (0.17)	0.01 (0.01)	0.01	-0.13 to 0.12
Placebo	32	0.73 (0.16)	0.74 (0.18)	0.01 (0.01)	0.01	-0.13 to 0.35
Week 12						
MK-3102 25 mg	67	0.74 (0.17)	0.75 (0.17)	0.01 (0.01)	0.01	-0.19 to 0.16
Placebo	30	0.72 (0.15)	0.71 (0.15)	-0.01 (0.01)	-0.02	-0.09 to 0.09
Week 24						
MK-3102 25 mg	67	0.74 (0.17)	0.76 (0.20)	0.03 (0.01)	0.02	-0.14 to 0.71
Placebo	29	0.73 (0.15)	0.72 (0.13)	-0.01 (0.01)	0.00	-0.11 to 0.09

Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	5.01 (1.08)	-	-	-	-
Placebo	63	4.76 (1.32)	-	-	-	-
Week 4						
MK-3102 25 mg	126	5.01 (1.08)	5.36 (1.23)	0.35 (0.07)	0.35	-2.50 to 3.40
Placebo	63	4.76 (1.32)	4.79 (1.25)	0.03 (0.07)	0.00	-1.50 to 1.00
Week 8						
MK-3102 25 mg	125	5.01 (1.09)	5.41 (1.18)	0.39 (0.06)	0.40	-1.70 to 1.90
Placebo	63	4.76 (1.32)	4.86 (1.40)	0.09 (0.07)	0.00	-1.00 to 1.70
Week 12						
MK-3102 25 mg	124	5.02 (1.09)	5.37 (1.23)	0.36 (0.06)	0.35	-2.40 to 1.80
Placebo	63	4.76 (1.32)	4.82 (1.38)	0.05 (0.08)	0.00	-1.60 to 1.30
Week 24						
MK-3102 25 mg	122	5.00 (1.09)	5.47 (1.17)	0.47 (0.07)	0.50	-3.30 to 3.00
Placebo	62	4.75 (1.32)	4.96 (1.47)	0.22 (0.07)	0.20	-0.90 to 1.40

Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	5.32 (1.22)	-	-	-	-
Placebo	34	5.02 (1.07)	-	-	-	-
Week 4						
MK-3102 25 mg	65	5.32 (1.22)	5.63 (1.34)	0.31 (0.08)	0.30	-1.40 to 2.00
Placebo	34	5.02 (1.07)	5.02 (1.13)	-0.00 (0.10)	0.05	-1.80 to 1.30
Week 8						
MK-3102 25 mg	65	5.32 (1.22)	5.53 (1.29)	0.21 (0.08)	0.20	-1.50 to 1.90
Placebo	34	5.02 (1.07)	4.87 (1.15)	-0.15 (0.11)	-0.30	-1.00 to 2.30
Week 12						
MK-3102 25 mg	62	5.27 (1.20)	5.51 (1.35)	0.24 (0.08)	0.25	-1.90 to 1.70
Placebo	34	5.02 (1.07)	5.08 (1.22)	0.06 (0.11)	-0.10	-0.80 to 1.70
Week 24						
MK-3102 25 mg	61	5.30 (1.19)	5.79 (1.34)	0.49 (0.09)	0.40	-0.80 to 2.70
Placebo	31	5.05 (1.12)	5.20 (1.26)	0.16 (0.10)	0.10	-0.90 to 1.40

Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	4.90 (1.28)	-	-	-	-
Placebo	33	4.92 (0.89)	-	-	-	-
Week 4						
MK-3102 25 mg	66	4.90 (1.28)	5.00 (1.31)	0.10 (0.06)	0.10	-0.90 to 1.20
Placebo	33	4.92 (0.89)	5.01 (0.81)	0.08 (0.11)	0.10	-2.00 to 1.40
Week 8						
MK-3102 25 mg	66	4.90 (1.28)	5.22 (1.32)	0.32 (0.07)	0.35	-0.70 to 1.80
Placebo	33	4.92 (0.89)	4.90 (0.83)	-0.02 (0.09)	0.00	-0.90 to 1.80
Week 12						
MK-3102 25 mg	66	4.90 (1.28)	5.08 (1.28)	0.18 (0.08)	0.10	-1.20 to 2.00
Placebo	33	4.92 (0.89)	4.93 (0.89)	0.00 (0.09)	0.00	-1.00 to 0.90
Week 24						
MK-3102 25 mg	65	4.90 (1.29)	5.22 (1.26)	0.32 (0.09)	0.30	-1.10 to 2.00
Placebo	33	4.92 (0.89)	5.12 (0.99)	0.19 (0.13)	0.00	-1.20 to 1.90

Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	4.72 (1.23)	-	-	-	-
Placebo	34	5.04 (1.29)	-	-	-	-
Week 4						
MK-3102 25 mg	65	4.72 (1.23)	5.04 (1.40)	0.31 (0.06)	0.30	-0.80 to 1.50
Placebo	34	5.04 (1.29)	4.87 (1.08)	-0.18 (0.12)	0.00	-2.30 to 1.00
Week 8						
MK-3102 25 mg	65	4.72 (1.23)	5.26 (1.44)	0.54 (0.08)	0.50	-0.70 to 3.20
Placebo	33	5.09 (1.29)	4.88 (1.13)	-0.21 (0.09)	-0.20	-1.70 to 0.80
Week 12						
MK-3102 25 mg	64	4.75 (1.22)	5.11 (1.38)	0.36 (0.08)	0.25	-0.80 to 1.90
Placebo	33	5.09 (1.29)	4.99 (1.30)	-0.10 (0.10)	-0.20	-1.60 to 1.30
Week 24						
MK-3102 25 mg	63	4.74 (1.23)	5.32 (1.49)	0.58 (0.09)	0.50	-1.00 to 3.00
Placebo	33	5.09 (1.29)	5.05 (1.24)	-0.04 (0.12)	0.00	-1.30 to 1.70

Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	4.98 (1.12)	-	-	-	-
Placebo	32	5.16 (1.35)	-	-	-	-
Week 4						
MK-3102 25 mg	67	4.98 (1.12)	5.25 (0.98)	0.27 (0.08)	0.20	-1.60 to 1.50
Placebo	32	5.16 (1.35)	5.20 (1.43)	0.04 (0.10)	0.15	-1.30 to 1.20
Week 8						
MK-3102 25 mg	67	4.98 (1.12)	5.41 (1.17)	0.43 (0.09)	0.50	-1.30 to 2.20
Placebo	32	5.16 (1.35)	5.06 (1.32)	-0.10 (0.09)	-0.10	-0.80 to 1.10
Week 12						
MK-3102 25 mg	67	4.98 (1.12)	5.42 (1.20)	0.44 (0.08)	0.30	-0.90 to 2.20
Placebo	30	5.17 (1.39)	5.16 (1.25)	-0.00 (0.10)	-0.10	-1.00 to 1.20
Week 24						
MK-3102 25 mg	67	4.98 (1.12)	5.61 (1.24)	0.63 (0.10)	0.60	-1.70 to 2.70
Placebo	29	5.17 (1.42)	5.35 (1.41)	0.18 (0.13)	0.10	-0.60 to 1.90

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	140.63 (1.78)	-	-	-	-
Placebo	63	140.11 (2.01)	-	-	-	-
Week 4						
MK-3102 25 mg	126	140.63 (1.78)	141.26 (1.90)	0.63 (0.16)	1.00	-4.00 to 6.00
Placebo	63	140.11 (2.01)	140.78 (1.72)	0.67 (0.24)	1.00	-4.00 to 7.00
Week 8						
MK-3102 25 mg	125	140.62 (1.78)	141.04 (1.62)	0.42 (0.14)	0.00	-3.00 to 4.00
Placebo	63	140.11 (2.01)	140.57 (1.77)	0.46 (0.24)	0.00	-5.00 to 7.00
Week 12						
MK-3102 25 mg	124	140.64 (1.78)	141.37 (1.77)	0.73 (0.15)	1.00	-3.00 to 5.00
Placebo	63	140.11 (2.01)	140.35 (1.77)	0.24 (0.24)	0.00	-5.00 to 6.00
Week 24						
MK-3102 25 mg	122	140.66 (1.79)	141.08 (1.81)	0.43 (0.16)	0.00	-4.00 to 4.00
Placebo	62	140.13 (2.02)	140.81 (1.58)	0.68 (0.25)	0.50	-4.00 to 7.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	140.06 (2.00)	-	-	-	-
Placebo	34	139.76 (1.71)	-	-	-	-
Week 4						
MK-3102 25 mg	65	140.06 (2.00)	140.78 (1.94)	0.72 (0.20)	1.00	-3.00 to 7.00
Placebo	34	139.76 (1.71)	140.32 (2.04)	0.56 (0.26)	1.00	-4.00 to 3.00
Week 8						
MK-3102 25 mg	65	140.06 (2.00)	140.49 (1.91)	0.43 (0.20)	0.00	-2.00 to 5.00
Placebo	34	139.76 (1.71)	140.15 (1.76)	0.38 (0.21)	1.00	-2.00 to 3.00
Week 12						
MK-3102 25 mg	62	140.05 (2.03)	140.69 (1.78)	0.65 (0.21)	1.00	-4.00 to 4.00
Placebo	34	139.76 (1.71)	140.74 (1.52)	0.97 (0.28)	1.00	-3.00 to 4.00
Week 24						
MK-3102 25 mg	61	140.13 (1.94)	140.87 (2.22)	0.74 (0.23)	1.00	-3.00 to 5.00
Placebo	31	139.90 (1.70)	140.87 (1.52)	0.97 (0.26)	1.00	-1.00 to 4.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	139.91 (1.86)	-	-	-	-
Placebo	33	140.61 (1.52)	-	-	-	-
Week 4						
MK-3102 25 mg	66	139.91 (1.86)	140.73 (1.61)	0.82 (0.20)	1.00	-3.00 to 4.00
Placebo	33	140.61 (1.52)	140.33 (1.31)	-0.27 (0.25)	0.00	-3.00 to 3.00
Week 8						
MK-3102 25 mg	66	139.91 (1.86)	140.62 (1.75)	0.71 (0.20)	1.00	-3.00 to 5.00
Placebo	33	140.61 (1.52)	140.67 (1.49)	0.06 (0.28)	0.00	-4.00 to 4.00
Week 12						
MK-3102 25 mg	66	139.91 (1.86)	140.83 (1.96)	0.92 (0.22)	1.00	-4.00 to 5.00
Placebo	33	140.61 (1.52)	140.91 (1.40)	0.30 (0.26)	0.00	-3.00 to 3.00
Week 24						
MK-3102 25 mg	65	139.92 (1.87)	140.82 (1.58)	0.89 (0.20)	1.00	-2.00 to 5.00
Placebo	33	140.61 (1.52)	141.09 (1.23)	0.48 (0.23)	0.00	-2.00 to 4.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	140.43 (1.64)	-	-	-	-
Placebo	34	141.09 (1.78)	-	-	-	-
Week 4						
MK-3102 25 mg	65	140.43 (1.64)	140.80 (1.68)	0.37 (0.21)	0.00	-4.00 to 4.00
Placebo	34	141.09 (1.78)	140.82 (1.75)	-0.26 (0.24)	0.00	-3.00 to 3.00
Week 8						
MK-3102 25 mg	65	140.43 (1.64)	140.72 (1.52)	0.29 (0.20)	0.00	-3.00 to 4.00
Placebo	33	141.24 (1.56)	140.79 (1.96)	-0.45 (0.31)	0.00	-4.00 to 3.00
Week 12						
MK-3102 25 mg	64	140.42 (1.65)	141.13 (1.57)	0.70 (0.23)	0.00	-3.00 to 5.00
Placebo	33	141.24 (1.56)	141.36 (1.90)	0.12 (0.34)	0.00	-4.00 to 4.00
Week 24						
MK-3102 25 mg	63	140.44 (1.65)	141.13 (1.88)	0.68 (0.22)	1.00	-3.00 to 5.00
Placebo	33	141.24 (1.56)	141.48 (1.92)	0.24 (0.29)	1.00	-3.00 to 3.00

C Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	140.31 (1.77)	-	-	-	-
Placebo	32	140.00 (1.68)	-	-	-	-
Week 4						
MK-3102 25 mg	67	140.31 (1.77)	140.94 (2.05)	0.63 (0.20)	0.00	-2.00 to 4.00
Placebo	32	140.00 (1.68)	140.44 (1.63)	0.44 (0.26)	0.00	-2.00 to 4.00
Week 8						
MK-3102 25 mg	67	140.31 (1.77)	140.82 (1.82)	0.51 (0.18)	1.00	-3.00 to 4.00
Placebo	32	140.00 (1.68)	140.28 (1.65)	0.28 (0.32)	0.00	-4.00 to 4.00
Week 12						
MK-3102 25 mg	67	140.31 (1.77)	141.07 (1.58)	0.76 (0.19)	1.00	-3.00 to 5.00
Placebo	30	140.03 (1.69)	140.37 (2.04)	0.33 (0.34)	1.00	-5.00 to 3.00
Week 24						
MK-3102 25 mg	67	140.31 (1.77)	141.07 (1.88)	0.76 (0.22)	1.00	-3.00 to 6.00
Placebo	29	140.00 (1.71)	140.83 (1.85)	0.83 (0.31)	1.00	-3.00 to 4.00

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	4.30 (0.36)	-	-	-	-
Placebo	63	4.31 (0.35)	-	-	-	-
Week 4						
MK-3102 25 mg	126	4.30 (0.36)	4.36 (0.34)	0.06 (0.03)	0.05	-0.80 to 1.00
Placebo	63	4.31 (0.35)	4.44 (0.31)	0.13 (0.04)	0.20	-0.70 to 0.60
Week 8						
MK-3102 25 mg	125	4.30 (0.36)	4.35 (0.31)	0.05 (0.03)	0.00	-0.90 to 0.90
Placebo	63	4.31 (0.35)	4.39 (0.35)	0.08 (0.04)	0.10	-0.50 to 0.80
Week 12						
MK-3102 25 mg	124	4.30 (0.37)	4.35 (0.35)	0.05 (0.03)	0.00	-0.90 to 0.90
Placebo	63	4.31 (0.35)	4.29 (0.32)	-0.01 (0.03)	0.00	-0.60 to 0.70
Week 24						
MK-3102 25 mg	122	4.30 (0.37)	4.24 (0.34)	-0.06 (0.03)	-0.05	-0.90 to 1.50
Placebo	62	4.30 (0.35)	4.28 (0.31)	-0.03 (0.04)	0.00	-0.60 to 0.90

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	4.28 (0.30)	-	-	-	-
Placebo	34	4.23 (0.36)	-	-	-	-
Week 4						
MK-3102 25 mg	65	4.28 (0.30)	4.35 (0.35)	0.07 (0.04)	0.10	-0.70 to 0.70
Placebo	34	4.23 (0.36)	4.33 (0.39)	0.09 (0.06)	0.00	-0.60 to 1.10
Week 8						
MK-3102 25 mg	65	4.28 (0.30)	4.36 (0.36)	0.08 (0.04)	0.10	-0.50 to 0.90
Placebo	34	4.23 (0.36)	4.27 (0.31)	0.04 (0.06)	0.00	-0.80 to 0.70
Week 12						
MK-3102 25 mg	62	4.29 (0.31)	4.35 (0.41)	0.07 (0.04)	0.00	-0.60 to 1.00
Placebo	34	4.23 (0.36)	4.27 (0.28)	0.04 (0.05)	0.00	-0.60 to 0.70
Week 24						
MK-3102 25 mg	61	4.30 (0.28)	4.30 (0.37)	-0.00 (0.05)	0.00	-0.90 to 1.10
Placebo	31	4.23 (0.35)	4.22 (0.30)	-0.01 (0.06)	0.00	-0.90 to 0.70

Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	4.38 (0.35)	-	-	-	-
Placebo	33	4.22 (0.33)	-	-	-	-
Week 4						
MK-3102 25 mg	66	4.38 (0.35)	4.41 (0.31)	0.03 (0.04)	0.05	-0.60 to 1.10
Placebo	33	4.22 (0.33)	4.39 (0.42)	0.18 (0.06)	0.10	-0.60 to 1.00
Week 8						
MK-3102 25 mg	66	4.38 (0.35)	4.38 (0.32)	0.01 (0.04)	0.00	-0.70 to 1.00
Placebo	33	4.22 (0.33)	4.37 (0.38)	0.15 (0.06)	0.10	-0.60 to 0.90
Week 12						
MK-3102 25 mg	66	4.38 (0.35)	4.35 (0.30)	-0.02 (0.04)	0.00	-0.80 to 0.70
Placebo	33	4.22 (0.33)	4.32 (0.33)	0.10 (0.06)	0.00	-0.60 to 1.00
Week 24						
MK-3102 25 mg	65	4.38 (0.35)	4.28 (0.28)	-0.10 (0.04)	-0.10	-0.90 to 0.70
Placebo	33	4.22 (0.33)	4.17 (0.25)	-0.05 (0.05)	0.00	-0.60 to 0.70

Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	4.28 (0.30)	-	-	-	-
Placebo	34	4.33 (0.43)	-	-	-	-
Week 4						
MK-3102 25 mg	65	4.28 (0.30)	4.33 (0.33)	0.06 (0.04)	0.10	-0.70 to 1.30
Placebo	34	4.33 (0.43)	4.31 (0.32)	-0.01 (0.06)	0.00	-0.90 to 0.70
Week 8						
MK-3102 25 mg	65	4.28 (0.30)	4.39 (0.34)	0.11 (0.04)	0.10	-0.70 to 0.90
Placebo	33	4.33 (0.44)	4.29 (0.41)	-0.03 (0.06)	0.00	-0.80 to 0.70
Week 12						
MK-3102 25 mg	64	4.28 (0.30)	4.34 (0.39)	0.06 (0.04)	0.05	-0.70 to 1.30
Placebo	33	4.33 (0.44)	4.25 (0.37)	-0.08 (0.06)	-0.10	-0.90 to 0.70
Week 24						
MK-3102 25 mg	63	4.28 (0.30)	4.25 (0.34)	-0.03 (0.03)	0.00	-0.60 to 0.70
Placebo	33	4.33 (0.44)	4.22 (0.37)	-0.11 (0.06)	-0.10	-0.80 to 0.70

Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	4.23 (0.37)	-	-	-	-
Placebo	32	4.34 (0.48)	-	-	-	-
Week 4						
MK-3102 25 mg	67	4.23 (0.37)	4.38 (0.38)	0.15 (0.04)	0.20	-0.60 to 0.80
Placebo	32	4.34 (0.48)	4.36 (0.44)	0.01 (0.05)	-0.10	-0.50 to 0.80
Week 8						
MK-3102 25 mg	67	4.23 (0.37)	4.34 (0.33)	0.11 (0.04)	0.10	-0.70 to 0.70
Placebo	32	4.34 (0.48)	4.39 (0.44)	0.05 (0.05)	0.05	-0.80 to 0.60
Week 12						
MK-3102 25 mg	67	4.23 (0.37)	4.36 (0.40)	0.12 (0.04)	0.10	-0.70 to 1.00
Placebo	30	4.37 (0.47)	4.34 (0.46)	-0.03 (0.06)	0.00	-1.00 to 0.80
Week 24						
MK-3102 25 mg	67	4.23 (0.37)	4.18 (0.28)	-0.06 (0.04)	0.00	-0.70 to 0.80
Placebo	29	4.38 (0.48)	4.23 (0.35)	-0.15 (0.07)	-0.10	-0.90 to 0.60

Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	101.79 (2.22)	-	-	-	-
Placebo	63	101.43 (2.60)	-	-	-	-
Week 4						
MK-3102 25 mg	126	101.79 (2.22)	102.28 (2.02)	0.48 (0.20)	0.00	-7.00 to 7.00
Placebo	63	101.43 (2.60)	101.40 (1.95)	-0.03 (0.28)	0.00	-4.00 to 6.00
Week 8						
MK-3102 25 mg	125	101.78 (2.22)	102.85 (2.30)	1.06 (0.21)	1.00	-6.00 to 6.00
Placebo	63	101.43 (2.60)	101.84 (2.31)	0.41 (0.30)	0.00	-4.00 to 7.00
Week 12						
MK-3102 25 mg	124	101.81 (2.22)	103.08 (2.27)	1.27 (0.21)	1.00	-6.00 to 7.00
Placebo	63	101.43 (2.60)	102.00 (1.89)	0.57 (0.28)	0.00	-4.00 to 6.00
Week 24						
MK-3102 25 mg	122	101.83 (2.21)	103.10 (2.25)	1.27 (0.22)	1.00	-5.00 to 8.00
Placebo	62	101.50 (2.56)	102.65 (2.07)	1.15 (0.33)	1.00	-4.00 to 8.00

Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	100.95 (2.62)	-	-	-	-
Placebo	34	101.12 (2.18)	-	-	-	-
Week 4						
MK-3102 25 mg	65	100.95 (2.62)	101.83 (2.32)	0.88 (0.31)	1.00	-3.00 to 8.00
Placebo	34	101.12 (2.18)	101.41 (1.97)	0.29 (0.31)	0.00	-3.00 to 4.00
Week 8						
MK-3102 25 mg	65	100.95 (2.62)	101.68 (2.42)	0.72 (0.33)	0.00	-5.00 to 9.00
Placebo	34	101.12 (2.18)	101.38 (2.06)	0.26 (0.31)	0.00	-4.00 to 3.00
Week 12						
MK-3102 25 mg	62	100.94 (2.67)	101.56 (2.48)	0.63 (0.33)	1.00	-7.00 to 9.00
Placebo	34	101.12 (2.18)	101.79 (1.84)	0.68 (0.38)	1.00	-4.00 to 4.00
Week 24						
MK-3102 25 mg	61	101.02 (2.61)	102.69 (2.38)	1.67 (0.33)	2.00	-6.00 to 7.00
Placebo	31	101.35 (2.12)	102.39 (2.08)	1.03 (0.30)	1.00	-2.00 to 4.00

Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	100.79 (2.33)	-	-	-	-
Placebo	33	101.06 (1.68)	-	-	-	-
Week 4						
MK-3102 25 mg	66	100.79 (2.33)	101.77 (2.26)	0.98 (0.27)	1.00	-4.00 to 5.00
Placebo	33	101.06 (1.68)	100.85 (1.68)	-0.21 (0.32)	0.00	-3.00 to 3.00
Week 8						
MK-3102 25 mg	66	100.79 (2.33)	101.65 (1.78)	0.86 (0.24)	1.00	-4.00 to 5.00
Placebo	33	101.06 (1.68)	101.58 (1.79)	0.52 (0.32)	1.00	-3.00 to 4.00
Week 12						
MK-3102 25 mg	66	100.79 (2.33)	101.89 (2.33)	1.11 (0.26)	1.00	-3.00 to 7.00
Placebo	33	101.06 (1.68)	101.85 (2.12)	0.79 (0.37)	1.00	-5.00 to 6.00
Week 24						
MK-3102 25 mg	65	100.80 (2.35)	102.97 (1.98)	2.17 (0.27)	2.00	-2.00 to 6.00
Placebo	33	101.06 (1.68)	102.48 (1.87)	1.42 (0.42)	1.00	-2.00 to 8.00

Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	101.52 (2.25)	-	-	-	-
Placebo	34	101.59 (2.19)	-	-	-	-
Week 4						
MK-3102 25 mg	65	101.52 (2.25)	102.12 (2.25)	0.60 (0.23)	1.00	-3.00 to 4.00
Placebo	34	101.59 (2.19)	101.82 (1.93)	0.24 (0.35)	0.50	-5.00 to 4.00
Week 8						
MK-3102 25 mg	65	101.52 (2.25)	102.05 (2.20)	0.52 (0.24)	0.00	-4.00 to 4.00
Placebo	33	101.76 (1.98)	101.94 (1.89)	0.18 (0.38)	0.00	-6.00 to 4.00
Week 12						
MK-3102 25 mg	64	101.50 (2.26)	102.48 (2.48)	0.98 (0.26)	1.00	-4.00 to 5.00
Placebo	33	101.76 (1.98)	102.48 (1.95)	0.73 (0.41)	1.00	-4.00 to 5.00
Week 24						
MK-3102 25 mg	63	101.51 (2.28)	103.24 (2.59)	1.73 (0.32)	2.00	-4.00 to 6.00
Placebo	33	101.76 (1.98)	103.30 (1.91)	1.55 (0.41)	2.00	-4.00 to 6.00

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	101.49 (2.34)	-	-	-	-
Placebo	32	101.19 (2.04)	-	-	-	-
Week 4						
MK-3102 25 mg	67	101.49 (2.34)	102.13 (2.31)	0.64 (0.22)	0.00	-3.00 to 6.00
Placebo	32	101.19 (2.04)	101.81 (1.99)	0.63 (0.42)	1.00	-5.00 to 5.00
Week 8						
MK-3102 25 mg	67	101.49 (2.34)	102.24 (2.43)	0.75 (0.23)	1.00	-4.00 to 4.00
Placebo	32	101.19 (2.04)	101.38 (2.37)	0.19 (0.41)	0.00	-5.00 to 4.00
Week 12						
MK-3102 25 mg	67	101.49 (2.34)	102.25 (2.48)	0.76 (0.27)	1.00	-4.00 to 6.00
Placebo	30	101.23 (2.10)	101.73 (2.69)	0.50 (0.40)	1.00	-5.00 to 6.00
Week 24						
MK-3102 25 mg	67	101.49 (2.34)	103.12 (2.48)	1.63 (0.29)	2.00	-4.00 to 7.00
Placebo	29	101.21 (2.13)	102.59 (2.77)	1.38 (0.46)	1.00	-3.00 to 7.00

Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	9.15 (0.34)	-	-	-	-
Placebo	63	9.10 (0.35)	-	-	-	-
Week 4						
MK-3102 25 mg	126	9.15 (0.34)	9.15 (0.31)	0.00 (0.03)	0.00	-1.00 to 0.70
Placebo	63	9.10 (0.35)	9.17 (0.27)	0.08 (0.04)	0.10	-0.60 to 1.10
Week 8						
MK-3102 25 mg	125	9.15 (0.34)	9.14 (0.35)	-0.01 (0.03)	0.00	-0.80 to 0.80
Placebo	63	9.10 (0.35)	9.17 (0.32)	0.07 (0.04)	0.10	-0.80 to 1.10
Week 12						
MK-3102 25 mg	124	9.15 (0.33)	9.11 (0.32)	-0.04 (0.03)	0.00	-0.90 to 1.00
Placebo	63	9.10 (0.35)	9.08 (0.31)	-0.02 (0.04)	-0.10	-0.60 to 0.80
Week 24						
MK-3102 25 mg	122	9.15 (0.34)	9.03 (0.38)	-0.11 (0.03)	-0.10	-1.00 to 0.80
Placebo	62	9.09 (0.35)	9.06 (0.27)	-0.03 (0.03)	-0.10	-0.40 to 1.10

Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	9.20 (0.32)	-	-	-	-
Placebo	34	9.19 (0.33)	-	-	-	-
Week 4						
MK-3102 25 mg	65	9.20 (0.32)	9.24 (0.33)	0.04 (0.03)	0.00	-0.60 to 0.60
Placebo	34	9.19 (0.33)	9.24 (0.33)	0.04 (0.05)	0.10	-0.70 to 0.70
Week 8						
MK-3102 25 mg	65	9.20 (0.32)	9.27 (0.29)	0.07 (0.04)	0.00	-0.80 to 0.90
Placebo	34	9.19 (0.33)	9.21 (0.30)	0.02 (0.05)	0.00	-0.60 to 0.80
Week 12						
MK-3102 25 mg	62	9.19 (0.31)	9.21 (0.35)	0.02 (0.04)	0.00	-0.70 to 0.80
Placebo	34	9.19 (0.33)	9.18 (0.29)	-0.02 (0.05)	-0.05	-0.60 to 0.50
Week 24						
MK-3102 25 mg	61	9.20 (0.30)	9.09 (0.33)	-0.12 (0.04)	-0.20	-0.90 to 0.70
Placebo	31	9.21 (0.33)	9.07 (0.28)	-0.14 (0.05)	-0.20	-0.70 to 0.40

Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	9.22 (0.30)	-	-	-	-
Placebo	33	9.21 (0.24)	-	-	-	-
Week 4						
MK-3102 25 mg	66	9.22 (0.30)	9.21 (0.27)	-0.01 (0.03)	0.00	-0.80 to 0.50
Placebo	33	9.21 (0.24)	9.25 (0.53)	0.04 (0.09)	0.10	-2.30 to 0.70
Week 8						
MK-3102 25 mg	66	9.22 (0.30)	9.22 (0.30)	-0.00 (0.03)	0.00	-0.60 to 0.70
Placebo	33	9.21 (0.24)	9.29 (0.33)	0.08 (0.05)	0.10	-0.80 to 0.70
Week 12						
MK-3102 25 mg	66	9.22 (0.30)	9.14 (0.31)	-0.08 (0.03)	-0.10	-0.80 to 0.40
Placebo	33	9.21 (0.24)	9.28 (0.30)	0.07 (0.05)	0.00	-0.50 to 0.80
Week 24						
MK-3102 25 mg	65	9.22 (0.30)	9.08 (0.29)	-0.14 (0.03)	-0.10	-0.70 to 0.60
Placebo	33	9.21 (0.24)	9.14 (0.29)	-0.07 (0.05)	0.00	-0.60 to 0.30

Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	9.25 (0.36)	-	-	-	-
Placebo	34	9.16 (0.37)	-	-	-	-
Week 4						
MK-3102 25 mg	65	9.25 (0.36)	9.22 (0.32)	-0.03 (0.03)	0.00	-0.90 to 0.50
Placebo	34	9.16 (0.37)	9.11 (0.35)	-0.05 (0.05)	-0.05	-0.60 to 0.70
Week 8						
MK-3102 25 mg	65	9.25 (0.36)	9.23 (0.34)	-0.02 (0.04)	-0.10	-0.70 to 0.80
Placebo	33	9.15 (0.38)	9.14 (0.36)	-0.01 (0.05)	0.00	-0.50 to 0.60
Week 12						
MK-3102 25 mg	64	9.26 (0.36)	9.14 (0.37)	-0.12 (0.04)	-0.10	-0.90 to 0.90
Placebo	33	9.15 (0.38)	9.11 (0.37)	-0.04 (0.05)	0.00	-0.80 to 0.70
Week 24						
MK-3102 25 mg	63	9.26 (0.36)	9.05 (0.37)	-0.21 (0.04)	-0.20	-1.10 to 0.60
Placebo	33	9.15 (0.38)	9.01 (0.33)	-0.14 (0.05)	-0.10	-0.70 to 0.40

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	9.16 (0.34)	-	-	-	-
Placebo	32	9.19 (0.34)	-	-	-	-
Week 4						
MK-3102 25 mg	67	9.16 (0.34)	9.22 (0.36)	0.07 (0.03)	0.00	-0.70 to 0.80
Placebo	32	9.19 (0.34)	9.15 (0.35)	-0.04 (0.05)	-0.10	-0.60 to 0.50
Week 8						
MK-3102 25 mg	67	9.16 (0.34)	9.20 (0.37)	0.04 (0.03)	0.10	-0.80 to 0.80
Placebo	32	9.19 (0.34)	9.21 (0.40)	0.02 (0.06)	0.05	-0.80 to 0.70
Week 12						
MK-3102 25 mg	67	9.16 (0.34)	9.17 (0.35)	0.01 (0.03)	0.10	-0.60 to 0.70
Placebo	30	9.20 (0.34)	9.09 (0.36)	-0.10 (0.06)	-0.10	-0.80 to 0.70
Week 24						
MK-3102 25 mg	67	9.16 (0.34)	9.05 (0.36)	-0.11 (0.04)	-0.10	-0.80 to 1.00
Placebo	29	9.20 (0.35)	8.98 (0.33)	-0.22 (0.06)	-0.20	-0.90 to 0.50

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	3.26 (0.43)	-	-	-	-
Placebo	63	3.38 (0.46)	-	-	-	-
Week 4						
MK-3102 25 mg	126	3.26 (0.43)	3.20 (0.44)	-0.06 (0.03)	-0.05	-1.00 to 0.70
Placebo	63	3.38 (0.46)	3.40 (0.47)	0.02 (0.04)	0.00	-0.90 to 0.80
Week 8						
MK-3102 25 mg	125	3.26 (0.43)	3.22 (0.47)	-0.04 (0.03)	-0.10	-1.10 to 1.30
Placebo	63	3.38 (0.46)	3.40 (0.45)	0.02 (0.05)	0.00	-0.50 to 1.00
Week 12						
MK-3102 25 mg	124	3.26 (0.43)	3.19 (0.45)	-0.07 (0.03)	-0.10	-0.90 to 1.70
Placebo	63	3.38 (0.46)	3.39 (0.45)	0.01 (0.04)	0.00	-0.70 to 0.80
Week 24						
MK-3102 25 mg	122	3.27 (0.43)	3.28 (0.40)	0.01 (0.03)	0.00	-0.80 to 1.10
Placebo	62	3.37 (0.46)	3.38 (0.45)	0.01 (0.04)	0.00	-0.70 to 1.00

Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	3.36 (0.42)	-	-	-	-
Placebo	34	3.29 (0.43)	-	-	-	-
Week 4						
MK-3102 25 mg	65	3.36 (0.42)	3.30 (0.48)	-0.06 (0.05)	0.00	-0.90 to 0.60
Placebo	34	3.29 (0.43)	3.20 (0.39)	-0.09 (0.06)	-0.10	-0.80 to 0.70
Week 8						
MK-3102 25 mg	65	3.36 (0.42)	3.30 (0.47)	-0.06 (0.05)	0.00	-0.90 to 0.60
Placebo	34	3.29 (0.43)	3.16 (0.34)	-0.14 (0.06)	-0.15	-0.80 to 0.80
Week 12						
MK-3102 25 mg	62	3.36 (0.42)	3.31 (0.46)	-0.05 (0.05)	-0.10	-0.90 to 1.30
Placebo	34	3.29 (0.43)	3.28 (0.40)	-0.02 (0.06)	-0.10	-0.60 to 1.30
Week 24						
MK-3102 25 mg	61	3.37 (0.41)	3.31 (0.43)	-0.06 (0.04)	-0.10	-0.70 to 0.70
Placebo	31	3.27 (0.44)	3.26 (0.43)	-0.00 (0.06)	-0.10	-0.70 to 0.70

Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	3.39 (0.42)	-	-	-	-
Placebo	33	3.38 (0.45)	-	-	-	-
Week 4						
MK-3102 25 mg	66	3.39 (0.42)	3.27 (0.42)	-0.12 (0.04)	-0.10	-0.90 to 1.20
Placebo	33	3.38 (0.45)	3.46 (0.45)	0.09 (0.06)	0.20	-0.60 to 0.90
Week 8						
MK-3102 25 mg	66	3.39 (0.42)	3.38 (0.41)	-0.01 (0.04)	0.00	-0.80 to 1.30
Placebo	33	3.38 (0.45)	3.47 (0.46)	0.10 (0.06)	0.00	-0.60 to 0.80
Week 12						
MK-3102 25 mg	66	3.39 (0.42)	3.30 (0.43)	-0.08 (0.04)	-0.10	-1.00 to 1.10
Placebo	33	3.38 (0.45)	3.40 (0.37)	0.03 (0.05)	0.00	-0.50 to 0.70
Week 24						
MK-3102 25 mg	65	3.39 (0.42)	3.35 (0.47)	-0.04 (0.04)	0.00	-1.00 to 0.80
Placebo	33	3.38 (0.45)	3.40 (0.46)	0.02 (0.06)	0.00	-0.60 to 0.90

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	3.30 (0.44)	-	-	-	-
Placebo	34	3.30 (0.45)	-	-	-	-
Week 4						
MK-3102 25 mg	65	3.30 (0.44)	3.23 (0.48)	-0.08 (0.04)	-0.10	-0.80 to 0.70
Placebo	34	3.30 (0.45)	3.17 (0.44)	-0.13 (0.06)	-0.10	-1.10 to 0.80
Week 8						
MK-3102 25 mg	65	3.30 (0.44)	3.26 (0.46)	-0.04 (0.04)	0.00	-0.70 to 0.60
Placebo	33	3.32 (0.45)	3.28 (0.44)	-0.04 (0.06)	0.00	-0.80 to 0.70
Week 12						
MK-3102 25 mg	64	3.30 (0.44)	3.22 (0.46)	-0.08 (0.04)	-0.10	-0.80 to 0.90
Placebo	33	3.32 (0.45)	3.27 (0.44)	-0.05 (0.05)	-0.10	-1.00 to 0.60
Week 24						
MK-3102 25 mg	63	3.29 (0.44)	3.23 (0.50)	-0.06 (0.06)	-0.10	-1.00 to 1.40
Placebo	33	3.32 (0.45)	3.24 (0.43)	-0.07 (0.06)	0.00	-0.80 to 0.90

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	3.34 (0.39)	-	-	-	-
Placebo	32	3.55 (0.46)	-	-	-	-
Week 4						
MK-3102 25 mg	67	3.34 (0.39)	3.30 (0.41)	-0.04 (0.04)	-0.10	-0.90 to 0.60
Placebo	32	3.55 (0.46)	3.42 (0.43)	-0.13 (0.06)	-0.10	-0.70 to 0.40
Week 8						
MK-3102 25 mg	67	3.34 (0.39)	3.26 (0.43)	-0.09 (0.04)	-0.10	-0.80 to 0.80
Placebo	32	3.55 (0.46)	3.53 (0.39)	-0.01 (0.07)	0.00	-0.90 to 0.80
Week 12						
MK-3102 25 mg	67	3.34 (0.39)	3.37 (0.42)	0.02 (0.04)	0.10	-0.80 to 0.90
Placebo	30	3.59 (0.44)	3.47 (0.37)	-0.12 (0.08)	-0.10	-1.00 to 0.70
Week 24						
MK-3102 25 mg	67	3.34 (0.39)	3.32 (0.45)	-0.03 (0.05)	-0.10	-0.80 to 1.10
Placebo	29	3.60 (0.45)	3.49 (0.34)	-0.11 (0.06)	-0.10	-1.10 to 0.50

Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	198.12 (32.20)	-	-	-	-
Placebo	63	191.02 (28.80)	-	-	-	-
Week 4						
MK-3102 25 mg	126	198.12 (32.20)	194.82 (32.00)	-3.30 (1.87)	-2.50	-95.00 to 56.00
Placebo	63	191.02 (28.80)	197.00 (28.13)	5.98 (2.69)	6.00	-40.00 to 58.00
Week 12						
MK-3102 25 mg	124	198.00 (32.15)	191.55 (31.32)	-6.45 (1.91)	-6.00	-70.00 to 64.00
Placebo	63	191.02 (28.80)	191.68 (32.36)	0.67 (3.25)	-1.00	-49.00 to 113.00
Week 24						
MK-3102 25 mg	122	197.91 (32.40)	186.86 (28.63)	-11.05 (1.75)	-11.00	-92.00 to 42.00
Placebo	62	190.68 (28.91)	187.53 (24.36)	-3.15 (3.01)	-3.50	-61.00 to 70.00

Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	201.68 (36.97)	-	-	-	-
Placebo	34	196.41 (33.32)	-	-	-	-
Week 4						
MK-3102 25 mg	65	201.68 (36.97)	200.23 (35.66)	-1.45 (2.60)	1.00	-101.00 to 46.00
Placebo	34	196.41 (33.32)	196.12 (31.74)	-0.29 (4.87)	-1.50	-69.00 to 75.00
Week 12						
MK-3102 25 mg	63	200.02 (36.05)	196.35 (33.92)	-3.67 (2.76)	-4.00	-109.00 to 39.00
Placebo	34	196.41 (33.32)	193.38 (24.32)	-3.03 (3.68)	-2.00	-59.00 to 39.00
Week 24						
MK-3102 25 mg	61	201.41 (35.78)	191.36 (33.32)	-10.05 (2.91)	-9.00	-105.00 to 39.00
Placebo	31	194.32 (33.95)	184.52 (24.47)	-9.81 (4.03)	-10.00	-46.00 to 38.00

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	201.05 (31.82)	-	-	-	-
Placebo	33	193.76 (35.69)	-	-	-	-
Week 4						
MK-3102 25 mg	66	201.05 (31.82)	194.39 (26.67)	-6.65 (2.17)	-3.00	-58.00 to 39.00
Placebo	33	193.76 (35.69)	197.15 (32.97)	3.39 (4.49)	2.00	-82.00 to 45.00
Week 12						
MK-3102 25 mg	66	201.05 (31.82)	189.79 (28.28)	-11.26 (2.63)	-8.00	-71.00 to 37.00
Placebo	33	193.76 (35.69)	191.76 (32.21)	-2.00 (4.16)	-4.00	-74.00 to 42.00
Week 24						
MK-3102 25 mg	65	200.89 (32.04)	185.60 (25.29)	-15.29 (2.50)	-13.00	-70.00 to 25.00
Placebo	33	193.76 (35.69)	185.61 (25.42)	-8.15 (3.75)	-6.00	-78.00 to 33.00

Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	205.72 (34.37)	-	-	-	-
Placebo	34	196.56 (32.40)	-	-	-	-
Week 4						
MK-3102 25 mg	65	205.72 (34.37)	201.98 (34.67)	-3.74 (2.56)	-4.00	-59.00 to 55.00
Placebo	34	196.56 (32.40)	196.82 (27.99)	0.26 (3.16)	6.00	-49.00 to 29.00
Week 12						
MK-3102 25 mg	64	205.95 (34.59)	200.84 (35.38)	-5.11 (2.91)	-6.00	-55.00 to 61.00
Placebo	33	197.48 (32.44)	197.82 (30.46)	0.33 (3.32)	1.00	-48.00 to 38.00
Week 24						
MK-3102 25 mg	63	205.75 (34.83)	195.38 (34.14)	-10.37 (3.68)	-14.00	-59.00 to 117.00
Placebo	33	197.48 (32.44)	191.79 (28.46)	-5.70 (3.97)	-6.00	-94.00 to 44.00

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	205.72 (35.54)	-	-	-	-
Placebo	32	197.34 (32.49)	-	-	-	-
Week 4						
MK-3102 25 mg	67	205.72 (35.54)	201.06 (38.30)	-4.66 (2.92)	-5.00	-65.00 to 50.00
Placebo	32	197.34 (32.49)	195.06 (28.79)	-2.28 (2.42)	-3.00	-29.00 to 20.00
Week 12						
MK-3102 25 mg	67	205.72 (35.54)	200.96 (35.25)	-4.76 (3.04)	-1.00	-79.00 to 53.00
Placebo	30	198.67 (32.63)	190.90 (33.96)	-7.77 (2.75)	-9.00	-40.00 to 22.00
Week 24						
MK-3102 25 mg	67	205.72 (35.54)	195.90 (35.39)	-9.82 (2.85)	-9.00	-81.00 to 39.00
Placebo	29	199.17 (33.09)	182.07 (32.40)	-17.10 (3.98)	-13.00	-66.00 to 22.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	57.44 (13.28)	-	-	-	-
Placebo	63	56.40 (18.39)	-	-	-	-
Week 4						
MK-3102 25 mg	126	57.44 (13.28)	56.15 (12.80)	-1.29 (0.56)	-1.00	-16.00 to 27.00
Placebo	63	56.40 (18.39)	55.97 (17.73)	-0.43 (0.68)	-1.00	-12.00 to 13.00
Week 12						
MK-3102 25 mg	124	57.19 (12.96)	53.96 (11.45)	-3.23 (0.60)	-3.00	-30.00 to 19.00
Placebo	63	56.40 (18.39)	53.75 (16.43)	-2.65 (0.84)	-2.00	-23.00 to 12.00
Week 24						
MK-3102 25 mg	122	57.41 (12.94)	52.52 (11.50)	-4.89 (0.66)	-4.00	-33.00 to 17.00
Placebo	62	56.26 (18.51)	53.45 (14.91)	-2.81 (0.88)	-3.00	-18.00 to 14.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	56.60 (14.44)	-	-	-	-
Placebo	34	57.06 (12.45)	-	-	-	-
Week 4						
MK-3102 25 mg	65	56.60 (14.44)	56.29 (14.25)	-0.31 (0.65)	0.00	-11.00 to 14.00
Placebo	34	57.06 (12.45)	54.65 (11.50)	-2.41 (1.41)	0.00	-33.00 to 8.00
Week 12						
MK-3102 25 mg	63	56.60 (14.55)	55.86 (14.42)	-0.75 (0.70)	-1.00	-12.00 to 16.00
Placebo	34	57.06 (12.45)	55.76 (10.81)	-1.29 (1.15)	-2.00	-16.00 to 13.00
Week 24						
MK-3102 25 mg	61	56.84 (14.71)	52.87 (13.14)	-3.97 (0.66)	-3.00	-18.00 to 6.00
Placebo	31	56.39 (12.40)	52.71 (12.02)	-3.68 (1.00)	-1.00	-16.00 to 4.00

Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	58.79 (15.82)	-	-	-	-
Placebo	33	62.33 (22.10)	-	-	-	-
Week 4						
MK-3102 25 mg	66	58.79 (15.82)	57.35 (15.39)	-1.44 (0.81)	-2.00	-23.00 to 19.00
Placebo	33	62.33 (22.10)	61.79 (20.05)	-0.55 (1.28)	0.00	-21.00 to 12.00
Week 12						
MK-3102 25 mg	66	58.79 (15.82)	55.15 (13.18)	-3.64 (0.91)	-2.00	-26.00 to 18.00
Placebo	33	62.33 (22.10)	60.48 (22.53)	-1.85 (1.24)	-1.00	-20.00 to 17.00
Week 24						
MK-3102 25 mg	65	58.55 (15.83)	52.77 (12.48)	-5.78 (1.05)	-5.00	-34.00 to 29.00
Placebo	33	62.33 (22.10)	57.52 (17.12)	-4.82 (1.43)	-5.00	-34.00 to 8.00

Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	61.14 (15.12)	-	-	-	-
Placebo	34	63.82 (15.90)	-	-	-	-
Week 4						
MK-3102 25 mg	65	61.14 (15.12)	58.22 (14.11)	-2.92 (0.87)	-2.00	-27.00 to 17.00
Placebo	34	63.82 (15.90)	62.47 (15.82)	-1.35 (1.17)	-1.50	-22.00 to 12.00
Week 12						
MK-3102 25 mg	64	61.34 (15.15)	58.45 (14.70)	-2.89 (1.18)	-3.00	-32.00 to 23.00
Placebo	33	63.97 (16.12)	63.18 (17.64)	-0.79 (1.33)	-1.00	-22.00 to 17.00
Week 24						
MK-3102 25 mg	63	61.16 (15.20)	55.94 (13.12)	-5.22 (1.03)	-3.00	-27.00 to 10.00
Placebo	33	63.97 (16.12)	58.18 (13.51)	-5.79 (1.17)	-6.00	-31.00 to 10.00

Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	54.36 (11.84)	-	-	-	-
Placebo	32	55.69 (15.21)	-	-	-	-
Week 4						
MK-3102 25 mg	67	54.36 (11.84)	52.85 (12.49)	-1.51 (0.73)	-2.00	-16.00 to 19.00
Placebo	32	55.69 (15.21)	54.88 (14.39)	-0.81 (0.78)	-0.50	-12.00 to 7.00
Week 12						
MK-3102 25 mg	67	54.36 (11.84)	53.18 (12.69)	-1.18 (0.70)	-2.00	-14.00 to 12.00
Placebo	30	56.13 (15.62)	54.00 (14.70)	-2.13 (1.02)	-3.00	-14.00 to 8.00
Week 24						
MK-3102 25 mg	67	54.36 (11.84)	50.45 (11.55)	-3.91 (0.75)	-4.00	-22.00 to 13.00
Placebo	29	56.48 (15.78)	52.76 (15.51)	-3.72 (1.09)	-4.00	-17.00 to 7.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	118.02 (26.88)	-	-	-	-
Placebo	63	112.94 (25.00)	-	-	-	-
Week 4						
MK-3102 25 mg	126	118.02 (26.88)	115.24 (27.55)	-2.78 (1.44)	-2.50	-61.00 to 51.00
Placebo	63	112.94 (25.00)	117.05 (26.43)	4.11 (2.27)	3.00	-32.00 to 54.00
Week 12						
MK-3102 25 mg	124	118.00 (27.09)	113.63 (26.89)	-4.37 (1.50)	-2.00	-58.00 to 44.00
Placebo	63	112.94 (25.00)	111.67 (25.59)	-1.27 (2.39)	-1.00	-55.00 to 67.00
Week 24						
MK-3102 25 mg	122	117.71 (27.20)	113.25 (26.58)	-4.46 (1.53)	-3.00	-51.00 to 45.00
Placebo	62	112.48 (24.94)	112.21 (22.76)	-0.27 (2.50)	-0.50	-44.00 to 67.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	119.74 (28.49)	-	-	-	-
Placebo	34	115.74 (26.14)	-	-	-	-
Week 4						
MK-3102 25 mg	65	119.74 (28.49)	119.80 (31.23)	0.06 (2.02)	1.00	-55.00 to 53.00
Placebo	34	115.74 (26.14)	113.32 (25.78)	-2.41 (3.28)	-5.00	-44.00 to 35.00
Week 12						
MK-3102 25 mg	63	118.84 (28.47)	118.00 (28.62)	-0.84 (2.38)	0.00	-61.00 to 57.00
Placebo	34	115.74 (26.14)	111.26 (24.39)	-4.47 (2.89)	-5.50	-51.00 to 26.00
Week 24						
MK-3102 25 mg	61	119.84 (28.38)	117.52 (28.68)	-2.31 (2.36)	-2.00	-48.00 to 79.00
Placebo	31	114.61 (26.99)	110.00 (21.70)	-4.61 (3.13)	-6.00	-39.00 to 29.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	121.91 (24.52)	-	-	-	-
Placebo	33	111.91 (31.13)	-	-	-	-
Week 4						
MK-3102 25 mg	66	121.91 (24.52)	116.85 (22.48)	-5.06 (1.89)	-5.00	-39.00 to 42.00
Placebo	33	111.91 (31.13)	113.42 (27.33)	1.52 (4.01)	5.00	-73.00 to 34.00
Week 12						
MK-3102 25 mg	66	121.91 (24.52)	116.79 (23.93)	-5.12 (2.20)	-2.50	-52.00 to 37.00
Placebo	33	111.91 (31.13)	109.42 (24.78)	-2.48 (3.65)	-1.00	-55.00 to 40.00
Week 24						
MK-3102 25 mg	65	121.92 (24.71)	115.20 (22.37)	-6.72 (2.39)	-5.00	-64.00 to 65.00
Placebo	33	111.91 (31.13)	108.73 (26.28)	-3.18 (2.98)	-2.00	-52.00 to 27.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	121.95 (28.74)	-	-	-	-
Placebo	34	113.21 (26.01)	-	-	-	-
Week 4						
MK-3102 25 mg	65	121.95 (28.74)	118.91 (29.46)	-3.05 (2.04)	-4.00	-55.00 to 42.00
Placebo	34	113.21 (26.01)	112.53 (25.88)	-0.68 (2.28)	-0.50	-30.00 to 21.00
Week 12						
MK-3102 25 mg	64	121.84 (28.95)	118.53 (30.83)	-3.31 (2.23)	-5.50	-40.00 to 40.00
Placebo	33	113.61 (26.30)	113.24 (25.15)	-0.36 (2.63)	-1.00	-24.00 to 39.00
Week 24						
MK-3102 25 mg	63	121.68 (29.15)	119.51 (30.17)	-2.17 (3.13)	-6.00	-41.00 to 109.00
Placebo	33	113.61 (26.30)	111.03 (28.03)	-2.58 (3.52)	-4.00	-70.00 to 55.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	126.37 (30.77)	-	-	-	-
Placebo	32	121.69 (29.96)	-	-	-	-
Week 4						
MK-3102 25 mg	67	126.37 (30.77)	122.16 (33.27)	-4.21 (2.56)	-5.00	-59.00 to 45.00
Placebo	32	121.69 (29.96)	117.00 (27.63)	-4.69 (2.11)	-2.00	-35.00 to 10.00
Week 12						
MK-3102 25 mg	67	126.37 (30.77)	123.78 (31.33)	-2.60 (2.45)	-1.00	-55.00 to 38.00
Placebo	30	122.30 (30.25)	114.00 (32.27)	-8.30 (2.54)	-7.50	-47.00 to 14.00
Week 24						
MK-3102 25 mg	67	126.37 (30.77)	121.75 (31.42)	-4.63 (2.43)	-5.00	-59.00 to 34.00
Placebo	29	122.21 (30.79)	110.21 (28.56)	-12.00 (3.68)	-9.00	-56.00 to 19.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	126.33 (111.34)	-	-	-	-
Placebo	63	117.08 (78.38)	-	-	-	-
Week 4						
MK-3102 25 mg	126	126.33 (111.34)	115.48 (63.09)	-10.84 (8.50)	-4.00	-893.00 to 259.00
Placebo	63	117.08 (78.38)	127.06 (92.11)	9.98 (8.90)	9.00	-261.00 to 393.00
Week 12						
MK-3102 25 mg	124	127.29 (111.97)	125.91 (82.34)	-1.38 (8.09)	2.00	-651.00 to 534.00
Placebo	63	117.08 (78.38)	141.71 (200.62)	24.63 (22.91)	6.00	-337.00 to 1322.00
Week 24						
MK-3102 25 mg	122	126.85 (112.69)	124.70 (69.16)	-2.15 (9.25)	0.00	-894.00 to 360.00
Placebo	62	117.48 (78.96)	124.56 (114.90)	7.08 (12.23)	6.00	-363.00 to 577.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	148.98 (133.79)	-	-	-	-
Placebo	34	138.71 (71.56)	-	-	-	-
Week 4						
MK-3102 25 mg	65	148.98 (133.79)	129.86 (90.92)	-19.12 (10.37)	-3.00	-357.00 to 160.00
Placebo	34	138.71 (71.56)	177.74 (311.33)	39.03 (55.39)	-6.00	-192.00 to 1826.00
Week 12						
MK-3102 25 mg	63	142.86 (124.91)	123.59 (101.59)	-19.27 (8.38)	-11.00	-367.00 to 157.00
Placebo	34	138.71 (71.56)	138.62 (96.78)	-0.09 (13.80)	0.00	-147.00 to 337.00
Week 24						
MK-3102 25 mg	61	142.56 (126.89)	123.98 (84.64)	-18.57 (11.60)	-5.00	-455.00 to 105.00
Placebo	31	134.52 (68.62)	131.32 (66.15)	-3.19 (7.32)	-3.00	-101.00 to 87.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	131.24 (139.61)	-	-	-	-
Placebo	33	112.79 (47.35)	-	-	-	-
Week 4						
MK-3102 25 mg	66	131.24 (139.61)	114.65 (62.30)	-16.59 (11.49)	1.00	-664.00 to 81.00
Placebo	33	112.79 (47.35)	119.30 (78.63)	6.52 (12.07)	5.00	-79.00 to 275.00
Week 12						
MK-3102 25 mg	66	131.24 (139.61)	105.06 (47.73)	-26.18 (14.11)	-4.00	-831.00 to 69.00
Placebo	33	112.79 (47.35)	117.48 (75.98)	4.70 (11.07)	0.00	-109.00 to 241.00
Week 24						
MK-3102 25 mg	65	131.09 (140.69)	116.66 (53.05)	-14.43 (16.42)	-1.00	-923.00 to 178.00
Placebo	33	112.79 (47.35)	118.03 (57.72)	5.24 (8.59)	1.00	-79.00 to 189.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	119.42 (62.76)	-	-	-	-
Placebo	34	111.26 (56.44)	-	-	-	-
Week 4						
MK-3102 25 mg	65	119.42 (62.76)	123.85 (60.78)	4.43 (5.31)	6.00	-110.00 to 120.00
Placebo	34	111.26 (56.44)	99.91 (43.79)	-11.35 (8.29)	-5.50	-226.00 to 36.00
Week 12						
MK-3102 25 mg	64	119.31 (63.25)	121.63 (58.00)	2.31 (6.50)	1.50	-172.00 to 199.00
Placebo	33	111.82 (57.22)	101.09 (60.53)	-10.73 (9.93)	-9.00	-217.00 to 137.00
Week 24						
MK-3102 25 mg	63	119.92 (63.57)	113.08 (47.33)	-6.84 (6.33)	1.00	-229.00 to 78.00
Placebo	33	111.82 (57.22)	126.33 (78.38)	14.52 (8.11)	6.00	-60.00 to 121.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	139.60 (90.36)	-	-	-	-
Placebo	32	106.50 (52.11)	-	-	-	-
Week 4						
MK-3102 25 mg	67	139.60 (90.36)	133.19 (115.45)	-6.40 (8.64)	-8.00	-160.00 to 347.00
Placebo	32	106.50 (52.11)	111.53 (83.53)	5.03 (8.61)	-2.00	-67.00 to 221.00
Week 12						
MK-3102 25 mg	67	139.60 (90.36)	133.40 (83.88)	-6.19 (6.76)	-3.00	-187.00 to 160.00
Placebo	30	107.43 (53.55)	117.80 (132.27)	10.37 (18.52)	-0.50	-72.00 to 531.00
Week 24						
MK-3102 25 mg	67	139.60 (90.36)	140.81 (112.87)	1.21 (10.03)	-4.00	-182.00 to 397.00
Placebo	29	107.83 (54.45)	107.17 (66.31)	-0.66 (8.70)	-7.00	-92.00 to 193.00

C Confidential

付録 2.7.4: 20　　臨床検査値の PDLC に該当した被験者の割合
（レスキュー治療開始後のデータを除く）
（延長試験の安全性解析対象集団）
（P006-13）

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI[†])
Hemoglobin (g/dL)			
Last value with a decrease ≥ 1.5 gm/dL [‡]			
Placebo/Metformin	76	1 (1.3)	
Pooled MK-3102	392	10 (2.6)	1.2 (-4.6, 3.7)
WBC Count (10^3/microL)			
One value with a decrease ≥ 50% and value < LLN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value with a decrease ≥ 50% and value < LLN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value with an increase ≥ 20% and value > ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	23 (5.9)	5.9 (1.0, 8.7)
Last value with an increase ≥ 20% and value > ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	8 (2.0)	2.0 (-2.8, 4.0)
Neutrophil Count (10^3/microL)			
One value with a decrease ≥ 20% and value < LLN			
Placebo/Metformin	76	4 (5.3)	
Pooled MK-3102	392	27 (6.9)	1.6 (-6.1, 6.1)
Last value with a decrease ≥ 20% and value < LLN			
Placebo/Metformin	76	1 (1.3)	
Pooled MK-3102	392	4 (1.0)	-0.3 (-6.1, 1.7)
One value with an increase ≥ 20% and value > ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	26 (6.6)	6.6 (1.8, 9.5)
Last value with an increase ≥ 20% and value > ULN			
Placebo/Metformin	76	0 (0.0)	

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI†)
Pooled MK-3102	392	8 (2.0)	2.0 (-2.8, 4.0)
Lymphocyte Count (10^3/microL)			
One value with a decrease ≥ 20% and value < LLN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	6 (1.5)	1.5 (-3.3, 3.3)
Last value with a decrease ≥ 20% and value < LLN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	1 (0.3)	0.3
One value with an increase ≥ 20% and value > ULN			
Placebo/Metformin	76	5 (6.6)	
Pooled MK-3102	392	32 (8.2)	1.6 (-6.6, 6.6)
Last value with an increase ≥ 20% and value > ULN			
Placebo/Metformin	76	3 (3.9)	
Pooled MK-3102	392	8 (2.0)	-1.9 (-9.0, 1.3)
Platelet Count (10^3/microL)			
One value with a decrease ≥ 25% and value < LLN			
Placebo/Metformin	75	0 (0.0)	
Pooled MK-3102	391	3 (0.8)	0.8
Last value with a decrease ≥ 25% and value < LLN			
Placebo/Metformin	75	0 (0.0)	
Pooled MK-3102	391	1 (0.3)	0.3
One value with an increase ≥ 100% and value > ULN			
Placebo/Metformin	75	0 (0.0)	
Pooled MK-3102	391	0 (0.0)	0.0
Last value with an increase ≥ 100% and value > ULN			
Placebo/Metformin	75	0 (0.0)	
Pooled MK-3102	391	0 (0.0)	0.0
BUN (mg/dL)			
Last value with an increase ≥ 50% and value > ULN			

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI†)
Placebo/Metformin	76	1 (1.3)	
Pooled MK-3102	392	8 (2.0)	0.7 (-5.1, 3.0)
Serum Creatine Kinase (IU/L)			
One value > 5xULN			
Placebo/Metformin	76	1 (1.3)	
Pooled MK-3102	392	6 (1.5)	0.2 (-5.6, 2.4)
Last value > 5xULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 10xULN			
Placebo/Metformin	76	1 (1.3)	
Pooled MK-3102	392	3 (0.8)	-0.6
Last value > 10xULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Serum Creatinine (mg/dL)			
Last value with an increase ≥ 0.3 mg/dL			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	7 (1.8)	1.8 (-3.0, 3.6)
Total Bilirubin (mg/dL)			
One value ≥ 2xULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value ≥ 2xULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
AST (IU/L)			
One value ≥ 3×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI†)
Last value ≥ 3×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 10×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 10×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 20×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 20×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
ALT (IU/L)			
One value ≥ 3×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	5 (1.3)	1.3 (-3.6, 3.0)
Last value ≥ 3×ULN			
Placebo/Metformin	76	0 (0.0)	

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters Excluding Data After Glycemic Rescue (Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI[†])
Pooled MK-3102	392	1 (0.3)	0.3
One value > 5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 10×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 10×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 20×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 20×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
AST (IU/L) or ALT (IU/L)			
One value ≥ 3×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	5 (1.3)	1.3 (-3.6, 3.0)
One value > 5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 10×ULN			

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI†)
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
One value > 20×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value ≥ 3×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	1 (0.3)	0.3
Last value > 5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 10×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value > 20×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)			
One value meeting (AST ≥ 3*ULN or ALT ≥ 3*ULN) with Bilirubin ≥ 2*ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value meeting (AST ≥ 3*ULN or ALT ≥ 3*ULN) with Bilirubin ≥ 2*ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Alkaline Phosphatase (IU/L)			
One value > 1.5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	5 (1.3)	1.3 (-3.6, 3.0)

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI†)
Last value > 1.5×ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	3 (0.8)	0.8
Serum Uric Acid (mg/dL)			
One value with an increase ≥ 50% and value > ULN			
Placebo/Metformin	76	4 (5.3)	
Pooled MK-3102	392	15 (3.8)	-1.4 (-9.1, 2.6)
Last value with an increase ≥ 50% and value > ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	4 (1.0)	1.0 (-3.8, 2.6)
Serum Sodium (mEq/L)			
Last value with a decrease ≥ 10 mEq/L and value < LLN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value with an increase ≥ 10 mEq/L and value > ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Serum Potassium (mEq/L)			
Last value with a decrease ≥ 1.0 mEq/L and value < LLN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	0 (0.0)	0.0
Last value with an increase ≥ 1.0 mEq/L and value > ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	5 (1.3)	1.3 (-3.6, 3.0)
Serum Calcium (mg/dL)			
Last value with an increase ≥ 1.0 mg/dL and value > ULN			
Placebo/Metformin	76	0 (0.0)	
Pooled MK-3102	392	4 (1.0)	1.0 (-3.8, 2.6)
Last value with a decrease ≥ 1.0 mg/dL and value < LLN			
Placebo/Metformin	76	0 (0.0)	

C Confidential

Analysis of Patients Meeting Predefined Limits of Change for Selected Laboratory Parameters
Excluding Data After Glycemic Rescue
(Extension APaT)

	N	n (%)	Difference in % vs. Placebo/Metformin Estimate (95% CI[†])
Pooled MK-3102	392	2 (0.5)	0.5
QTc (milliseconds)			
Last value ≥ 500 msec			
Placebo/Metformin	71	0 (0.0)	
Pooled MK-3102	382	0 (0.0)	0.0
Last value with an increase ≥ 30 msec and value > gender specific ULN			
Placebo/Metformin	66	2 (3.0)	
Pooled MK-3102	358	12 (3.4)	0.3 (-7.2, 3.7)
Last value with an increase ≥ 60 msec and value > gender specific ULN			
Placebo/Metformin	66	0 (0.0)	
Pooled MK-3102	358	0 (0.0)	0.0

[†] Based on Miettinen & Nurminen method and computed only for those outcomes that occurred in ≥4 patients in at least 1 treatment group.

[‡] Increases and decreases are relative to baseline; last value=last on-treatment value from Week 14 to Week 78.

N = Patients in population

Confidential

付録 2.7.4: 21　　臨床検査値の PDLC に該当した被験者の割合
（安全性解析対象集団）
（P020、長期投与時）

Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
(ASaT) (Extensioin)

	N	n (%)
Hemoglobin (g/dL)		
Last value with a decrease >= 1.5 g/dL ‡		
MK-3102/MK-3102	166	5 (3.0)
Sitagliptin/MK-3102	161	1 (0.6)
Placebo/MK-3102	80	1 (1.3)
WBC Count (10^3/microL)		
One value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	1 (0.6)
Placebo/MK-3102	80	0 (0.0)
Last value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	166	12 (7.2)
Sitagliptin/MK-3102	161	5 (3.1)
Placebo/MK-3102	80	4 (5.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	166	2 (1.2)
Sitagliptin/MK-3102	161	3 (1.9)
Placebo/MK-3102	80	1 (1.3)
Neutrophil Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	166	6 (3.6)
Sitagliptin/MK-3102	161	2 (1.2)
Placebo/MK-3102	80	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	166	13 (7.8)
Sitagliptin/MK-3102	161	4 (2.5)
Placebo/MK-3102	80	4 (5.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	166	2 (1.2)
Sitagliptin/MK-3102	161	3 (1.9)
Placebo/MK-3102	80	2 (2.5)
Lymphocyte Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Platelet Count (10^3/microL)		
One value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	166	2 (1.2)
Sitagliptin/MK-3102	161	1 (0.6)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
Last value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	1 (0.6)
Placebo/MK-3102	80	0 (0.0)
One value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
BUN (mg/dL)		
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Serum Creatine Kinase (IU/L)		
One value with an increase > 5×ULN		
MK-3102/MK-3102	166	2 (1.2)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value with an increase > 5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value with an increase > 10×ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
Last value with an increase > 10×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Serum Creatinine (mg/dL)		
Last value with an increase >= 0.3 mg/dL		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Total Bilirubin (mg/dL)		
One value >= 2×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value >= 2×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
AST (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
Last value > 5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
One value > 5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
AST (IU/L) or ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
One value > 5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)		
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	160	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Alkaline Phosphatase (IU/L)		
One value > 1.5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value > 1.5×ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Serum Uric Acid (mg/dL)		
One value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	166	2 (1.2)
Sitagliptin/MK-3102	161	1 (0.6)
Placebo/MK-3102	80	0 (0.0)
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Serum Sodium (mEq/L)		
Last value with a decrease >= 10 mEq/L and value < LLN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
Last value with an increase >= 10 mEq/L and value > ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Serum Potassium (mEq/L)		
Last value with a decrease >= 1.0 mEq/L and value < LLN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value with an increase >= 1.0 mEq/L and value > ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Serum Calcium (mg/dL)		
Last value with an increase >= 1.0 mg/dL and value > ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
Last value with a decrease >= 1.0 mg/dL and value < LLN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	0 (0.0)
Placebo/MK-3102	80	0 (0.0)
QTc (milliseconds)		
Last value >= 500 msec		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	2 (1.2)
Placebo/MK-3102	80	1 (1.3)
Last value with an increase >= 30 msec and value > gender specific ULN		
MK-3102/MK-3102	166	1 (0.6)
Sitagliptin/MK-3102	161	6 (3.7)
Placebo/MK-3102	80	3 (3.8)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters (ASaT) (Extensioin)

	N	n (%)
Last value with an increase >= 60 msec and value > gender specific ULN		
MK-3102/MK-3102	166	0 (0.0)
Sitagliptin/MK-3102	161	3 (1.9)
Placebo/MK-3102	80	0 (0.0)

Baseline is defined as Week 0 for the MK-3102/MK-3102 group and Week 24 for the Sitagliptin/MK-3102 and Placebo/MK-3102 groups.

Percentages represent data collected over a 52-week time period for the MK-3102/MK-3102 group (Week 0 to Week 52) and a 28-week time period for the Sitagliptin/MK-3102 and Placebo/MK-3102 groups (Week 24 to Week 52).

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 52.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

付録 2.7.4: 22　　臨床検査値のベースラインからの変化量
（安全性解析対象集団）
（P020、長期投与時）

C Confidential

Summary of Change From Baseline by Week in RBC (10^6/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	4.81 (0.42)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	4.81 (0.42)	4.77 (0.44)	-0.04 (0.01)	-0.05	-0.51 to 0.56
Week 8						
MK-3102/MK-3102	165	4.81 (0.42)	4.78 (0.43)	-0.02 (0.01)	-0.01	-0.59 to 0.38
Week 12						
MK-3102/MK-3102	165	4.81 (0.42)	4.79 (0.46)	-0.02 (0.02)	0.00	-0.70 to 0.48
Week 24						
MK-3102/MK-3102	163	4.81 (0.42)	4.70 (0.43)	-0.11 (0.02)	-0.11	-0.78 to 0.41
Week 28						
MK-3102/MK-3102	159	4.82 (0.42)	4.72 (0.44)	-0.10 (0.02)	-0.11	-0.80 to 0.60
Week 36						
MK-3102/MK-3102	156	4.82 (0.43)	4.75 (0.46)	-0.06 (0.02)	-0.05	-0.91 to 0.69
Week 52						
MK-3102/MK-3102	148	4.81 (0.42)	4.83 (0.45)	0.03 (0.02)	0.00	-0.45 to 0.67

Confidential

Summary of Change From Baseline by Week in RBC (10^6/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	4.74 (0.40)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	4.74 (0.40)	4.75 (0.41)	0.01 (0.01)	0.00	-0.39 to 0.50
Week 36						
Sitagliptin/MK-3102	158	4.75 (0.40)	4.79 (0.42)	0.04 (0.01)	0.04	-0.43 to 0.55
Week 52						
Sitagliptin/MK-3102	149	4.75 (0.39)	4.87 (0.44)	0.12 (0.02)	0.12	-0.64 to 0.69

Confidential

Summary of Change From Baseline by Week in RBC (10^6/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	4.71 (0.44)	-	-	-	-
Week 28						
Placebo/MK-3102	80	4.71 (0.44)	4.65 (0.47)	-0.06 (0.02)	-0.05	-0.63 to 0.36
Week 36						
Placebo/MK-3102	80	4.71 (0.44)	4.74 (0.48)	0.03 (0.02)	0.03	-0.42 to 0.48
Week 52						
Placebo/MK-3102	76	4.69 (0.44)	4.77 (0.44)	0.08 (0.02)	0.10	-0.66 to 0.53

Confidential

Summary of Change From Baseline by Week in Hemoglobin (gm/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	14.68 (1.39)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	14.68 (1.39)	14.53 (1.39)	-0.14 (0.05)	-0.20	-1.70 to 1.60
Week 8						
MK-3102/MK-3102	165	14.66 (1.38)	14.58 (1.33)	-0.09 (0.05)	-0.10	-1.90 to 2.20
Week 12						
MK-3102/MK-3102	165	14.66 (1.38)	14.58 (1.42)	-0.08 (0.05)	0.00	-1.90 to 1.80
Week 24						
MK-3102/MK-3102	163	14.67 (1.39)	14.34 (1.34)	-0.31 (0.05)	-0.40	-2.60 to 2.40
Week 28						
MK-3102/MK-3102	159	14.69 (1.40)	14.41 (1.37)	-0.27 (0.06)	-0.30	-2.20 to 2.30
Week 36						
MK-3102/MK-3102	156	14.67 (1.41)	14.51 (1.43)	-0.15 (0.06)	-0.20	-3.00 to 2.40
Week 52						
MK-3102/MK-3102	148	14.67 (1.37)	14.76 (1.42)	0.09 (0.06)	0.10	-1.70 to 3.50

Confidential

Summary of Change From Baseline by Week in Hemoglobin (gm/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	14.45 (1.22)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	14.45 (1.22)	14.52 (1.26)	0.07 (0.05)	0.00	-1.20 to 1.70
Week 36						
Sitagliptin/MK-3102	158	14.46 (1.22)	14.62 (1.31)	0.16 (0.05)	0.10	-1.50 to 2.00
Week 52						
Sitagliptin/MK-3102	149	14.44 (1.18)	14.85 (1.31)	0.41 (0.06)	0.30	-2.20 to 2.70

C Confidential

Summary of Change From Baseline by Week in Hemoglobin (gm/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	14.43 (1.47)	-	-	-	-
Week 28						
Placebo/MK-3102	80	14.43 (1.47)	14.30 (1.46)	-0.13 (0.07)	-0.10	-2.00 to 1.00
Week 36						
Placebo/MK-3102	80	14.43 (1.47)	14.55 (1.57)	0.13 (0.07)	0.10	-1.50 to 1.70
Week 52						
Placebo/MK-3102	76	14.37 (1.44)	14.66 (1.42)	0.28 (0.08)	0.40	-2.20 to 2.30

Confidential

Summary of Change From Baseline by Week in Hematocrit (%) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	44.67 (3.66)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	44.67 (3.66)	44.51 (3.72)	-0.16 (0.13)	-0.40	-5.00 to 4.90
Week 8						
MK-3102/MK-3102	165	44.63 (3.64)	44.60 (3.62)	-0.04 (0.14)	0.05	-6.00 to 5.70
Week 12						
MK-3102/MK-3102	165	44.63 (3.64)	44.73 (3.93)	0.09 (0.16)	0.30	-6.60 to 5.40
Week 24						
MK-3102/MK-3102	163	44.64 (3.67)	43.45 (3.66)	-1.17 (0.16)	-1.20	-6.20 to 5.40
Week 28						
MK-3102/MK-3102	159	44.70 (3.67)	43.43 (3.68)	-1.28 (0.17)	-1.20	-7.00 to 4.90
Week 36						
MK-3102/MK-3102	156	44.65 (3.68)	43.50 (3.82)	-1.14 (0.17)	-1.10	-8.00 to 6.20
Week 52						
MK-3102/MK-3102	148	44.65 (3.63)	44.43 (3.75)	-0.21 (0.16)	-0.30	-5.30 to 6.70

C Confidential

Summary of Change From Baseline by Week in Hematocrit (%) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	43.66 (3.34)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	43.66 (3.34)	43.58 (3.48)	-0.07 (0.14)	-0.20	-4.10 to 4.50
Week 36						
Sitagliptin/MK-3102	158	43.68 (3.34)	43.69 (3.50)	0.02 (0.16)	0.00	-5.20 to 5.80
Week 52						
Sitagliptin/MK-3102	149	43.66 (3.30)	44.55 (3.59)	0.89 (0.17)	1.00	-5.60 to 7.90

C Confidential

Summary of Change From Baseline by Week in Hematocrit (%) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	43.67 (3.77)	-	-	-	-
Week 28						
Placebo/MK-3102	80	43.67 (3.77)	42.97 (3.85)	-0.70 (0.20)	-0.70	-5.10 to 3.20
Week 36						
Placebo/MK-3102	80	43.67 (3.77)	43.62 (4.10)	-0.05 (0.24)	0.00	-4.60 to 5.90
Week 52						
Placebo/MK-3102	76	43.55 (3.72)	43.97 (3.61)	0.42 (0.23)	0.50	-6.90 to 5.50

C Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	32.84 (0.97)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	32.84 (0.97)	32.63 (0.96)	-0.20 (0.04)	-0.20	-1.90 to 1.10
Week 8						
MK-3102/MK-3102	165	32.83 (0.97)	32.66 (0.89)	-0.17 (0.04)	-0.10	-1.70 to 1.00
Week 12						
MK-3102/MK-3102	165	32.83 (0.97)	32.58 (0.91)	-0.24 (0.04)	-0.30	-2.10 to 1.20
Week 24						
MK-3102/MK-3102	163	32.83 (0.98)	32.99 (0.99)	0.17 (0.06)	0.10	-1.60 to 3.10
Week 28						
MK-3102/MK-3102	159	32.82 (0.98)	33.16 (0.98)	0.35 (0.06)	0.30	-1.90 to 2.60
Week 36						
MK-3102/MK-3102	156	32.82 (0.98)	33.33 (0.92)	0.51 (0.05)	0.50	-1.20 to 2.80
Week 52						
MK-3102/MK-3102	148	32.83 (0.93)	33.20 (0.91)	0.37 (0.05)	0.40	-1.90 to 3.00

Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	33.08 (0.89)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	33.08 (0.89)	33.30 (0.93)	0.22 (0.05)	0.20	-1.30 to 2.00
Week 36						
Sitagliptin/MK-3102	158	33.10 (0.89)	33.44 (0.85)	0.34 (0.05)	0.40	-1.60 to 1.70
Week 52						
Sitagliptin/MK-3102	149	33.08 (0.87)	33.32 (0.88)	0.24 (0.07)	0.20	-2.00 to 2.70

Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	33.01 (1.08)	-	-	-	-
Week 28						
Placebo/MK-3102	80	33.01 (1.08)	33.26 (1.01)	0.25 (0.06)	0.25	-1.20 to 1.20
Week 36						
Placebo/MK-3102	80	33.01 (1.08)	33.33 (0.97)	0.32 (0.07)	0.40	-1.10 to 2.10
Week 52						
Placebo/MK-3102	76	32.98 (1.09)	33.31 (1.02)	0.33 (0.09)	0.25	-1.50 to 2.50

Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular Volume (fL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	92.98 (4.82)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	92.98 (4.82)	93.44 (4.85)	0.42 (0.10)	0.40	-3.00 to 4.90
Week 8						
MK-3102/MK-3102	165	92.96 (4.83)	93.40 (4.73)	0.42 (0.12)	0.40	-3.70 to 6.20
Week 12						
MK-3102/MK-3102	165	92.96 (4.83)	93.51 (4.78)	0.52 (0.14)	0.45	-4.00 to 8.80
Week 24						
MK-3102/MK-3102	163	92.89 (4.79)	92.58 (4.66)	-0.35 (0.19)	-0.60	-4.40 to 12.00
Week 28						
MK-3102/MK-3102	159	92.94 (4.81)	92.24 (4.74)	-0.75 (0.20)	-1.20	-5.40 to 11.50
Week 36						
MK-3102/MK-3102	156	92.87 (4.80)	91.71 (4.73)	-1.19 (0.19)	-1.50	-7.40 to 12.60
Week 52						
MK-3102/MK-3102	148	93.09 (4.70)	92.22 (4.87)	-0.90 (0.18)	-0.90	-7.00 to 13.50

Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular Volume (fL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	92.22 (4.75)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	92.22 (4.75)	91.88 (4.63)	-0.35 (0.11)	-0.40	-4.40 to 3.70
Week 36						
Sitagliptin/MK-3102	158	92.16 (4.73)	91.39 (4.58)	-0.77 (0.14)	-0.80	-5.80 to 3.40
Week 52						
Sitagliptin/MK-3102	149	92.16 (4.75)	91.72 (4.71)	-0.44 (0.15)	-0.70	-4.40 to 5.80

Confidential

Summary of Change From Baseline by Week in Ery. Mean Corpuscular Volume (fL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	92.95 (5.20)	-	-	-	-
Week 28						
Placebo/MK-3102	80	92.95 (5.20)	92.64 (5.35)	-0.31 (0.17)	-0.20	-4.00 to 4.10
Week 36						
Placebo/MK-3102	80	92.95 (5.20)	92.24 (5.22)	-0.71 (0.23)	-0.95	-4.70 to 6.30
Week 52						
Placebo/MK-3102	76	93.05 (5.29)	92.38 (4.99)	-0.67 (0.24)	-0.70	-4.40 to 4.10

C Confidential

Summary of Change From Baseline by Week in Platelet (10^3/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	233.39 (52.37)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	233.39 (52.37)	232.08 (51.87)	-1.14 (1.92)	-1.00	-80.00 to 83.00
Week 8						
MK-3102/MK-3102	165	233.88 (52.15)	228.62 (50.25)	-5.01 (1.77)	-6.00	-75.00 to 96.00
Week 12						
MK-3102/MK-3102	165	233.88 (52.15)	228.62 (49.91)	-5.06 (1.93)	-5.50	-87.00 to 84.00
Week 24						
MK-3102/MK-3102	163	233.73 (52.33)	222.59 (48.15)	-10.75 (1.84)	-10.00	-112.00 to 54.00
Week 28						
MK-3102/MK-3102	159	234.44 (52.09)	228.26 (50.08)	-5.98 (2.17)	-5.00	-111.00 to 130.00
Week 36						
MK-3102/MK-3102	156	234.43 (52.44)	229.17 (51.78)	-4.97 (2.52)	-8.00	-141.00 to 172.00
Week 52						
MK-3102/MK-3102	148	232.80 (51.41)	232.00 (49.71)	-0.55 (2.18)	-1.00	-94.00 to 76.00

Confidential

Summary of Change From Baseline by Week in Platelet (10^3/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	229.50 (50.63)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	229.50 (50.63)	229.96 (47.79)	0.46 (1.78)	1.00	-85.00 to 87.00
Week 36						
Sitagliptin/MK-3102	158	229.78 (50.80)	230.41 (49.28)	0.63 (2.16)	2.00	-105.00 to 101.00
Week 52						
Sitagliptin/MK-3102	149	231.13 (50.35)	233.96 (48.40)	2.83 (1.97)	7.00	-86.00 to 54.00

C Confidential

Summary of Change From Baseline by Week in Platelet (10^3/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	233.75 (61.63)	-	-	-	-
Week 28						
Placebo/MK-3102	80	233.75 (61.63)	231.66 (59.78)	-2.09 (2.00)	-2.50	-52.00 to 35.00
Week 36						
Placebo/MK-3102	80	233.75 (61.63)	235.90 (64.58)	2.15 (2.64)	6.50	-62.00 to 97.00
Week 52						
Placebo/MK-3102	76	235.29 (62.54)	243.43 (62.33)	8.14 (3.08)	7.50	-48.00 to 75.00

Confidential

Summary of Change From Baseline by Week in WBC (cells/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	5494.55 (1609.66)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	5494.55 (1609.66)	5806.02 (1833.71)	321.82 (81.74)	300.00	-2500.00 to 5400.00
Week 8						
MK-3102/MK-3102	165	5495.73 (1614.52)	5839.39 (1518.81)	354.27 (74.04)	400.00	-4200.00 to 2600.00
Week 12						
MK-3102/MK-3102	165	5495.73 (1614.52)	5849.09 (1843.96)	363.41 (106.52)	300.00	-2400.00 to 12000.00
Week 24						
MK-3102/MK-3102	163	5503.70 (1622.66)	5789.57 (1897.29)	296.30 (90.71)	300.00	-3400.00 to 4700.00
Week 28						
MK-3102/MK-3102	159	5524.05 (1624.59)	5842.14 (1507.97)	328.48 (81.95)	400.00	-3900.00 to 3200.00
Week 36						
MK-3102/MK-3102	156	5516.77 (1637.78)	6003.85 (1603.70)	497.42 (82.92)	500.00	-3600.00 to 3600.00
Week 52						
MK-3102/MK-3102	148	5501.36 (1657.61)	5884.46 (1701.93)	393.20 (98.30)	400.00	-4600.00 to 4700.00

Confidential

Summary of Change From Baseline by Week in WBC (cells/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	6024.38 (1620.65)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	6024.38 (1620.65)	6157.50 (1590.80)	133.13 (88.75)	200.00	-7400.00 to 4300.00
Week 36						
Sitagliptin/MK-3102	158	6031.65 (1629.16)	6286.08 (1723.63)	254.43 (81.67)	300.00	-5700.00 to 3000.00
Week 52						
Sitagliptin/MK-3102	149	6027.52 (1652.76)	6074.50 (1742.75)	46.98 (94.87)	0.00	-7200.00 to 3400.00

Confidential

Summary of Change From Baseline by Week in WBC (cells/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	5802.50 (1474.25)	-	-	-	-
Week 28						
Placebo/MK-3102	80	5802.50 (1474.25)	5946.25 (1713.53)	143.75 (128.15)	100.00	-2200.00 to 5400.00
Week 36						
Placebo/MK-3102	80	5802.50 (1474.25)	6105.00 (1686.42)	302.50 (118.51)	300.00	-2800.00 to 3300.00
Week 52						
Placebo/MK-3102	76	5801.32 (1491.08)	6018.42 (1701.11)	217.11 (116.75)	100.00	-2400.00 to 3300.00

Confidential

Summary of Change From Baseline by Week in Neutrophils (cells/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	3243.53 (1284.78)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	3243.53 (1284.78)	3502.72 (1551.98)	267.85 (78.70)	179.10	-2207.30 to 5446.80
Week 8						
MK-3102/MK-3102	165	3244.14 (1288.69)	3484.07 (1195.15)	247.85 (66.04)	311.80	-3710.40 to 2549.20
Week 12						
MK-3102/MK-3102	165	3244.14 (1288.69)	3520.36 (1523.79)	283.50 (96.05)	227.20	-2621.40 to 10736.10
Week 24						
MK-3102/MK-3102	163	3253.49 (1293.58)	3505.59 (1549.86)	261.39 (82.90)	204.10	-2950.80 to 4842.30
Week 28						
MK-3102/MK-3102	159	3262.02 (1303.61)	3472.01 (1189.96)	216.52 (72.58)	216.60	-3793.50 to 2735.70
Week 36						
MK-3102/MK-3102	156	3262.33 (1316.23)	3617.15 (1331.93)	363.97 (76.78)	372.40	-3381.00 to 4496.40
Week 52						
MK-3102/MK-3102	148	3254.31 (1333.76)	3603.52 (1353.30)	357.57 (88.62)	305.00	-4128.80 to 4280.50

Confidential

Summary of Change From Baseline by Week in Neutrophils (cells/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	3604.08 (1284.70)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	3604.08 (1284.70)	3609.41 (1193.35)	5.32 (75.99)	136.05	-6894.60 to 2356.40
Week 36						
Sitagliptin/MK-3102	158	3606.52 (1291.37)	3763.85 (1322.50)	157.33 (74.17)	137.10	-5500.50 to 3126.00
Week 52						
Sitagliptin/MK-3102	149	3602.96 (1300.82)	3657.13 (1305.08)	54.17 (83.75)	38.40	-6759.00 to 3111.60

Confidential

Summary of Change From Baseline by Week in Neutrophils (cells/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	3381.04 (1164.33)	-	-	-	-
Week 28						
Placebo/MK-3102	80	3381.04 (1164.33)	3474.59 (1311.86)	93.56 (108.22)	80.10	-2394.70 to 4806.00
Week 36						
Placebo/MK-3102	80	3381.04 (1164.33)	3642.99 (1347.92)	261.95 (109.83)	169.20	-2979.90 to 2625.50
Week 52						
Placebo/MK-3102	76	3369.80 (1155.57)	3701.72 (1440.11)	331.92 (109.92)	325.85	-2586.90 to 3524.90

Confidential

Summary of Change From Baseline by Week in Lymphocytes (cells/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	1784.20 (538.92)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	1784.20 (538.92)	1806.23 (488.62)	22.59 (25.32)	16.80	-1234.50 to 929.70
Week 8						
MK-3102/MK-3102	165	1784.19 (540.58)	1836.03 (508.89)	52.89 (24.52)	88.50	-1173.80 to 811.70
Week 12						
MK-3102/MK-3102	165	1784.19 (540.58)	1813.48 (529.95)	30.79 (25.83)	21.65	-1295.00 to 851.60
Week 24						
MK-3102/MK-3102	163	1781.39 (543.32)	1782.97 (513.24)	1.55 (23.98)	13.75	-879.80 to 1067.40
Week 28						
MK-3102/MK-3102	159	1794.39 (539.55)	1869.78 (485.17)	77.61 (29.71)	74.65	-1574.30 to 1204.60
Week 36						
MK-3102/MK-3102	156	1789.85 (540.15)	1870.44 (460.19)	80.69 (31.42)	76.20	-1732.00 to 1039.30
Week 52						
MK-3102/MK-3102	148	1780.12 (544.23)	1779.87 (526.79)	-0.11 (28.10)	-10.60	-1269.80 to 1091.50

Confidential

Summary of Change From Baseline by Week in Lymphocytes (cells/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	1885.42 (636.30)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	1885.42 (636.30)	1986.21 (636.31)	100.78 (29.69)	100.80	-1307.00 to 1947.60
Week 36						
Sitagliptin/MK-3102	158	1889.80 (638.35)	1960.00 (667.31)	70.20 (28.43)	45.00	-993.10 to 1325.20
Week 52						
Sitagliptin/MK-3102	149	1888.50 (641.56)	1857.14 (667.42)	-31.36 (26.96)	-51.60	-1011.40 to 883.40

Confidential

Summary of Change From Baseline by Week in Lymphocytes (cells/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	1901.47 (541.12)	-	-	-	-
Week 28						
Placebo/MK-3102	80	1901.47 (541.12)	1897.33 (515.77)	-4.14 (41.94)	2.40	-1139.40 to 980.60
Week 36						
Placebo/MK-3102	80	1901.47 (541.12)	1884.50 (474.36)	-16.97 (40.86)	22.90	-975.60 to 980.80
Week 52						
Placebo/MK-3102	76	1911.20 (552.34)	1774.94 (490.52)	-136.26 (34.78)	-135.40	-785.00 to 751.40

Confidential

Summary of Change From Baseline by Week in Monocytes (cells/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	281.04 (83.00)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	281.04 (83.00)	307.62 (95.29)	27.10 (5.13)	27.50	-196.40 to 335.20
Week 8						
MK-3102/MK-3102	165	281.17 (83.23)	316.98 (90.53)	36.69 (5.43)	39.55	-156.10 to 261.70
Week 12						
MK-3102/MK-3102	165	281.17 (83.23)	318.08 (114.73)	37.36 (8.29)	28.90	-175.20 to 1034.40
Week 24						
MK-3102/MK-3102	163	281.99 (83.42)	309.06 (97.82)	27.56 (5.72)	29.15	-143.20 to 232.70
Week 28						
MK-3102/MK-3102	159	282.09 (82.95)	308.21 (84.50)	26.80 (5.58)	26.80	-202.10 to 171.30
Week 36						
MK-3102/MK-3102	156	281.60 (83.51)	326.69 (98.13)	45.49 (6.50)	45.50	-144.10 to 426.20
Week 52						
MK-3102/MK-3102	148	281.99 (85.06)	314.56 (90.60)	33.48 (6.04)	35.20	-201.90 to 229.50

Confidential

Summary of Change From Baseline by Week in Monocytes (cells/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	330.81 (106.31)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	330.81 (106.31)	348.18 (112.55)	17.37 (6.21)	10.45	-237.20 to 282.90
Week 36						
Sitagliptin/MK-3102	158	331.37 (106.59)	343.32 (112.06)	11.95 (6.11)	5.40	-190.00 to 266.10
Week 52						
Sitagliptin/MK-3102	149	328.67 (108.52)	346.33 (128.21)	17.66 (7.32)	9.90	-252.00 to 401.10

Confidential

Summary of Change From Baseline by Week in Monocytes (cells/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	305.49 (99.39)	-	-	-	-
Week 28						
Placebo/MK-3102	80	305.49 (99.39)	343.58 (111.89)	38.09 (10.87)	32.00	-249.70 to 421.20
Week 36						
Placebo/MK-3102	80	305.49 (99.39)	350.63 (111.05)	45.14 (10.04)	38.00	-227.30 to 275.30
Week 52						
Placebo/MK-3102	76	303.89 (101.14)	334.13 (108.51)	30.23 (10.55)	23.20	-344.30 to 300.00

Confidential

Summary of Change From Baseline by Week in Eosinophils (cells/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	152.81 (97.77)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	152.81 (97.77)	156.48 (102.94)	4.20 (4.42)	-1.20	-128.00 to 253.30
Week 8						
MK-3102/MK-3102	165	153.13 (97.99)	166.79 (112.85)	14.38 (6.27)	-0.40	-177.80 to 644.70
Week 12						
MK-3102/MK-3102	165	153.13 (97.99)	163.06 (113.70)	10.67 (5.56)	-0.15	-153.30 to 373.80
Week 24						
MK-3102/MK-3102	163	153.72 (98.41)	159.16 (101.35)	6.04 (5.87)	-2.40	-201.90 to 391.60
Week 28						
MK-3102/MK-3102	159	152.46 (97.99)	157.83 (105.94)	6.18 (5.48)	-1.45	-281.10 to 329.10
Week 36						
MK-3102/MK-3102	156	150.08 (95.49)	155.37 (108.37)	6.03 (4.99)	0.00	-131.60 to 254.00
Week 52						
MK-3102/MK-3102	148	151.88 (96.83)	153.78 (101.98)	2.52 (5.05)	-0.90	-200.30 to 273.20

Confidential

Summary of Change From Baseline by Week in Eosinophils (cells/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	169.88 (113.56)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	169.88 (113.56)	178.89 (116.49)	9.01 (3.97)	9.35	-183.70 to 174.30
Week 36						
Sitagliptin/MK-3102	158	169.80 (114.22)	182.84 (120.65)	13.04 (5.74)	9.55	-178.50 to 252.40
Week 52						
Sitagliptin/MK-3102	149	172.62 (115.31)	178.59 (130.65)	5.97 (9.24)	-0.50	-305.50 to 734.40

Confidential

Summary of Change From Baseline by Week in Eosinophils (cells/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	180.07 (126.68)	-	-	-	-
Week 28						
Placebo/MK-3102	80	180.07 (126.68)	196.82 (153.93)	16.75 (8.41)	7.90	-178.60 to 367.20
Week 36						
Placebo/MK-3102	80	180.07 (126.68)	190.73 (131.16)	10.66 (9.90)	2.55	-219.20 to 496.80
Week 52						
Placebo/MK-3102	76	181.72 (128.21)	171.95 (101.49)	-9.77 (7.66)	-8.75	-187.20 to 155.30

Confidential

Summary of Change From Baseline by Week in Basophils (cells/microL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	32.96 (17.85)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	32.96 (17.85)	32.98 (18.57)	0.10 (1.21)	-1.00	-45.90 to 51.50
Week 8						
MK-3102/MK-3102	165	33.10 (17.82)	35.52 (18.75)	2.47 (1.21)	1.30	-51.30 to 47.40
Week 12						
MK-3102/MK-3102	165	33.10 (17.82)	34.11 (18.20)	1.09 (1.14)	0.45	-56.50 to 40.80
Week 24						
MK-3102/MK-3102	163	33.12 (17.93)	32.79 (16.79)	-0.25 (1.10)	-0.30	-46.30 to 45.20
Week 28						
MK-3102/MK-3102	159	33.10 (17.96)	34.31 (16.76)	1.38 (1.22)	1.00	-61.00 to 40.80
Week 36						
MK-3102/MK-3102	156	32.92 (18.06)	34.20 (16.68)	1.25 (1.21)	0.80	-55.00 to 50.40
Week 52						
MK-3102/MK-3102	148	33.06 (18.23)	32.73 (19.74)	-0.26 (1.49)	-0.40	-70.50 to 92.40

Confidential

Summary of Change From Baseline by Week in Basophils (cells/microL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	34.18 (19.43)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	34.18 (19.43)	34.82 (21.47)	0.64 (1.02)	0.25	-33.70 to 52.70
Week 36						
Sitagliptin/MK-3102	158	34.15 (19.47)	36.07 (21.43)	1.91 (1.15)	1.00	-40.70 to 51.20
Week 52						
Sitagliptin/MK-3102	149	34.77 (19.74)	35.30 (20.68)	0.53 (1.16)	0.00	-39.60 to 43.50

Confidential

Summary of Change From Baseline by Week in Basophils (cells/microL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	34.43 (23.07)	-	-	-	-
Week 28						
Placebo/MK-3102	80	34.43 (23.07)	33.92 (20.65)	-0.51 (1.68)	-0.10	-59.40 to 25.20
Week 36						
Placebo/MK-3102	80	34.43 (23.07)	36.15 (20.95)	1.73 (1.98)	-0.60	-45.70 to 40.40
Week 52						
Placebo/MK-3102	76	34.70 (23.25)	35.69 (22.56)	0.99 (1.98)	-0.10	-52.10 to 41.20

C Confidential

Summary of Change From Baseline by Week in Protein (gm/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	7.28 (0.47)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	7.28 (0.47)	7.28 (0.41)	-0.00 (0.03)	0.00	-2.60 to 1.00
Week 8						
MK-3102/MK-3102	165	7.28 (0.47)	7.31 (0.39)	0.04 (0.03)	0.00	-2.70 to 1.00
Week 12						
MK-3102/MK-3102	165	7.28 (0.47)	7.31 (0.36)	0.03 (0.03)	0.10	-2.60 to 1.20
Week 24						
MK-3102/MK-3102	163	7.28 (0.47)	7.24 (0.36)	-0.04 (0.03)	0.00	-2.50 to 0.90
Week 28						
MK-3102/MK-3102	159	7.29 (0.48)	7.29 (0.36)	0.01 (0.03)	0.00	-2.70 to 0.90
Week 36						
MK-3102/MK-3102	156	7.29 (0.48)	7.32 (0.39)	0.03 (0.03)	0.10	-2.40 to 0.90
Week 52						
MK-3102/MK-3102	148	7.29 (0.49)	7.37 (0.43)	0.07 (0.04)	0.10	-2.40 to 1.20

Confidential

Summary of Change From Baseline by Week in Protein (gm/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	7.27 (0.38)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	7.27 (0.38)	7.33 (0.40)	0.06 (0.02)	0.00	-0.70 to 1.00
Week 36						
Sitagliptin/MK-3102	158	7.27 (0.38)	7.35 (0.43)	0.07 (0.03)	0.10	-0.90 to 1.20
Week 52						
Sitagliptin/MK-3102	149	7.28 (0.37)	7.38 (0.43)	0.10 (0.03)	0.10	-0.70 to 1.30

Confidential

Summary of Change From Baseline by Week in Protein (gm/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	7.15 (0.42)	-	-	-	-
Week 28						
Placebo/MK-3102	80	7.15 (0.42)	7.17 (0.41)	0.02 (0.03)	0.00	-0.60 to 0.70
Week 36						
Placebo/MK-3102	80	7.15 (0.42)	7.26 (0.41)	0.11 (0.03)	0.10	-0.50 to 0.80
Week 52						
Placebo/MK-3102	76	7.14 (0.40)	7.28 (0.38)	0.13 (0.04)	0.10	-0.60 to 0.80

C Confidential

Summary of Change From Baseline by Week in Albumin (gm/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	4.44 (0.26)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	4.44 (0.26)	4.44 (0.26)	-0.00 (0.02)	0.00	-0.80 to 0.80
Week 8						
MK-3102/MK-3102	165	4.44 (0.26)	4.45 (0.24)	0.01 (0.02)	0.00	-0.70 to 0.60
Week 12						
MK-3102/MK-3102	165	4.44 (0.26)	4.43 (0.24)	-0.01 (0.02)	0.00	-0.70 to 0.70
Week 24						
MK-3102/MK-3102	163	4.44 (0.26)	4.40 (0.23)	-0.03 (0.02)	0.00	-0.80 to 0.60
Week 28						
MK-3102/MK-3102	159	4.44 (0.26)	4.45 (0.24)	0.01 (0.02)	0.00	-0.80 to 0.60
Week 36						
MK-3102/MK-3102	156	4.44 (0.26)	4.48 (0.24)	0.03 (0.02)	0.10	-0.90 to 0.60
Week 52						
MK-3102/MK-3102	148	4.44 (0.26)	4.45 (0.27)	0.01 (0.02)	0.00	-0.80 to 0.70

Confidential

Summary of Change From Baseline by Week in Albumin (gm/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	4.40 (0.24)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	4.40 (0.24)	4.44 (0.22)	0.05 (0.02)	0.00	-0.50 to 0.90
Week 36						
Sitagliptin/MK-3102	158	4.39 (0.24)	4.46 (0.24)	0.06 (0.02)	0.10	-0.50 to 0.60
Week 52						
Sitagliptin/MK-3102	149	4.40 (0.23)	4.43 (0.24)	0.03 (0.02)	0.00	-0.60 to 0.90

Confidential

Summary of Change From Baseline by Week in Albumin (gm/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	4.35 (0.23)	-	-	-	-
Week 28						
Placebo/MK-3102	80	4.35 (0.23)	4.35 (0.22)	0.00 (0.02)	0.00	-0.40 to 0.50
Week 36						
Placebo/MK-3102	80	4.35 (0.23)	4.40 (0.23)	0.06 (0.02)	0.00	-0.40 to 0.60
Week 52						
Placebo/MK-3102	76	4.34 (0.22)	4.37 (0.22)	0.03 (0.02)	0.00	-0.40 to 0.30

Confidential

Summary of Change From Baseline by Week in Bilirubin (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	0.68 (0.24)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	0.68 (0.24)	0.71 (0.27)	0.03 (0.02)	0.00	-0.70 to 1.50
Week 8						
MK-3102/MK-3102	165	0.67 (0.24)	0.71 (0.23)	0.04 (0.02)	0.00	-1.00 to 0.70
Week 12						
MK-3102/MK-3102	165	0.67 (0.24)	0.70 (0.24)	0.03 (0.01)	0.00	-0.50 to 0.40
Week 24						
MK-3102/MK-3102	163	0.67 (0.24)	0.71 (0.24)	0.04 (0.02)	0.10	-0.60 to 0.50
Week 28						
MK-3102/MK-3102	159	0.68 (0.24)	0.76 (0.26)	0.09 (0.01)	0.10	-0.50 to 0.60
Week 36						
MK-3102/MK-3102	156	0.68 (0.24)	0.73 (0.25)	0.06 (0.02)	0.10	-0.60 to 0.60
Week 52						
MK-3102/MK-3102	148	0.67 (0.24)	0.69 (0.22)	0.02 (0.02)	0.00	-0.60 to 0.70

C Confidential

Summary of Change From Baseline by Week in Bilirubin (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	0.70 (0.26)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	0.70 (0.26)	0.74 (0.27)	0.04 (0.02)	0.00	-0.60 to 0.80
Week 36						
Sitagliptin/MK-3102	158	0.70 (0.26)	0.69 (0.25)	-0.01 (0.02)	0.00	-0.60 to 0.60
Week 52						
Sitagliptin/MK-3102	149	0.70 (0.26)	0.70 (0.26)	0.01 (0.02)	0.00	-0.60 to 0.50

C Confidential

Summary of Change From Baseline by Week in Bilirubin (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	0.77 (0.30)	-	-	-	-
Week 28						
Placebo/MK-3102	80	0.77 (0.30)	0.75 (0.26)	-0.02 (0.02)	0.00	-0.90 to 0.50
Week 36						
Placebo/MK-3102	80	0.77 (0.30)	0.76 (0.28)	-0.01 (0.02)	0.00	-0.50 to 0.40
Week 52						
Placebo/MK-3102	76	0.75 (0.29)	0.73 (0.27)	-0.01 (0.02)	0.00	-0.50 to 0.70

Confidential

Summary of Change From Baseline by Week in Aspartate Aminotransferase (IU/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	23.15 (9.34)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	23.15 (9.34)	23.02 (10.50)	-0.13 (0.72)	0.00	-70.00 to 66.00
Week 8						
MK-3102/MK-3102	165	23.15 (9.37)	22.33 (7.91)	-0.82 (0.60)	-1.00	-73.00 to 14.00
Week 12						
MK-3102/MK-3102	165	23.15 (9.37)	22.48 (7.96)	-0.67 (0.66)	0.00	-68.00 to 27.00
Week 24						
MK-3102/MK-3102	163	23.15 (9.37)	22.67 (9.84)	-0.48 (0.79)	-1.00	-69.00 to 56.00
Week 28						
MK-3102/MK-3102	159	23.32 (9.40)	22.80 (9.08)	-0.52 (0.78)	-1.00	-72.00 to 42.00
Week 36						
MK-3102/MK-3102	156	23.29 (9.48)	23.01 (8.11)	-0.28 (0.73)	0.00	-66.00 to 51.00
Week 52						
MK-3102/MK-3102	148	23.43 (9.67)	24.96 (12.33)	1.53 (0.98)	1.00	-66.00 to 72.00

C Confidential

Summary of Change From Baseline by Week in Aspartate Aminotransferase (IU/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	22.85 (9.51)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	22.85 (9.51)	23.78 (10.43)	0.93 (0.44)	0.00	-20.00 to 41.00
Week 36						
Sitagliptin/MK-3102	158	22.65 (9.22)	23.28 (9.74)	0.63 (0.56)	1.00	-30.00 to 52.00
Week 52						
Sitagliptin/MK-3102	149	22.20 (8.86)	23.59 (8.76)	1.39 (0.61)	2.00	-44.00 to 34.00

Confidential

Summary of Change From Baseline by Week in Aspartate Aminotransferase (IU/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	19.83 (6.02)	-	-	-	-
Week 28						
Placebo/MK-3102	80	19.83 (6.02)	20.64 (5.78)	0.81 (0.46)	0.50	-11.00 to 14.00
Week 36						
Placebo/MK-3102	80	19.83 (6.02)	21.44 (6.99)	1.61 (0.51)	1.50	-10.00 to 19.00
Week 52						
Placebo/MK-3102	76	19.83 (6.11)	22.25 (9.14)	2.42 (0.85)	1.50	-13.00 to 42.00

Confidential

Summary of Change From Baseline by Week in Alanine Aminotransferase (IU/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	25.78 (12.73)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	25.78 (12.73)	24.71 (13.48)	-1.07 (0.59)	-1.00	-34.00 to 33.00
Week 8						
MK-3102/MK-3102	165	25.79 (12.77)	24.22 (13.52)	-1.57 (0.62)	-1.00	-37.00 to 22.00
Week 12						
MK-3102/MK-3102	165	25.79 (12.77)	24.07 (13.17)	-1.72 (0.67)	-2.00	-37.00 to 36.00
Week 24						
MK-3102/MK-3102	163	25.85 (12.79)	24.34 (13.71)	-1.51 (0.85)	-2.00	-39.00 to 49.00
Week 28						
MK-3102/MK-3102	159	26.00 (12.89)	23.75 (13.36)	-2.25 (0.72)	-3.00	-39.00 to 35.00
Week 36						
MK-3102/MK-3102	156	25.82 (12.70)	24.39 (12.52)	-1.43 (0.82)	-2.00	-37.00 to 42.00
Week 52						
MK-3102/MK-3102	148	25.72 (12.92)	26.51 (19.03)	0.80 (1.24)	-1.00	-35.00 to 80.00

Confidential

Summary of Change From Baseline by Week in Alanine Aminotransferase (IU/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	25.27 (14.11)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	25.27 (14.11)	26.44 (14.66)	1.18 (0.58)	0.00	-38.00 to 32.00
Week 36						
Sitagliptin/MK-3102	158	25.18 (14.06)	26.12 (14.38)	0.94 (0.60)	1.00	-35.00 to 39.00
Week 52						
Sitagliptin/MK-3102	149	24.34 (13.27)	26.18 (13.62)	1.84 (0.81)	1.00	-56.00 to 40.00

Confidential

Summary of Change From Baseline by Week in Alanine Aminotransferase (IU/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	20.68 (8.68)	-	-	-	-
Week 28						
Placebo/MK-3102	80	20.68 (8.68)	20.69 (7.72)	0.01 (0.48)	0.00	-13.00 to 17.00
Week 36						
Placebo/MK-3102	80	20.68 (8.68)	22.23 (9.64)	1.55 (0.73)	1.00	-16.00 to 31.00
Week 52						
Placebo/MK-3102	76	20.49 (8.67)	23.46 (13.34)	2.97 (1.10)	1.50	-13.00 to 60.00

Confidential

Summary of Change From Baseline by Week in Gamma Glutamyl Transferase (IU/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	42.83 (41.15)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	42.83 (41.15)	42.82 (44.81)	-0.01 (1.45)	-1.00	-75.00 to 123.00
Week 8						
MK-3102/MK-3102	165	42.93 (41.25)	41.73 (37.93)	-1.19 (1.27)	-1.00	-110.00 to 72.00
Week 12						
MK-3102/MK-3102	165	42.93 (41.25)	40.70 (33.75)	-2.22 (1.78)	-1.00	-134.00 to 114.00
Week 24						
MK-3102/MK-3102	163	43.09 (41.44)	45.23 (44.28)	2.14 (2.37)	0.00	-107.00 to 272.00
Week 28						
MK-3102/MK-3102	159	43.21 (41.69)	43.90 (40.01)	0.69 (1.94)	0.00	-116.00 to 105.00
Week 36						
MK-3102/MK-3102	156	42.89 (41.84)	44.85 (43.61)	1.96 (2.37)	0.50	-141.00 to 194.00
Week 52						
MK-3102/MK-3102	148	43.36 (42.58)	45.40 (39.96)	2.03 (1.80)	0.00	-105.00 to 147.00

Confidential

Summary of Change From Baseline by Week in Gamma Glutamyl Transferase (IU/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	41.54 (34.30)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	41.54 (34.30)	44.90 (40.79)	3.36 (1.10)	1.00	-33.00 to 131.00
Week 36						
Sitagliptin/MK-3102	158	40.57 (32.17)	45.08 (44.73)	4.51 (1.66)	1.00	-27.00 to 198.00
Week 52						
Sitagliptin/MK-3102	149	39.26 (29.93)	44.09 (36.47)	4.83 (1.32)	1.00	-34.00 to 89.00

Confidential

Summary of Change From Baseline by Week in Gamma Glutamyl Transferase (IU/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	38.63 (33.47)	-	-	-	-
Week 28						
Placebo/MK-3102	80	38.63 (33.47)	37.00 (31.42)	-1.63 (1.51)	-1.00	-63.00 to 66.00
Week 36						
Placebo/MK-3102	80	38.63 (33.47)	42.29 (40.65)	3.66 (2.30)	1.00	-53.00 to 116.00
Week 52						
Placebo/MK-3102	76	36.51 (28.82)	42.14 (50.92)	5.63 (3.59)	1.00	-38.00 to 248.00

Confidential

Summary of Change From Baseline by Week in Alkaline Phosphatase (IU/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	237.77 (72.01)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	237.77 (72.01)	228.69 (64.79)	-9.08 (2.37)	-10.00	-119.00 to 121.00
Week 8						
MK-3102/MK-3102	165	238.10 (72.11)	222.71 (63.09)	-15.39 (2.35)	-14.00	-133.00 to 91.00
Week 12						
MK-3102/MK-3102	165	238.10 (72.11)	218.79 (60.60)	-19.31 (2.46)	-17.00	-143.00 to 50.00
Week 24						
MK-3102/MK-3102	163	237.72 (72.47)	215.45 (60.04)	-22.27 (3.01)	-19.00	-185.00 to 189.00
Week 28						
MK-3102/MK-3102	159	237.38 (72.99)	214.08 (57.01)	-23.30 (2.62)	-20.00	-165.00 to 41.00
Week 36						
MK-3102/MK-3102	156	235.61 (70.85)	217.22 (57.34)	-18.39 (2.70)	-16.00	-156.00 to 79.00
Week 52						
MK-3102/MK-3102	148	237.26 (72.16)	226.22 (61.87)	-11.03 (2.80)	-8.00	-152.00 to 65.00

Confidential

Summary of Change From Baseline by Week in Alkaline Phosphatase (IU/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	217.74 (59.21)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	217.74 (59.21)	221.86 (60.48)	4.13 (1.44)	4.00	-54.00 to 72.00
Week 36						
Sitagliptin/MK-3102	158	216.95 (58.31)	227.12 (63.45)	10.17 (2.35)	9.00	-73.00 to 123.00
Week 52						
Sitagliptin/MK-3102	149	215.70 (57.57)	230.78 (60.71)	15.08 (2.42)	13.00	-94.00 to 152.00

Confidential

Summary of Change From Baseline by Week in Alkaline Phosphatase (IU/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	236.19 (63.24)	-	-	-	-
Week 28						
Placebo/MK-3102	80	236.19 (63.24)	226.79 (60.42)	-9.40 (2.52)	-12.00	-100.00 to 44.00
Week 36						
Placebo/MK-3102	80	236.19 (63.24)	227.50 (67.20)	-8.69 (4.53)	-12.50	-152.00 to 203.00
Week 52						
Placebo/MK-3102	76	235.61 (61.82)	234.13 (67.56)	-1.47 (4.84)	-5.50	-120.00 to 176.00

C Confidential

Summary of Change From Baseline by Week in Lactate Dehydrogenase (IU/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	184.58 (86.63)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	184.58 (86.63)	180.40 (34.24)	-4.18 (6.84)	4.50	-1063.00 to 250.00
Week 8						
MK-3102/MK-3102	165	184.70 (86.88)	178.75 (31.06)	-5.96 (6.67)	2.00	-1056.00 to 45.00
Week 12						
MK-3102/MK-3102	165	184.70 (86.88)	181.03 (30.61)	-3.67 (6.76)	2.00	-1060.00 to 73.00
Week 24						
MK-3102/MK-3102	163	185.16 (87.30)	180.32 (31.54)	-4.84 (6.83)	2.00	-1061.00 to 74.00
Week 28						
MK-3102/MK-3102	159	185.86 (88.27)	183.51 (34.72)	-2.35 (7.06)	4.00	-1057.00 to 99.00
Week 36						
MK-3102/MK-3102	156	186.17 (89.04)	184.27 (32.70)	-1.90 (7.14)	5.00	-1052.00 to 90.00
Week 52						
MK-3102/MK-3102	148	185.92 (90.85)	183.63 (33.10)	-2.29 (7.49)	4.00	-1058.00 to 68.00

C Confidential

Summary of Change From Baseline by Week in Lactate Dehydrogenase (IU/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	171.49 (28.71)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	171.49 (28.71)	175.43 (28.47)	3.94 (1.23)	2.00	-44.00 to 49.00
Week 36						
Sitagliptin/MK-3102	158	171.23 (28.72)	176.25 (28.80)	5.03 (1.42)	3.00	-46.00 to 91.00
Week 52						
Sitagliptin/MK-3102	149	171.70 (28.25)	177.66 (30.96)	5.96 (1.75)	6.00	-52.00 to 112.00

Confidential

Summary of Change From Baseline by Week in Lactate Dehydrogenase (IU/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	168.28 (28.99)	-	-	-	-
Week 28						
Placebo/MK-3102	80	168.28 (28.99)	173.80 (29.69)	5.53 (1.52)	4.00	-22.00 to 51.00
Week 36						
Placebo/MK-3102	80	168.28 (28.99)	177.21 (34.69)	8.94 (2.07)	6.00	-22.00 to 104.00
Week 52						
Placebo/MK-3102	76	168.75 (29.11)	177.29 (31.99)	8.54 (1.80)	9.50	-28.00 to 46.00

Confidential

Summary of Change From Baseline by Week in Creatine Kinase (IU/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	114.22 (65.74)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	114.22 (65.74)	119.34 (90.04)	5.12 (5.57)	2.00	-202.00 to 702.00
Week 8						
MK-3102/MK-3102	165	114.05 (65.91)	117.06 (78.38)	3.01 (4.15)	1.00	-189.00 to 414.00
Week 12						
MK-3102/MK-3102	165	114.05 (65.91)	119.01 (78.53)	4.96 (5.20)	2.00	-175.00 to 583.00
Week 24						
MK-3102/MK-3102	163	114.75 (66.00)	127.61 (81.27)	12.85 (5.26)	6.00	-169.00 to 382.00
Week 28						
MK-3102/MK-3102	159	115.08 (66.39)	118.48 (70.61)	3.40 (3.83)	4.00	-157.00 to 206.00
Week 36						
MK-3102/MK-3102	156	115.86 (66.72)	117.60 (66.05)	1.74 (3.70)	5.00	-174.00 to 174.00
Week 52						
MK-3102/MK-3102	148	116.87 (67.90)	124.61 (89.07)	7.74 (6.24)	4.50	-220.00 to 489.00

Confidential

Summary of Change From Baseline by Week in Creatine Kinase (IU/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	113.73 (70.85)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	113.73 (70.85)	110.43 (63.12)	-3.30 (5.33)	-1.00	-468.00 to 241.00
Week 36						
Sitagliptin/MK-3102	158	111.05 (65.38)	114.56 (73.86)	3.51 (5.87)	1.00	-435.00 to 683.00
Week 52						
Sitagliptin/MK-3102	149	112.90 (66.14)	116.67 (53.30)	3.77 (4.92)	3.00	-462.00 to 172.00

Confidential

Summary of Change From Baseline by Week in Creatine Kinase (IU/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	114.58 (107.55)	-	-	-	-
Week 28						
Placebo/MK-3102	80	114.58 (107.55)	115.95 (100.65)	1.38 (13.21)	6.50	-864.00 to 460.00
Week 36						
Placebo/MK-3102	80	114.58 (107.55)	103.58 (54.45)	-11.00 (11.91)	0.00	-859.00 to 162.00
Week 52						
Placebo/MK-3102	76	115.62 (110.08)	111.28 (68.53)	-4.34 (13.08)	4.50	-866.00 to 165.00

Confidential

Summary of Change From Baseline by Week in Blood Urea Nitrogen (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	13.79 (2.95)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	13.79 (2.95)	14.09 (3.33)	0.30 (0.19)	0.20	-7.50 to 8.50
Week 8						
MK-3102/MK-3102	165	13.77 (2.94)	14.26 (3.31)	0.49 (0.20)	0.30	-8.10 to 10.20
Week 12						
MK-3102/MK-3102	165	13.77 (2.94)	14.00 (3.13)	0.24 (0.21)	0.00	-7.40 to 8.80
Week 24						
MK-3102/MK-3102	163	13.80 (2.94)	14.02 (3.53)	0.23 (0.23)	0.00	-8.30 to 8.10
Week 28						
MK-3102/MK-3102	159	13.73 (2.94)	13.99 (3.32)	0.26 (0.21)	0.50	-8.10 to 10.50
Week 36						
MK-3102/MK-3102	156	13.77 (2.94)	13.87 (3.18)	0.10 (0.22)	0.00	-8.70 to 7.50
Week 52						
MK-3102/MK-3102	148	13.77 (2.97)	13.78 (3.15)	0.02 (0.24)	-0.10	-6.00 to 13.60

Confidential

Summary of Change From Baseline by Week in Blood Urea Nitrogen (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	14.39 (3.66)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	14.39 (3.66)	14.18 (3.51)	-0.21 (0.25)	-0.10	-10.60 to 14.40
Week 36						
Sitagliptin/MK-3102	158	14.42 (3.66)	13.74 (3.30)	-0.68 (0.27)	-0.40	-13.20 to 10.50
Week 52						
Sitagliptin/MK-3102	149	14.41 (3.63)	13.98 (3.37)	-0.43 (0.26)	-0.40	-14.70 to 6.80

Confidential

Summary of Change From Baseline by Week in Blood Urea Nitrogen (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	13.93 (4.20)	-	-	-	-
Week 28						
Placebo/MK-3102	80	13.93 (4.20)	13.68 (3.89)	-0.26 (0.33)	-0.25	-8.20 to 6.70
Week 36						
Placebo/MK-3102	80	13.93 (4.20)	13.69 (3.83)	-0.24 (0.32)	-0.05	-7.90 to 5.70
Week 52						
Placebo/MK-3102	76	13.82 (4.07)	13.76 (4.12)	-0.06 (0.36)	-0.35	-8.00 to 7.70

C Confidential

Summary of Change From Baseline by Week in Creatinine (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	0.70 (0.15)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	0.70 (0.15)	0.71 (0.15)	0.01 (0.00)	0.01	-0.18 to 0.18
Week 8						
MK-3102/MK-3102	165	0.70 (0.15)	0.71 (0.15)	0.01 (0.00)	0.01	-0.23 to 0.20
Week 12						
MK-3102/MK-3102	165	0.70 (0.15)	0.70 (0.15)	0.01 (0.00)	0.01	-0.15 to 0.26
Week 24						
MK-3102/MK-3102	163	0.70 (0.15)	0.70 (0.16)	0.01 (0.00)	0.01	-0.14 to 0.21
Week 28						
MK-3102/MK-3102	159	0.70 (0.15)	0.72 (0.16)	0.02 (0.01)	0.02	-0.13 to 0.23
Week 36						
MK-3102/MK-3102	156	0.70 (0.15)	0.71 (0.16)	0.01 (0.01)	0.01	-0.18 to 0.22
Week 52						
MK-3102/MK-3102	148	0.70 (0.15)	0.71 (0.15)	0.01 (0.00)	0.01	-0.21 to 0.20

Confidential

Summary of Change From Baseline by Week in Creatinine (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	0.74 (0.16)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	0.74 (0.16)	0.74 (0.16)	0.01 (0.01)	0.00	-0.27 to 0.24
Week 36						
Sitagliptin/MK-3102	158	0.74 (0.16)	0.74 (0.16)	0.00 (0.01)	0.00	-0.19 to 0.48
Week 52						
Sitagliptin/MK-3102	149	0.74 (0.16)	0.74 (0.16)	-0.00 (0.01)	0.00	-0.27 to 0.20

C Confidential

Summary of Change From Baseline by Week in Creatinine (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	0.71 (0.16)	-	-	-	-
Week 28						
Placebo/MK-3102	80	0.71 (0.16)	0.73 (0.17)	0.02 (0.01)	0.00	-0.14 to 0.17
Week 36						
Placebo/MK-3102	80	0.71 (0.16)	0.73 (0.17)	0.02 (0.01)	0.02	-0.16 to 0.19
Week 52						
Placebo/MK-3102	76	0.71 (0.16)	0.72 (0.16)	0.01 (0.01)	0.02	-0.18 to 0.14

C Confidential

Summary of Change From Baseline by Week in Urate (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	4.94 (1.20)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	4.94 (1.20)	5.14 (1.24)	0.20 (0.05)	0.20	-1.40 to 2.50
Week 8						
MK-3102/MK-3102	165	4.93 (1.20)	5.26 (1.33)	0.33 (0.05)	0.30	-1.50 to 3.10
Week 12						
MK-3102/MK-3102	165	4.93 (1.20)	5.23 (1.26)	0.30 (0.04)	0.30	-1.30 to 1.80
Week 24						
MK-3102/MK-3102	163	4.93 (1.20)	5.24 (1.36)	0.32 (0.05)	0.30	-1.20 to 3.20
Week 28						
MK-3102/MK-3102	159	4.94 (1.18)	5.33 (1.29)	0.39 (0.05)	0.40	-1.50 to 2.00
Week 36						
MK-3102/MK-3102	156	4.94 (1.18)	5.28 (1.35)	0.33 (0.05)	0.30	-1.50 to 2.10
Week 52						
MK-3102/MK-3102	148	4.96 (1.20)	5.11 (1.25)	0.15 (0.05)	0.10	-1.90 to 1.60

Confidential

Summary of Change From Baseline by Week in Urate (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	5.41 (1.29)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	5.41 (1.29)	5.51 (1.33)	0.09 (0.05)	0.10	-1.50 to 2.50
Week 36						
Sitagliptin/MK-3102	158	5.42 (1.29)	5.37 (1.20)	-0.05 (0.06)	-0.05	-2.10 to 2.90
Week 52						
Sitagliptin/MK-3102	149	5.42 (1.27)	5.27 (1.21)	-0.16 (0.06)	-0.10	-2.60 to 2.40

C Confidential

Summary of Change From Baseline by Week in Urate (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	4.93 (1.05)	-	-	-	-
Week 28						
Placebo/MK-3102	80	4.93 (1.05)	5.25 (1.13)	0.31 (0.07)	0.30	-1.10 to 1.90
Week 36						
Placebo/MK-3102	80	4.93 (1.05)	5.23 (1.03)	0.29 (0.06)	0.30	-0.90 to 1.60
Week 52						
Placebo/MK-3102	76	4.92 (1.06)	5.01 (1.01)	0.10 (0.07)	0.10	-1.70 to 1.20

C Confidential

Summary of Change From Baseline by Week in Sodium (mEq/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	140.45 (2.10)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	140.45 (2.10)	140.88 (1.75)	0.43 (0.14)	0.00	-3.00 to 8.00
Week 8						
MK-3102/MK-3102	165	140.44 (2.10)	140.81 (1.86)	0.37 (0.15)	0.00	-4.00 to 10.00
Week 12						
MK-3102/MK-3102	165	140.44 (2.10)	140.98 (1.73)	0.54 (0.14)	1.00	-4.00 to 9.00
Week 24						
MK-3102/MK-3102	163	140.43 (2.09)	140.93 (1.80)	0.50 (0.15)	0.00	-4.00 to 9.00
Week 28						
MK-3102/MK-3102	159	140.39 (2.07)	140.91 (1.62)	0.52 (0.15)	1.00	-4.00 to 9.00
Week 36						
MK-3102/MK-3102	156	140.40 (2.07)	140.56 (1.93)	0.17 (0.17)	0.00	-5.00 to 9.00
Week 52						
MK-3102/MK-3102	148	140.45 (2.08)	140.68 (1.97)	0.24 (0.16)	0.00	-5.00 to 10.00

Confidential

Summary of Change From Baseline by Week in Sodium (mEq/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	140.81 (1.98)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	140.81 (1.98)	140.66 (1.87)	-0.15 (0.13)	0.00	-5.00 to 6.00
Week 36						
Sitagliptin/MK-3102	158	140.80 (1.99)	140.39 (1.89)	-0.42 (0.15)	-1.00	-5.00 to 7.00
Week 52						
Sitagliptin/MK-3102	149	140.83 (2.01)	140.66 (1.80)	-0.17 (0.15)	0.00	-4.00 to 8.00

Confidential

Summary of Change From Baseline by Week in Sodium (mEq/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	140.21 (1.97)	-	-	-	-
Week 28						
Placebo/MK-3102	80	140.21 (1.97)	140.93 (1.83)	0.71 (0.19)	1.00	-4.00 to 6.00
Week 36						
Placebo/MK-3102	80	140.21 (1.97)	140.11 (1.88)	-0.10 (0.18)	0.00	-3.00 to 4.00
Week 52						
Placebo/MK-3102	76	140.21 (1.99)	140.57 (2.13)	0.36 (0.22)	0.00	-4.00 to 6.00

C Confidential

Summary of Change From Baseline by Week in Potassium (mEq/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	4.35 (0.70)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	4.35 (0.70)	4.36 (0.34)	0.00 (0.05)	0.00	-7.60 to 1.30
Week 8						
MK-3102/MK-3102	165	4.35 (0.71)	4.34 (0.34)	-0.02 (0.05)	0.00	-7.40 to 1.00
Week 12						
MK-3102/MK-3102	165	4.35 (0.71)	4.35 (0.38)	-0.00 (0.05)	0.00	-7.30 to 1.30
Week 24						
MK-3102/MK-3102	163	4.35 (0.71)	4.19 (0.31)	-0.16 (0.05)	-0.10	-7.40 to 0.70
Week 28						
MK-3102/MK-3102	159	4.35 (0.72)	4.28 (0.36)	-0.07 (0.05)	0.00	-7.10 to 1.10
Week 36						
MK-3102/MK-3102	156	4.36 (0.72)	4.26 (0.32)	-0.10 (0.06)	-0.10	-7.40 to 1.00
Week 52						
MK-3102/MK-3102	148	4.37 (0.73)	4.21 (0.35)	-0.16 (0.06)	-0.10	-7.80 to 0.90

Confidential

Summary of Change From Baseline by Week in Potassium (mEq/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	4.20 (0.32)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	4.20 (0.32)	4.27 (0.30)	0.07 (0.02)	0.10	-0.50 to 1.20
Week 36						
Sitagliptin/MK-3102	158	4.20 (0.32)	4.23 (0.32)	0.03 (0.02)	0.00	-0.80 to 1.40
Week 52						
Sitagliptin/MK-3102	149	4.21 (0.32)	4.16 (0.34)	-0.05 (0.02)	0.00	-0.90 to 0.80

Confidential

Summary of Change From Baseline by Week in Potassium (mEq/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	4.11 (0.25)	-	-	-	-
Week 28						
Placebo/MK-3102	80	4.11 (0.25)	4.15 (0.25)	0.04 (0.03)	0.10	-0.80 to 0.60
Week 36						
Placebo/MK-3102	80	4.11 (0.25)	4.17 (0.24)	0.06 (0.03)	0.10	-0.70 to 0.70
Week 52						
Placebo/MK-3102	76	4.10 (0.26)	4.08 (0.24)	-0.02 (0.03)	0.00	-0.70 to 0.60

C Confidential

Summary of Change From Baseline by Week in Chloride (mEQ/L) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	101.22 (2.31)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	101.22 (2.31)	102.08 (2.20)	0.86 (0.17)	1.00	-5.00 to 7.00
Week 8						
MK-3102/MK-3102	165	101.23 (2.31)	101.88 (2.20)	0.65 (0.18)	0.00	-5.00 to 7.00
Week 12						
MK-3102/MK-3102	165	101.23 (2.31)	102.16 (2.35)	0.93 (0.18)	1.00	-6.00 to 8.00
Week 24						
MK-3102/MK-3102	163	101.25 (2.30)	102.74 (2.30)	1.49 (0.18)	2.00	-6.00 to 7.00
Week 28						
MK-3102/MK-3102	159	101.16 (2.20)	103.18 (2.05)	2.02 (0.18)	2.00	-5.00 to 8.00
Week 36						
MK-3102/MK-3102	156	101.17 (2.22)	102.99 (2.22)	1.82 (0.18)	2.00	-4.00 to 10.00
Week 52						
MK-3102/MK-3102	148	101.23 (2.15)	101.96 (2.34)	0.73 (0.17)	1.00	-4.00 to 8.00

Confidential

Summary of Change From Baseline by Week in Chloride (mEQ/L) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	102.64 (2.57)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	102.64 (2.57)	103.08 (2.45)	0.44 (0.17)	0.00	-6.00 to 6.00
Week 36						
Sitagliptin/MK-3102	158	102.66 (2.58)	103.02 (2.37)	0.36 (0.19)	0.00	-5.00 to 10.00
Week 52						
Sitagliptin/MK-3102	149	102.70 (2.62)	102.00 (2.13)	-0.70 (0.20)	-1.00	-6.00 to 10.00

Confidential

Summary of Change From Baseline by Week in Chloride (mEQ/L) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	102.10 (2.33)	-	-	-	-
Week 28						
Placebo/MK-3102	80	102.10 (2.33)	103.31 (2.21)	1.21 (0.27)	1.00	-8.00 to 7.00
Week 36						
Placebo/MK-3102	80	102.10 (2.33)	102.90 (2.30)	0.80 (0.26)	1.00	-6.00 to 7.00
Week 52						
Placebo/MK-3102	76	102.09 (2.37)	102.13 (2.20)	0.04 (0.29)	0.00	-8.00 to 6.00

Confidential

Summary of Change From Baseline by Week in Calcium (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	9.20 (0.39)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	9.20 (0.39)	9.22 (0.37)	0.01 (0.03)	0.00	-0.80 to 1.50
Week 8						
MK-3102/MK-3102	165	9.20 (0.39)	9.24 (0.37)	0.04 (0.03)	0.00	-0.90 to 1.30
Week 12						
MK-3102/MK-3102	165	9.20 (0.39)	9.18 (0.37)	-0.03 (0.03)	0.00	-1.10 to 1.50
Week 24						
MK-3102/MK-3102	163	9.20 (0.39)	9.09 (0.37)	-0.10 (0.03)	-0.10	-1.30 to 1.50
Week 28						
MK-3102/MK-3102	159	9.21 (0.39)	9.20 (0.35)	-0.01 (0.03)	0.00	-0.90 to 1.60
Week 36						
MK-3102/MK-3102	156	9.21 (0.39)	9.20 (0.35)	-0.01 (0.03)	0.00	-0.80 to 1.70
Week 52						
MK-3102/MK-3102	148	9.21 (0.39)	9.21 (0.37)	-0.01 (0.03)	0.00	-1.20 to 1.20

C Confidential

Summary of Change From Baseline by Week in Calcium (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	9.04 (0.31)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	9.04 (0.31)	9.15 (0.33)	0.11 (0.02)	0.10	-0.50 to 1.10
Week 36						
Sitagliptin/MK-3102	158	9.04 (0.31)	9.14 (0.34)	0.10 (0.02)	0.10	-0.80 to 1.10
Week 52						
Sitagliptin/MK-3102	149	9.04 (0.29)	9.11 (0.31)	0.08 (0.03)	0.10	-0.80 to 1.00

Confidential

Summary of Change From Baseline by Week in Calcium (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	9.01 (0.31)	-	-	-	-
Week 28						
Placebo/MK-3102	80	9.01 (0.31)	9.04 (0.33)	0.03 (0.03)	0.00	-0.60 to 0.80
Week 36						
Placebo/MK-3102	80	9.01 (0.31)	9.11 (0.38)	0.10 (0.04)	0.10	-0.60 to 1.20
Week 52						
Placebo/MK-3102	76	9.01 (0.31)	9.04 (0.30)	0.03 (0.03)	0.00	-0.70 to 0.70

Confidential

Summary of Change From Baseline by Week in Phosphate (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	3.48 (0.47)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	3.48 (0.47)	3.36 (0.47)	-0.12 (0.03)	-0.10	-2.00 to 1.20
Week 8						
MK-3102/MK-3102	165	3.48 (0.47)	3.41 (0.45)	-0.07 (0.03)	-0.10	-2.20 to 0.80
Week 12						
MK-3102/MK-3102	165	3.48 (0.47)	3.40 (0.45)	-0.08 (0.03)	-0.10	-2.20 to 0.90
Week 24						
MK-3102/MK-3102	163	3.48 (0.47)	3.39 (0.47)	-0.09 (0.03)	0.00	-2.20 to 1.10
Week 28						
MK-3102/MK-3102	159	3.48 (0.47)	3.42 (0.45)	-0.05 (0.03)	0.00	-2.30 to 1.00
Week 36						
MK-3102/MK-3102	156	3.48 (0.47)	3.39 (0.41)	-0.09 (0.03)	-0.10	-2.00 to 1.00
Week 52						
MK-3102/MK-3102	148	3.47 (0.46)	3.36 (0.47)	-0.12 (0.04)	-0.10	-2.20 to 0.90

Confidential

Summary of Change From Baseline by Week in Phosphate (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	3.36 (0.46)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	3.36 (0.46)	3.41 (0.47)	0.05 (0.03)	0.00	-0.80 to 1.00
Week 36						
Sitagliptin/MK-3102	158	3.35 (0.47)	3.38 (0.50)	0.03 (0.03)	0.00	-0.80 to 1.00
Week 52						
Sitagliptin/MK-3102	149	3.36 (0.47)	3.34 (0.51)	-0.02 (0.03)	0.00	-1.10 to 1.00

Confidential

Summary of Change From Baseline by Week in Phosphate (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	3.36 (0.46)	-	-	-	-
Week 28						
Placebo/MK-3102	80	3.36 (0.46)	3.32 (0.43)	-0.04 (0.04)	0.00	-1.00 to 0.80
Week 36						
Placebo/MK-3102	80	3.36 (0.46)	3.37 (0.49)	0.02 (0.04)	0.00	-0.90 to 0.80
Week 52						
Placebo/MK-3102	76	3.35 (0.46)	3.29 (0.44)	-0.05 (0.04)	0.00	-0.70 to 0.90

Confidential

Summary of Change From Baseline by Week in Total Cholesterol (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	210.25 (34.03)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	210.25 (34.03)	205.33 (32.67)	-4.93 (1.72)	-3.00	-111.00 to 88.00
Week 12						
MK-3102/MK-3102	165	210.05 (34.04)	206.56 (34.49)	-3.50 (2.08)	-3.00	-94.00 to 127.00
Week 24						
MK-3102/MK-3102	163	210.04 (34.25)	198.78 (30.11)	-11.26 (1.88)	-8.00	-87.00 to 51.00
Week 28						
MK-3102/MK-3102	159	210.74 (34.26)	201.96 (31.30)	-8.78 (1.98)	-9.00	-85.00 to 65.00
Week 52						
MK-3102/MK-3102	149	210.58 (34.31)	208.58 (32.91)	-2.00 (1.87)	-2.00	-76.00 to 72.00

C Confidential

Summary of Change From Baseline by Week in Total Cholesterol (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	198.01 (32.66)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	198.01 (32.66)	199.91 (34.08)	1.91 (1.45)	0.00	-43.00 to 52.00
Week 52						
Sitagliptin/MK-3102	150	198.37 (32.44)	204.40 (33.35)	6.03 (2.08)	6.00	-96.00 to 93.00

Confidential

Summary of Change From Baseline by Week in Total Cholesterol (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	195.16 (28.75)	-	-	-	-
Week 28						
Placebo/MK-3102	80	195.16 (28.75)	193.39 (29.24)	-1.78 (2.11)	-1.00	-71.00 to 39.00
Week 52						
Placebo/MK-3102	77	195.16 (29.28)	197.94 (27.88)	2.78 (2.54)	6.00	-82.00 to 53.00

C Confidential

Summary of Change From Baseline by Week in HDL Cholesterol (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	59.31 (15.31)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	59.31 (15.31)	58.08 (14.30)	-1.23 (0.60)	-2.00	-47.00 to 29.00
Week 12						
MK-3102/MK-3102	165	59.25 (15.34)	57.68 (13.40)	-1.56 (0.58)	-1.00	-37.00 to 21.00
Week 24						
MK-3102/MK-3102	163	59.25 (15.43)	55.63 (13.33)	-3.61 (0.55)	-3.00	-24.00 to 29.00
Week 28						
MK-3102/MK-3102	159	59.56 (15.40)	56.21 (13.41)	-3.35 (0.64)	-3.00	-32.00 to 41.00
Week 52						
MK-3102/MK-3102	149	59.93 (15.57)	58.72 (14.64)	-1.21 (0.67)	-1.00	-45.00 to 38.00

C Confidential

Summary of Change From Baseline by Week in HDL Cholesterol (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	52.25 (11.78)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	52.25 (11.78)	52.63 (11.14)	0.38 (0.43)	0.00	-17.00 to 14.00
Week 52						
Sitagliptin/MK-3102	150	52.63 (11.83)	55.83 (12.41)	3.19 (0.63)	3.00	-28.00 to 28.00

C Confidential

Summary of Change From Baseline by Week in HDL Cholesterol (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	53.99 (12.04)	-	-	-	-
Week 28						
Placebo/MK-3102	80	53.99 (12.04)	54.35 (12.16)	0.36 (0.70)	1.00	-16.00 to 25.00
Week 52						
Placebo/MK-3102	77	54.22 (12.10)	56.97 (13.35)	2.75 (0.83)	3.00	-14.00 to 24.00

Confidential

Summary of Change From Baseline by Week in LDL Cholesterol (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	129.68 (29.36)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	129.68 (29.36)	125.84 (27.70)	-3.84 (1.47)	-3.00	-82.00 to 69.00
Week 12						
MK-3102/MK-3102	165	129.53 (29.39)	127.60 (29.70)	-1.93 (1.79)	-1.00	-75.00 to 116.00
Week 24						
MK-3102/MK-3102	163	129.51 (29.56)	124.56 (26.60)	-4.95 (1.67)	-2.00	-76.00 to 49.00
Week 28						
MK-3102/MK-3102	159	129.91 (29.69)	126.76 (28.56)	-3.14 (1.79)	-2.00	-75.00 to 60.00
Week 52						
MK-3102/MK-3102	149	129.66 (29.65)	134.23 (29.28)	4.57 (1.56)	6.00	-54.00 to 68.00

C Confidential

Summary of Change From Baseline by Week in LDL Cholesterol (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	124.86 (30.75)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	124.86 (30.75)	125.26 (32.10)	0.40 (1.24)	0.00	-39.00 to 41.00
Week 52						
Sitagliptin/MK-3102	150	125.50 (30.50)	130.38 (31.30)	4.88 (1.73)	3.00	-77.00 to 53.00

C Confidential

Summary of Change From Baseline by Week in LDL Cholesterol (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	120.05 (26.48)	-	-	-	-
Week 28						
Placebo/MK-3102	80	120.05 (26.48)	120.85 (28.91)	0.80 (1.90)	0.00	-42.00 to 49.00
Week 52						
Placebo/MK-3102	77	120.14 (26.62)	125.36 (28.58)	5.22 (2.27)	4.00	-71.00 to 61.00

Confidential

Summary of Change From Baseline by Week in Triglycerides (mg/dL) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	121.98 (98.34)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	121.98 (98.34)	111.08 (58.58)	-10.89 (6.72)	-4.00	-962.00 to 183.00
Week 12						
MK-3102/MK-3102	165	122.03 (98.64)	118.56 (80.63)	-3.47 (4.34)	3.00	-360.00 to 179.00
Week 24						
MK-3102/MK-3102	163	122.48 (99.12)	114.01 (60.82)	-8.48 (6.46)	-1.00	-809.00 to 224.00
Week 28						
MK-3102/MK-3102	159	122.97 (99.92)	118.45 (69.51)	-4.53 (6.89)	1.00	-742.00 to 294.00
Week 52						
MK-3102/MK-3102	149	120.13 (100.70)	117.83 (53.28)	-2.30 (7.19)	1.00	-851.00 to 190.00

C Confidential

Summary of Change From Baseline by Week in Triglycerides (mg/dL) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	133.83 (82.45)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	133.83 (82.45)	138.31 (76.38)	4.48 (3.89)	6.00	-165.00 to 202.00
Week 52						
Sitagliptin/MK-3102	150	128.93 (73.36)	133.47 (78.68)	4.54 (4.71)	0.00	-159.00 to 236.00

Confidential

Summary of Change From Baseline by Week in Triglycerides (mg/dL) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	131.20 (114.05)	-	-	-	-
Week 28						
Placebo/MK-3102	80	131.20 (114.05)	114.10 (65.91)	-17.10 (10.06)	-5.50	-596.00 to 263.00
Week 52						
Placebo/MK-3102	77	129.35 (114.09)	114.51 (81.18)	-14.84 (12.34)	-4.00	-767.00 to 276.00

Confidential

付録 2.7.4: 23　　臨床検査値の PDLC に該当した被験者の割合
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P015、長期投与時）

Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Hemoglobin (g/dL)		
Last value with a decrease >= 1.5 gm/dL ‡		
MK-3102/MK-3102	126	1 (0.8)
Placebo/MK-3102	61	0 (0.0)
WBC Count (10^3/microL)		
One value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Last value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	126	7 (5.6)
Placebo/MK-3102	61	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	126	1 (0.8)
Placebo/MK-3102	61	0 (0.0)
Neutrophil Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	126	3 (2.4)
Placebo/MK-3102	61	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	126	1 (0.8)
Placebo/MK-3102	61	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	126	5 (4.0)
Placebo/MK-3102	61	1 (1.6)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	126	2 (1.6)
Placebo/MK-3102	61	0 (0.0)
Lymphocyte Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		

Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	126	1 (0.8)
Placebo/MK-3102	61	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Platelet Count (10^3/microL)		
One value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Last value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
One value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Last value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
BUN (mg/dL)		
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Serum Creatine Kinase (IU/L)		
One value with an increase > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	61	0 (0.0)
Last value with an increase > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
One value with an increase > 10×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Last value with an increase > 10×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Serum Creatinine (mg/dL)		
Last value with an increase >= 0.3 mg/dL		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Total Bilirubin (mg/dL)		
One value >= 2×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value >= 2×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
AST (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	126	1 (0.8)
Placebo/MK-3102	62	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 10×ULN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
AST (IU/L) or ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	126	1 (0.8)
Placebo/MK-3102	62	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	126	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	62	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)		
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Alkaline Phosphatase (IU/L)		
One value > 1.5×ULN		
MK-3102/MK-3102	126	1 (0.8)
Placebo/MK-3102	62	0 (0.0)
Last value > 1.5×ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	62	0 (0.0)
Serum Uric Acid (mg/dL)		
One value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	126	2 (1.6)
Placebo/MK-3102	61	0 (0.0)
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Serum Sodium (mEq/L)		
Last value with a decrease >= 10 mEq/L and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Sulfonylureas (SUs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value with an increase >= 10 mEq/L and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Serum Potassium (mEq/L)		
Last value with a decrease >= 1.0 mEq/L and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Last value with an increase >= 1.0 mEq/L and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Serum Calcium (mg/dL)		
Last value with an increase >= 1.0 mg/dL and value > ULN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
Last value with a decrease >= 1.0 mg/dL and value < LLN		
MK-3102/MK-3102	126	0 (0.0)
Placebo/MK-3102	61	0 (0.0)
QTc (milliseconds)		
Last value >= 500 msec		
MK-3102/MK-3102	124	2 (1.6)
Placebo/MK-3102	62	1 (1.6)
Last value with an increase >= 30 msec and value > gender specific ULN		
MK-3102/MK-3102	124	5 (4.0)
Placebo/MK-3102	61	1 (1.6)
Last value with an increase >= 60 msec and value > gender specific ULN		
MK-3102/MK-3102	124	2 (1.6)
Placebo/MK-3102	61	1 (1.6)

Baseline is defined as Week 0 for the MK-3102/MK-3102 group and Week 24 for the Placebo/MK-3102 group.

Percentages represent data collected over a 52-week time period for the MK-3102/MK-3102 group (Week 0 to Week 52) and a 28-week time period for the Placebo/MK-3102 group (Week 24 to Week 52).

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 52.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Hemoglobin (g/dL)		
Last value with a decrease >= 1.5 gm/dL ‡		
MK-3102/MK-3102	65	4 (6.2)
Placebo/MK-3102	31	0 (0.0)
WBC Count (10^3/microL)		
One value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	3 (4.6)
Placebo/MK-3102	31	2 (6.5)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	2 (6.5)
Neutrophil Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	3 (4.6)
Placebo/MK-3102	31	1 (3.2)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	31	1 (3.2)
Lymphocyte Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	31	1 (3.2)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	31	1 (3.2)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Platelet Count (10^3/microL)		
One value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	31	0 (0.0)
Last value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
BUN (mg/dL)		
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Serum Creatine Kinase (IU/L)		
One value with an increase > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value with an increase > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Serum Creatinine (mg/dL)		
Last value with an increase >= 0.3 mg/dL		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Total Bilirubin (mg/dL)		
One value >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	1 (3.2)
Last value >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
AST (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Last value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 10×ULN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
AST (IU/L) or ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	31	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)		
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Alkaline Phosphatase (IU/L)		
One value > 1.5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value > 1.5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Serum Uric Acid (mg/dL)		
One value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Serum Sodium (mEq/L)		
Last value with a decrease >= 10 mEq/L and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Glinides
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Last value with an increase >= 10 mEq/L and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Serum Potassium (mEq/L)		
Last value with a decrease >= 1.0 mEq/L and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase >= 1.0 mEq/L and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Serum Calcium (mg/dL)		
Last value with an increase >= 1.0 mg/dL and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with a decrease >= 1.0 mg/dL and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
QTc (milliseconds)		
Last value >= 500 msec		
MK-3102/MK-3102	64	0 (0.0)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase >= 30 msec and value > gender specific ULN		
MK-3102/MK-3102	64	5 (7.8)
Placebo/MK-3102	31	0 (0.0)
Last value with an increase >= 60 msec and value > gender specific ULN		
MK-3102/MK-3102	64	0 (0.0)
Placebo/MK-3102	31	0 (0.0)

Baseline is defined as Week 0 for the MK-3102/MK-3102 group and Week 24 for the Placebo/MK-3102 group.

Percentages represent data collected over a 52-week time period for the MK-3102/MK-3102 group (Week 0 to Week 52) and a 28-week time period for the Placebo/MK-3102 group (Week 24 to Week 52).

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 52.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Biguanides (BGs)
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Hemoglobin (g/dL)		
Last value with a decrease >= 1.5 gm/dL ‡		
MK-3102/MK-3102	66	2 (3.0)
Placebo/MK-3102	33	0 (0.0)
WBC Count (10^3/microL)		
One value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	66	6 (9.1)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	66	3 (4.5)
Placebo/MK-3102	33	0 (0.0)
Neutrophil Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	66	5 (7.6)
Placebo/MK-3102	33	1 (3.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	66	2 (3.0)
Placebo/MK-3102	33	0 (0.0)
Lymphocyte Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Platelet Count (10^3/microL)		
One value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	66	2 (3.0)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
BUN (mg/dL)		
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Creatine Kinase (IU/L)		
One value with an increase > 5×ULN		
MK-3102/MK-3102	66	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase > 5×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase > 10×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase > 10×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Creatinine (mg/dL)		
Last value with an increase >= 0.3 mg/dL		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Total Bilirubin (mg/dL)		
One value >= 2×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value >= 2×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
AST (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value > 5×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 10×ULN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
AST (IU/L) or ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	66	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Biguanides (BGs)
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	33	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)		
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Alkaline Phosphatase (IU/L)		
One value > 1.5×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 1.5×ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Uric Acid (mg/dL)		
One value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Sodium (mEq/L)		
Last value with a decrease >= 10 mEq/L and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Biguanides (BGs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value with an increase >= 10 mEq/L and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Potassium (mEq/L)		
Last value with a decrease >= 1.0 mEq/L and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 1.0 mEq/L and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Calcium (mg/dL)		
Last value with an increase >= 1.0 mg/dL and value > ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 1.0 mg/dL and value < LLN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
QTc (milliseconds)		
Last value >= 500 msec		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 30 msec and value > gender specific ULN		
MK-3102/MK-3102	66	1 (1.5)
Placebo/MK-3102	33	2 (6.1)
Last value with an increase >= 60 msec and value > gender specific ULN		
MK-3102/MK-3102	66	0 (0.0)
Placebo/MK-3102	33	0 (0.0)

Baseline is defined as Week 0 for the MK-3102/MK-3102 group and Week 24 for the Placebo/MK-3102 group.

Percentages represent data collected over a 52-week time period for the MK-3102/MK-3102 group (Week 0 to Week 52) and a 28-week time period for the Placebo/MK-3102 group (Week 24 to Week 52).

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 52.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Hemoglobin (g/dL)		
Last value with a decrease >= 1.5 gm/dL ‡		
MK-3102/MK-3102	65	3 (4.6)
Placebo/MK-3102	33	0 (0.0)
WBC Count (10^3/microL)		
One value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	5 (7.7)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	2 (3.1)
Placebo/MK-3102	33	0 (0.0)
Neutrophil Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	3 (4.6)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Lymphocyte Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	65	2 (3.1)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Platelet Count (10^3/microL)		
One value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
BUN (mg/dL)		
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Creatine Kinase (IU/L)		
One value with an increase > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value with an increase > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Creatinine (mg/dL)		
Last value with an increase >= 0.3 mg/dL		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Total Bilirubin (mg/dL)		
One value >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
AST (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 10×ULN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
AST (IU/L) or ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	65	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	33	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)		
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Alkaline Phosphatase (IU/L)		
One value > 1.5×ULN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value > 1.5×ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Uric Acid (mg/dL)		
One value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
Serum Sodium (mEq/L)		
Last value with a decrease >= 10 mEq/L and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value with an increase >= 10 mEq/L and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Potassium (mEq/L)		
Last value with a decrease >= 1.0 mEq/L and value < LLN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 1.0 mEq/L and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Serum Calcium (mg/dL)		
Last value with an increase >= 1.0 mg/dL and value > ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with a decrease >= 1.0 mg/dL and value < LLN		
MK-3102/MK-3102	65	1 (1.5)
Placebo/MK-3102	33	0 (0.0)
QTc (milliseconds)		
Last value >= 500 msec		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)
Last value with an increase >= 30 msec and value > gender specific ULN		
MK-3102/MK-3102	65	3 (4.6)
Placebo/MK-3102	33	1 (3.0)
Last value with an increase >= 60 msec and value > gender specific ULN		
MK-3102/MK-3102	65	0 (0.0)
Placebo/MK-3102	33	0 (0.0)

Baseline is defined as Week 0 for the MK-3102/MK-3102 group and Week 24 for the Placebo/MK-3102 group.

Percentages represent data collected over a 52-week time period for the MK-3102/MK-3102 group (Week 0 to Week 52) and a 28-week time period for the Placebo/MK-3102 group (Week 24 to Week 52).

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 52.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data After Glycemic Rescue
(ASaT) (Extensioin)

	N	n (%)
Hemoglobin (g/dL)		
Last value with a decrease >= 1.5 gm/dL ‡		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
WBC Count (10^3/microL)		
One value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with a decrease >= 50% and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	67	5 (7.5)
Placebo/MK-3102	28	1 (3.6)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	67	1 (1.5)
Placebo/MK-3102	28	1 (3.6)
Neutrophil Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	67	6 (9.0)
Placebo/MK-3102	28	1 (3.6)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	67	2 (3.0)
Placebo/MK-3102	28	1 (3.6)
Lymphocyte Count (10^3/microL)		
One value with a decrease >= 20% and value < LLN		

Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with a decrease >= 20% and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase >= 20% and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Platelet Count (10^3/microL)		
One value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	67	1 (1.5)
Placebo/MK-3102	28	0 (0.0)
Last value with a decrease >= 25% and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase >= 100% and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
BUN (mg/dL)		
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Serum Creatine Kinase (IU/L)		
One value with an increase > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value with an increase > 10×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase > 10×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Serum Creatinine (mg/dL)		
Last value with an increase >= 0.3 mg/dL		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Total Bilirubin (mg/dL)		
One value >= 2×ULN		
MK-3102/MK-3102	67	1 (1.5)
Placebo/MK-3102	28	0 (0.0)
Last value >= 2×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
AST (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 10×ULN		

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
AST (IU/L) or ALT (IU/L)		
One value >= 3×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 10×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
One value > 20×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value >= 3×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 5×ULN		
MK-3102/MK-3102	67	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Placebo/MK-3102	28	0 (0.0)
Last value > 10×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 20×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
(AST (IU/L) or ALT (IU/L)) + Total Bilirubin (mg/dL)		
One value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value meeting (AST >= 3×ULN or ALT >= 3×ULN) with Bilirubin >= 2×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Alkaline Phosphatase (IU/L)		
One value > 1.5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value > 1.5×ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Serum Uric Acid (mg/dL)		
One value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	67	2 (3.0)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase >= 50% and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Serum Sodium (mEq/L)		
Last value with a decrease >= 10 mEq/L and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)

C Confidential

Analysis of Subjects Meeting Predefined Limits of Change for Selected Laboratory Parameters Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data After Glycemic Rescue (ASaT) (Extensioin)

	N	n (%)
Last value with an increase >= 10 mEq/L and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Serum Potassium (mEq/L)		
Last value with a decrease >= 1.0 mEq/L and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase >= 1.0 mEq/L and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	1 (3.6)
Serum Calcium (mg/dL)		
Last value with an increase >= 1.0 mg/dL and value > ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
Last value with a decrease >= 1.0 mg/dL and value < LLN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)
QTc (milliseconds)		
Last value >= 500 msec		
MK-3102/MK-3102	67	1 (1.5)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase >= 30 msec and value > gender specific ULN		
MK-3102/MK-3102	67	2 (3.0)
Placebo/MK-3102	28	0 (0.0)
Last value with an increase >= 60 msec and value > gender specific ULN		
MK-3102/MK-3102	67	0 (0.0)
Placebo/MK-3102	28	0 (0.0)

Baseline is defined as Week 0 for the MK-3102/MK-3102 group and Week 24 for the Placebo/MK-3102 group.

Percentages represent data collected over a 52-week time period for the MK-3102/MK-3102 group (Week 0 to Week 52) and a 28-week time period for the Placebo/MK-3102 group (Week 24 to Week 52).

‡ Increases and decreases are relative to baseline; last value=last on-treatment value from Baseline to Week 52.

N = Subjects in population.

LLN=Lower Limit of Normal, ULN=Upper Limit of Normal.

C Confidential

付録 2.7.4: 24　　臨床検査値のベースラインからの変化量
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P015、長期投与時）

C Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	4.77 (0.41)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	4.77 (0.41)	4.75 (0.42)	-0.02 (0.02)	-0.04	-0.42 to 0.40
Week 8						
MK-3102/MK-3102	125	4.77 (0.41)	4.74 (0.44)	-0.03 (0.02)	-0.04	-0.50 to 0.62
Week 12						
MK-3102/MK-3102	124	4.77 (0.41)	4.75 (0.39)	-0.03 (0.02)	-0.00	-0.50 to 0.60
Week 24						
MK-3102/MK-3102	122	4.77 (0.41)	4.68 (0.41)	-0.09 (0.02)	-0.10	-0.86 to 0.36
Week 28						
MK-3102/MK-3102	122	4.77 (0.41)	4.69 (0.42)	-0.08 (0.02)	-0.08	-1.14 to 0.40
Week 36						
MK-3102/MK-3102	118	4.77 (0.41)	4.74 (0.43)	-0.03 (0.02)	-0.02	-0.97 to 0.47
Week 52						
MK-3102/MK-3102	112	4.77 (0.41)	4.81 (0.42)	0.04 (0.02)	0.03	-0.42 to 0.66

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	4.76 (0.41)	-	-	-	-
Week 28						
Placebo/MK-3102	62	4.76 (0.41)	4.74 (0.44)	-0.03 (0.02)	-0.04	-0.29 to 0.42
Week 36						
Placebo/MK-3102	61	4.76 (0.41)	4.79 (0.45)	0.02 (0.02)	-0.00	-0.25 to 0.49
Week 52						
Placebo/MK-3102	56	4.77 (0.43)	4.88 (0.46)	0.10 (0.02)	0.11	-0.26 to 0.49

C Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	4.86 (0.42)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	4.86 (0.42)	4.83 (0.39)	-0.03 (0.02)	0.00	-0.62 to 0.38
Week 8						
MK-3102/MK-3102	65	4.86 (0.42)	4.84 (0.36)	-0.01 (0.02)	0.01	-0.56 to 0.40
Week 12						
MK-3102/MK-3102	62	4.83 (0.40)	4.82 (0.40)	-0.01 (0.02)	0.00	-0.68 to 0.33
Week 24						
MK-3102/MK-3102	61	4.83 (0.40)	4.77 (0.40)	-0.07 (0.03)	-0.08	-0.54 to 0.41
Week 28						
MK-3102/MK-3102	61	4.83 (0.40)	4.74 (0.37)	-0.09 (0.03)	-0.07	-0.71 to 0.42
Week 36						
MK-3102/MK-3102	61	4.83 (0.40)	4.74 (0.38)	-0.10 (0.02)	-0.05	-0.62 to 0.29
Week 52						
MK-3102/MK-3102	59	4.84 (0.41)	4.83 (0.40)	-0.00 (0.03)	0.03	-0.67 to 0.39

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	4.86 (0.37)	-	-	-	-
Week 28						
Placebo/MK-3102	31	4.86 (0.37)	4.75 (0.32)	-0.11 (0.03)	-0.11	-0.42 to 0.18
Week 36						
Placebo/MK-3102	30	4.86 (0.38)	4.82 (0.33)	-0.05 (0.03)	-0.07	-0.47 to 0.26
Week 52						
Placebo/MK-3102	30	4.86 (0.38)	4.91 (0.35)	0.04 (0.04)	0.06	-0.36 to 0.44

C Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	4.78 (0.41)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	4.78 (0.41)	4.76 (0.39)	-0.01 (0.02)	-0.01	-0.42 to 0.46
Week 8						
MK-3102/MK-3102	66	4.78 (0.41)	4.78 (0.40)	0.00 (0.03)	0.02	-0.48 to 0.42
Week 12						
MK-3102/MK-3102	66	4.78 (0.41)	4.75 (0.39)	-0.02 (0.02)	0.01	-0.46 to 0.55
Week 24						
MK-3102/MK-3102	65	4.77 (0.41)	4.68 (0.42)	-0.09 (0.03)	-0.09	-0.52 to 0.68
Week 28						
MK-3102/MK-3102	65	4.77 (0.41)	4.67 (0.45)	-0.10 (0.03)	-0.09	-0.58 to 0.40
Week 36						
MK-3102/MK-3102	64	4.77 (0.41)	4.74 (0.41)	-0.03 (0.03)	-0.05	-0.50 to 0.67
Week 52						
MK-3102/MK-3102	64	4.77 (0.41)	4.80 (0.44)	0.03 (0.02)	0.04	-0.50 to 0.41

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	4.78 (0.39)	-	-	-	-
Week 28						
Placebo/MK-3102	32	4.78 (0.39)	4.72 (0.38)	-0.05 (0.03)	-0.04	-0.52 to 0.21
Week 36						
Placebo/MK-3102	33	4.78 (0.39)	4.79 (0.34)	0.01 (0.04)	0.02	-0.66 to 0.33
Week 52						
Placebo/MK-3102	33	4.78 (0.39)	4.86 (0.38)	0.09 (0.03)	0.08	-0.23 to 0.49

C Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	4.74 (0.43)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	4.74 (0.43)	4.70 (0.48)	-0.04 (0.02)	-0.03	-0.61 to 0.26
Week 8						
MK-3102/MK-3102	65	4.74 (0.43)	4.70 (0.47)	-0.04 (0.02)	-0.02	-0.61 to 0.29
Week 12						
MK-3102/MK-3102	64	4.74 (0.43)	4.69 (0.48)	-0.05 (0.02)	-0.06	-0.54 to 0.39
Week 24						
MK-3102/MK-3102	63	4.74 (0.44)	4.60 (0.52)	-0.14 (0.03)	-0.12	-1.02 to 0.28
Week 28						
MK-3102/MK-3102	63	4.74 (0.44)	4.62 (0.48)	-0.12 (0.03)	-0.08	-1.00 to 0.37
Week 36						
MK-3102/MK-3102	61	4.74 (0.44)	4.60 (0.43)	-0.14 (0.03)	-0.13	-0.94 to 0.29
Week 52						
MK-3102/MK-3102	60	4.75 (0.44)	4.72 (0.46)	-0.03 (0.03)	-0.00	-0.76 to 0.46

C Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	4.67 (0.42)	-	-	-	-
Week 28						
Placebo/MK-3102	33	4.67 (0.42)	4.63 (0.39)	-0.05 (0.03)	-0.06	-0.48 to 0.26
Week 36						
Placebo/MK-3102	33	4.67 (0.42)	4.67 (0.43)	0.00 (0.04)	-0.02	-0.43 to 0.61
Week 52						
Placebo/MK-3102	32	4.68 (0.42)	4.76 (0.42)	0.08 (0.03)	0.05	-0.27 to 0.37

C Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	4.82 (0.47)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	4.82 (0.47)	4.82 (0.46)	-0.01 (0.02)	0.02	-0.39 to 0.23
Week 8						
MK-3102/MK-3102	67	4.82 (0.47)	4.82 (0.46)	-0.00 (0.02)	-0.02	-0.47 to 0.42
Week 12						
MK-3102/MK-3102	67	4.82 (0.47)	4.83 (0.48)	0.01 (0.02)	0.05	-0.48 to 0.46
Week 24						
MK-3102/MK-3102	67	4.82 (0.47)	4.76 (0.45)	-0.06 (0.03)	-0.07	-0.67 to 0.57
Week 28						
MK-3102/MK-3102	67	4.82 (0.47)	4.75 (0.44)	-0.07 (0.03)	-0.08	-0.62 to 0.51
Week 36						
MK-3102/MK-3102	67	4.82 (0.47)	4.77 (0.46)	-0.05 (0.02)	-0.09	-0.38 to 0.47
Week 52						
MK-3102/MK-3102	65	4.81 (0.47)	4.83 (0.46)	0.02 (0.03)	0.06	-0.49 to 0.53

Confidential

Summary of Change from Baseline by Week in RBC (10^6/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	4.66 (0.38)	-	-	-	-
Week 28						
Placebo/MK-3102	28	4.66 (0.38)	4.56 (0.35)	-0.10 (0.03)	-0.10	-0.36 to 0.20
Week 36						
Placebo/MK-3102	28	4.66 (0.38)	4.59 (0.35)	-0.07 (0.04)	-0.05	-0.69 to 0.41
Week 52						
Placebo/MK-3102	28	4.66 (0.38)	4.70 (0.39)	0.04 (0.05)	0.01	-0.54 to 0.60

C Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	14.61 (1.16)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	14.61 (1.16)	14.51 (1.24)	-0.09 (0.05)	-0.10	-1.40 to 1.30
Week 8						
MK-3102/MK-3102	125	14.61 (1.17)	14.49 (1.32)	-0.12 (0.06)	-0.20	-1.90 to 1.90
Week 12						
MK-3102/MK-3102	124	14.62 (1.17)	14.49 (1.15)	-0.13 (0.05)	-0.10	-1.40 to 2.30
Week 24						
MK-3102/MK-3102	122	14.57 (1.13)	14.24 (1.16)	-0.33 (0.06)	-0.30	-2.10 to 1.70
Week 28						
MK-3102/MK-3102	122	14.57 (1.13)	14.30 (1.19)	-0.27 (0.06)	-0.30	-2.40 to 1.60
Week 36						
MK-3102/MK-3102	118	14.58 (1.14)	14.45 (1.20)	-0.13 (0.06)	-0.10	-1.80 to 1.50
Week 52						
MK-3102/MK-3102	112	14.58 (1.14)	14.68 (1.25)	0.10 (0.06)	0.10	-1.80 to 2.00

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	14.58 (1.25)	-	-	-	-
Week 28						
Placebo/MK-3102	62	14.58 (1.25)	14.56 (1.33)	-0.06 (0.06)	0.00	-1.20 to 1.30
Week 36						
Placebo/MK-3102	61	14.60 (1.24)	14.69 (1.37)	0.06 (0.06)	-0.05	-1.00 to 1.50
Week 52						
Placebo/MK-3102	56	14.64 (1.27)	14.99 (1.35)	0.31 (0.08)	0.30	-1.00 to 1.50

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	14.98 (1.33)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	14.98 (1.33)	14.88 (1.32)	-0.11 (0.08)	-0.10	-1.90 to 1.30
Week 8						
MK-3102/MK-3102	65	14.98 (1.33)	14.87 (1.21)	-0.12 (0.08)	-0.10	-1.90 to 1.40
Week 12						
MK-3102/MK-3102	62	14.91 (1.28)	14.79 (1.35)	-0.12 (0.07)	0.00	-2.00 to 1.00
Week 24						
MK-3102/MK-3102	61	14.92 (1.29)	14.63 (1.34)	-0.29 (0.08)	-0.30	-1.70 to 1.40
Week 28						
MK-3102/MK-3102	61	14.92 (1.29)	14.59 (1.29)	-0.33 (0.10)	-0.30	-2.10 to 1.20
Week 36						
MK-3102/MK-3102	61	14.92 (1.29)	14.56 (1.35)	-0.35 (0.08)	-0.30	-2.10 to 1.30
Week 52						
MK-3102/MK-3102	59	14.92 (1.31)	14.79 (1.40)	-0.13 (0.09)	-0.10	-2.20 to 1.10

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	14.75 (1.23)	-	-	-	-
Week 28						
Placebo/MK-3102	31	14.75 (1.23)	14.45 (1.26)	-0.29 (0.10)	-0.30	-1.70 to 0.70
Week 36						
Placebo/MK-3102	30	14.79 (1.23)	14.65 (1.19)	-0.13 (0.10)	-0.10	-1.20 to 0.80
Week 52						
Placebo/MK-3102	30	14.79 (1.23)	14.91 (1.22)	0.13 (0.12)	0.05	-1.10 to 1.50

C Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	14.43 (1.40)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	14.43 (1.40)	14.36 (1.39)	-0.07 (0.06)	-0.10	-1.20 to 1.50
Week 8						
MK-3102/MK-3102	66	14.43 (1.40)	14.40 (1.46)	-0.04 (0.08)	0.00	-1.40 to 1.10
Week 12						
MK-3102/MK-3102	66	14.43 (1.40)	14.30 (1.44)	-0.13 (0.06)	-0.10	-1.50 to 0.90
Week 24						
MK-3102/MK-3102	65	14.43 (1.41)	14.05 (1.57)	-0.38 (0.08)	-0.40	-1.80 to 2.10
Week 28						
MK-3102/MK-3102	65	14.43 (1.41)	14.05 (1.67)	-0.38 (0.08)	-0.30	-2.40 to 1.30
Week 36						
MK-3102/MK-3102	64	14.44 (1.41)	14.26 (1.49)	-0.18 (0.09)	-0.20	-1.90 to 2.10
Week 52						
MK-3102/MK-3102	64	14.44 (1.41)	14.45 (1.53)	0.00 (0.08)	0.10	-1.80 to 2.00

C Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	14.43 (1.09)	-	-	-	-
Week 28						
Placebo/MK-3102	32	14.43 (1.11)	14.34 (1.21)	-0.10 (0.09)	0.00	-1.30 to 0.80
Week 36						
Placebo/MK-3102	33	14.43 (1.09)	14.45 (1.20)	0.02 (0.12)	0.00	-1.80 to 1.60
Week 52						
Placebo/MK-3102	33	14.43 (1.09)	14.65 (1.12)	0.22 (0.09)	0.10	-0.60 to 1.80

C Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	14.42 (1.52)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	14.42 (1.52)	14.23 (1.55)	-0.19 (0.06)	-0.10	-1.80 to 0.70
Week 8						
MK-3102/MK-3102	65	14.42 (1.52)	14.24 (1.56)	-0.17 (0.07)	-0.10	-1.60 to 1.00
Week 12						
MK-3102/MK-3102	64	14.41 (1.54)	14.18 (1.63)	-0.23 (0.07)	-0.25	-1.50 to 1.20
Week 24						
MK-3102/MK-3102	63	14.43 (1.54)	13.94 (1.79)	-0.49 (0.11)	-0.40	-4.50 to 0.90
Week 28						
MK-3102/MK-3102	63	14.43 (1.54)	14.03 (1.61)	-0.40 (0.09)	-0.30	-2.80 to 1.80
Week 36						
MK-3102/MK-3102	61	14.41 (1.56)	13.95 (1.45)	-0.46 (0.09)	-0.40	-2.80 to 1.40
Week 52						
MK-3102/MK-3102	60	14.43 (1.57)	14.30 (1.56)	-0.12 (0.09)	-0.10	-2.50 to 1.80

Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	14.37 (1.31)	-	-	-	-
Week 28						
Placebo/MK-3102	33	14.37 (1.31)	14.28 (1.29)	-0.08 (0.09)	0.00	-1.40 to 0.80
Week 36						
Placebo/MK-3102	33	14.37 (1.31)	14.44 (1.31)	0.08 (0.11)	0.10	-1.20 to 1.90
Week 52						
Placebo/MK-3102	32	14.36 (1.33)	14.70 (1.36)	0.34 (0.09)	0.25	-0.70 to 1.10

C Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	14.75 (1.45)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	14.75 (1.45)	14.71 (1.35)	-0.04 (0.06)	0.00	-1.10 to 1.00
Week 8						
MK-3102/MK-3102	67	14.75 (1.45)	14.69 (1.40)	-0.06 (0.07)	-0.10	-1.50 to 1.40
Week 12						
MK-3102/MK-3102	67	14.75 (1.45)	14.73 (1.47)	-0.03 (0.08)	0.00	-1.40 to 1.40
Week 24						
MK-3102/MK-3102	67	14.75 (1.45)	14.54 (1.28)	-0.22 (0.08)	-0.20	-2.20 to 1.60
Week 28						
MK-3102/MK-3102	67	14.75 (1.45)	14.52 (1.18)	-0.23 (0.09)	-0.30	-1.80 to 2.60
Week 36						
MK-3102/MK-3102	67	14.75 (1.45)	14.59 (1.26)	-0.16 (0.08)	-0.30	-1.20 to 1.70
Week 52						
MK-3102/MK-3102	65	14.68 (1.41)	14.77 (1.25)	0.09 (0.08)	0.10	-1.20 to 1.90

C Confidential

Summary of Change from Baseline by Week in Hemoglobin (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	14.03 (1.43)	-	-	-	-
Week 28						
Placebo/MK-3102	28	14.03 (1.43)	13.73 (1.34)	-0.30 (0.09)	-0.25	-1.40 to 0.70
Week 36						
Placebo/MK-3102	28	14.03 (1.43)	13.81 (1.33)	-0.22 (0.12)	-0.10	-2.00 to 1.40
Week 52						
Placebo/MK-3102	28	14.03 (1.43)	14.29 (1.18)	0.26 (0.21)	-0.05	-1.00 to 4.00

C Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	44.40 (3.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	44.40 (3.22)	44.48 (3.49)	0.09 (0.15)	0.05	-3.60 to 4.40
Week 8						
MK-3102/MK-3102	125	44.42 (3.22)	44.40 (3.68)	-0.02 (0.18)	-0.10	-4.80 to 6.20
Week 12						
MK-3102/MK-3102	124	44.43 (3.23)	44.35 (3.30)	-0.08 (0.16)	-0.15	-3.90 to 6.20
Week 24						
MK-3102/MK-3102	122	44.35 (3.20)	43.09 (3.27)	-1.27 (0.17)	-1.20	-6.60 to 4.10
Week 28						
MK-3102/MK-3102	122	44.35 (3.20)	43.17 (3.29)	-1.19 (0.18)	-1.05	-7.70 to 3.50
Week 36						
MK-3102/MK-3102	118	44.38 (3.23)	43.40 (3.36)	-0.97 (0.18)	-1.00	-5.70 to 3.50
Week 52						
MK-3102/MK-3102	112	44.41 (3.24)	44.12 (3.46)	-0.28 (0.17)	-0.20	-5.90 to 5.50

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	43.70 (3.41)	-	-	-	-
Week 28						
Placebo/MK-3102	62	43.70 (3.41)	43.74 (3.81)	-0.12 (0.21)	-0.50	-2.90 to 4.90
Week 36						
Placebo/MK-3102	61	43.78 (3.38)	43.99 (3.82)	0.10 (0.23)	0.25	-3.90 to 4.50
Week 52						
Placebo/MK-3102	56	43.91 (3.48)	44.77 (3.68)	0.74 (0.26)	1.00	-3.00 to 4.30

C Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	45.18 (3.70)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	45.18 (3.70)	45.08 (3.70)	-0.10 (0.24)	-0.10	-4.90 to 6.80
Week 8						
MK-3102/MK-3102	65	45.18 (3.70)	45.18 (3.27)	0.00 (0.24)	-0.20	-5.30 to 4.40
Week 12						
MK-3102/MK-3102	62	44.99 (3.62)	45.07 (3.72)	0.08 (0.23)	0.15	-5.70 to 5.10
Week 24						
MK-3102/MK-3102	61	45.04 (3.64)	44.32 (3.61)	-0.72 (0.27)	-0.50	-5.70 to 4.30
Week 28						
MK-3102/MK-3102	61	45.04 (3.64)	44.16 (3.62)	-0.88 (0.33)	-0.80	-7.00 to 4.50
Week 36						
MK-3102/MK-3102	61	45.04 (3.64)	43.44 (3.54)	-1.60 (0.25)	-1.30	-7.00 to 1.60
Week 52						
MK-3102/MK-3102	59	45.06 (3.70)	44.19 (3.79)	-0.86 (0.27)	-0.80	-6.40 to 3.10

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	44.78 (3.65)	-	-	-	-
Week 28						
Placebo/MK-3102	31	44.78 (3.65)	43.88 (3.60)	-0.90 (0.37)	-1.00	-5.50 to 2.90
Week 36						
Placebo/MK-3102	30	44.86 (3.68)	43.70 (3.12)	-1.17 (0.38)	-0.95	-6.00 to 3.10
Week 52						
Placebo/MK-3102	30	44.86 (3.68)	44.38 (3.33)	-0.48 (0.39)	-0.35	-4.20 to 2.80

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	43.98 (3.60)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	43.98 (3.60)	44.03 (3.63)	0.05 (0.20)	0.20	-3.10 to 4.50
Week 8						
MK-3102/MK-3102	66	43.98 (3.60)	44.08 (3.89)	0.10 (0.24)	0.10	-4.60 to 3.90
Week 12						
MK-3102/MK-3102	66	43.98 (3.60)	43.88 (3.67)	-0.11 (0.20)	-0.15	-4.00 to 3.50
Week 24						
MK-3102/MK-3102	65	43.96 (3.63)	42.60 (4.15)	-1.36 (0.27)	-1.50	-5.70 to 6.50
Week 28						
MK-3102/MK-3102	65	43.96 (3.63)	42.40 (4.30)	-1.56 (0.26)	-1.60	-6.30 to 4.20
Week 36						
MK-3102/MK-3102	64	44.00 (3.64)	42.87 (3.77)	-1.13 (0.28)	-1.25	-4.90 to 5.40
Week 52						
MK-3102/MK-3102	64	44.00 (3.64)	43.48 (4.05)	-0.52 (0.27)	-0.25	-6.50 to 5.30

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	43.62 (2.84)	-	-	-	-
Week 28						
Placebo/MK-3102	32	43.64 (2.88)	43.12 (3.27)	-0.52 (0.29)	-0.35	-4.50 to 2.20
Week 36						
Placebo/MK-3102	33	43.62 (2.84)	43.38 (2.93)	-0.23 (0.35)	-0.20	-6.70 to 3.10
Week 52						
Placebo/MK-3102	33	43.62 (2.84)	44.03 (2.83)	0.42 (0.25)	0.10	-2.50 to 4.20

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	44.36 (3.89)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	44.36 (3.89)	43.91 (4.18)	-0.46 (0.20)	-0.20	-5.50 to 2.40
Week 8						
MK-3102/MK-3102	65	44.36 (3.89)	44.10 (4.16)	-0.26 (0.23)	-0.30	-4.90 to 4.30
Week 12						
MK-3102/MK-3102	64	44.37 (3.92)	44.00 (4.35)	-0.37 (0.21)	-0.45	-4.00 to 3.70
Week 24						
MK-3102/MK-3102	63	44.41 (3.94)	42.78 (5.00)	-1.62 (0.32)	-1.30	-12.70 to 2.40
Week 28						
MK-3102/MK-3102	63	44.41 (3.94)	42.91 (4.55)	-1.50 (0.30)	-1.30	-9.20 to 3.40
Week 36						
MK-3102/MK-3102	61	44.38 (3.99)	42.35 (3.77)	-2.03 (0.27)	-1.80	-8.50 to 2.30
Week 52						
MK-3102/MK-3102	60	44.43 (4.00)	43.55 (4.06)	-0.89 (0.26)	-1.00	-6.90 to 3.70

C Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	43.91 (3.64)	-	-	-	-
Week 28						
Placebo/MK-3102	33	43.91 (3.64)	43.55 (3.81)	-0.36 (0.31)	0.00	-3.70 to 3.40
Week 36						
Placebo/MK-3102	33	43.91 (3.64)	43.62 (3.39)	-0.29 (0.39)	-0.50	-4.40 to 6.50
Week 52						
Placebo/MK-3102	32	43.89 (3.70)	44.46 (3.75)	0.57 (0.30)	0.40	-2.80 to 3.30

C Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	44.90 (4.11)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	44.90 (4.11)	44.91 (3.85)	0.01 (0.18)	0.30	-3.10 to 3.30
Week 8						
MK-3102/MK-3102	67	44.90 (4.11)	44.99 (3.84)	0.09 (0.21)	0.00	-4.50 to 4.00
Week 12						
MK-3102/MK-3102	67	44.90 (4.11)	45.15 (4.13)	0.24 (0.23)	0.50	-4.20 to 5.00
Week 24						
MK-3102/MK-3102	67	44.90 (4.11)	44.15 (3.88)	-0.75 (0.26)	-0.80	-7.10 to 5.40
Week 28						
MK-3102/MK-3102	67	44.90 (4.11)	43.86 (3.45)	-1.05 (0.28)	-0.90	-6.10 to 7.20
Week 36						
MK-3102/MK-3102	67	44.90 (4.11)	43.75 (3.55)	-1.16 (0.22)	-1.30	-4.60 to 3.20
Week 52						
MK-3102/MK-3102	65	44.74 (4.07)	44.28 (3.66)	-0.46 (0.25)	-0.40	-4.10 to 5.20

Confidential

Summary of Change from Baseline by Week in Hematocrit (%) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	42.76 (3.70)	-	-	-	-
Week 28						
Placebo/MK-3102	28	42.76 (3.70)	41.77 (3.49)	-1.00 (0.28)	-0.85	-3.40 to 1.60
Week 36						
Placebo/MK-3102	28	42.76 (3.70)	41.61 (3.39)	-1.15 (0.43)	-1.25	-6.70 to 3.00
Week 52						
Placebo/MK-3102	28	42.76 (3.70)	42.79 (3.35)	0.02 (0.57)	-0.45	-4.20 to 8.50

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	32.90 (0.84)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	32.90 (0.84)	32.62 (0.77)	-0.28 (0.04)	-0.30	-1.50 to 0.80
Week 8						
MK-3102/MK-3102	125	32.89 (0.84)	32.62 (0.87)	-0.26 (0.05)	-0.20	-1.60 to 1.40
Week 12						
MK-3102/MK-3102	124	32.89 (0.84)	32.66 (0.87)	-0.23 (0.05)	-0.25	-1.90 to 2.60
Week 24						
MK-3102/MK-3102	122	32.85 (0.79)	33.05 (0.91)	0.19 (0.07)	0.20	-2.10 to 1.90
Week 28						
MK-3102/MK-3102	122	32.85 (0.79)	33.11 (0.83)	0.26 (0.06)	0.30	-1.60 to 2.40
Week 36						
MK-3102/MK-3102	118	32.85 (0.80)	33.29 (0.81)	0.44 (0.05)	0.40	-0.80 to 2.10
Week 52						
MK-3102/MK-3102	112	32.84 (0.81)	33.27 (0.87)	0.43 (0.05)	0.30	-1.20 to 1.90

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	33.34 (0.96)	-	-	-	-
Week 28						
Placebo/MK-3102	62	33.34 (0.96)	33.28 (0.82)	-0.04 (0.08)	-0.10	-1.10 to 1.60
Week 36						
Placebo/MK-3102	61	33.34 (0.97)	33.38 (0.85)	0.05 (0.09)	0.00	-1.60 to 1.50
Week 52						
Placebo/MK-3102	56	33.33 (0.97)	33.47 (0.84)	0.14 (0.09)	0.10	-1.20 to 1.70

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	33.15 (0.74)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	33.15 (0.74)	32.99 (0.67)	-0.16 (0.07)	-0.20	-2.10 to 0.90
Week 8						
MK-3102/MK-3102	65	33.15 (0.74)	32.89 (0.73)	-0.26 (0.06)	-0.30	-1.30 to 0.70
Week 12						
MK-3102/MK-3102	62	33.13 (0.74)	32.80 (0.67)	-0.33 (0.06)	-0.30	-1.50 to 0.50
Week 24						
MK-3102/MK-3102	61	33.11 (0.73)	33.00 (0.86)	-0.11 (0.07)	-0.20	-1.30 to 1.20
Week 28						
MK-3102/MK-3102	61	33.11 (0.73)	33.04 (0.79)	-0.07 (0.08)	0.00	-1.60 to 1.30
Week 36						
MK-3102/MK-3102	61	33.11 (0.73)	33.50 (0.79)	0.38 (0.07)	0.40	-0.90 to 2.00
Week 52						
MK-3102/MK-3102	59	33.11 (0.75)	33.44 (0.79)	0.33 (0.08)	0.30	-0.80 to 1.80

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	32.95 (0.90)	-	-	-	-
Week 28						
Placebo/MK-3102	31	32.95 (0.90)	32.94 (0.93)	-0.01 (0.11)	0.10	-1.50 to 1.10
Week 36						
Placebo/MK-3102	30	32.97 (0.90)	33.52 (0.96)	0.55 (0.13)	0.50	-0.60 to 2.10
Week 52						
Placebo/MK-3102	30	32.97 (0.90)	33.59 (0.92)	0.62 (0.14)	0.60	-0.60 to 2.20

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	32.78 (0.93)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	32.78 (0.93)	32.59 (0.93)	-0.19 (0.06)	-0.15	-2.20 to 0.80
Week 8						
MK-3102/MK-3102	66	32.78 (0.93)	32.63 (0.94)	-0.15 (0.05)	-0.20	-1.00 to 0.80
Week 12						
MK-3102/MK-3102	66	32.78 (0.93)	32.55 (1.04)	-0.23 (0.08)	-0.30	-1.80 to 2.00
Week 24						
MK-3102/MK-3102	65	32.78 (0.93)	32.96 (1.25)	0.18 (0.11)	0.20	-2.20 to 2.30
Week 28						
MK-3102/MK-3102	65	32.78 (0.93)	33.08 (1.21)	0.30 (0.09)	0.30	-1.70 to 1.60
Week 36						
MK-3102/MK-3102	64	32.79 (0.94)	33.23 (1.09)	0.44 (0.08)	0.40	-1.90 to 2.40
Week 52						
MK-3102/MK-3102	64	32.79 (0.94)	33.21 (0.96)	0.42 (0.08)	0.35	-1.70 to 1.90

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	33.08 (0.94)	-	-	-	-
Week 28						
Placebo/MK-3102	32	33.07 (0.95)	33.24 (1.09)	0.17 (0.12)	0.10	-1.40 to 1.70
Week 36						
Placebo/MK-3102	33	33.08 (0.94)	33.26 (0.89)	0.18 (0.12)	0.10	-0.80 to 1.50
Week 52						
Placebo/MK-3102	33	33.08 (0.94)	33.25 (0.91)	0.18 (0.13)	0.30	-1.30 to 1.90

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	32.46 (1.03)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	32.46 (1.03)	32.38 (0.95)	-0.08 (0.07)	-0.10	-1.50 to 1.30
Week 8						
MK-3102/MK-3102	65	32.46 (1.03)	32.25 (0.96)	-0.21 (0.07)	-0.20	-1.70 to 1.20
Week 12						
MK-3102/MK-3102	64	32.45 (1.04)	32.18 (0.90)	-0.26 (0.06)	-0.30	-1.70 to 1.10
Week 24						
MK-3102/MK-3102	63	32.45 (1.05)	32.54 (1.03)	0.09 (0.11)	0.00	-2.50 to 2.50
Week 28						
MK-3102/MK-3102	63	32.45 (1.05)	32.67 (1.03)	0.22 (0.09)	0.20	-1.80 to 2.10
Week 36						
MK-3102/MK-3102	61	32.43 (1.05)	32.90 (1.04)	0.48 (0.09)	0.50	-0.90 to 2.60
Week 52						
MK-3102/MK-3102	60	32.43 (1.06)	32.81 (1.00)	0.38 (0.09)	0.40	-1.30 to 1.90

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	32.71 (0.86)	-	-	-	-
Week 28						
Placebo/MK-3102	33	32.71 (0.86)	32.80 (0.82)	0.09 (0.10)	0.10	-1.30 to 1.10
Week 36						
Placebo/MK-3102	33	32.71 (0.86)	33.08 (0.84)	0.38 (0.11)	0.30	-0.80 to 2.00
Week 52						
Placebo/MK-3102	32	32.70 (0.87)	33.06 (0.81)	0.36 (0.10)	0.50	-0.90 to 1.30

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	32.84 (0.75)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	32.84 (0.75)	32.75 (0.71)	-0.09 (0.06)	0.00	-1.50 to 1.40
Week 8						
MK-3102/MK-3102	67	32.84 (0.75)	32.63 (0.74)	-0.22 (0.06)	-0.20	-1.30 to 0.60
Week 12						
MK-3102/MK-3102	67	32.84 (0.75)	32.60 (0.78)	-0.25 (0.06)	-0.30	-1.60 to 1.30
Week 24						
MK-3102/MK-3102	67	32.84 (0.75)	32.93 (0.82)	0.09 (0.09)	0.10	-2.30 to 1.50
Week 28						
MK-3102/MK-3102	67	32.84 (0.75)	33.10 (0.75)	0.26 (0.09)	0.20	-1.40 to 1.90
Week 36						
MK-3102/MK-3102	67	32.84 (0.75)	33.35 (0.70)	0.51 (0.07)	0.50	-0.70 to 1.90
Week 52						
MK-3102/MK-3102	65	32.80 (0.72)	33.36 (0.64)	0.56 (0.07)	0.50	-0.70 to 2.10

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular HB Concentration (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	32.78 (1.05)	-	-	-	-
Week 28						
Placebo/MK-3102	28	32.78 (1.05)	32.85 (1.03)	0.07 (0.12)	0.00	-1.40 to 1.30
Week 36						
Placebo/MK-3102	28	32.78 (1.05)	33.16 (0.91)	0.38 (0.15)	0.45	-1.20 to 2.00
Week 52						
Placebo/MK-3102	28	32.78 (1.05)	33.40 (0.79)	0.62 (0.18)	0.50	-1.00 to 3.30

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	93.29 (4.90)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	93.29 (4.90)	93.89 (5.07)	0.59 (0.09)	0.65	-1.50 to 3.40
Week 8						
MK-3102/MK-3102	125	93.28 (4.92)	93.86 (5.04)	0.58 (0.11)	0.50	-2.30 to 3.00
Week 12						
MK-3102/MK-3102	124	93.29 (4.94)	93.60 (5.10)	0.30 (0.12)	0.50	-3.20 to 3.90
Week 24						
MK-3102/MK-3102	122	93.29 (4.97)	92.32 (5.38)	-0.97 (0.19)	-1.40	-7.30 to 10.60
Week 28						
MK-3102/MK-3102	122	93.29 (4.97)	92.29 (5.49)	-1.00 (0.19)	-1.10	-7.30 to 13.10
Week 36						
MK-3102/MK-3102	118	93.30 (5.03)	91.84 (5.74)	-1.45 (0.20)	-1.70	-7.90 to 13.60
Week 52						
MK-3102/MK-3102	112	93.32 (5.12)	91.93 (5.34)	-1.38 (0.16)	-1.20	-7.40 to 2.60

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	92.03 (3.73)	-	-	-	-
Week 28						
Placebo/MK-3102	62	92.03 (3.73)	92.32 (3.85)	0.28 (0.20)	0.50	-4.00 to 3.30
Week 36						
Placebo/MK-3102	61	92.15 (3.64)	92.03 (3.60)	-0.11 (0.24)	0.00	-4.20 to 3.40
Week 52						
Placebo/MK-3102	56	92.23 (3.62)	91.90 (3.91)	-0.33 (0.24)	-0.40	-4.00 to 3.30

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	93.16 (4.09)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	93.16 (4.09)	93.39 (3.94)	0.24 (0.17)	0.10	-1.70 to 7.50
Week 8						
MK-3102/MK-3102	65	93.16 (4.09)	93.42 (3.98)	0.26 (0.17)	0.10	-2.40 to 6.40
Week 12						
MK-3102/MK-3102	62	93.23 (4.12)	93.61 (4.19)	0.38 (0.19)	0.55	-2.70 to 6.20
Week 24						
MK-3102/MK-3102	61	93.26 (4.15)	93.11 (4.12)	-0.15 (0.22)	0.20	-3.70 to 3.30
Week 28						
MK-3102/MK-3102	61	93.26 (4.15)	93.14 (4.53)	-0.12 (0.21)	-0.10	-4.60 to 3.30
Week 36						
MK-3102/MK-3102	61	93.26 (4.15)	91.78 (4.10)	-1.48 (0.19)	-1.30	-5.80 to 1.50
Week 52						
MK-3102/MK-3102	59	93.27 (4.22)	91.52 (4.54)	-1.75 (0.21)	-1.60	-6.30 to 2.10

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	92.28 (4.01)	-	-	-	-
Week 28						
Placebo/MK-3102	31	92.28 (4.01)	92.48 (4.41)	0.20 (0.29)	0.30	-3.60 to 3.50
Week 36						
Placebo/MK-3102	30	92.34 (4.06)	90.82 (3.95)	-1.52 (0.31)	-1.70	-3.90 to 1.90
Week 52						
Placebo/MK-3102	30	92.34 (4.06)	90.53 (4.08)	-1.81 (0.23)	-1.85	-4.70 to 0.70

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	92.22 (4.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	92.22 (4.22)	92.56 (4.38)	0.34 (0.16)	0.30	-2.40 to 4.20
Week 8						
MK-3102/MK-3102	66	92.22 (4.22)	92.37 (4.56)	0.15 (0.14)	0.10	-4.20 to 2.80
Week 12						
MK-3102/MK-3102	66	92.22 (4.22)	92.42 (4.75)	0.20 (0.20)	-0.05	-5.40 to 5.10
Week 24						
MK-3102/MK-3102	65	92.26 (4.25)	91.14 (4.66)	-1.12 (0.28)	-1.20	-7.30 to 5.30
Week 28						
MK-3102/MK-3102	65	92.26 (4.25)	90.84 (4.83)	-1.42 (0.23)	-1.60	-6.20 to 5.70
Week 36						
MK-3102/MK-3102	64	92.31 (4.26)	90.55 (4.37)	-1.76 (0.22)	-1.85	-8.10 to 3.80
Week 52						
MK-3102/MK-3102	64	92.31 (4.26)	90.64 (4.33)	-1.67 (0.27)	-2.00	-6.80 to 7.40

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	91.47 (4.18)	-	-	-	-
Week 28						
Placebo/MK-3102	32	91.56 (4.21)	91.40 (4.30)	-0.17 (0.24)	-0.20	-3.30 to 2.30
Week 36						
Placebo/MK-3102	33	91.47 (4.18)	90.72 (4.25)	-0.75 (0.32)	-0.70	-3.90 to 3.10
Week 52						
Placebo/MK-3102	33	91.47 (4.18)	90.70 (4.18)	-0.77 (0.33)	-0.90	-5.40 to 2.40

C Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	93.75 (4.90)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	93.75 (4.90)	93.63 (5.03)	-0.12 (0.14)	-0.10	-3.40 to 2.90
Week 8						
MK-3102/MK-3102	65	93.75 (4.90)	93.94 (5.05)	0.19 (0.16)	0.20	-2.00 to 3.00
Week 12						
MK-3102/MK-3102	64	93.77 (4.94)	94.01 (5.11)	0.24 (0.17)	0.10	-2.70 to 4.20
Week 24						
MK-3102/MK-3102	63	93.83 (4.96)	93.02 (5.18)	-0.80 (0.30)	-0.90	-11.20 to 4.40
Week 28						
MK-3102/MK-3102	63	93.83 (4.96)	93.00 (4.94)	-0.83 (0.28)	-0.90	-7.20 to 6.90
Week 36						
MK-3102/MK-3102	61	93.70 (4.98)	92.21 (4.86)	-1.48 (0.27)	-1.50	-5.80 to 7.30
Week 52						
MK-3102/MK-3102	60	93.67 (5.02)	92.38 (5.02)	-1.29 (0.29)	-1.60	-5.30 to 8.80

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	94.11 (3.79)	-	-	-	-
Week 28						
Placebo/MK-3102	33	94.11 (3.79)	94.22 (3.91)	0.11 (0.27)	0.30	-2.70 to 3.70
Week 36						
Placebo/MK-3102	33	94.11 (3.79)	93.50 (3.66)	-0.60 (0.30)	-0.30	-3.80 to 2.40
Week 52						
Placebo/MK-3102	32	94.00 (3.80)	93.57 (3.69)	-0.43 (0.26)	-0.55	-2.90 to 1.90

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	93.24 (4.65)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	93.24 (4.65)	93.43 (4.60)	0.19 (0.15)	0.40	-3.30 to 4.80
Week 8						
MK-3102/MK-3102	67	93.24 (4.65)	93.46 (4.62)	0.22 (0.17)	0.10	-2.40 to 6.40
Week 12						
MK-3102/MK-3102	67	93.24 (4.65)	93.60 (4.68)	0.36 (0.18)	0.40	-3.40 to 5.50
Week 24						
MK-3102/MK-3102	67	93.24 (4.65)	92.82 (4.37)	-0.42 (0.25)	-0.30	-6.10 to 5.10
Week 28						
MK-3102/MK-3102	67	93.24 (4.65)	92.53 (4.44)	-0.71 (0.25)	-0.90	-4.30 to 6.30
Week 36						
MK-3102/MK-3102	67	93.24 (4.65)	91.94 (4.41)	-1.29 (0.24)	-1.70	-4.00 to 7.70
Week 52						
MK-3102/MK-3102	65	93.22 (4.71)	91.86 (4.46)	-1.37 (0.25)	-1.50	-4.80 to 9.50

Confidential

Summary of Change from Baseline by Week in Ery. Mean Corpuscular Volume (fL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	91.88 (4.38)	-	-	-	-
Week 28						
Placebo/MK-3102	28	91.88 (4.38)	91.68 (4.73)	-0.20 (0.25)	-0.15	-3.30 to 2.20
Week 36						
Placebo/MK-3102	28	91.88 (4.38)	90.75 (4.52)	-1.13 (0.40)	-1.20	-4.70 to 3.10
Week 52						
Placebo/MK-3102	28	91.88 (4.38)	91.21 (3.53)	-0.67 (0.57)	-0.80	-4.40 to 10.50

C Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	227.82 (52.70)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	227.82 (52.70)	226.15 (50.34)	-1.67 (2.03)	-2.00	-109.00 to 63.00
Week 8						
MK-3102/MK-3102	125	227.70 (52.89)	224.82 (52.88)	-2.88 (2.21)	-4.00	-72.00 to 91.00
Week 12						
MK-3102/MK-3102	124	227.40 (52.99)	220.59 (47.34)	-6.81 (2.11)	-6.00	-99.00 to 57.00
Week 24						
MK-3102/MK-3102	122	228.24 (53.01)	220.11 (47.78)	-8.13 (2.51)	-7.00	-98.00 to 102.00
Week 28						
MK-3102/MK-3102	122	228.24 (53.01)	220.07 (49.35)	-8.17 (2.22)	-9.00	-100.00 to 55.00
Week 36						
MK-3102/MK-3102	118	228.69 (53.29)	224.14 (55.08)	-4.55 (2.56)	-5.50	-78.00 to 103.00
Week 52						
MK-3102/MK-3102	112	226.70 (48.69)	227.37 (50.98)	0.67 (2.55)	1.50	-75.00 to 134.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	214.93 (62.75)	-	-	-	-
Week 28						
Placebo/MK-3102	62	214.93 (62.75)	214.47 (52.65)	-1.26 (3.27)	-2.00	-144.00 to 74.00
Week 36						
Placebo/MK-3102	61	215.28 (63.22)	218.31 (59.00)	2.02 (4.10)	4.00	-146.00 to 91.00
Week 52						
Placebo/MK-3102	56	215.76 (60.09)	225.89 (51.85)	8.82 (4.13)	12.00	-132.00 to 79.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	224.66 (55.40)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	224.66 (55.40)	218.68 (51.12)	-5.98 (2.47)	-7.00	-63.00 to 61.00
Week 8						
MK-3102/MK-3102	65	224.66 (55.40)	221.72 (52.96)	-2.94 (2.39)	-1.00	-50.00 to 52.00
Week 12						
MK-3102/MK-3102	62	226.10 (55.50)	219.29 (57.18)	-6.81 (3.17)	-10.00	-50.00 to 121.00
Week 24						
MK-3102/MK-3102	61	226.79 (55.69)	221.34 (53.74)	-5.44 (2.64)	-6.00	-61.00 to 49.00
Week 28						
MK-3102/MK-3102	61	226.79 (55.69)	220.64 (52.55)	-6.15 (2.70)	-3.00	-66.00 to 48.00
Week 36						
MK-3102/MK-3102	61	226.79 (55.69)	221.70 (56.71)	-5.08 (2.88)	-6.00	-62.00 to 69.00
Week 52						
MK-3102/MK-3102	59	226.81 (56.52)	225.61 (53.88)	-1.20 (2.60)	-1.00	-46.00 to 40.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	218.06 (41.07)	-	-	-	-
Week 28						
Placebo/MK-3102	31	218.06 (41.07)	218.52 (42.23)	0.45 (3.32)	4.00	-36.00 to 25.00
Week 36						
Placebo/MK-3102	30	215.13 (38.33)	213.50 (36.59)	-1.63 (3.09)	-2.00	-51.00 to 27.00
Week 52						
Placebo/MK-3102	30	215.13 (38.33)	225.20 (49.33)	10.07 (4.87)	10.00	-81.00 to 68.00

C Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	238.56 (67.23)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	238.56 (67.23)	233.88 (64.83)	-4.68 (3.60)	-4.00	-117.00 to 66.00
Week 8						
MK-3102/MK-3102	66	238.56 (67.23)	234.61 (64.69)	-3.95 (3.70)	-4.00	-119.00 to 105.00
Week 12						
MK-3102/MK-3102	66	238.56 (67.23)	233.48 (65.20)	-5.08 (3.53)	-5.00	-105.00 to 73.00
Week 24						
MK-3102/MK-3102	65	239.32 (67.46)	229.74 (68.25)	-9.58 (3.42)	-6.00	-77.00 to 91.00
Week 28						
MK-3102/MK-3102	65	239.32 (67.46)	230.42 (65.50)	-8.91 (3.15)	-9.00	-109.00 to 64.00
Week 36						
MK-3102/MK-3102	64	238.94 (67.92)	236.20 (65.63)	-2.73 (3.65)	1.50	-117.00 to 51.00
Week 52						
MK-3102/MK-3102	64	238.94 (67.92)	239.11 (66.92)	0.17 (4.53)	3.00	-139.00 to 80.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	229.30 (41.46)	-	-	-	-
Week 28						
Placebo/MK-3102	32	229.84 (42.01)	233.19 (50.29)	3.34 (4.29)	3.50	-66.00 to 60.00
Week 36						
Placebo/MK-3102	33	229.30 (41.46)	231.70 (45.41)	2.39 (3.18)	3.00	-53.00 to 53.00
Week 52						
Placebo/MK-3102	33	229.30 (41.46)	238.21 (54.82)	8.91 (4.39)	5.00	-37.00 to 106.00

C Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	222.11 (56.70)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	222.11 (56.70)	220.12 (62.62)	-1.98 (2.87)	-2.00	-64.00 to 52.00
Week 8						
MK-3102/MK-3102	65	222.11 (56.70)	221.77 (60.09)	-0.34 (2.94)	-2.00	-49.00 to 78.00
Week 12						
MK-3102/MK-3102	64	222.70 (56.94)	225.95 (63.56)	3.25 (3.88)	0.00	-82.00 to 124.00
Week 24						
MK-3102/MK-3102	63	220.27 (53.94)	215.86 (57.22)	-4.41 (3.73)	-4.00	-64.00 to 113.00
Week 28						
MK-3102/MK-3102	63	220.27 (53.94)	218.79 (55.05)	-1.48 (4.26)	-2.00	-94.00 to 107.00
Week 36						
MK-3102/MK-3102	61	221.79 (53.92)	223.31 (59.82)	1.52 (5.11)	-2.00	-96.00 to 192.00
Week 52						
MK-3102/MK-3102	60	220.12 (52.75)	226.95 (54.37)	6.83 (3.53)	6.50	-43.00 to 112.00

Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	207.30 (46.47)	-	-	-	-
Week 28						
Placebo/MK-3102	33	207.30 (46.47)	207.67 (47.25)	0.36 (4.16)	1.00	-68.00 to 62.00
Week 36						
Placebo/MK-3102	33	207.30 (46.47)	207.94 (48.80)	0.64 (4.19)	-4.00	-44.00 to 49.00
Week 52						
Placebo/MK-3102	32	207.13 (47.20)	215.25 (50.00)	8.13 (3.60)	8.50	-37.00 to 57.00

C Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	230.30 (63.81)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	230.30 (63.81)	224.90 (63.05)	-5.40 (3.62)	-2.00	-179.00 to 42.00
Week 8						
MK-3102/MK-3102	67	230.30 (63.81)	223.88 (56.80)	-6.42 (3.59)	-6.00	-164.00 to 52.00
Week 12						
MK-3102/MK-3102	67	230.30 (63.81)	225.78 (56.58)	-4.52 (2.46)	-7.00	-72.00 to 58.00
Week 24						
MK-3102/MK-3102	67	230.30 (63.81)	214.66 (47.73)	-15.64 (3.82)	-11.00	-177.00 to 26.00
Week 28						
MK-3102/MK-3102	67	230.30 (63.81)	218.19 (50.74)	-12.10 (4.06)	-11.00	-162.00 to 66.00
Week 36						
MK-3102/MK-3102	67	230.30 (63.81)	218.97 (46.15)	-11.33 (3.96)	-12.00	-148.00 to 50.00
Week 52						
MK-3102/MK-3102	65	230.37 (64.58)	230.80 (56.33)	0.43 (4.59)	-3.00	-123.00 to 163.00

C Confidential

Summary of Change from Baseline by Week in Platelet (10^3/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	234.89 (57.64)	-	-	-	-
Week 28						
Placebo/MK-3102	28	234.89 (57.64)	231.75 (53.02)	-3.14 (4.06)	-2.00	-75.00 to 34.00
Week 36						
Placebo/MK-3102	28	234.89 (57.64)	232.43 (55.30)	-2.46 (4.70)	-5.00	-76.00 to 49.00
Week 52						
Placebo/MK-3102	28	234.89 (57.64)	235.68 (55.98)	0.79 (4.63)	-1.50	-54.00 to 41.00

C Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	5972.22 (1515.92)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	5972.22 (1515.92)	6092.06 (1505.33)	119.84 (111.83)	100.00	-8000.00 to 4000.00
Week 8						
MK-3102/MK-3102	125	5968.00 (1521.28)	6076.00 (1462.51)	108.00 (115.95)	200.00	-8200.00 to 3300.00
Week 12						
MK-3102/MK-3102	124	5980.65 (1520.84)	6112.10 (1415.91)	131.45 (109.13)	200.00	-6400.00 to 3600.00
Week 24						
MK-3102/MK-3102	122	5973.77 (1532.34)	6149.18 (1501.86)	175.41 (116.52)	200.00	-7600.00 to 2800.00
Week 28						
MK-3102/MK-3102	122	5973.77 (1532.34)	6154.10 (1501.52)	180.33 (97.33)	300.00	-5200.00 to 3000.00
Week 36						
MK-3102/MK-3102	118	5973.73 (1526.88)	6156.78 (1396.85)	183.05 (127.91)	300.00	-7300.00 to 3700.00
Week 52						
MK-3102/MK-3102	112	5913.39 (1505.69)	6225.89 (1462.12)	312.50 (139.84)	250.00	-6900.00 to 4600.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	5636.07 (1553.17)	-	-	-	-
Week 28						
Placebo/MK-3102	62	5636.07 (1553.17)	5916.13 (1495.59)	278.69 (112.72)	300.00	-1400.00 to 3600.00
Week 36						
Placebo/MK-3102	61	5625.00 (1563.85)	6065.57 (1603.73)	436.67 (148.25)	350.00	-2600.00 to 5600.00
Week 52						
Placebo/MK-3102	56	5585.45 (1605.82)	5880.36 (1461.06)	296.36 (122.93)	400.00	-2400.00 to 2300.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	5604.62 (1551.25)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	5604.62 (1551.25)	5816.92 (1503.80)	212.31 (104.98)	200.00	-1500.00 to 2800.00
Week 8						
MK-3102/MK-3102	65	5604.62 (1551.25)	5963.08 (1698.86)	358.46 (129.33)	300.00	-2000.00 to 3100.00
Week 12						
MK-3102/MK-3102	62	5609.68 (1585.56)	5898.39 (1594.82)	288.71 (124.35)	150.00	-1800.00 to 3100.00
Week 24						
MK-3102/MK-3102	61	5596.72 (1595.41)	5857.38 (1444.47)	260.66 (106.39)	300.00	-1500.00 to 2300.00
Week 28						
MK-3102/MK-3102	61	5596.72 (1595.41)	6108.20 (1550.52)	511.48 (129.61)	400.00	-2100.00 to 2800.00
Week 36						
MK-3102/MK-3102	61	5596.72 (1595.41)	6263.93 (1728.68)	667.21 (125.20)	700.00	-1300.00 to 3800.00
Week 52						
MK-3102/MK-3102	59	5581.36 (1612.72)	5864.41 (1407.46)	283.05 (136.14)	400.00	-3000.00 to 3000.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	5570.97 (1153.02)	-	-	-	-
Week 28						
Placebo/MK-3102	31	5570.97 (1153.02)	5819.35 (1130.91)	248.39 (117.85)	200.00	-900.00 to 1700.00
Week 36						
Placebo/MK-3102	30	5546.67 (1164.63)	5986.67 (1244.50)	440.00 (129.60)	250.00	-900.00 to 2300.00
Week 52						
Placebo/MK-3102	30	5546.67 (1164.63)	6293.33 (1615.00)	746.67 (202.61)	550.00	-1600.00 to 3000.00

C Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	5986.36 (1682.20)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	5986.36 (1682.20)	6083.33 (1718.64)	96.97 (122.31)	50.00	-2200.00 to 3800.00
Week 8						
MK-3102/MK-3102	66	5986.36 (1682.20)	6101.52 (1626.18)	115.15 (150.70)	100.00	-2400.00 to 5800.00
Week 12						
MK-3102/MK-3102	66	5986.36 (1682.20)	6206.06 (1620.24)	219.70 (144.97)	100.00	-2200.00 to 4000.00
Week 24						
MK-3102/MK-3102	65	6001.54 (1690.74)	6186.15 (1567.63)	184.62 (125.69)	200.00	-2300.00 to 3200.00
Week 28						
MK-3102/MK-3102	65	6001.54 (1690.74)	6304.62 (1783.38)	303.08 (125.69)	200.00	-1700.00 to 3200.00
Week 36						
MK-3102/MK-3102	64	5998.44 (1703.92)	6362.50 (1737.59)	364.06 (128.51)	300.00	-2700.00 to 2900.00
Week 52						
MK-3102/MK-3102	64	5998.44 (1703.92)	6382.81 (1811.04)	384.38 (146.42)	300.00	-2500.00 to 4300.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	6045.45 (1722.12)	-	-	-	-
Week 28						
Placebo/MK-3102	32	6096.88 (1723.74)	6500.00 (1928.73)	403.13 (187.59)	250.00	-1300.00 to 3600.00
Week 36						
Placebo/MK-3102	33	6045.45 (1722.12)	6227.27 (1619.27)	181.82 (176.96)	400.00	-2300.00 to 2000.00
Week 52						
Placebo/MK-3102	33	6045.45 (1722.12)	6118.18 (1582.02)	72.73 (180.29)	200.00	-2700.00 to 1700.00

C Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	5940.00 (1726.43)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	5940.00 (1726.43)	5793.85 (1591.57)	-146.15 (157.96)	100.00	-5000.00 to 4500.00
Week 8						
MK-3102/MK-3102	65	5940.00 (1726.43)	5852.31 (1573.42)	-87.69 (141.17)	100.00	-5100.00 to 2100.00
Week 12						
MK-3102/MK-3102	64	5950.00 (1738.18)	5857.81 (1639.28)	-92.19 (161.01)	0.00	-6700.00 to 2600.00
Week 24						
MK-3102/MK-3102	63	5904.76 (1713.74)	5888.89 (1529.08)	-15.87 (179.79)	200.00	-6800.00 to 3200.00
Week 28						
MK-3102/MK-3102	63	5904.76 (1713.74)	5882.54 (1641.94)	-22.22 (176.04)	200.00	-6300.00 to 2700.00
Week 36						
MK-3102/MK-3102	61	5911.48 (1735.52)	5945.90 (1703.78)	34.43 (177.93)	200.00	-6900.00 to 2800.00
Week 52						
MK-3102/MK-3102	60	5880.00 (1732.52)	5975.00 (1934.05)	95.00 (184.76)	300.00	-4700.00 to 5800.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	5121.21 (1517.56)	-	-	-	-
Week 28						
Placebo/MK-3102	33	5121.21 (1517.56)	5593.94 (1518.42)	472.73 (143.76)	400.00	-800.00 to 3900.00
Week 36						
Placebo/MK-3102	33	5121.21 (1517.56)	5306.06 (1462.65)	184.85 (96.54)	100.00	-1200.00 to 1900.00
Week 52						
Placebo/MK-3102	32	5078.13 (1521.19)	5496.88 (1554.08)	418.75 (137.26)	350.00	-800.00 to 2200.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	5949.25 (1926.17)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	5949.25 (1926.17)	6114.93 (1530.52)	165.67 (176.23)	200.00	-5300.00 to 4900.00
Week 8						
MK-3102/MK-3102	67	5949.25 (1926.17)	5952.24 (1339.76)	2.99 (175.58)	200.00	-6500.00 to 2500.00
Week 12						
MK-3102/MK-3102	67	5949.25 (1926.17)	6116.42 (1499.96)	167.16 (176.07)	200.00	-5700.00 to 3500.00
Week 24						
MK-3102/MK-3102	67	5949.25 (1926.17)	6016.42 (1362.66)	67.16 (167.84)	300.00	-7000.00 to 2600.00
Week 28						
MK-3102/MK-3102	67	5949.25 (1926.17)	6346.27 (1705.90)	397.01 (138.32)	500.00	-2700.00 to 3000.00
Week 36						
MK-3102/MK-3102	67	5949.25 (1926.17)	6386.57 (1407.44)	437.31 (182.16)	400.00	-4800.00 to 5300.00
Week 52						
MK-3102/MK-3102	65	5929.23 (1934.45)	6290.77 (1463.16)	361.54 (185.53)	300.00	-4700.00 to 5100.00

Confidential

Summary of Change from Baseline by Week in WBC (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	5603.57 (2034.24)	-	-	-	-
Week 28						
Placebo/MK-3102	28	5603.57 (2034.24)	5807.14 (1640.67)	203.57 (215.93)	50.00	-3000.00 to 3100.00
Week 36						
Placebo/MK-3102	28	5603.57 (2034.24)	5700.00 (1533.09)	96.43 (276.05)	150.00	-5600.00 to 2900.00
Week 52						
Placebo/MK-3102	28	5603.57 (2034.24)	5646.43 (1978.49)	42.86 (390.48)	-150.00	-6500.00 to 7800.00

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	3497.14 (1220.88)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	3497.14 (1220.88)	3672.53 (1220.57)	175.39 (105.27)	112.80	-7741.80 to 4258.60
Week 8						
MK-3102/MK-3102	125	3502.81 (1224.13)	3650.07 (1136.03)	147.27 (108.78)	169.80	-7919.20 to 3810.10
Week 12						
MK-3102/MK-3102	124	3510.44 (1226.11)	3618.73 (1049.67)	108.29 (99.52)	127.35	-6504.20 to 3136.80
Week 24						
MK-3102/MK-3102	122	3505.86 (1235.02)	3682.03 (1135.28)	176.16 (107.52)	225.25	-7535.60 to 2872.80
Week 28						
MK-3102/MK-3102	122	3505.86 (1235.02)	3692.59 (1167.10)	186.73 (87.67)	262.10	-5209.20 to 2824.30
Week 36						
MK-3102/MK-3102	118	3497.11 (1225.31)	3663.59 (1060.54)	166.48 (116.74)	260.25	-7568.90 to 3230.40
Week 52						
MK-3102/MK-3102	112	3443.83 (1211.92)	3791.03 (1131.05)	347.19 (129.26)	319.45	-7013.70 to 5049.60

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	3273.91 (1222.17)	-	-	-	-
Week 28						
Placebo/MK-3102	62	3273.91 (1222.17)	3615.76 (1159.68)	332.57 (112.41)	348.00	-2110.00 to 4138.80
Week 36						
Placebo/MK-3102	61	3258.02 (1226.12)	3728.27 (1247.56)	463.30 (139.63)	427.20	-2416.00 to 5509.10
Week 52						
Placebo/MK-3102	56	3262.41 (1263.34)	3617.96 (1055.63)	345.82 (115.69)	342.50	-2178.20 to 2201.40

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	3210.75 (1152.80)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	3210.75 (1152.80)	3421.86 (1191.40)	211.11 (93.10)	230.20	-1016.30 to 2454.50
Week 8						
MK-3102/MK-3102	65	3210.75 (1152.80)	3551.72 (1341.31)	340.96 (109.10)	251.90	-1631.80 to 2978.70
Week 12						
MK-3102/MK-3102	62	3201.36 (1174.48)	3443.90 (1253.74)	242.55 (91.72)	178.50	-1028.20 to 2970.60
Week 24						
MK-3102/MK-3102	61	3191.41 (1181.59)	3449.72 (1138.25)	258.31 (82.83)	261.00	-954.70 to 2508.40
Week 28						
MK-3102/MK-3102	61	3191.41 (1181.59)	3646.25 (1220.86)	454.84 (109.59)	272.20	-1261.40 to 3142.50
Week 36						
MK-3102/MK-3102	61	3191.41 (1181.59)	3730.65 (1424.48)	539.24 (103.61)	509.20	-810.70 to 3482.40
Week 52						
MK-3102/MK-3102	59	3188.08 (1201.58)	3508.36 (1154.44)	320.27 (111.08)	307.00	-1985.80 to 3204.00

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	3279.49 (879.52)	-	-	-	-
Week 28						
Placebo/MK-3102	31	3279.49 (879.52)	3596.99 (869.05)	317.50 (105.36)	279.30	-789.40 to 1458.60
Week 36						
Placebo/MK-3102	30	3252.73 (881.62)	3735.40 (983.76)	482.67 (117.14)	369.00	-724.60 to 2259.80
Week 52						
Placebo/MK-3102	30	3252.73 (881.62)	3977.04 (1327.51)	724.31 (195.07)	388.40	-1442.50 to 3131.00

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	3570.91 (1295.52)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	3570.91 (1295.52)	3689.54 (1329.49)	118.63 (108.02)	84.25	-2589.90 to 3239.30
Week 8						
MK-3102/MK-3102	66	3570.91 (1295.52)	3757.89 (1277.07)	186.98 (134.64)	160.10	-2844.00 to 5335.40
Week 12						
MK-3102/MK-3102	66	3570.91 (1295.52)	3832.02 (1343.66)	261.11 (129.70)	164.00	-2527.40 to 4043.90
Week 24						
MK-3102/MK-3102	65	3577.62 (1304.44)	3742.91 (1169.47)	165.29 (105.73)	168.00	-1881.40 to 2187.10
Week 28						
MK-3102/MK-3102	65	3577.62 (1304.44)	3825.26 (1279.22)	247.64 (105.58)	209.20	-1850.20 to 2533.50
Week 36						
MK-3102/MK-3102	64	3575.39 (1314.63)	3910.75 (1354.93)	335.36 (121.09)	253.80	-2579.70 to 2944.00
Week 52						
MK-3102/MK-3102	64	3575.39 (1314.63)	3939.67 (1371.34)	364.27 (129.16)	286.50	-1984.40 to 4273.40

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	3520.69 (1437.36)	-	-	-	-
Week 28						
Placebo/MK-3102	32	3545.05 (1453.42)	3997.14 (1685.69)	452.09 (187.54)	245.75	-992.80 to 4866.40
Week 36						
Placebo/MK-3102	33	3520.69 (1437.36)	3710.48 (1241.74)	189.79 (139.90)	313.80	-1879.70 to 1683.20
Week 52						
Placebo/MK-3102	33	3520.69 (1437.36)	3649.14 (1213.53)	128.45 (154.67)	329.20	-2331.00 to 1901.80

Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	3500.32 (1312.84)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	3500.32 (1312.84)	3448.85 (1360.24)	-51.48 (148.75)	16.50	-4816.20 to 4605.40
Week 8						
MK-3102/MK-3102	65	3500.32 (1312.84)	3483.64 (1231.06)	-16.69 (128.64)	122.60	-4777.20 to 1810.40
Week 12						
MK-3102/MK-3102	64	3516.18 (1316.93)	3413.66 (1170.00)	-102.52 (137.61)	30.55	-5857.70 to 2308.70
Week 24						
MK-3102/MK-3102	63	3486.37 (1305.55)	3477.36 (1069.85)	-9.00 (156.76)	108.00	-5822.40 to 2375.10
Week 28						
MK-3102/MK-3102	63	3486.37 (1305.55)	3455.45 (1116.87)	-30.92 (154.65)	69.50	-5719.80 to 2611.90
Week 36						
MK-3102/MK-3102	61	3505.68 (1315.78)	3507.01 (1287.93)	1.33 (163.99)	185.60	-6521.80 to 2387.00
Week 52						
MK-3102/MK-3102	60	3471.29 (1298.94)	3647.75 (1585.02)	176.46 (187.99)	292.85	-4687.00 to 6957.40

C Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	2910.53 (1197.00)	-	-	-	-
Week 28						
Placebo/MK-3102	33	2910.53 (1197.00)	3330.25 (1155.58)	419.71 (136.55)	366.90	-1019.20 to 3742.10
Week 36						
Placebo/MK-3102	33	2910.53 (1197.00)	3124.81 (1066.90)	214.28 (85.67)	188.40	-1019.70 to 1335.30
Week 52						
Placebo/MK-3102	32	2888.35 (1209.24)	3295.72 (1117.86)	407.37 (115.21)	314.60	-727.80 to 1724.40

C Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	3658.11 (1554.59)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	3658.11 (1554.59)	3824.73 (1273.34)	166.62 (156.30)	135.00	-4596.40 to 4785.70
Week 8						
MK-3102/MK-3102	67	3658.11 (1554.59)	3605.11 (1048.76)	-53.00 (160.13)	61.60	-6315.00 to 3119.00
Week 12						
MK-3102/MK-3102	67	3658.11 (1554.59)	3727.14 (1191.02)	69.03 (151.60)	119.70	-5246.40 to 2143.10
Week 24						
MK-3102/MK-3102	67	3658.11 (1554.59)	3615.98 (971.10)	-42.13 (147.43)	109.40	-6136.00 to 2010.30
Week 28						
MK-3102/MK-3102	67	3658.11 (1554.59)	3853.86 (1334.10)	195.75 (111.59)	213.20	-2405.80 to 2127.70
Week 36						
MK-3102/MK-3102	67	3658.11 (1554.59)	3908.33 (1205.73)	250.22 (169.62)	216.90	-4289.50 to 5434.70
Week 52						
MK-3102/MK-3102	65	3644.90 (1562.82)	3905.88 (1190.47)	260.99 (177.85)	118.20	-4576.60 to 4397.90

C Confidential

Summary of Change from Baseline by Week in Neutrophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	3217.25 (1832.09)	-	-	-	-
Week 28						
Placebo/MK-3102	28	3217.25 (1832.09)	3493.12 (1420.69)	275.87 (223.34)	233.35	-3401.80 to 3463.20
Week 36						
Placebo/MK-3102	28	3217.25 (1832.09)	3327.15 (1227.25)	109.90 (261.31)	172.95	-5667.00 to 2751.80
Week 52						
Placebo/MK-3102	28	3217.25 (1832.09)	3404.96 (1717.16)	187.72 (366.75)	99.10	-6341.40 to 7462.40

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	1937.70 (557.96)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	1937.70 (557.96)	1860.70 (512.20)	-76.99 (24.83)	-40.05	-908.80 to 609.00
Week 8						
MK-3102/MK-3102	125	1928.86 (551.29)	1873.95 (582.05)	-54.92 (30.01)	-35.80	-1324.80 to 812.70
Week 12						
MK-3102/MK-3102	124	1933.49 (551.08)	1931.70 (563.26)	-1.79 (27.45)	16.20	-1049.60 to 750.80
Week 24						
MK-3102/MK-3102	122	1930.33 (553.61)	1911.33 (575.70)	-19.00 (26.26)	-36.75	-965.60 to 1051.60
Week 28						
MK-3102/MK-3102	122	1930.33 (553.61)	1911.78 (535.35)	-18.55 (29.95)	-6.60	-1106.90 to 927.60
Week 36						
MK-3102/MK-3102	118	1937.51 (559.49)	1935.49 (549.08)	-2.02 (29.96)	-15.40	-961.20 to 621.20
Week 52						
MK-3102/MK-3102	112	1932.07 (560.46)	1886.89 (558.59)	-45.17 (27.52)	-46.45	-747.60 to 888.30

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	1873.77 (556.82)	-	-	-	-
Week 28						
Placebo/MK-3102	62	1873.77 (556.82)	1776.62 (494.96)	-89.76 (35.57)	-20.40	-815.10 to 510.80
Week 36						
Placebo/MK-3102	61	1876.44 (561.12)	1792.40 (547.67)	-80.42 (41.98)	-18.20	-975.90 to 592.80
Week 52						
Placebo/MK-3102	56	1831.56 (560.58)	1748.82 (539.09)	-72.77 (39.68)	-136.00	-728.30 to 746.90

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	1873.02 (612.91)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	1873.02 (612.91)	1853.54 (538.93)	-19.48 (41.82)	41.60	-1272.20 to 1193.50
Week 8						
MK-3102/MK-3102	65	1873.02 (612.91)	1883.12 (612.55)	10.10 (52.68)	-39.60	-760.40 to 2025.70
Week 12						
MK-3102/MK-3102	62	1887.18 (623.43)	1898.31 (556.25)	11.13 (51.61)	27.75	-796.10 to 1768.80
Week 24						
MK-3102/MK-3102	61	1884.23 (628.16)	1896.50 (558.79)	12.28 (50.30)	35.80	-907.90 to 1635.00
Week 28						
MK-3102/MK-3102	61	1884.23 (628.16)	1946.10 (571.95)	61.88 (51.24)	24.20	-940.90 to 1550.70
Week 36						
MK-3102/MK-3102	61	1884.23 (628.16)	1993.48 (614.63)	109.25 (52.96)	105.70	-968.50 to 1433.40
Week 52						
MK-3102/MK-3102	59	1868.51 (614.32)	1815.23 (554.79)	-53.28 (52.85)	-71.00	-784.60 to 1612.80

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	1835.98 (553.59)	-	-	-	-
Week 28						
Placebo/MK-3102	31	1835.98 (553.59)	1749.47 (493.02)	-86.51 (42.56)	-100.40	-608.00 to 730.20
Week 36						
Placebo/MK-3102	30	1837.12 (563.02)	1765.89 (545.91)	-71.23 (37.56)	-97.00	-511.00 to 383.10
Week 52						
Placebo/MK-3102	30	1837.12 (563.02)	1780.50 (568.53)	-56.62 (39.18)	-100.50	-457.40 to 451.30

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	1873.16 (585.83)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	1873.16 (585.83)	1843.39 (540.70)	-29.77 (33.07)	-67.35	-500.00 to 636.60
Week 8						
MK-3102/MK-3102	66	1873.16 (585.83)	1807.57 (532.15)	-65.59 (39.31)	-65.15	-800.70 to 619.60
Week 12						
MK-3102/MK-3102	66	1873.16 (585.83)	1823.92 (583.90)	-49.23 (40.67)	-71.05	-762.00 to 1092.30
Week 24						
MK-3102/MK-3102	65	1879.74 (587.92)	1898.77 (530.94)	19.02 (41.26)	18.90	-785.20 to 893.40
Week 28						
MK-3102/MK-3102	65	1879.74 (587.92)	1918.09 (648.72)	38.34 (45.17)	-34.50	-1115.30 to 955.50
Week 36						
MK-3102/MK-3102	64	1878.31 (592.46)	1908.86 (607.86)	30.55 (41.24)	20.20	-938.80 to 1083.10
Week 52						
MK-3102/MK-3102	64	1878.31 (592.46)	1881.62 (589.80)	3.31 (39.90)	-70.20	-475.20 to 920.40

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	1997.19 (534.31)	-	-	-	-
Week 28						
Placebo/MK-3102	32	2018.49 (528.44)	1950.32 (568.62)	-68.17 (70.13)	-52.95	-1132.40 to 819.00
Week 36						
Placebo/MK-3102	33	1997.19 (534.31)	1934.33 (491.61)	-62.85 (55.65)	10.20	-912.40 to 537.40
Week 52						
Placebo/MK-3102	33	1997.19 (534.31)	1910.62 (485.84)	-86.57 (56.18)	-76.20	-959.60 to 445.80

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	1919.28 (560.91)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	1919.28 (560.91)	1798.91 (462.00)	-120.37 (36.65)	-87.90	-965.00 to 620.20
Week 8						
MK-3102/MK-3102	65	1919.28 (560.91)	1821.82 (526.72)	-97.46 (34.61)	-82.90	-870.00 to 492.60
Week 12						
MK-3102/MK-3102	64	1911.75 (562.02)	1897.76 (584.70)	-13.99 (36.53)	-3.35	-796.40 to 961.50
Week 24						
MK-3102/MK-3102	63	1901.31 (560.25)	1846.46 (595.13)	-54.85 (42.81)	8.60	-907.60 to 708.90
Week 28						
MK-3102/MK-3102	63	1901.31 (560.25)	1871.40 (629.01)	-29.92 (41.86)	-63.00	-604.20 to 1425.70
Week 36						
MK-3102/MK-3102	61	1890.21 (565.77)	1885.00 (607.38)	-5.21 (46.23)	81.60	-1295.80 to 818.80
Week 52						
MK-3102/MK-3102	60	1891.69 (570.43)	1775.16 (613.41)	-116.53 (39.51)	-144.80	-822.60 to 594.30

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	1778.62 (582.69)	-	-	-	-
Week 28						
Placebo/MK-3102	33	1778.62 (582.69)	1777.27 (671.23)	-1.34 (44.73)	-70.40	-433.60 to 468.80
Week 36						
Placebo/MK-3102	33	1778.62 (582.69)	1717.67 (656.75)	-60.95 (50.18)	-60.00	-947.70 to 474.90
Week 52						
Placebo/MK-3102	32	1757.21 (578.68)	1721.78 (705.55)	-35.43 (49.04)	-122.05	-441.60 to 764.80

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	1788.54 (498.08)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	1788.54 (498.08)	1750.75 (494.63)	-37.79 (43.18)	27.50	-1558.50 to 631.80
Week 8						
MK-3102/MK-3102	67	1788.54 (498.08)	1814.62 (465.03)	26.08 (38.39)	78.10	-1136.60 to 757.70
Week 12						
MK-3102/MK-3102	67	1788.54 (498.08)	1841.65 (526.50)	53.11 (43.98)	85.20	-715.00 to 1149.50
Week 24						
MK-3102/MK-3102	67	1788.54 (498.08)	1861.20 (554.96)	72.66 (41.14)	93.20	-690.00 to 778.60
Week 28						
MK-3102/MK-3102	67	1788.54 (498.08)	1921.39 (569.90)	132.84 (46.48)	135.60	-650.40 to 1189.10
Week 36						
MK-3102/MK-3102	67	1788.54 (498.08)	1911.50 (531.88)	122.96 (38.10)	143.50	-811.60 to 927.00
Week 52						
MK-3102/MK-3102	65	1780.61 (502.37)	1832.50 (546.85)	51.89 (42.09)	79.00	-776.50 to 920.30

Confidential

Summary of Change from Baseline by Week in Lymphocytes (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	1894.05 (438.38)	-	-	-	-
Week 28						
Placebo/MK-3102	28	1894.05 (438.38)	1817.27 (448.47)	-76.78 (52.63)	-95.90	-666.70 to 513.30
Week 36						
Placebo/MK-3102	28	1894.05 (438.38)	1868.75 (463.97)	-25.31 (48.17)	23.35	-696.00 to 577.70
Week 52						
Placebo/MK-3102	28	1894.05 (438.38)	1734.55 (483.34)	-159.50 (60.34)	-120.10	-1068.00 to 389.90

C Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	319.43 (99.94)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	319.43 (99.94)	335.21 (112.30)	15.78 (6.72)	7.65	-208.60 to 289.20
Week 8						
MK-3102/MK-3102	125	318.50 (99.80)	339.82 (105.03)	21.32 (7.25)	18.10	-219.70 to 265.20
Week 12						
MK-3102/MK-3102	124	319.36 (99.73)	332.81 (100.86)	13.45 (6.64)	12.85	-266.90 to 259.00
Week 24						
MK-3102/MK-3102	122	319.23 (100.08)	340.12 (111.66)	20.89 (7.58)	19.80	-203.00 to 354.50
Week 28						
MK-3102/MK-3102	122	319.23 (100.08)	334.16 (99.92)	14.93 (6.21)	18.10	-262.40 to 189.90
Week 36						
MK-3102/MK-3102	118	319.04 (100.35)	339.15 (101.50)	20.11 (7.42)	13.60	-244.80 to 241.00
Week 52						
MK-3102/MK-3102	112	316.86 (99.79)	336.23 (102.94)	19.37 (8.73)	20.75	-264.00 to 389.10

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	292.07 (89.11)	-	-	-	-
Week 28						
Placebo/MK-3102	62	292.07 (89.11)	331.77 (112.58)	38.25 (9.80)	30.90	-121.90 to 418.20
Week 36						
Placebo/MK-3102	61	292.63 (89.75)	333.43 (112.07)	38.16 (10.15)	29.95	-100.40 to 337.50
Week 52						
Placebo/MK-3102	56	290.26 (87.92)	322.10 (93.29)	30.74 (8.83)	30.00	-135.60 to 195.20

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	311.33 (92.63)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	311.33 (92.63)	328.33 (89.14)	17.00 (10.61)	18.50	-211.70 to 289.90
Week 8						
MK-3102/MK-3102	65	311.33 (92.63)	333.08 (98.27)	21.75 (10.11)	13.20	-191.40 to 248.90
Week 12						
MK-3102/MK-3102	62	311.92 (94.53)	337.36 (80.10)	25.44 (10.71)	26.20	-176.70 to 221.20
Week 24						
MK-3102/MK-3102	61	310.84 (94.93)	310.09 (76.45)	-0.75 (10.06)	-2.10	-237.50 to 181.20
Week 28						
MK-3102/MK-3102	61	310.84 (94.93)	318.60 (81.76)	7.77 (10.31)	9.40	-253.40 to 181.50
Week 36						
MK-3102/MK-3102	61	310.84 (94.93)	341.00 (97.51)	30.17 (10.73)	32.80	-199.70 to 187.40
Week 52						
MK-3102/MK-3102	59	310.85 (95.10)	324.10 (97.33)	13.25 (11.78)	7.60	-186.40 to 287.00

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	293.76 (82.80)	-	-	-	-
Week 28						
Placebo/MK-3102	31	293.76 (82.80)	339.92 (89.56)	46.16 (9.97)	45.00	-51.50 to 180.70
Week 36						
Placebo/MK-3102	30	294.94 (83.95)	334.93 (99.67)	39.99 (9.48)	39.30	-68.60 to 142.40
Week 52						
Placebo/MK-3102	30	294.94 (83.95)	373.55 (135.97)	78.61 (14.03)	66.60	-30.00 to 241.60

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	327.13 (122.85)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	327.13 (122.85)	329.47 (136.23)	2.34 (9.35)	9.55	-257.60 to 209.30
Week 8						
MK-3102/MK-3102	66	327.13 (122.85)	334.28 (113.67)	7.15 (11.06)	16.35	-262.80 to 364.40
Week 12						
MK-3102/MK-3102	66	327.13 (122.85)	350.50 (137.30)	23.38 (10.37)	18.90	-166.70 to 234.00
Week 24						
MK-3102/MK-3102	65	326.78 (123.78)	340.65 (123.20)	13.88 (9.74)	3.60	-125.70 to 284.40
Week 28						
MK-3102/MK-3102	65	326.78 (123.78)	356.12 (155.03)	29.34 (11.27)	28.30	-123.00 to 355.10
Week 36						
MK-3102/MK-3102	64	327.04 (124.74)	338.55 (127.26)	11.51 (9.32)	7.00	-168.90 to 178.80
Week 52						
MK-3102/MK-3102	64	327.04 (124.74)	351.76 (129.39)	24.72 (10.91)	19.10	-231.60 to 339.30

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	322.29 (102.85)	-	-	-	-
Week 28						
Placebo/MK-3102	32	325.08 (103.23)	350.99 (103.63)	25.91 (12.91)	39.70	-170.40 to 160.60
Week 36						
Placebo/MK-3102	33	322.29 (102.85)	353.93 (107.01)	31.64 (11.22)	30.50	-126.40 to 192.00
Week 52						
Placebo/MK-3102	33	322.29 (102.85)	347.97 (96.55)	25.68 (11.24)	31.70	-124.20 to 182.00

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	308.44 (101.35)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	308.44 (101.35)	329.06 (112.42)	20.62 (11.39)	12.80	-265.40 to 254.50
Week 8						
MK-3102/MK-3102	65	308.44 (101.35)	335.43 (111.02)	26.99 (12.26)	30.50	-305.40 to 354.50
Week 12						
MK-3102/MK-3102	64	308.87 (102.09)	330.04 (108.30)	21.17 (10.94)	23.10	-224.10 to 205.80
Week 24						
MK-3102/MK-3102	63	306.65 (101.34)	337.67 (115.21)	31.02 (13.53)	29.20	-339.80 to 461.60
Week 28						
MK-3102/MK-3102	63	306.65 (101.34)	328.58 (112.87)	21.93 (10.00)	22.10	-209.10 to 229.00
Week 36						
MK-3102/MK-3102	61	304.36 (102.09)	328.85 (111.11)	24.49 (12.56)	19.80	-308.70 to 395.50
Week 52						
MK-3102/MK-3102	60	304.62 (102.93)	335.74 (117.61)	31.11 (10.50)	22.80	-153.20 to 289.40

C Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	274.84 (78.78)	-	-	-	-
Week 28						
Placebo/MK-3102	33	274.84 (78.78)	321.76 (96.45)	46.92 (10.38)	43.80	-59.60 to 184.40
Week 36						
Placebo/MK-3102	33	274.84 (78.78)	304.57 (95.56)	29.73 (7.73)	29.80	-59.00 to 124.80
Week 52						
Placebo/MK-3102	32	274.69 (80.04)	305.23 (95.35)	30.54 (10.90)	26.50	-67.80 to 165.20

C Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	310.78 (101.73)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	310.78 (101.73)	353.16 (121.01)	42.38 (10.41)	24.60	-161.70 to 264.80
Week 8						
MK-3102/MK-3102	67	310.78 (101.73)	337.49 (103.74)	26.70 (9.43)	19.50	-130.40 to 213.00
Week 12						
MK-3102/MK-3102	67	310.78 (101.73)	348.88 (104.27)	38.10 (8.01)	36.50	-120.80 to 184.00
Week 24						
MK-3102/MK-3102	67	310.78 (101.73)	336.43 (104.90)	25.65 (9.18)	19.90	-210.70 to 209.60
Week 28						
MK-3102/MK-3102	67	310.78 (101.73)	353.96 (111.23)	43.18 (10.60)	32.10	-175.20 to 296.90
Week 36						
MK-3102/MK-3102	67	310.78 (101.73)	361.34 (102.72)	50.56 (10.22)	56.00	-142.80 to 236.50
Week 52						
MK-3102/MK-3102	65	310.58 (102.13)	354.92 (126.69)	44.33 (12.21)	29.20	-129.80 to 564.10

Confidential

Summary of Change from Baseline by Week in Monocytes (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	299.98 (86.37)	-	-	-	-
Week 28						
Placebo/MK-3102	28	299.98 (86.37)	318.38 (93.12)	18.40 (10.57)	15.05	-85.20 to 135.00
Week 36						
Placebo/MK-3102	28	299.98 (86.37)	318.64 (85.04)	18.66 (12.61)	17.25	-109.80 to 145.20
Week 52						
Placebo/MK-3102	28	299.98 (86.37)	321.75 (107.02)	21.77 (15.39)	8.80	-101.40 to 245.40

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	183.49 (132.15)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	183.49 (132.15)	186.89 (141.46)	3.41 (6.66)	1.95	-208.40 to 293.30
Week 8						
MK-3102/MK-3102	125	183.34 (132.67)	191.64 (146.14)	8.30 (7.60)	-2.90	-205.20 to 627.20
Week 12						
MK-3102/MK-3102	124	182.98 (133.15)	193.27 (145.16)	10.30 (7.66)	3.40	-243.40 to 327.60
Week 24						
MK-3102/MK-3102	122	183.82 (134.06)	182.20 (124.75)	-1.62 (8.05)	5.10	-328.80 to 240.60
Week 28						
MK-3102/MK-3102	122	183.82 (134.06)	182.06 (121.18)	-1.76 (6.66)	1.20	-314.60 to 225.70
Week 36						
MK-3102/MK-3102	118	185.19 (135.85)	183.72 (133.24)	-1.47 (7.75)	-0.40	-291.20 to 232.40
Week 52						
MK-3102/MK-3102	112	186.70 (136.29)	178.33 (130.38)	-8.37 (7.78)	-1.25	-326.00 to 297.80

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	161.05 (102.58)	-	-	-	-
Week 28						
Placebo/MK-3102	62	161.05 (102.58)	158.87 (104.64)	-0.56 (5.67)	-7.00	-77.60 to 172.30
Week 36						
Placebo/MK-3102	61	162.26 (103.00)	177.16 (121.28)	16.70 (8.35)	15.15	-152.50 to 195.00
Week 52						
Placebo/MK-3102	56	165.63 (104.70)	159.50 (89.44)	-4.17 (9.53)	-8.40	-199.00 to 174.40

C Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	173.15 (113.25)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	173.15 (113.25)	178.83 (120.52)	5.69 (7.47)	-7.70	-117.00 to 208.50
Week 8						
MK-3102/MK-3102	65	173.15 (113.25)	162.61 (104.44)	-10.54 (9.05)	-6.70	-208.20 to 215.10
Week 12						
MK-3102/MK-3102	62	172.83 (112.47)	184.83 (147.04)	12.00 (15.05)	-2.45	-169.80 to 726.20
Week 24						
MK-3102/MK-3102	61	173.56 (113.26)	167.18 (111.50)	-6.39 (11.17)	-6.10	-249.70 to 302.40
Week 28						
MK-3102/MK-3102	61	173.56 (113.26)	165.58 (89.89)	-7.98 (8.12)	-12.00	-165.20 to 130.50
Week 36						
MK-3102/MK-3102	61	173.56 (113.26)	165.17 (91.07)	-8.39 (8.83)	-11.90	-181.60 to 172.20
Week 52						
MK-3102/MK-3102	59	177.22 (113.29)	183.38 (160.57)	6.16 (18.46)	-13.90	-243.60 to 835.60

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	135.27 (115.32)	-	-	-	-
Week 28						
Placebo/MK-3102	31	135.27 (115.32)	106.86 (76.46)	-28.41 (8.72)	-14.60	-222.30 to 33.80
Week 36						
Placebo/MK-3102	30	136.21 (117.17)	124.89 (107.11)	-11.32 (6.94)	-16.35	-120.00 to 68.70
Week 52						
Placebo/MK-3102	30	136.21 (117.17)	133.93 (128.53)	-2.28 (11.83)	-9.70	-112.40 to 197.30

C Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	178.07 (123.35)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	178.07 (123.35)	183.50 (142.19)	5.43 (9.61)	1.20	-114.80 to 342.00
Week 8						
MK-3102/MK-3102	66	178.07 (123.35)	167.58 (129.67)	-10.48 (6.81)	-11.30	-160.80 to 152.90
Week 12						
MK-3102/MK-3102	66	178.07 (123.35)	163.32 (114.05)	-14.75 (9.58)	-7.25	-440.00 to 128.40
Week 24						
MK-3102/MK-3102	65	179.89 (123.41)	168.51 (104.67)	-11.37 (7.76)	-7.50	-266.50 to 158.50
Week 28						
MK-3102/MK-3102	65	179.89 (123.41)	170.21 (118.86)	-9.67 (7.71)	-1.70	-184.40 to 165.50
Week 36						
MK-3102/MK-3102	64	180.18 (124.37)	168.49 (125.66)	-11.69 (10.04)	-11.15	-209.90 to 287.10
Week 52						
MK-3102/MK-3102	64	180.18 (124.37)	174.09 (126.72)	-6.09 (9.37)	-13.80	-162.50 to 299.50

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	168.62 (116.58)	-	-	-	-
Week 28						
Placebo/MK-3102	32	170.73 (117.81)	167.31 (110.99)	-3.42 (10.99)	-8.00	-191.20 to 165.10
Week 36						
Placebo/MK-3102	33	168.62 (116.58)	187.42 (109.36)	18.79 (9.83)	23.20	-85.20 to 161.30
Week 52						
Placebo/MK-3102	33	168.62 (116.58)	171.32 (122.84)	2.70 (9.05)	-0.60	-104.20 to 182.00

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	180.05 (118.37)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	180.05 (118.37)	184.19 (126.92)	4.14 (6.77)	-7.00	-127.70 to 212.20
Week 8						
MK-3102/MK-3102	65	180.05 (118.37)	180.38 (138.34)	0.33 (8.50)	0.30	-111.80 to 388.60
Week 12						
MK-3102/MK-3102	64	180.96 (119.08)	185.89 (167.91)	4.93 (13.78)	-5.15	-137.10 to 754.90
Week 24						
MK-3102/MK-3102	63	178.10 (117.81)	196.33 (206.86)	18.23 (20.20)	0.00	-116.00 to 1195.40
Week 28						
MK-3102/MK-3102	63	178.10 (117.81)	195.76 (181.18)	17.66 (17.44)	-9.80	-118.50 to 911.00
Week 36						
MK-3102/MK-3102	61	179.59 (119.45)	193.52 (167.00)	13.93 (14.11)	2.20	-187.40 to 551.40
Week 52						
MK-3102/MK-3102	60	180.38 (120.30)	182.25 (138.03)	1.88 (12.91)	-5.85	-284.40 to 444.40

Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	128.97 (65.89)	-	-	-	-
Week 28						
Placebo/MK-3102	33	128.97 (65.89)	139.05 (83.25)	10.08 (6.33)	9.30	-72.60 to 113.90
Week 36						
Placebo/MK-3102	33	128.97 (65.89)	133.49 (68.48)	4.52 (6.46)	0.00	-41.60 to 94.00
Week 52						
Placebo/MK-3102	32	129.35 (66.91)	146.19 (106.25)	16.85 (13.93)	8.10	-66.00 to 409.60

C Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	158.59 (109.81)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	158.59 (109.81)	155.83 (107.36)	-2.77 (7.51)	-1.10	-174.80 to 235.20
Week 8						
MK-3102/MK-3102	67	158.59 (109.81)	158.64 (126.85)	0.05 (11.12)	-6.90	-283.40 to 538.00
Week 12						
MK-3102/MK-3102	67	158.59 (109.81)	164.72 (110.52)	6.13 (7.76)	12.20	-171.20 to 274.50
Week 24						
MK-3102/MK-3102	67	158.59 (109.81)	169.42 (102.65)	10.83 (6.89)	16.40	-136.50 to 228.60
Week 28						
MK-3102/MK-3102	67	158.59 (109.81)	183.39 (143.94)	24.80 (12.56)	17.00	-107.90 to 724.40
Week 36						
MK-3102/MK-3102	67	158.59 (109.81)	171.74 (125.34)	13.14 (9.97)	7.00	-145.20 to 427.10
Week 52						
MK-3102/MK-3102	65	159.86 (111.21)	163.17 (128.09)	3.31 (10.55)	2.40	-151.20 to 456.80

C Confidential

Summary of Change from Baseline by Week in Eosinophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	157.50 (100.55)	-	-	-	-
Week 28						
Placebo/MK-3102	28	157.50 (100.55)	144.93 (103.73)	-12.57 (10.11)	-10.25	-161.20 to 131.80
Week 36						
Placebo/MK-3102	28	157.50 (100.55)	151.05 (101.43)	-6.45 (9.22)	-8.50	-110.40 to 126.80
Week 52						
Placebo/MK-3102	28	157.50 (100.55)	150.49 (87.07)	-7.01 (12.45)	0.30	-187.20 to 98.90

C Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	34.48 (21.49)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	34.48 (21.49)	36.73 (22.26)	2.25 (1.32)	0.70	-28.30 to 60.60
Week 8						
MK-3102/MK-3102	125	34.49 (21.57)	35.72 (22.21)	1.22 (1.20)	0.80	-33.20 to 42.60
Week 12						
MK-3102/MK-3102	124	34.38 (21.62)	35.59 (22.24)	1.21 (1.48)	0.00	-38.00 to 91.80
Week 24						
MK-3102/MK-3102	122	34.52 (21.75)	33.51 (21.17)	-1.01 (1.15)	0.55	-45.90 to 26.20
Week 28						
MK-3102/MK-3102	122	34.52 (21.75)	33.50 (20.07)	-1.02 (1.33)	0.00	-43.20 to 51.40
Week 36						
MK-3102/MK-3102	118	34.88 (21.95)	34.83 (20.82)	-0.04 (1.51)	0.10	-73.60 to 57.60
Week 52						
MK-3102/MK-3102	112	33.93 (18.07)	33.41 (20.81)	-0.52 (1.33)	-0.10	-33.30 to 48.10

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	35.27 (21.72)	-	-	-	-
Week 28						
Placebo/MK-3102	62	35.27 (21.72)	33.11 (19.89)	-1.81 (1.72)	-0.80	-32.00 to 31.60
Week 36						
Placebo/MK-3102	61	35.65 (21.70)	34.32 (20.85)	-1.07 (1.54)	-1.55	-32.20 to 30.60
Week 52						
Placebo/MK-3102	56	35.60 (21.05)	31.97 (19.42)	-3.26 (1.53)	-1.20	-31.00 to 31.60

C Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	36.37 (19.62)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	36.37 (19.62)	34.35 (19.00)	-2.02 (1.83)	-0.40	-35.30 to 32.00
Week 8						
MK-3102/MK-3102	65	36.37 (19.62)	32.56 (17.60)	-3.81 (1.85)	-2.30	-32.10 to 32.30
Week 12						
MK-3102/MK-3102	62	36.40 (19.98)	33.99 (21.28)	-2.41 (2.01)	-1.85	-38.60 to 48.60
Week 24						
MK-3102/MK-3102	61	36.68 (20.03)	33.89 (19.14)	-2.79 (1.81)	-1.80	-30.10 to 42.00
Week 28						
MK-3102/MK-3102	61	36.68 (20.03)	31.65 (14.37)	-5.03 (1.73)	-3.60	-48.00 to 25.20
Week 36						
MK-3102/MK-3102	61	36.68 (20.03)	33.63 (15.04)	-3.05 (2.03)	-3.40	-53.40 to 39.00
Week 52						
MK-3102/MK-3102	59	36.70 (19.79)	33.34 (18.29)	-3.36 (2.04)	-2.20	-42.80 to 39.00

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	26.46 (19.10)	-	-	-	-
Week 28						
Placebo/MK-3102	31	26.46 (19.10)	26.10 (23.51)	-0.36 (2.06)	-0.40	-28.00 to 30.50
Week 36						
Placebo/MK-3102	30	25.66 (18.89)	25.56 (18.59)	-0.10 (2.12)	0.00	-27.40 to 31.20
Week 52						
Placebo/MK-3102	30	25.66 (18.89)	28.32 (18.68)	2.66 (2.00)	1.50	-21.50 to 22.30

C Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	37.10 (21.28)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	37.10 (21.28)	37.43 (20.47)	0.33 (1.87)	-0.40	-46.80 to 51.00
Week 8						
MK-3102/MK-3102	66	37.10 (21.28)	34.20 (22.39)	-2.90 (1.93)	-2.00	-45.10 to 46.30
Week 12						
MK-3102/MK-3102	66	37.10 (21.28)	36.30 (21.92)	-0.80 (1.72)	-0.90	-41.30 to 37.90
Week 24						
MK-3102/MK-3102	65	37.52 (21.17)	35.31 (19.36)	-2.21 (1.85)	-1.00	-49.00 to 29.60
Week 28						
MK-3102/MK-3102	65	37.52 (21.17)	34.94 (20.52)	-2.57 (1.84)	-0.80	-61.10 to 24.10
Week 36						
MK-3102/MK-3102	64	37.52 (21.34)	35.86 (20.96)	-1.66 (1.79)	-0.15	-58.40 to 31.20
Week 52						
MK-3102/MK-3102	64	37.52 (21.34)	35.68 (18.34)	-1.84 (1.82)	-0.20	-41.00 to 40.80

C Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	36.66 (19.96)	-	-	-	-
Week 28						
Placebo/MK-3102	32	37.53 (19.64)	34.24 (16.64)	-3.29 (2.95)	-0.70	-50.60 to 25.50
Week 36						
Placebo/MK-3102	33	36.66 (19.96)	41.12 (23.81)	4.45 (3.66)	1.00	-55.00 to 41.70
Week 52						
Placebo/MK-3102	33	36.66 (19.96)	39.12 (25.21)	2.46 (3.39)	-0.30	-36.00 to 58.80

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	31.91 (22.29)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	31.91 (22.29)	32.84 (21.88)	0.94 (2.41)	1.00	-101.00 to 57.20
Week 8						
MK-3102/MK-3102	65	31.91 (22.29)	31.04 (16.68)	-0.86 (2.12)	0.20	-102.50 to 32.80
Week 12						
MK-3102/MK-3102	64	32.24 (22.30)	30.46 (20.23)	-1.78 (2.52)	-0.45	-102.00 to 46.20
Week 24						
MK-3102/MK-3102	63	32.33 (22.46)	31.07 (21.41)	-1.27 (2.29)	-1.00	-91.20 to 50.30
Week 28						
MK-3102/MK-3102	63	32.33 (22.46)	31.36 (16.48)	-0.97 (2.22)	0.30	-88.20 to 34.80
Week 36						
MK-3102/MK-3102	61	31.63 (22.32)	31.52 (20.50)	-0.11 (2.24)	1.70	-92.40 to 51.10
Week 52						
MK-3102/MK-3102	60	32.03 (22.29)	34.10 (19.97)	2.08 (2.36)	2.75	-100.00 to 31.40

C Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	28.25 (16.00)	-	-	-	-
Week 28						
Placebo/MK-3102	33	28.25 (16.00)	25.61 (12.71)	-2.65 (1.62)	-0.50	-22.00 to 12.10
Week 36						
Placebo/MK-3102	33	28.25 (16.00)	25.52 (15.37)	-2.74 (2.22)	-3.00	-28.60 to 29.20
Week 52						
Placebo/MK-3102	32	28.53 (16.17)	27.96 (18.91)	-0.57 (2.10)	-1.35	-15.60 to 33.30

C Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	33.22 (18.45)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	33.22 (18.45)	30.46 (20.37)	-2.76 (1.90)	-2.40	-51.20 to 31.20
Week 8						
MK-3102/MK-3102	67	33.22 (18.45)	36.38 (21.71)	3.16 (1.57)	1.50	-20.00 to 48.40
Week 12						
MK-3102/MK-3102	67	33.22 (18.45)	34.03 (17.88)	0.81 (1.63)	-0.40	-23.20 to 30.20
Week 24						
MK-3102/MK-3102	67	33.22 (18.45)	33.38 (17.06)	0.16 (1.69)	0.00	-37.00 to 30.30
Week 28						
MK-3102/MK-3102	67	33.22 (18.45)	33.67 (21.84)	0.45 (1.86)	-0.40	-43.60 to 71.10
Week 36						
MK-3102/MK-3102	67	33.22 (18.45)	33.65 (15.76)	0.43 (1.67)	0.40	-32.70 to 29.20
Week 52						
MK-3102/MK-3102	65	33.27 (18.73)	34.30 (19.32)	1.02 (1.66)	-0.20	-29.90 to 30.30

Confidential

Summary of Change from Baseline by Week in Basophils (cells/microL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	34.79 (26.73)	-	-	-	-
Week 28						
Placebo/MK-3102	28	34.79 (26.73)	33.44 (22.84)	-1.35 (3.26)	0.25	-49.50 to 30.00
Week 36						
Placebo/MK-3102	28	34.79 (26.73)	34.41 (29.18)	-0.38 (2.56)	0.20	-23.20 to 28.80
Week 52						
Placebo/MK-3102	28	34.79 (26.73)	34.66 (23.62)	-0.12 (2.11)	0.35	-20.80 to 22.20

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	7.25 (0.39)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	7.25 (0.39)	7.28 (0.38)	0.03 (0.03)	0.00	-0.90 to 0.90
Week 8						
MK-3102/MK-3102	125	7.25 (0.39)	7.30 (0.39)	0.05 (0.03)	0.00	-0.90 to 1.40
Week 12						
MK-3102/MK-3102	124	7.25 (0.40)	7.28 (0.38)	0.02 (0.03)	0.00	-0.80 to 0.90
Week 24						
MK-3102/MK-3102	122	7.26 (0.40)	7.24 (0.37)	-0.02 (0.03)	0.00	-0.90 to 1.10
Week 28						
MK-3102/MK-3102	122	7.26 (0.40)	7.29 (0.38)	0.03 (0.03)	0.10	-0.80 to 0.80
Week 36						
MK-3102/MK-3102	118	7.26 (0.40)	7.31 (0.36)	0.05 (0.03)	0.00	-1.00 to 1.00
Week 52						
MK-3102/MK-3102	112	7.26 (0.39)	7.38 (0.33)	0.12 (0.03)	0.10	-0.90 to 1.00

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	7.18 (0.42)	-	-	-	-
Week 28						
Placebo/MK-3102	62	7.18 (0.42)	7.26 (0.43)	0.10 (0.04)	0.10	-0.60 to 0.80
Week 36						
Placebo/MK-3102	61	7.17 (0.42)	7.29 (0.40)	0.12 (0.03)	0.10	-0.60 to 0.60
Week 52						
Placebo/MK-3102	56	7.15 (0.43)	7.35 (0.48)	0.21 (0.04)	0.20	-0.40 to 1.10

C Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	7.33 (0.49)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	7.33 (0.49)	7.37 (0.47)	0.04 (0.05)	0.00	-1.20 to 0.80
Week 8						
MK-3102/MK-3102	65	7.33 (0.49)	7.41 (0.44)	0.08 (0.05)	0.10	-1.30 to 1.40
Week 12						
MK-3102/MK-3102	62	7.35 (0.48)	7.46 (0.51)	0.11 (0.05)	0.15	-1.20 to 0.70
Week 24						
MK-3102/MK-3102	61	7.35 (0.48)	7.34 (0.48)	-0.01 (0.06)	0.00	-1.40 to 1.00
Week 28						
MK-3102/MK-3102	61	7.35 (0.48)	7.35 (0.45)	-0.01 (0.06)	0.10	-1.40 to 0.70
Week 36						
MK-3102/MK-3102	61	7.35 (0.48)	7.40 (0.47)	0.05 (0.06)	0.10	-1.30 to 0.90
Week 52						
MK-3102/MK-3102	59	7.36 (0.49)	7.46 (0.41)	0.10 (0.05)	0.20	-0.80 to 0.80

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	7.35 (0.45)	-	-	-	-
Week 28						
Placebo/MK-3102	31	7.35 (0.45)	7.33 (0.46)	-0.02 (0.06)	0.00	-0.60 to 0.50
Week 36						
Placebo/MK-3102	31	7.35 (0.45)	7.43 (0.40)	0.08 (0.05)	0.10	-0.50 to 0.60
Week 52						
Placebo/MK-3102	30	7.32 (0.44)	7.53 (0.47)	0.21 (0.06)	0.20	-0.60 to 1.00

C Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	7.33 (0.37)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	7.33 (0.37)	7.38 (0.42)	0.05 (0.04)	0.00	-0.60 to 1.10
Week 8						
MK-3102/MK-3102	66	7.33 (0.37)	7.41 (0.41)	0.08 (0.04)	0.10	-0.60 to 1.00
Week 12						
MK-3102/MK-3102	66	7.33 (0.37)	7.34 (0.39)	0.02 (0.04)	0.00	-0.80 to 0.80
Week 24						
MK-3102/MK-3102	65	7.32 (0.37)	7.28 (0.42)	-0.04 (0.04)	0.00	-1.20 to 0.70
Week 28						
MK-3102/MK-3102	65	7.32 (0.37)	7.25 (0.39)	-0.07 (0.04)	0.00	-1.00 to 0.70
Week 36						
MK-3102/MK-3102	64	7.31 (0.36)	7.34 (0.45)	0.03 (0.05)	0.00	-0.80 to 1.50
Week 52						
MK-3102/MK-3102	64	7.31 (0.36)	7.33 (0.37)	0.02 (0.04)	0.05	-0.70 to 0.80

Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	7.18 (0.47)	-	-	-	-
Week 28						
Placebo/MK-3102	32	7.18 (0.48)	7.17 (0.48)	-0.01 (0.04)	0.00	-0.50 to 0.40
Week 36						
Placebo/MK-3102	33	7.18 (0.47)	7.33 (0.48)	0.14 (0.05)	0.10	-0.50 to 0.90
Week 52						
Placebo/MK-3102	33	7.18 (0.47)	7.30 (0.44)	0.12 (0.05)	0.10	-0.50 to 0.80

C Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	7.35 (0.45)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	7.35 (0.45)	7.32 (0.43)	-0.03 (0.04)	0.00	-0.70 to 0.80
Week 8						
MK-3102/MK-3102	65	7.35 (0.45)	7.37 (0.50)	0.02 (0.05)	0.00	-0.70 to 1.00
Week 12						
MK-3102/MK-3102	64	7.35 (0.45)	7.33 (0.45)	-0.02 (0.04)	-0.10	-0.80 to 1.00
Week 24						
MK-3102/MK-3102	63	7.35 (0.46)	7.21 (0.42)	-0.13 (0.04)	-0.10	-0.90 to 0.70
Week 28						
MK-3102/MK-3102	63	7.35 (0.46)	7.27 (0.38)	-0.08 (0.05)	-0.20	-1.00 to 0.80
Week 36						
MK-3102/MK-3102	61	7.35 (0.46)	7.27 (0.37)	-0.08 (0.05)	-0.10	-0.80 to 1.00
Week 52						
MK-3102/MK-3102	60	7.35 (0.47)	7.34 (0.38)	-0.01 (0.05)	0.00	-0.70 to 1.00

C Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	7.06 (0.36)	-	-	-	-
Week 28						
Placebo/MK-3102	33	7.06 (0.36)	7.10 (0.41)	0.04 (0.05)	0.00	-0.60 to 0.70
Week 36						
Placebo/MK-3102	33	7.06 (0.36)	7.21 (0.41)	0.15 (0.06)	0.10	-0.50 to 1.40
Week 52						
Placebo/MK-3102	32	7.05 (0.35)	7.24 (0.43)	0.19 (0.06)	0.20	-0.60 to 1.20

C Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	7.30 (0.40)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	7.30 (0.40)	7.31 (0.34)	0.01 (0.04)	0.00	-0.70 to 0.80
Week 8						
MK-3102/MK-3102	67	7.30 (0.40)	7.34 (0.38)	0.03 (0.04)	0.00	-0.70 to 0.90
Week 12						
MK-3102/MK-3102	67	7.30 (0.40)	7.38 (0.39)	0.08 (0.05)	0.10	-0.80 to 1.10
Week 24						
MK-3102/MK-3102	67	7.30 (0.40)	7.29 (0.37)	-0.01 (0.05)	0.00	-0.80 to 0.90
Week 28						
MK-3102/MK-3102	67	7.30 (0.40)	7.30 (0.35)	-0.00 (0.05)	0.00	-1.00 to 0.60
Week 36						
MK-3102/MK-3102	67	7.30 (0.40)	7.36 (0.38)	0.05 (0.04)	0.00	-0.70 to 0.90
Week 52						
MK-3102/MK-3102	65	7.31 (0.40)	7.38 (0.38)	0.06 (0.05)	0.10	-1.00 to 0.90

C Confidential

Summary of Change from Baseline by Week in Protein (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	7.05 (0.38)	-	-	-	-
Week 28						
Placebo/MK-3102	28	7.05 (0.38)	7.03 (0.35)	-0.03 (0.05)	-0.10	-0.50 to 0.50
Week 36						
Placebo/MK-3102	28	7.05 (0.38)	7.10 (0.38)	0.05 (0.04)	0.10	-0.40 to 0.40
Week 52						
Placebo/MK-3102	28	7.05 (0.38)	7.19 (0.35)	0.14 (0.08)	0.00	-0.50 to 0.90

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	4.39 (0.23)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	4.39 (0.23)	4.40 (0.25)	0.01 (0.02)	0.00	-0.40 to 0.60
Week 8						
MK-3102/MK-3102	125	4.39 (0.23)	4.39 (0.25)	0.00 (0.02)	0.00	-0.50 to 0.70
Week 12						
MK-3102/MK-3102	124	4.39 (0.23)	4.39 (0.24)	-0.00 (0.02)	0.00	-0.60 to 0.50
Week 24						
MK-3102/MK-3102	122	4.39 (0.23)	4.35 (0.26)	-0.04 (0.02)	0.00	-0.70 to 0.50
Week 28						
MK-3102/MK-3102	122	4.39 (0.23)	4.41 (0.25)	0.02 (0.02)	0.00	-0.50 to 0.50
Week 36						
MK-3102/MK-3102	118	4.40 (0.23)	4.42 (0.23)	0.03 (0.02)	0.00	-0.70 to 0.50
Week 52						
MK-3102/MK-3102	112	4.39 (0.23)	4.46 (0.24)	0.06 (0.02)	0.05	-0.60 to 0.60

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	4.33 (0.24)	-	-	-	-
Week 28						
Placebo/MK-3102	62	4.33 (0.24)	4.38 (0.25)	0.06 (0.02)	0.10	-0.40 to 0.50
Week 36						
Placebo/MK-3102	61	4.33 (0.24)	4.38 (0.22)	0.05 (0.02)	0.00	-0.20 to 0.40
Week 52						
Placebo/MK-3102	56	4.31 (0.24)	4.40 (0.24)	0.09 (0.02)	0.00	-0.20 to 0.50

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	4.50 (0.27)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	4.50 (0.27)	4.51 (0.28)	0.01 (0.03)	0.00	-0.70 to 0.70
Week 8						
MK-3102/MK-3102	65	4.50 (0.27)	4.53 (0.23)	0.03 (0.03)	0.00	-0.70 to 0.70
Week 12						
MK-3102/MK-3102	62	4.50 (0.27)	4.50 (0.27)	0.00 (0.03)	0.00	-0.60 to 0.60
Week 24						
MK-3102/MK-3102	61	4.51 (0.27)	4.47 (0.27)	-0.04 (0.03)	0.00	-0.70 to 0.60
Week 28						
MK-3102/MK-3102	61	4.51 (0.27)	4.49 (0.25)	-0.02 (0.03)	0.00	-0.90 to 0.40
Week 36						
MK-3102/MK-3102	61	4.51 (0.27)	4.52 (0.25)	0.01 (0.03)	0.00	-0.80 to 0.50
Week 52						
MK-3102/MK-3102	59	4.51 (0.27)	4.52 (0.23)	0.01 (0.03)	0.10	-0.60 to 0.70

Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	4.42 (0.20)	-	-	-	-
Week 28						
Placebo/MK-3102	31	4.42 (0.20)	4.39 (0.28)	-0.03 (0.03)	0.00	-0.50 to 0.30
Week 36						
Placebo/MK-3102	31	4.42 (0.20)	4.47 (0.24)	0.05 (0.03)	0.00	-0.30 to 0.40
Week 52						
Placebo/MK-3102	30	4.42 (0.20)	4.45 (0.29)	0.03 (0.04)	0.00	-0.50 to 0.70

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	4.47 (0.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	4.47 (0.22)	4.47 (0.26)	0.01 (0.03)	0.00	-0.50 to 0.70
Week 8						
MK-3102/MK-3102	66	4.47 (0.22)	4.47 (0.23)	0.00 (0.02)	0.00	-0.50 to 0.50
Week 12						
MK-3102/MK-3102	66	4.47 (0.22)	4.43 (0.22)	-0.03 (0.03)	0.00	-0.60 to 0.50
Week 24						
MK-3102/MK-3102	65	4.46 (0.23)	4.41 (0.23)	-0.06 (0.03)	-0.10	-0.70 to 0.50
Week 28						
MK-3102/MK-3102	65	4.46 (0.23)	4.41 (0.20)	-0.05 (0.02)	0.00	-0.60 to 0.30
Week 36						
MK-3102/MK-3102	64	4.46 (0.23)	4.49 (0.26)	0.02 (0.03)	0.00	-0.50 to 0.90
Week 52						
MK-3102/MK-3102	64	4.46 (0.23)	4.43 (0.25)	-0.03 (0.02)	0.00	-0.70 to 0.40

Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	4.45 (0.18)	-	-	-	-
Week 28						
Placebo/MK-3102	32	4.45 (0.18)	4.42 (0.24)	-0.03 (0.03)	0.00	-0.40 to 0.30
Week 36						
Placebo/MK-3102	33	4.45 (0.18)	4.50 (0.23)	0.05 (0.04)	0.10	-0.60 to 0.40
Week 52						
Placebo/MK-3102	33	4.45 (0.18)	4.44 (0.20)	-0.00 (0.03)	0.00	-0.40 to 0.30

Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	4.39 (0.27)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	4.39 (0.27)	4.38 (0.28)	-0.00 (0.02)	0.00	-0.40 to 0.60
Week 8						
MK-3102/MK-3102	65	4.39 (0.27)	4.39 (0.26)	0.00 (0.03)	0.00	-0.50 to 0.60
Week 12						
MK-3102/MK-3102	64	4.39 (0.27)	4.36 (0.27)	-0.03 (0.03)	0.00	-0.60 to 0.70
Week 24						
MK-3102/MK-3102	63	4.40 (0.27)	4.32 (0.26)	-0.08 (0.02)	-0.10	-0.60 to 0.30
Week 28						
MK-3102/MK-3102	63	4.40 (0.27)	4.37 (0.26)	-0.03 (0.03)	-0.10	-0.90 to 0.50
Week 36						
MK-3102/MK-3102	61	4.40 (0.28)	4.39 (0.27)	-0.01 (0.03)	0.00	-0.50 to 0.50
Week 52						
MK-3102/MK-3102	60	4.40 (0.28)	4.40 (0.29)	0.00 (0.03)	0.00	-0.60 to 0.70

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	4.31 (0.23)	-	-	-	-
Week 28						
Placebo/MK-3102	33	4.31 (0.23)	4.31 (0.31)	-0.01 (0.03)	0.00	-0.40 to 0.30
Week 36						
Placebo/MK-3102	33	4.31 (0.23)	4.39 (0.24)	0.08 (0.03)	0.10	-0.30 to 0.60
Week 52						
Placebo/MK-3102	32	4.30 (0.23)	4.32 (0.31)	0.02 (0.04)	0.00	-0.60 to 0.40

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	4.45 (0.31)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	4.45 (0.31)	4.44 (0.25)	-0.01 (0.03)	0.00	-0.50 to 0.50
Week 8						
MK-3102/MK-3102	67	4.45 (0.31)	4.42 (0.28)	-0.03 (0.02)	0.00	-0.50 to 0.40
Week 12						
MK-3102/MK-3102	67	4.45 (0.31)	4.43 (0.24)	-0.02 (0.03)	0.00	-0.60 to 0.50
Week 24						
MK-3102/MK-3102	67	4.45 (0.31)	4.40 (0.28)	-0.05 (0.03)	-0.10	-0.60 to 0.50
Week 28						
MK-3102/MK-3102	67	4.45 (0.31)	4.40 (0.25)	-0.05 (0.03)	0.00	-0.60 to 0.50
Week 36						
MK-3102/MK-3102	67	4.45 (0.31)	4.45 (0.27)	0.00 (0.02)	0.00	-0.40 to 0.50
Week 52						
MK-3102/MK-3102	65	4.45 (0.31)	4.40 (0.28)	-0.05 (0.03)	0.00	-0.70 to 0.60

C Confidential

Summary of Change from Baseline by Week in Albumin (gm/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	4.29 (0.25)	-	-	-	-
Week 28						
Placebo/MK-3102	28	4.29 (0.25)	4.26 (0.21)	-0.04 (0.03)	-0.10	-0.30 to 0.30
Week 36						
Placebo/MK-3102	28	4.29 (0.25)	4.33 (0.25)	0.04 (0.03)	0.00	-0.30 to 0.30
Week 52						
Placebo/MK-3102	28	4.29 (0.25)	4.35 (0.26)	0.06 (0.05)	0.00	-0.50 to 0.60

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	0.64 (0.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	0.64 (0.22)	0.66 (0.22)	0.02 (0.01)	0.00	-0.40 to 0.40
Week 8						
MK-3102/MK-3102	125	0.64 (0.22)	0.62 (0.21)	-0.02 (0.01)	0.00	-0.50 to 0.60
Week 12						
MK-3102/MK-3102	124	0.64 (0.22)	0.63 (0.20)	-0.01 (0.02)	0.00	-0.50 to 0.50
Week 24						
MK-3102/MK-3102	122	0.64 (0.22)	0.67 (0.24)	0.04 (0.02)	0.10	-0.50 to 0.50
Week 28						
MK-3102/MK-3102	122	0.64 (0.22)	0.67 (0.24)	0.03 (0.02)	0.00	-0.40 to 0.50
Week 36						
MK-3102/MK-3102	118	0.64 (0.22)	0.66 (0.23)	0.02 (0.01)	0.00	-0.40 to 0.40
Week 52						
MK-3102/MK-3102	112	0.64 (0.22)	0.69 (0.24)	0.04 (0.02)	0.10	-0.60 to 0.50

Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	0.77 (0.29)	-	-	-	-
Week 28						
Placebo/MK-3102	62	0.77 (0.29)	0.75 (0.28)	-0.02 (0.03)	0.00	-0.70 to 0.40
Week 36						
Placebo/MK-3102	61	0.77 (0.29)	0.70 (0.22)	-0.07 (0.02)	-0.05	-0.70 to 0.30
Week 52						
Placebo/MK-3102	56	0.77 (0.30)	0.72 (0.21)	-0.05 (0.03)	0.00	-0.70 to 0.60

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	0.69 (0.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	0.69 (0.22)	0.72 (0.24)	0.04 (0.02)	0.00	-0.30 to 0.40
Week 8						
MK-3102/MK-3102	65	0.69 (0.22)	0.70 (0.25)	0.02 (0.02)	0.00	-0.30 to 0.50
Week 12						
MK-3102/MK-3102	62	0.69 (0.23)	0.71 (0.26)	0.02 (0.02)	0.00	-0.30 to 0.60
Week 24						
MK-3102/MK-3102	61	0.69 (0.23)	0.70 (0.26)	0.02 (0.02)	0.00	-0.40 to 0.40
Week 28						
MK-3102/MK-3102	61	0.69 (0.23)	0.73 (0.22)	0.04 (0.02)	0.10	-0.50 to 0.40
Week 36						
MK-3102/MK-3102	61	0.69 (0.23)	0.73 (0.26)	0.04 (0.02)	0.00	-0.40 to 0.40
Week 52						
MK-3102/MK-3102	59	0.69 (0.23)	0.73 (0.26)	0.04 (0.02)	0.00	-0.50 to 0.40

Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	0.87 (0.43)	-	-	-	-
Week 28						
Placebo/MK-3102	31	0.87 (0.43)	0.84 (0.40)	-0.04 (0.04)	0.00	-0.70 to 0.40
Week 36						
Placebo/MK-3102	31	0.87 (0.43)	0.85 (0.45)	-0.03 (0.04)	0.00	-0.50 to 0.90
Week 52						
Placebo/MK-3102	30	0.88 (0.43)	0.87 (0.46)	-0.02 (0.05)	-0.05	-0.50 to 0.90

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	0.62 (0.28)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	0.62 (0.28)	0.65 (0.25)	0.02 (0.02)	0.00	-0.60 to 0.30
Week 8						
MK-3102/MK-3102	66	0.62 (0.28)	0.68 (0.29)	0.05 (0.02)	0.05	-0.30 to 0.70
Week 12						
MK-3102/MK-3102	66	0.62 (0.28)	0.69 (0.29)	0.07 (0.02)	0.10	-0.30 to 0.70
Week 24						
MK-3102/MK-3102	65	0.62 (0.28)	0.67 (0.25)	0.04 (0.02)	0.00	-0.40 to 0.40
Week 28						
MK-3102/MK-3102	65	0.62 (0.28)	0.72 (0.28)	0.09 (0.02)	0.10	-0.40 to 0.70
Week 36						
MK-3102/MK-3102	64	0.63 (0.28)	0.69 (0.32)	0.06 (0.03)	0.10	-0.60 to 0.80
Week 52						
MK-3102/MK-3102	64	0.63 (0.28)	0.65 (0.31)	0.02 (0.02)	0.00	-0.40 to 0.60

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	0.83 (0.34)	-	-	-	-
Week 28						
Placebo/MK-3102	32	0.84 (0.34)	0.80 (0.39)	-0.04 (0.04)	-0.10	-0.60 to 0.60
Week 36						
Placebo/MK-3102	33	0.83 (0.34)	0.75 (0.34)	-0.08 (0.04)	0.00	-0.50 to 0.30
Week 52						
Placebo/MK-3102	33	0.83 (0.34)	0.75 (0.36)	-0.07 (0.03)	-0.10	-0.40 to 0.30

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	0.58 (0.19)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	0.58 (0.19)	0.63 (0.21)	0.05 (0.02)	0.10	-0.20 to 0.50
Week 8						
MK-3102/MK-3102	65	0.58 (0.19)	0.63 (0.22)	0.05 (0.02)	0.00	-0.30 to 0.70
Week 12						
MK-3102/MK-3102	64	0.58 (0.20)	0.62 (0.20)	0.03 (0.02)	0.00	-0.30 to 0.40
Week 24						
MK-3102/MK-3102	63	0.59 (0.20)	0.62 (0.18)	0.03 (0.02)	0.00	-0.40 to 0.70
Week 28						
MK-3102/MK-3102	63	0.59 (0.20)	0.65 (0.23)	0.07 (0.02)	0.10	-0.40 to 0.50
Week 36						
MK-3102/MK-3102	61	0.59 (0.20)	0.63 (0.19)	0.04 (0.02)	0.00	-0.50 to 0.60
Week 52						
MK-3102/MK-3102	60	0.59 (0.19)	0.60 (0.23)	0.02 (0.02)	0.00	-0.30 to 0.40

C Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	0.65 (0.24)	-	-	-	-
Week 28						
Placebo/MK-3102	33	0.65 (0.24)	0.66 (0.31)	0.02 (0.03)	0.00	-0.40 to 0.80
Week 36						
Placebo/MK-3102	33	0.65 (0.24)	0.67 (0.23)	0.02 (0.03)	0.00	-0.30 to 0.30
Week 52						
Placebo/MK-3102	32	0.65 (0.24)	0.61 (0.17)	-0.04 (0.03)	0.00	-0.40 to 0.30

Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	0.70 (0.26)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	0.70 (0.26)	0.73 (0.31)	0.03 (0.03)	0.00	-0.50 to 0.70
Week 8						
MK-3102/MK-3102	67	0.70 (0.26)	0.72 (0.30)	0.02 (0.02)	0.00	-0.40 to 0.50
Week 12						
MK-3102/MK-3102	67	0.70 (0.26)	0.72 (0.30)	0.01 (0.02)	0.00	-0.40 to 0.60
Week 24						
MK-3102/MK-3102	67	0.70 (0.26)	0.79 (0.35)	0.08 (0.03)	0.10	-0.40 to 1.20
Week 28						
MK-3102/MK-3102	67	0.70 (0.26)	0.76 (0.36)	0.06 (0.03)	0.10	-0.50 to 1.10
Week 36						
MK-3102/MK-3102	67	0.70 (0.26)	0.78 (0.34)	0.08 (0.02)	0.10	-0.50 to 0.70
Week 52						
MK-3102/MK-3102	65	0.68 (0.24)	0.72 (0.32)	0.04 (0.03)	0.00	-0.30 to 0.70

Confidential

Summary of Change from Baseline by Week in Bilirubin (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	0.72 (0.20)	-	-	-	-
Week 28						
Placebo/MK-3102	28	0.72 (0.20)	0.67 (0.19)	-0.05 (0.03)	0.00	-0.30 to 0.20
Week 36						
Placebo/MK-3102	28	0.72 (0.20)	0.70 (0.24)	-0.01 (0.04)	0.00	-0.50 to 0.40
Week 52						
Placebo/MK-3102	28	0.72 (0.20)	0.68 (0.20)	-0.04 (0.03)	0.00	-0.40 to 0.30

C Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	21.79 (7.49)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	21.79 (7.49)	22.16 (7.55)	0.37 (0.37)	0.00	-13.00 to 12.00
Week 8						
MK-3102/MK-3102	125	21.82 (7.51)	21.57 (6.59)	-0.26 (0.47)	0.00	-20.00 to 26.00
Week 12						
MK-3102/MK-3102	124	21.90 (7.50)	21.16 (5.83)	-0.73 (0.47)	-0.50	-22.00 to 15.00
Week 24						
MK-3102/MK-3102	122	21.94 (7.55)	22.35 (8.09)	0.41 (0.51)	0.00	-23.00 to 18.00
Week 28						
MK-3102/MK-3102	122	21.94 (7.55)	22.50 (8.23)	0.56 (0.51)	0.50	-19.00 to 25.00
Week 36						
MK-3102/MK-3102	118	22.04 (7.50)	22.80 (7.62)	0.75 (0.63)	1.00	-20.00 to 45.00
Week 52						
MK-3102/MK-3102	112	21.92 (7.27)	22.62 (8.31)	0.70 (0.63)	0.00	-19.00 to 24.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	21.15 (6.52)	-	-	-	-
Week 28						
Placebo/MK-3102	62	21.15 (6.52)	21.89 (11.04)	0.70 (0.92)	0.00	-9.00 to 47.00
Week 36						
Placebo/MK-3102	61	21.18 (6.57)	22.77 (9.71)	1.52 (0.78)	1.00	-11.00 to 27.00
Week 52						
Placebo/MK-3102	56	21.02 (6.00)	22.00 (6.17)	0.98 (0.68)	1.00	-14.00 to 16.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	24.80 (11.17)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	24.80 (11.17)	24.29 (9.87)	-0.51 (0.67)	-1.00	-17.00 to 18.00
Week 8						
MK-3102/MK-3102	65	24.80 (11.17)	23.46 (8.52)	-1.34 (0.95)	0.00	-30.00 to 19.00
Week 12						
MK-3102/MK-3102	62	24.66 (10.57)	22.63 (7.31)	-2.03 (0.95)	-1.00	-33.00 to 10.00
Week 24						
MK-3102/MK-3102	61	24.26 (10.17)	24.44 (10.27)	0.18 (0.92)	0.00	-18.00 to 24.00
Week 28						
MK-3102/MK-3102	61	24.26 (10.17)	24.36 (9.82)	0.10 (0.89)	0.00	-16.00 to 20.00
Week 36						
MK-3102/MK-3102	61	24.26 (10.17)	24.75 (10.30)	0.49 (1.02)	-1.00	-23.00 to 24.00
Week 52						
MK-3102/MK-3102	59	23.54 (8.06)	26.08 (9.79)	2.54 (0.87)	1.00	-9.00 to 33.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	23.81 (13.05)	-	-	-	-
Week 28						
Placebo/MK-3102	31	23.81 (13.05)	22.32 (8.97)	-1.48 (1.10)	0.00	-28.00 to 6.00
Week 36						
Placebo/MK-3102	31	23.81 (13.05)	23.35 (9.30)	-0.45 (1.24)	0.00	-33.00 to 9.00
Week 52						
Placebo/MK-3102	30	24.10 (13.17)	23.80 (10.52)	-0.30 (1.78)	1.00	-36.00 to 15.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	23.59 (9.99)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	23.59 (9.99)	23.06 (8.39)	-0.53 (0.63)	0.00	-17.00 to 15.00
Week 8						
MK-3102/MK-3102	66	23.59 (9.99)	22.82 (7.63)	-0.77 (0.72)	0.00	-22.00 to 11.00
Week 12						
MK-3102/MK-3102	66	23.59 (9.99)	22.39 (8.43)	-1.20 (0.79)	-1.00	-32.00 to 14.00
Week 24						
MK-3102/MK-3102	65	23.20 (9.54)	22.55 (8.21)	-0.65 (1.04)	0.00	-29.00 to 33.00
Week 28						
MK-3102/MK-3102	65	23.20 (9.54)	22.09 (8.41)	-1.11 (0.98)	0.00	-36.00 to 28.00
Week 36						
MK-3102/MK-3102	64	22.67 (8.61)	22.44 (8.78)	-0.23 (0.79)	-1.00	-18.00 to 27.00
Week 52						
MK-3102/MK-3102	64	22.67 (8.61)	23.36 (8.03)	0.69 (0.87)	1.00	-25.00 to 18.00

C Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	24.52 (11.36)	-	-	-	-
Week 28						
Placebo/MK-3102	32	24.72 (11.48)	24.84 (13.35)	0.13 (1.02)	-1.00	-10.00 to 18.00
Week 36						
Placebo/MK-3102	33	24.52 (11.36)	24.91 (12.55)	0.39 (0.78)	1.00	-9.00 to 8.00
Week 52						
Placebo/MK-3102	33	24.52 (11.36)	24.64 (14.57)	0.12 (1.22)	-1.00	-10.00 to 30.00

C Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	22.46 (7.23)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	22.46 (7.23)	22.80 (7.19)	0.34 (0.56)	0.00	-15.00 to 13.00
Week 8						
MK-3102/MK-3102	65	22.46 (7.23)	22.42 (7.67)	-0.05 (0.61)	0.00	-11.00 to 22.00
Week 12						
MK-3102/MK-3102	64	22.22 (7.02)	22.45 (6.67)	0.23 (0.59)	0.00	-14.00 to 14.00
Week 24						
MK-3102/MK-3102	63	22.22 (7.07)	22.17 (8.01)	-0.05 (0.58)	0.00	-14.00 to 18.00
Week 28						
MK-3102/MK-3102	63	22.22 (7.07)	23.03 (8.12)	0.81 (0.59)	1.00	-13.00 to 18.00
Week 36						
MK-3102/MK-3102	61	22.28 (7.17)	22.79 (7.87)	0.51 (0.64)	1.00	-12.00 to 14.00
Week 52						
MK-3102/MK-3102	60	22.35 (7.21)	23.22 (9.33)	0.87 (0.65)	1.00	-10.00 to 22.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	20.21 (5.15)	-	-	-	-
Week 28						
Placebo/MK-3102	33	20.21 (5.15)	20.91 (5.25)	0.70 (0.46)	0.00	-6.00 to 7.00
Week 36						
Placebo/MK-3102	33	20.21 (5.15)	22.24 (7.42)	2.03 (0.78)	1.00	-4.00 to 20.00
Week 52						
Placebo/MK-3102	32	20.16 (5.22)	22.88 (6.95)	2.72 (0.81)	2.00	-2.00 to 17.00

C Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	23.57 (8.05)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	23.57 (8.05)	23.00 (9.64)	-0.57 (0.70)	0.00	-15.00 to 20.00
Week 8						
MK-3102/MK-3102	67	23.57 (8.05)	22.52 (7.47)	-1.04 (0.68)	-1.00	-19.00 to 19.00
Week 12						
MK-3102/MK-3102	67	23.57 (8.05)	22.52 (8.14)	-1.04 (0.72)	0.00	-18.00 to 20.00
Week 24						
MK-3102/MK-3102	67	23.57 (8.05)	24.22 (11.37)	0.66 (0.92)	1.00	-16.00 to 33.00
Week 28						
MK-3102/MK-3102	67	23.57 (8.05)	22.93 (8.61)	-0.64 (0.73)	0.00	-15.00 to 12.00
Week 36						
MK-3102/MK-3102	67	23.57 (8.05)	23.52 (8.81)	-0.04 (0.71)	0.00	-13.00 to 23.00
Week 52						
MK-3102/MK-3102	65	23.68 (8.10)	24.17 (11.39)	0.49 (1.05)	1.00	-14.00 to 44.00

Confidential

Summary of Change from Baseline by Week in Aspartate Aminotransferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	21.57 (10.20)	-	-	-	-
Week 28						
Placebo/MK-3102	28	21.57 (10.20)	21.18 (9.88)	-0.39 (0.70)	0.00	-11.00 to 5.00
Week 36						
Placebo/MK-3102	28	21.57 (10.20)	21.75 (9.00)	0.18 (1.10)	1.00	-19.00 to 14.00
Week 52						
Placebo/MK-3102	28	21.57 (10.20)	22.07 (6.89)	0.50 (1.21)	2.00	-18.00 to 13.00

C Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	24.52 (12.41)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	24.52 (12.41)	23.94 (11.17)	-0.57 (0.55)	0.00	-28.00 to 17.00
Week 8						
MK-3102/MK-3102	125	24.54 (12.46)	23.30 (11.80)	-1.23 (0.73)	-1.00	-26.00 to 50.00
Week 12						
MK-3102/MK-3102	124	24.63 (12.46)	23.27 (10.86)	-1.35 (0.73)	-1.00	-30.00 to 34.00
Week 24						
MK-3102/MK-3102	122	24.60 (12.52)	23.60 (10.65)	-1.00 (0.69)	-1.50	-29.00 to 20.00
Week 28						
MK-3102/MK-3102	122	24.60 (12.52)	23.85 (11.53)	-0.75 (0.65)	0.00	-25.00 to 21.00
Week 36						
MK-3102/MK-3102	118	24.53 (12.40)	24.83 (11.80)	0.30 (0.89)	0.00	-34.00 to 35.00
Week 52						
MK-3102/MK-3102	112	24.24 (12.02)	24.04 (11.58)	-0.20 (1.01)	0.00	-46.00 to 37.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	23.67 (12.38)	-	-	-	-
Week 28						
Placebo/MK-3102	62	23.67 (12.38)	23.63 (14.97)	-0.02 (0.87)	-1.00	-17.00 to 33.00
Week 36						
Placebo/MK-3102	61	23.77 (12.47)	24.25 (14.10)	0.45 (0.89)	-1.00	-15.00 to 25.00
Week 52						
Placebo/MK-3102	56	23.49 (12.25)	23.34 (12.01)	-0.09 (1.07)	-1.00	-32.00 to 26.00

C Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	28.25 (15.84)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	28.25 (15.84)	26.66 (15.60)	-1.58 (0.94)	-1.00	-26.00 to 31.00
Week 8						
MK-3102/MK-3102	65	28.25 (15.84)	26.38 (14.25)	-1.86 (1.14)	-1.00	-31.00 to 31.00
Week 12						
MK-3102/MK-3102	62	27.98 (14.95)	25.63 (12.48)	-2.35 (1.10)	-1.00	-33.00 to 14.00
Week 24						
MK-3102/MK-3102	61	27.97 (15.07)	27.80 (16.93)	-0.16 (1.42)	-1.00	-32.00 to 42.00
Week 28						
MK-3102/MK-3102	61	27.97 (15.07)	27.80 (16.50)	-0.16 (1.42)	-1.00	-30.00 to 36.00
Week 36						
MK-3102/MK-3102	61	27.97 (15.07)	27.38 (15.48)	-0.59 (1.27)	-1.00	-31.00 to 23.00
Week 52						
MK-3102/MK-3102	59	27.05 (13.09)	28.69 (15.52)	1.64 (1.07)	1.00	-15.00 to 30.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	26.68 (12.79)	-	-	-	-
Week 28						
Placebo/MK-3102	31	26.68 (12.79)	24.23 (11.61)	-2.45 (0.59)	-2.00	-11.00 to 3.00
Week 36						
Placebo/MK-3102	31	26.68 (12.79)	25.74 (12.48)	-0.94 (0.71)	-1.00	-9.00 to 10.00
Week 52						
Placebo/MK-3102	30	26.97 (12.90)	25.40 (13.28)	-1.57 (1.41)	-1.00	-20.00 to 18.00

C Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	26.68 (13.88)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	26.68 (13.88)	24.97 (12.61)	-1.71 (0.86)	-1.00	-25.00 to 20.00
Week 8						
MK-3102/MK-3102	66	26.68 (13.88)	24.80 (13.24)	-1.88 (1.04)	-1.00	-38.00 to 14.00
Week 12						
MK-3102/MK-3102	66	26.68 (13.88)	24.47 (14.40)	-2.21 (1.05)	-1.50	-46.00 to 20.00
Week 24						
MK-3102/MK-3102	65	25.80 (11.98)	24.55 (14.25)	-1.25 (1.50)	-1.00	-44.00 to 56.00
Week 28						
MK-3102/MK-3102	65	25.80 (11.98)	23.91 (12.49)	-1.89 (1.36)	-1.00	-53.00 to 27.00
Week 36						
MK-3102/MK-3102	64	25.77 (12.07)	24.45 (13.59)	-1.31 (1.32)	0.00	-36.00 to 34.00
Week 52						
MK-3102/MK-3102	64	25.77 (12.07)	25.67 (13.41)	-0.09 (1.43)	0.00	-37.00 to 39.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	31.21 (19.10)	-	-	-	-
Week 28						
Placebo/MK-3102	32	31.34 (19.39)	30.66 (22.52)	-0.69 (1.50)	-2.00	-19.00 to 28.00
Week 36						
Placebo/MK-3102	33	31.21 (19.10)	31.30 (21.56)	0.09 (1.28)	-1.00	-16.00 to 19.00
Week 52						
Placebo/MK-3102	33	31.21 (19.10)	31.06 (21.94)	-0.15 (1.63)	-1.00	-16.00 to 34.00

C Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	22.66 (10.20)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	22.66 (10.20)	21.58 (10.33)	-1.08 (0.68)	-1.00	-17.00 to 15.00
Week 8						
MK-3102/MK-3102	65	22.66 (10.20)	21.00 (10.03)	-1.66 (0.62)	-1.00	-20.00 to 8.00
Week 12						
MK-3102/MK-3102	64	22.36 (9.98)	21.27 (9.93)	-1.09 (0.75)	-1.00	-20.00 to 17.00
Week 24						
MK-3102/MK-3102	63	22.40 (10.05)	20.60 (10.84)	-1.79 (0.81)	-2.00	-18.00 to 24.00
Week 28						
MK-3102/MK-3102	63	22.40 (10.05)	21.27 (9.72)	-1.13 (0.78)	-1.00	-20.00 to 14.00
Week 36						
MK-3102/MK-3102	61	22.38 (10.18)	20.79 (9.56)	-1.59 (0.84)	-1.00	-21.00 to 15.00
Week 52						
MK-3102/MK-3102	60	22.50 (10.22)	21.65 (12.21)	-0.85 (0.99)	-1.00	-20.00 to 27.00

C Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	21.30 (8.55)	-	-	-	-
Week 28						
Placebo/MK-3102	33	21.30 (8.55)	20.85 (9.01)	-0.45 (0.54)	-1.00	-5.00 to 8.00
Week 36						
Placebo/MK-3102	33	21.30 (8.55)	21.97 (11.15)	0.67 (0.71)	0.00	-7.00 to 12.00
Week 52						
Placebo/MK-3102	32	21.44 (8.65)	22.94 (13.36)	1.50 (1.28)	-1.00	-11.00 to 27.00

Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	28.81 (14.10)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	28.81 (14.10)	27.79 (16.12)	-1.01 (1.07)	-2.00	-21.00 to 25.00
Week 8						
MK-3102/MK-3102	67	28.81 (14.10)	26.55 (12.21)	-2.25 (1.12)	-2.00	-31.00 to 31.00
Week 12						
MK-3102/MK-3102	67	28.81 (14.10)	26.30 (13.35)	-2.51 (1.31)	-2.00	-36.00 to 42.00
Week 24						
MK-3102/MK-3102	67	28.81 (14.10)	28.97 (17.78)	0.16 (1.20)	0.00	-21.00 to 39.00
Week 28						
MK-3102/MK-3102	67	28.81 (14.10)	26.87 (14.28)	-1.94 (1.16)	-1.00	-40.00 to 15.00
Week 36						
MK-3102/MK-3102	67	28.81 (14.10)	27.45 (14.38)	-1.36 (1.20)	-1.00	-36.00 to 36.00
Week 52						
MK-3102/MK-3102	65	28.97 (14.28)	27.34 (13.20)	-1.63 (1.27)	-1.00	-28.00 to 32.00

C Confidential

Summary of Change from Baseline by Week in Alanine Aminotransferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	24.46 (11.08)	-	-	-	-
Week 28						
Placebo/MK-3102	28	24.46 (11.08)	22.25 (10.53)	-2.21 (1.16)	-2.00	-20.00 to 7.00
Week 36						
Placebo/MK-3102	28	24.46 (11.08)	23.14 (11.19)	-1.32 (1.46)	-1.50	-21.00 to 21.00
Week 52						
Placebo/MK-3102	28	24.46 (11.08)	24.32 (12.63)	-0.14 (1.70)	-1.00	-19.00 to 27.00

C Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	45.67 (40.56)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	45.67 (40.56)	43.40 (38.13)	-2.26 (1.56)	-1.00	-118.00 to 98.00
Week 8						
MK-3102/MK-3102	125	45.63 (40.72)	45.24 (50.74)	-0.39 (2.60)	-1.00	-104.00 to 222.00
Week 12						
MK-3102/MK-3102	124	45.84 (40.82)	44.24 (40.13)	-1.60 (1.64)	-1.00	-96.00 to 72.00
Week 24						
MK-3102/MK-3102	122	45.86 (41.09)	45.65 (43.74)	-0.21 (2.59)	-1.00	-124.00 to 254.00
Week 28						
MK-3102/MK-3102	122	45.86 (41.09)	47.43 (48.86)	1.57 (2.75)	-1.00	-91.00 to 277.00
Week 36						
MK-3102/MK-3102	118	45.19 (41.14)	46.73 (47.30)	1.53 (3.23)	0.00	-117.00 to 306.00
Week 52						
MK-3102/MK-3102	112	44.96 (41.42)	46.21 (46.52)	1.26 (2.96)	1.00	-190.00 to 152.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	45.25 (55.69)	-	-	-	-
Week 28						
Placebo/MK-3102	62	45.25 (55.69)	49.77 (116.86)	4.98 (8.49)	-1.00	-37.00 to 510.00
Week 36						
Placebo/MK-3102	61	45.77 (56.01)	40.23 (33.15)	-5.28 (3.29)	-1.00	-183.00 to 19.00
Week 52						
Placebo/MK-3102	56	38.58 (22.39)	36.09 (17.74)	-2.24 (1.74)	-1.00	-63.00 to 24.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	45.58 (45.53)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	45.58 (45.53)	42.92 (39.14)	-2.66 (2.30)	-1.00	-111.00 to 52.00
Week 8						
MK-3102/MK-3102	65	45.58 (45.53)	42.38 (38.17)	-3.20 (2.27)	-1.00	-122.00 to 51.00
Week 12						
MK-3102/MK-3102	62	45.48 (46.31)	41.19 (41.01)	-4.29 (2.63)	-1.00	-143.00 to 34.00
Week 24						
MK-3102/MK-3102	61	44.74 (46.32)	42.11 (34.90)	-2.62 (3.08)	0.00	-149.00 to 48.00
Week 28						
MK-3102/MK-3102	61	44.74 (46.32)	44.10 (42.64)	-0.64 (2.71)	0.00	-137.00 to 48.00
Week 36						
MK-3102/MK-3102	61	44.74 (46.32)	44.10 (44.59)	-0.64 (2.82)	-1.00	-144.00 to 52.00
Week 52						
MK-3102/MK-3102	59	44.34 (47.01)	44.02 (41.23)	-0.32 (2.32)	1.00	-87.00 to 61.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	51.77 (39.35)	-	-	-	-
Week 28						
Placebo/MK-3102	31	51.77 (39.35)	47.97 (36.50)	-3.81 (1.65)	-3.00	-42.00 to 11.00
Week 36						
Placebo/MK-3102	31	51.77 (39.35)	52.87 (45.57)	1.10 (2.51)	0.00	-26.00 to 51.00
Week 52						
Placebo/MK-3102	30	52.80 (39.60)	51.97 (42.96)	-0.83 (2.11)	1.00	-32.00 to 34.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	37.58 (23.41)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	37.58 (23.41)	35.36 (23.71)	-2.21 (1.06)	-1.00	-36.00 to 26.00
Week 8						
MK-3102/MK-3102	66	37.58 (23.41)	35.56 (26.36)	-2.02 (1.49)	-1.00	-38.00 to 49.00
Week 12						
MK-3102/MK-3102	66	37.58 (23.41)	36.08 (28.61)	-1.50 (2.15)	-2.00	-37.00 to 112.00
Week 24						
MK-3102/MK-3102	65	37.46 (23.57)	37.57 (36.38)	0.11 (3.38)	-2.00	-39.00 to 194.00
Week 28						
MK-3102/MK-3102	65	37.46 (23.57)	38.08 (46.88)	0.62 (4.96)	-2.00	-43.00 to 307.00
Week 36						
MK-3102/MK-3102	64	36.61 (22.73)	34.78 (21.72)	-1.83 (1.45)	0.00	-47.00 to 27.00
Week 52						
MK-3102/MK-3102	64	36.61 (22.73)	38.88 (37.55)	2.27 (3.85)	0.00	-75.00 to 173.00

C Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	43.88 (44.12)	-	-	-	-
Week 28						
Placebo/MK-3102	32	44.28 (44.77)	41.97 (43.76)	-2.31 (3.47)	-0.50	-88.00 to 51.00
Week 36						
Placebo/MK-3102	33	43.88 (44.12)	43.52 (42.62)	-0.36 (2.28)	1.00	-66.00 to 25.00
Week 52						
Placebo/MK-3102	33	43.88 (44.12)	44.64 (40.24)	0.76 (1.68)	1.00	-38.00 to 20.00

C Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	36.75 (36.59)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	36.75 (36.59)	34.38 (33.16)	-2.37 (0.91)	-1.00	-42.00 to 13.00
Week 8						
MK-3102/MK-3102	65	36.75 (36.59)	35.08 (31.08)	-1.68 (1.91)	-1.00	-101.00 to 46.00
Week 12						
MK-3102/MK-3102	64	36.77 (36.88)	32.81 (27.50)	-3.95 (3.24)	-1.00	-199.00 to 32.00
Week 24						
MK-3102/MK-3102	63	37.06 (37.10)	36.17 (34.99)	-0.89 (1.85)	-1.00	-75.00 to 37.00
Week 28						
MK-3102/MK-3102	63	37.06 (37.10)	36.51 (37.20)	-0.56 (1.76)	-1.00	-49.00 to 60.00
Week 36						
MK-3102/MK-3102	61	37.44 (37.65)	36.05 (34.93)	-1.39 (1.72)	0.00	-56.00 to 37.00
Week 52						
MK-3102/MK-3102	60	37.52 (37.96)	33.65 (28.67)	-3.87 (3.11)	0.00	-167.00 to 37.00

C Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	39.67 (41.53)	-	-	-	-
Week 28						
Placebo/MK-3102	33	39.67 (41.53)	36.55 (34.66)	-3.12 (1.99)	-2.00	-52.00 to 13.00
Week 36						
Placebo/MK-3102	33	39.67 (41.53)	42.42 (45.06)	2.76 (2.86)	0.00	-40.00 to 64.00
Week 52						
Placebo/MK-3102	32	40.13 (42.11)	46.13 (55.11)	6.00 (5.85)	1.00	-75.00 to 163.00

C Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	35.67 (24.46)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	35.67 (24.46)	33.03 (20.99)	-2.64 (1.04)	-1.00	-33.00 to 21.00
Week 8						
MK-3102/MK-3102	67	35.67 (24.46)	33.51 (24.03)	-2.16 (1.16)	-1.00	-29.00 to 21.00
Week 12						
MK-3102/MK-3102	67	35.67 (24.46)	33.64 (22.02)	-2.03 (1.20)	-1.00	-36.00 to 35.00
Week 24						
MK-3102/MK-3102	67	35.67 (24.46)	35.81 (25.56)	0.13 (1.90)	0.00	-47.00 to 70.00
Week 28						
MK-3102/MK-3102	67	35.67 (24.46)	34.90 (24.38)	-0.78 (1.75)	-1.00	-53.00 to 48.00
Week 36						
MK-3102/MK-3102	67	35.67 (24.46)	35.55 (22.91)	-0.12 (1.71)	0.00	-52.00 to 52.00
Week 52						
MK-3102/MK-3102	65	35.05 (24.38)	35.65 (24.32)	0.60 (1.36)	0.00	-30.00 to 41.00

Confidential

Summary of Change from Baseline by Week in Gamma Glutamyl Transferase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	30.14 (13.21)	-	-	-	-
Week 28						
Placebo/MK-3102	28	30.14 (13.21)	28.43 (13.00)	-1.71 (0.89)	-2.00	-14.00 to 8.00
Week 36						
Placebo/MK-3102	28	30.14 (13.21)	34.21 (24.99)	4.07 (3.29)	-1.00	-9.00 to 78.00
Week 52						
Placebo/MK-3102	28	30.14 (13.21)	33.14 (18.98)	3.00 (1.95)	0.00	-11.00 to 37.00

C Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	243.71 (72.98)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	243.71 (72.98)	235.54 (68.66)	-8.17 (2.34)	-6.00	-117.00 to 77.00
Week 8						
MK-3102/MK-3102	125	243.35 (73.16)	229.26 (66.32)	-14.09 (2.68)	-11.00	-144.00 to 93.00
Week 12						
MK-3102/MK-3102	124	243.20 (73.44)	227.30 (64.76)	-15.90 (3.07)	-15.50	-134.00 to 108.00
Week 24						
MK-3102/MK-3102	122	243.66 (73.93)	224.35 (64.49)	-19.31 (3.15)	-18.00	-169.00 to 85.00
Week 28						
MK-3102/MK-3102	122	243.66 (73.93)	225.56 (62.53)	-18.11 (3.37)	-16.50	-166.00 to 70.00
Week 36						
MK-3102/MK-3102	118	244.95 (74.30)	233.62 (66.44)	-11.33 (3.90)	-10.00	-175.00 to 119.00
Week 52						
MK-3102/MK-3102	112	241.62 (74.32)	235.62 (64.37)	-6.00 (3.61)	-4.50	-150.00 to 84.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	240.41 (84.37)	-	-	-	-
Week 28						
Placebo/MK-3102	62	240.41 (84.37)	229.58 (66.27)	-9.52 (4.97)	-6.00	-231.00 to 66.00
Week 36						
Placebo/MK-3102	61	241.37 (84.74)	226.90 (66.84)	-13.08 (4.41)	-10.50	-143.00 to 64.00
Week 52						
Placebo/MK-3102	56	232.67 (58.05)	223.80 (55.57)	-7.75 (3.43)	-11.00	-71.00 to 55.00

C Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	242.09 (66.91)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	242.09 (66.91)	234.88 (62.30)	-7.22 (3.99)	-6.00	-145.00 to 117.00
Week 8						
MK-3102/MK-3102	65	242.09 (66.91)	229.78 (64.30)	-12.31 (4.01)	-12.00	-136.00 to 83.00
Week 12						
MK-3102/MK-3102	62	241.81 (67.76)	227.00 (61.12)	-14.81 (3.25)	-12.00	-99.00 to 38.00
Week 24						
MK-3102/MK-3102	61	241.59 (68.30)	219.20 (60.07)	-22.39 (5.42)	-18.00	-221.00 to 66.00
Week 28						
MK-3102/MK-3102	61	241.59 (68.30)	221.85 (59.45)	-19.74 (5.12)	-20.00	-172.00 to 105.00
Week 36						
MK-3102/MK-3102	61	241.59 (68.30)	221.92 (53.82)	-19.67 (4.67)	-14.00	-180.00 to 46.00
Week 52						
MK-3102/MK-3102	59	239.81 (67.66)	230.27 (62.13)	-9.54 (3.74)	-10.00	-70.00 to 94.00

C Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	239.87 (89.35)	-	-	-	-
Week 28						
Placebo/MK-3102	31	239.87 (89.35)	222.68 (72.46)	-17.19 (4.75)	-13.00	-99.00 to 39.00
Week 36						
Placebo/MK-3102	31	239.87 (89.35)	224.00 (74.79)	-15.87 (6.29)	-17.00	-112.00 to 117.00
Week 52						
Placebo/MK-3102	30	231.77 (78.44)	229.73 (69.94)	-2.03 (4.47)	0.00	-71.00 to 48.00

C Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	231.70 (63.93)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	231.70 (63.93)	225.17 (68.25)	-6.53 (2.57)	-9.00	-50.00 to 59.00
Week 8						
MK-3102/MK-3102	66	231.70 (63.93)	218.24 (67.83)	-13.45 (2.76)	-14.50	-57.00 to 93.00
Week 12						
MK-3102/MK-3102	66	231.70 (63.93)	217.26 (64.60)	-14.44 (2.74)	-16.50	-50.00 to 67.00
Week 24						
MK-3102/MK-3102	65	231.55 (64.42)	213.43 (61.55)	-18.12 (2.96)	-20.00	-65.00 to 71.00
Week 28						
MK-3102/MK-3102	65	231.55 (64.42)	216.28 (73.08)	-15.28 (4.03)	-18.00	-63.00 to 184.00
Week 36						
MK-3102/MK-3102	64	231.98 (64.83)	215.47 (60.34)	-16.52 (2.90)	-11.00	-89.00 to 31.00
Week 52						
MK-3102/MK-3102	64	231.98 (64.83)	224.95 (63.60)	-7.03 (3.66)	-9.00	-95.00 to 95.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	219.03 (49.46)	-	-	-	-
Week 28						
Placebo/MK-3102	32	218.25 (50.05)	216.03 (53.17)	-2.22 (6.08)	-7.50	-79.00 to 118.00
Week 36						
Placebo/MK-3102	33	219.03 (49.46)	216.94 (55.70)	-2.09 (5.27)	-3.00	-101.00 to 72.00
Week 52						
Placebo/MK-3102	33	219.03 (49.46)	225.03 (59.64)	6.00 (6.26)	5.00	-98.00 to 100.00

C Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	232.15 (60.38)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	232.15 (60.38)	219.98 (62.31)	-12.17 (2.43)	-12.00	-60.00 to 39.00
Week 8						
MK-3102/MK-3102	65	232.15 (60.38)	217.46 (70.60)	-14.69 (3.96)	-19.00	-65.00 to 160.00
Week 12						
MK-3102/MK-3102	64	231.31 (60.47)	215.44 (69.00)	-15.88 (3.29)	-18.50	-64.00 to 55.00
Week 24						
MK-3102/MK-3102	63	231.62 (60.90)	205.75 (61.17)	-25.87 (3.30)	-24.00	-111.00 to 40.00
Week 28						
MK-3102/MK-3102	63	231.62 (60.90)	207.75 (60.72)	-23.87 (3.46)	-23.00	-129.00 to 30.00
Week 36						
MK-3102/MK-3102	61	231.90 (61.21)	205.69 (55.84)	-26.21 (3.77)	-27.00	-117.00 to 44.00
Week 52						
MK-3102/MK-3102	60	231.30 (61.55)	218.08 (58.01)	-13.22 (3.52)	-11.50	-95.00 to 61.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	224.48 (49.48)	-	-	-	-
Week 28						
Placebo/MK-3102	33	224.48 (49.48)	219.33 (56.17)	-5.15 (3.59)	-8.00	-43.00 to 59.00
Week 36						
Placebo/MK-3102	33	224.48 (49.48)	211.03 (53.68)	-13.45 (3.47)	-13.00	-56.00 to 37.00
Week 52						
Placebo/MK-3102	32	225.19 (50.11)	216.38 (51.74)	-8.81 (5.27)	-3.50	-70.00 to 55.00

C Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	230.60 (63.06)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	230.60 (63.06)	219.88 (58.00)	-10.72 (2.38)	-9.00	-85.00 to 42.00
Week 8						
MK-3102/MK-3102	67	230.60 (63.06)	212.90 (54.05)	-17.70 (2.90)	-17.00	-73.00 to 41.00
Week 12						
MK-3102/MK-3102	67	230.60 (63.06)	212.06 (52.19)	-18.54 (3.08)	-15.00	-97.00 to 50.00
Week 24						
MK-3102/MK-3102	67	230.60 (63.06)	205.30 (47.01)	-25.30 (3.19)	-22.00	-113.00 to 16.00
Week 28						
MK-3102/MK-3102	67	230.60 (63.06)	206.10 (48.44)	-24.49 (3.53)	-24.00	-145.00 to 36.00
Week 36						
MK-3102/MK-3102	67	230.60 (63.06)	206.07 (47.78)	-24.52 (3.44)	-25.00	-135.00 to 36.00
Week 52						
MK-3102/MK-3102	65	228.52 (60.88)	212.32 (49.36)	-16.20 (3.55)	-15.00	-97.00 to 36.00

Confidential

Summary of Change from Baseline by Week in Alkaline Phosphatase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	231.71 (91.13)	-	-	-	-
Week 28						
Placebo/MK-3102	28	231.71 (91.13)	220.79 (86.46)	-10.93 (5.79)	-6.00	-107.00 to 69.00
Week 36						
Placebo/MK-3102	28	231.71 (91.13)	215.32 (78.90)	-16.39 (6.59)	-5.00	-91.00 to 57.00
Week 52						
Placebo/MK-3102	28	231.71 (91.13)	222.00 (73.43)	-9.71 (10.49)	0.50	-202.00 to 72.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	174.11 (32.79)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	174.11 (32.79)	176.86 (30.57)	2.75 (1.78)	4.00	-78.00 to 90.00
Week 8						
MK-3102/MK-3102	125	174.02 (32.90)	176.46 (29.83)	2.45 (1.70)	3.00	-70.00 to 51.00
Week 12						
MK-3102/MK-3102	124	174.09 (33.02)	175.45 (28.41)	1.36 (1.67)	3.50	-72.00 to 41.00
Week 24						
MK-3102/MK-3102	122	174.43 (33.18)	177.21 (34.23)	2.78 (2.19)	3.00	-83.00 to 168.00
Week 28						
MK-3102/MK-3102	122	174.43 (33.18)	180.61 (33.31)	6.17 (1.75)	6.00	-87.00 to 75.00
Week 36						
MK-3102/MK-3102	118	174.69 (33.25)	179.33 (29.87)	4.64 (1.86)	6.50	-82.00 to 65.00
Week 52						
MK-3102/MK-3102	112	175.04 (33.98)	182.04 (35.54)	7.00 (2.22)	7.00	-86.00 to 91.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	174.10 (28.77)	-	-	-	-
Week 28						
Placebo/MK-3102	62	174.10 (28.77)	178.34 (25.69)	4.18 (2.04)	3.00	-31.00 to 41.00
Week 36						
Placebo/MK-3102	61	174.97 (28.20)	181.52 (29.10)	5.82 (2.17)	5.50	-39.00 to 57.00
Week 52						
Placebo/MK-3102	56	175.25 (27.34)	183.55 (23.91)	8.42 (2.77)	7.00	-28.00 to 100.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	172.40 (36.03)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	172.40 (36.03)	176.22 (36.71)	3.82 (2.10)	2.00	-53.00 to 38.00
Week 8						
MK-3102/MK-3102	65	172.40 (36.03)	174.29 (32.39)	1.89 (2.63)	2.00	-77.00 to 50.00
Week 12						
MK-3102/MK-3102	62	172.26 (35.34)	173.40 (29.24)	1.15 (2.31)	-2.00	-66.00 to 53.00
Week 24						
MK-3102/MK-3102	61	170.72 (33.48)	175.93 (36.76)	5.21 (2.47)	1.00	-36.00 to 74.00
Week 28						
MK-3102/MK-3102	61	170.72 (33.48)	175.15 (31.78)	4.43 (1.99)	6.00	-33.00 to 45.00
Week 36						
MK-3102/MK-3102	61	170.72 (33.48)	174.52 (34.37)	3.80 (2.27)	2.00	-51.00 to 46.00
Week 52						
MK-3102/MK-3102	59	169.25 (32.76)	183.34 (39.43)	14.08 (3.31)	9.00	-37.00 to 113.00

Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	164.94 (29.40)	-	-	-	-
Week 28						
Placebo/MK-3102	31	164.94 (29.40)	163.77 (25.39)	-1.16 (3.27)	2.00	-56.00 to 42.00
Week 36						
Placebo/MK-3102	31	164.94 (29.40)	162.10 (27.99)	-2.84 (3.01)	0.00	-44.00 to 25.00
Week 52						
Placebo/MK-3102	30	164.17 (29.58)	167.97 (28.35)	3.80 (3.76)	3.50	-40.00 to 62.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	163.85 (28.76)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	163.85 (28.76)	165.53 (26.89)	1.68 (2.31)	2.50	-53.00 to 56.00
Week 8						
MK-3102/MK-3102	66	163.85 (28.76)	166.48 (28.37)	2.64 (2.29)	3.50	-59.00 to 39.00
Week 12						
MK-3102/MK-3102	66	163.85 (28.76)	164.71 (26.24)	0.86 (2.32)	4.50	-61.00 to 60.00
Week 24						
MK-3102/MK-3102	65	163.45 (28.79)	164.97 (28.82)	1.52 (3.47)	1.00	-50.00 to 127.00
Week 28						
MK-3102/MK-3102	65	163.45 (28.79)	163.06 (27.03)	-0.38 (2.49)	0.00	-56.00 to 44.00
Week 36						
MK-3102/MK-3102	64	162.67 (28.33)	165.00 (28.64)	2.33 (2.30)	1.50	-59.00 to 59.00
Week 52						
MK-3102/MK-3102	64	162.67 (28.33)	167.48 (29.06)	4.81 (2.62)	5.50	-54.00 to 51.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	160.85 (29.30)	-	-	-	-
Week 28						
Placebo/MK-3102	32	161.25 (29.68)	161.91 (26.57)	0.66 (2.27)	0.00	-23.00 to 24.00
Week 36						
Placebo/MK-3102	33	160.85 (29.30)	170.64 (44.79)	9.79 (4.36)	6.00	-37.00 to 116.00
Week 52						
Placebo/MK-3102	33	160.85 (29.30)	159.73 (28.83)	-1.12 (2.77)	-2.00	-29.00 to 33.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	188.28 (35.14)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	188.28 (35.14)	193.91 (36.18)	5.63 (2.40)	5.00	-46.00 to 82.00
Week 8						
MK-3102/MK-3102	65	188.28 (35.14)	196.52 (48.61)	8.25 (5.16)	4.00	-47.00 to 304.00
Week 12						
MK-3102/MK-3102	64	187.73 (35.14)	195.55 (38.68)	7.81 (2.70)	11.00	-43.00 to 64.00
Week 24						
MK-3102/MK-3102	63	187.83 (35.41)	192.13 (34.21)	4.30 (2.29)	4.00	-51.00 to 48.00
Week 28						
MK-3102/MK-3102	63	187.83 (35.41)	197.76 (37.96)	9.94 (2.50)	10.00	-33.00 to 75.00
Week 36						
MK-3102/MK-3102	61	188.11 (35.84)	195.18 (37.88)	7.07 (2.73)	5.00	-42.00 to 95.00
Week 52						
MK-3102/MK-3102	60	188.52 (36.01)	198.40 (38.94)	9.88 (2.42)	10.00	-31.00 to 49.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	191.82 (36.62)	-	-	-	-
Week 28						
Placebo/MK-3102	33	191.82 (36.62)	197.67 (38.65)	5.85 (2.89)	8.00	-27.00 to 57.00
Week 36						
Placebo/MK-3102	33	191.82 (36.62)	202.67 (40.65)	10.85 (3.10)	12.00	-20.00 to 51.00
Week 52						
Placebo/MK-3102	32	191.41 (37.13)	200.06 (33.34)	8.66 (3.18)	10.50	-28.00 to 55.00

C Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	170.49 (30.00)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	170.49 (30.00)	174.93 (34.90)	4.43 (2.21)	5.00	-38.00 to 67.00
Week 8						
MK-3102/MK-3102	67	170.49 (30.00)	173.48 (32.30)	2.99 (1.91)	4.00	-40.00 to 34.00
Week 12						
MK-3102/MK-3102	67	170.49 (30.00)	175.99 (32.13)	5.49 (2.33)	2.00	-26.00 to 76.00
Week 24						
MK-3102/MK-3102	67	170.49 (30.00)	177.67 (40.34)	7.18 (3.38)	5.00	-41.00 to 174.00
Week 28						
MK-3102/MK-3102	67	170.49 (30.00)	179.66 (33.89)	9.16 (2.60)	7.00	-41.00 to 68.00
Week 36						
MK-3102/MK-3102	67	170.49 (30.00)	176.46 (34.46)	5.97 (2.35)	4.00	-46.00 to 55.00
Week 52						
MK-3102/MK-3102	65	171.02 (30.30)	174.14 (33.77)	3.12 (2.51)	3.00	-51.00 to 51.00

Confidential

Summary of Change from Baseline by Week in Lactate Dehydrogenase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	166.00 (31.07)	-	-	-	-
Week 28						
Placebo/MK-3102	28	166.00 (31.07)	172.32 (34.44)	6.32 (2.76)	6.00	-13.00 to 50.00
Week 36						
Placebo/MK-3102	28	166.00 (31.07)	171.43 (29.75)	5.43 (2.54)	2.50	-19.00 to 32.00
Week 52						
Placebo/MK-3102	28	166.00 (31.07)	171.93 (28.12)	5.93 (3.17)	7.00	-31.00 to 43.00

C Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	104.25 (72.11)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	104.25 (72.11)	104.05 (50.81)	-0.20 (5.41)	0.00	-508.00 to 150.00
Week 8						
MK-3102/MK-3102	125	104.03 (72.36)	105.38 (64.52)	1.34 (6.12)	4.00	-438.00 to 382.00
Week 12						
MK-3102/MK-3102	124	104.23 (72.62)	106.51 (61.98)	2.27 (5.21)	2.50	-405.00 to 237.00
Week 24						
MK-3102/MK-3102	122	104.39 (73.19)	115.48 (76.49)	11.10 (6.10)	7.50	-477.00 to 310.00
Week 28						
MK-3102/MK-3102	122	104.39 (73.19)	122.71 (107.75)	18.33 (9.02)	10.00	-507.00 to 854.00
Week 36						
MK-3102/MK-3102	118	104.72 (73.70)	113.86 (61.77)	9.14 (6.22)	9.00	-484.00 to 227.00
Week 52						
MK-3102/MK-3102	112	105.26 (74.08)	110.96 (68.63)	5.70 (4.94)	6.00	-405.00 to 185.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	103.69 (50.41)	-	-	-	-
Week 28						
Placebo/MK-3102	62	103.69 (50.41)	101.05 (43.71)	-2.82 (4.59)	3.00	-120.00 to 78.00
Week 36						
Placebo/MK-3102	61	104.55 (50.38)	101.33 (50.37)	-3.45 (6.53)	1.00	-148.00 to 238.00
Week 52						
Placebo/MK-3102	56	105.25 (48.98)	111.63 (62.53)	7.05 (6.84)	3.00	-90.00 to 197.00

C Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	123.68 (78.63)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	123.68 (78.63)	124.06 (69.52)	0.38 (7.84)	0.00	-246.00 to 210.00
Week 8						
MK-3102/MK-3102	65	123.68 (78.63)	123.11 (70.58)	-0.57 (7.61)	2.00	-212.00 to 234.00
Week 12						
MK-3102/MK-3102	62	123.77 (79.01)	123.53 (54.73)	-0.24 (7.36)	4.00	-297.00 to 126.00
Week 24						
MK-3102/MK-3102	61	123.23 (79.55)	136.11 (94.09)	12.89 (9.28)	7.00	-157.00 to 406.00
Week 28						
MK-3102/MK-3102	61	123.23 (79.55)	133.25 (84.81)	10.02 (9.47)	6.00	-270.00 to 353.00
Week 36						
MK-3102/MK-3102	61	123.23 (79.55)	129.89 (68.61)	6.66 (6.04)	2.00	-154.00 to 114.00
Week 52						
MK-3102/MK-3102	59	123.98 (80.61)	149.51 (144.80)	25.53 (15.88)	2.00	-141.00 to 863.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	116.10 (76.18)	-	-	-	-
Week 28						
Placebo/MK-3102	31	116.10 (76.18)	101.10 (51.29)	-15.00 (11.47)	-1.00	-229.00 to 65.00
Week 36						
Placebo/MK-3102	31	116.10 (76.18)	107.74 (64.13)	-8.35 (13.07)	1.00	-282.00 to 130.00
Week 52						
Placebo/MK-3102	30	118.27 (76.50)	115.13 (86.98)	-3.13 (16.48)	0.00	-241.00 to 320.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	103.76 (77.55)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	103.76 (77.55)	97.82 (42.83)	-5.94 (7.34)	3.00	-317.00 to 81.00
Week 8						
MK-3102/MK-3102	66	103.76 (77.55)	104.38 (56.74)	0.62 (7.33)	7.00	-279.00 to 160.00
Week 12						
MK-3102/MK-3102	66	103.76 (77.55)	101.64 (66.67)	-2.12 (6.46)	2.00	-320.00 to 137.00
Week 24						
MK-3102/MK-3102	65	103.85 (78.15)	102.17 (53.63)	-1.68 (7.60)	4.00	-289.00 to 132.00
Week 28						
MK-3102/MK-3102	65	103.85 (78.15)	105.31 (65.96)	1.46 (6.85)	7.00	-297.00 to 151.00
Week 36						
MK-3102/MK-3102	64	103.84 (78.77)	106.14 (63.46)	2.30 (8.04)	5.00	-261.00 to 230.00
Week 52						
MK-3102/MK-3102	64	103.84 (78.77)	112.84 (125.86)	9.00 (10.81)	4.00	-296.00 to 553.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	105.55 (47.93)	-	-	-	-
Week 28						
Placebo/MK-3102	32	104.41 (48.24)	92.22 (42.52)	-12.19 (5.77)	-8.50	-105.00 to 74.00
Week 36						
Placebo/MK-3102	33	105.55 (47.93)	105.55 (49.45)	0.00 (8.06)	2.00	-108.00 to 129.00
Week 52						
Placebo/MK-3102	33	105.55 (47.93)	97.64 (42.91)	-7.91 (6.33)	-10.00	-90.00 to 80.00

C Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	130.22 (77.60)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	130.22 (77.60)	133.45 (82.17)	3.23 (6.61)	-1.00	-137.00 to 237.00
Week 8						
MK-3102/MK-3102	65	130.22 (77.60)	130.57 (69.94)	0.35 (6.42)	5.00	-159.00 to 153.00
Week 12						
MK-3102/MK-3102	64	131.30 (77.72)	141.33 (106.00)	10.03 (8.72)	7.50	-192.00 to 357.00
Week 24						
MK-3102/MK-3102	63	131.10 (78.32)	137.68 (83.16)	6.59 (6.86)	8.00	-144.00 to 187.00
Week 28						
MK-3102/MK-3102	63	131.10 (78.32)	141.14 (92.15)	10.05 (6.17)	0.00	-95.00 to 180.00
Week 36						
MK-3102/MK-3102	61	131.57 (79.55)	144.51 (81.66)	12.93 (9.30)	1.00	-136.00 to 322.00
Week 52						
MK-3102/MK-3102	60	132.87 (79.57)	158.38 (156.42)	25.52 (16.86)	5.50	-90.00 to 956.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	121.03 (63.38)	-	-	-	-
Week 28						
Placebo/MK-3102	33	121.03 (63.38)	120.33 (62.82)	-0.70 (8.46)	1.00	-111.00 to 161.00
Week 36						
Placebo/MK-3102	33	121.03 (63.38)	134.70 (81.68)	13.67 (7.94)	6.00	-50.00 to 135.00
Week 52						
Placebo/MK-3102	32	122.75 (63.61)	126.16 (61.22)	3.41 (10.08)	-0.50	-182.00 to 118.00

C Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	126.37 (99.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	126.37 (99.22)	120.81 (92.06)	-5.57 (10.26)	2.00	-376.00 to 209.00
Week 8						
MK-3102/MK-3102	67	126.37 (99.22)	126.63 (101.04)	0.25 (8.64)	3.00	-389.00 to 155.00
Week 12						
MK-3102/MK-3102	67	126.37 (99.22)	118.99 (72.22)	-7.39 (10.42)	5.00	-395.00 to 259.00
Week 24						
MK-3102/MK-3102	67	126.37 (99.22)	130.73 (95.92)	4.36 (12.29)	7.00	-389.00 to 448.00
Week 28						
MK-3102/MK-3102	67	126.37 (99.22)	129.12 (90.33)	2.75 (9.89)	7.00	-384.00 to 195.00
Week 36						
MK-3102/MK-3102	67	126.37 (99.22)	127.40 (97.92)	1.03 (11.99)	7.00	-396.00 to 436.00
Week 52						
MK-3102/MK-3102	65	126.86 (100.63)	120.80 (76.58)	-6.06 (9.60)	10.00	-387.00 to 109.00

Confidential

Summary of Change from Baseline by Week in Creatine Kinase (IU/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	102.68 (51.76)	-	-	-	-
Week 28						
Placebo/MK-3102	28	102.68 (51.76)	107.11 (45.17)	4.43 (5.07)	8.00	-87.00 to 49.00
Week 36						
Placebo/MK-3102	28	102.68 (51.76)	110.14 (47.16)	7.46 (5.58)	8.00	-58.00 to 70.00
Week 52						
Placebo/MK-3102	28	102.68 (51.76)	112.46 (59.92)	9.79 (9.44)	7.50	-107.00 to 185.00

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	14.54 (3.92)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	14.54 (3.92)	14.71 (4.02)	0.18 (0.28)	0.20	-8.70 to 11.60
Week 8						
MK-3102/MK-3102	125	14.56 (3.93)	14.69 (3.46)	0.14 (0.28)	0.10	-9.10 to 8.40
Week 12						
MK-3102/MK-3102	124	14.54 (3.94)	15.16 (4.05)	0.62 (0.33)	0.70	-10.40 to 18.70
Week 24						
MK-3102/MK-3102	122	14.58 (3.95)	15.24 (3.93)	0.66 (0.33)	1.10	-9.30 to 9.70
Week 28						
MK-3102/MK-3102	122	14.58 (3.95)	14.64 (3.60)	0.07 (0.32)	0.00	-12.10 to 10.50
Week 36						
MK-3102/MK-3102	118	14.62 (3.98)	14.70 (3.59)	0.08 (0.31)	0.55	-12.60 to 7.20
Week 52						
MK-3102/MK-3102	112	14.53 (3.93)	14.82 (3.34)	0.28 (0.27)	0.30	-7.70 to 6.90

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	14.87 (3.20)	-	-	-	-
Week 28						
Placebo/MK-3102	62	14.87 (3.20)	14.78 (3.40)	-0.15 (0.31)	0.20	-6.60 to 4.30
Week 36						
Placebo/MK-3102	61	14.94 (3.18)	14.41 (3.08)	-0.49 (0.37)	0.00	-6.50 to 4.50
Week 52						
Placebo/MK-3102	56	14.99 (3.22)	14.82 (3.18)	-0.24 (0.40)	-0.50	-6.90 to 5.50

C Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	13.09 (2.69)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	13.09 (2.69)	13.41 (3.15)	0.32 (0.30)	0.30	-5.90 to 7.20
Week 8						
MK-3102/MK-3102	65	13.09 (2.69)	13.16 (3.55)	0.07 (0.32)	0.20	-6.10 to 5.60
Week 12						
MK-3102/MK-3102	62	13.05 (2.69)	13.03 (3.35)	-0.02 (0.30)	-0.25	-5.50 to 5.60
Week 24						
MK-3102/MK-3102	61	13.07 (2.71)	13.56 (3.56)	0.49 (0.36)	0.30	-4.50 to 12.80
Week 28						
MK-3102/MK-3102	61	13.07 (2.71)	13.76 (3.73)	0.69 (0.39)	0.30	-4.90 to 10.30
Week 36						
MK-3102/MK-3102	61	13.07 (2.71)	13.18 (3.67)	0.10 (0.35)	-0.20	-5.00 to 7.80
Week 52						
MK-3102/MK-3102	59	13.09 (2.75)	13.28 (3.38)	0.19 (0.27)	0.30	-3.90 to 5.10

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	14.78 (4.20)	-	-	-	-
Week 28						
Placebo/MK-3102	31	14.78 (4.20)	14.35 (4.15)	-0.44 (0.72)	0.00	-9.90 to 9.50
Week 36						
Placebo/MK-3102	31	14.78 (4.20)	14.75 (3.62)	-0.03 (0.54)	0.10	-6.30 to 4.30
Week 52						
Placebo/MK-3102	30	14.91 (4.21)	14.11 (3.71)	-0.80 (0.55)	-0.80	-7.00 to 4.60

C Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	13.88 (2.92)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	13.88 (2.92)	13.50 (3.24)	-0.38 (0.34)	-0.80	-6.00 to 6.40
Week 8						
MK-3102/MK-3102	66	13.88 (2.92)	13.95 (3.56)	0.07 (0.37)	0.20	-4.80 to 9.80
Week 12						
MK-3102/MK-3102	66	13.88 (2.92)	13.62 (3.42)	-0.26 (0.32)	-0.40	-6.30 to 7.20
Week 24						
MK-3102/MK-3102	65	13.89 (2.94)	13.93 (3.69)	0.04 (0.36)	-0.30	-6.00 to 6.00
Week 28						
MK-3102/MK-3102	65	13.89 (2.94)	13.80 (3.41)	-0.10 (0.33)	0.00	-6.60 to 5.80
Week 36						
MK-3102/MK-3102	64	13.88 (2.96)	13.45 (3.14)	-0.43 (0.33)	-0.50	-6.10 to 6.20
Week 52						
MK-3102/MK-3102	64	13.88 (2.96)	13.50 (2.94)	-0.38 (0.31)	0.05	-7.60 to 5.00

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	14.65 (3.93)	-	-	-	-
Week 28						
Placebo/MK-3102	32	14.57 (3.97)	14.55 (4.42)	-0.02 (0.59)	0.10	-7.90 to 7.40
Week 36						
Placebo/MK-3102	33	14.65 (3.93)	14.00 (3.95)	-0.65 (0.66)	-1.00	-10.80 to 8.50
Week 52						
Placebo/MK-3102	33	14.65 (3.93)	14.51 (3.63)	-0.14 (0.50)	-0.50	-5.90 to 6.50

C Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	14.73 (4.01)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	14.73 (4.01)	14.44 (3.61)	-0.29 (0.41)	-0.30	-10.80 to 7.80
Week 8						
MK-3102/MK-3102	65	14.73 (4.01)	14.76 (3.77)	0.04 (0.36)	-0.50	-7.20 to 6.30
Week 12						
MK-3102/MK-3102	64	14.81 (3.99)	14.55 (3.69)	-0.26 (0.37)	-0.10	-7.10 to 8.00
Week 24						
MK-3102/MK-3102	63	14.78 (4.01)	14.83 (3.99)	0.05 (0.45)	-0.10	-7.80 to 12.30
Week 28						
MK-3102/MK-3102	63	14.78 (4.01)	14.75 (4.00)	-0.03 (0.48)	-0.20	-10.60 to 13.10
Week 36						
MK-3102/MK-3102	61	14.69 (4.02)	15.15 (4.36)	0.46 (0.46)	0.10	-9.10 to 9.60
Week 52						
MK-3102/MK-3102	60	14.64 (4.03)	15.16 (4.68)	0.52 (0.51)	0.40	-9.20 to 8.50

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	15.16 (3.43)	-	-	-	-
Week 28						
Placebo/MK-3102	33	15.16 (3.43)	15.23 (3.73)	0.07 (0.51)	-0.60	-5.70 to 7.60
Week 36						
Placebo/MK-3102	33	15.16 (3.43)	14.35 (2.77)	-0.80 (0.43)	-1.60	-6.50 to 2.90
Week 52						
Placebo/MK-3102	32	15.12 (3.48)	15.01 (3.32)	-0.11 (0.57)	-0.65	-5.90 to 5.80

C Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	13.43 (3.55)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	13.43 (3.55)	13.65 (3.46)	0.22 (0.28)	0.30	-5.10 to 6.80
Week 8						
MK-3102/MK-3102	67	13.43 (3.55)	13.24 (3.71)	-0.19 (0.28)	-0.10	-6.70 to 4.70
Week 12						
MK-3102/MK-3102	67	13.43 (3.55)	13.80 (3.57)	0.37 (0.28)	0.30	-4.80 to 7.50
Week 24						
MK-3102/MK-3102	67	13.43 (3.55)	14.40 (3.91)	0.97 (0.32)	0.90	-6.20 to 8.90
Week 28						
MK-3102/MK-3102	67	13.43 (3.55)	14.19 (3.99)	0.76 (0.35)	0.80	-8.40 to 7.10
Week 36						
MK-3102/MK-3102	67	13.43 (3.55)	13.80 (3.84)	0.37 (0.37)	-0.30	-5.60 to 7.70
Week 52						
MK-3102/MK-3102	65	13.41 (3.60)	13.65 (4.30)	0.24 (0.34)	-0.10	-4.80 to 9.30

Confidential

Summary of Change from Baseline by Week in Blood Urea Nitrogen (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	13.83 (3.72)	-	-	-	-
Week 28						
Placebo/MK-3102	28	13.83 (3.72)	13.55 (3.36)	-0.29 (0.47)	-0.20	-6.10 to 5.10
Week 36						
Placebo/MK-3102	28	13.83 (3.72)	13.50 (2.87)	-0.33 (0.54)	-0.20	-6.30 to 4.40
Week 52						
Placebo/MK-3102	28	13.83 (3.72)	14.61 (3.34)	0.78 (0.68)	1.35	-6.00 to 8.30

C Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	0.75 (0.15)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	0.75 (0.15)	0.76 (0.17)	0.02 (0.01)	0.01	-0.13 to 0.32
Week 8						
MK-3102/MK-3102	125	0.75 (0.15)	0.76 (0.16)	0.01 (0.01)	0.01	-0.16 to 0.18
Week 12						
MK-3102/MK-3102	124	0.75 (0.15)	0.77 (0.16)	0.02 (0.01)	0.01	-0.13 to 0.38
Week 24						
MK-3102/MK-3102	122	0.74 (0.15)	0.77 (0.17)	0.02 (0.01)	0.01	-0.13 to 0.24
Week 28						
MK-3102/MK-3102	122	0.74 (0.15)	0.77 (0.17)	0.03 (0.01)	0.02	-0.14 to 0.30
Week 36						
MK-3102/MK-3102	118	0.75 (0.15)	0.77 (0.16)	0.02 (0.01)	0.02	-0.20 to 0.20
Week 52						
MK-3102/MK-3102	112	0.75 (0.16)	0.77 (0.17)	0.02 (0.01)	0.02	-0.19 to 0.20

C Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	0.74 (0.16)	-	-	-	-
Week 28						
Placebo/MK-3102	62	0.74 (0.16)	0.75 (0.17)	0.01 (0.01)	0.01	-0.10 to 0.15
Week 36						
Placebo/MK-3102	61	0.74 (0.16)	0.76 (0.16)	0.02 (0.01)	0.01	-0.10 to 0.19
Week 52						
Placebo/MK-3102	56	0.74 (0.16)	0.76 (0.17)	0.01 (0.01)	0.01	-0.10 to 0.15

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	0.75 (0.17)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	0.75 (0.17)	0.76 (0.19)	0.00 (0.01)	0.00	-0.12 to 0.16
Week 8						
MK-3102/MK-3102	65	0.75 (0.17)	0.76 (0.18)	0.00 (0.01)	0.00	-0.13 to 0.14
Week 12						
MK-3102/MK-3102	62	0.75 (0.17)	0.76 (0.19)	0.01 (0.01)	0.01	-0.13 to 0.17
Week 24						
MK-3102/MK-3102	61	0.75 (0.17)	0.75 (0.18)	-0.00 (0.01)	-0.01	-0.18 to 0.16
Week 28						
MK-3102/MK-3102	61	0.75 (0.17)	0.77 (0.17)	0.01 (0.01)	0.00	-0.14 to 0.19
Week 36						
MK-3102/MK-3102	61	0.75 (0.17)	0.76 (0.17)	0.00 (0.01)	0.00	-0.15 to 0.21
Week 52						
MK-3102/MK-3102	59	0.76 (0.17)	0.75 (0.17)	-0.01 (0.01)	-0.01	-0.17 to 0.10

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	0.74 (0.17)	-	-	-	-
Week 28						
Placebo/MK-3102	31	0.74 (0.17)	0.79 (0.20)	0.04 (0.01)	0.03	-0.14 to 0.28
Week 36						
Placebo/MK-3102	31	0.74 (0.17)	0.76 (0.17)	0.02 (0.01)	0.02	-0.13 to 0.21
Week 52						
Placebo/MK-3102	30	0.75 (0.17)	0.76 (0.16)	0.01 (0.01)	0.02	-0.17 to 0.10

C Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	0.70 (0.15)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	0.70 (0.15)	0.69 (0.15)	-0.00 (0.01)	-0.01	-0.12 to 0.11
Week 8						
MK-3102/MK-3102	66	0.70 (0.15)	0.70 (0.14)	0.00 (0.01)	0.00	-0.13 to 0.15
Week 12						
MK-3102/MK-3102	66	0.70 (0.15)	0.70 (0.15)	-0.00 (0.01)	-0.01	-0.15 to 0.16
Week 24						
MK-3102/MK-3102	65	0.70 (0.15)	0.71 (0.15)	0.01 (0.01)	0.00	-0.17 to 0.21
Week 28						
MK-3102/MK-3102	65	0.70 (0.15)	0.72 (0.15)	0.02 (0.01)	0.02	-0.11 to 0.17
Week 36						
MK-3102/MK-3102	64	0.70 (0.15)	0.71 (0.14)	0.01 (0.01)	0.02	-0.15 to 0.15
Week 52						
MK-3102/MK-3102	64	0.70 (0.15)	0.71 (0.15)	0.01 (0.01)	0.01	-0.20 to 0.14

C Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	0.70 (0.13)	-	-	-	-
Week 28						
Placebo/MK-3102	32	0.70 (0.13)	0.70 (0.13)	0.01 (0.01)	0.01	-0.11 to 0.11
Week 36						
Placebo/MK-3102	33	0.70 (0.13)	0.72 (0.13)	0.02 (0.01)	0.02	-0.05 to 0.10
Week 52						
Placebo/MK-3102	33	0.70 (0.13)	0.73 (0.13)	0.03 (0.01)	0.02	-0.07 to 0.17

C Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	0.74 (0.19)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	0.74 (0.19)	0.75 (0.19)	0.01 (0.01)	0.01	-0.12 to 0.12
Week 8						
MK-3102/MK-3102	65	0.74 (0.19)	0.76 (0.20)	0.02 (0.01)	0.02	-0.12 to 0.17
Week 12						
MK-3102/MK-3102	64	0.74 (0.18)	0.75 (0.20)	0.01 (0.01)	0.01	-0.12 to 0.19
Week 24						
MK-3102/MK-3102	63	0.74 (0.18)	0.76 (0.21)	0.01 (0.01)	0.00	-0.18 to 0.39
Week 28						
MK-3102/MK-3102	63	0.74 (0.18)	0.75 (0.21)	0.01 (0.01)	-0.01	-0.13 to 0.29
Week 36						
MK-3102/MK-3102	61	0.74 (0.19)	0.76 (0.22)	0.02 (0.01)	0.00	-0.12 to 0.34
Week 52						
MK-3102/MK-3102	60	0.74 (0.19)	0.76 (0.21)	0.01 (0.01)	0.01	-0.18 to 0.28

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	0.71 (0.14)	-	-	-	-
Week 28						
Placebo/MK-3102	33	0.71 (0.14)	0.73 (0.13)	0.03 (0.01)	0.03	-0.09 to 0.13
Week 36						
Placebo/MK-3102	33	0.71 (0.14)	0.72 (0.13)	0.01 (0.01)	0.02	-0.12 to 0.13
Week 52						
Placebo/MK-3102	32	0.71 (0.14)	0.74 (0.14)	0.03 (0.01)	0.04	-0.08 to 0.12

C Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	0.74 (0.17)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	0.74 (0.17)	0.76 (0.17)	0.02 (0.01)	0.02	-0.18 to 0.14
Week 8						
MK-3102/MK-3102	67	0.74 (0.17)	0.75 (0.17)	0.01 (0.01)	0.01	-0.13 to 0.12
Week 12						
MK-3102/MK-3102	67	0.74 (0.17)	0.75 (0.17)	0.01 (0.01)	0.01	-0.19 to 0.16
Week 24						
MK-3102/MK-3102	67	0.74 (0.17)	0.76 (0.20)	0.03 (0.01)	0.02	-0.14 to 0.71
Week 28						
MK-3102/MK-3102	67	0.74 (0.17)	0.76 (0.18)	0.02 (0.01)	0.02	-0.15 to 0.28
Week 36						
MK-3102/MK-3102	67	0.74 (0.17)	0.76 (0.17)	0.02 (0.01)	0.02	-0.25 to 0.23
Week 52						
MK-3102/MK-3102	65	0.74 (0.17)	0.76 (0.18)	0.02 (0.01)	0.03	-0.08 to 0.14

Confidential

Summary of Change from Baseline by Week in Creatinine (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	0.72 (0.13)	-	-	-	-
Week 28						
Placebo/MK-3102	28	0.72 (0.13)	0.73 (0.17)	0.00 (0.01)	0.00	-0.08 to 0.22
Week 36						
Placebo/MK-3102	28	0.72 (0.13)	0.73 (0.14)	0.01 (0.01)	0.00	-0.08 to 0.15
Week 52						
Placebo/MK-3102	28	0.72 (0.13)	0.75 (0.16)	0.03 (0.01)	0.03	-0.07 to 0.16

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	5.01 (1.08)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	5.01 (1.08)	5.36 (1.23)	0.35 (0.07)	0.35	-2.50 to 3.40
Week 8						
MK-3102/MK-3102	125	5.01 (1.09)	5.41 (1.18)	0.39 (0.06)	0.40	-1.70 to 1.90
Week 12						
MK-3102/MK-3102	124	5.02 (1.09)	5.37 (1.23)	0.36 (0.06)	0.35	-2.40 to 1.80
Week 24						
MK-3102/MK-3102	122	5.00 (1.09)	5.47 (1.17)	0.47 (0.07)	0.50	-3.30 to 3.00
Week 28						
MK-3102/MK-3102	122	5.00 (1.09)	5.45 (1.24)	0.46 (0.06)	0.45	-2.40 to 2.20
Week 36						
MK-3102/MK-3102	118	4.99 (1.11)	5.33 (1.20)	0.34 (0.06)	0.40	-2.30 to 2.10
Week 52						
MK-3102/MK-3102	112	4.98 (1.12)	5.22 (1.22)	0.24 (0.07)	0.30	-1.40 to 1.90

Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	4.94 (1.47)	-	-	-	-
Week 28						
Placebo/MK-3102	62	4.94 (1.47)	5.11 (1.41)	0.16 (0.06)	0.20	-1.10 to 1.40
Week 36						
Placebo/MK-3102	61	4.92 (1.47)	5.07 (1.43)	0.14 (0.08)	0.20	-1.30 to 1.40
Week 52						
Placebo/MK-3102	56	4.84 (1.38)	5.03 (1.48)	0.14 (0.08)	0.10	-0.80 to 1.90

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	5.32 (1.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	5.32 (1.22)	5.63 (1.34)	0.31 (0.08)	0.30	-1.40 to 2.00
Week 8						
MK-3102/MK-3102	65	5.32 (1.22)	5.53 (1.29)	0.21 (0.08)	0.20	-1.50 to 1.90
Week 12						
MK-3102/MK-3102	62	5.27 (1.20)	5.51 (1.35)	0.24 (0.08)	0.25	-1.90 to 1.70
Week 24						
MK-3102/MK-3102	61	5.30 (1.19)	5.79 (1.34)	0.49 (0.09)	0.40	-0.80 to 2.70
Week 28						
MK-3102/MK-3102	61	5.30 (1.19)	5.87 (1.35)	0.57 (0.09)	0.60	-0.60 to 2.60
Week 36						
MK-3102/MK-3102	61	5.30 (1.19)	5.68 (1.28)	0.38 (0.09)	0.40	-1.40 to 2.30
Week 52						
MK-3102/MK-3102	59	5.31 (1.21)	5.38 (1.25)	0.08 (0.09)	0.10	-2.10 to 1.90

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	5.20 (1.26)	-	-	-	-
Week 28						
Placebo/MK-3102	31	5.20 (1.26)	5.50 (1.32)	0.30 (0.10)	0.30	-0.90 to 1.30
Week 36						
Placebo/MK-3102	31	5.20 (1.26)	5.40 (1.30)	0.20 (0.12)	0.20	-1.10 to 2.00
Week 52						
Placebo/MK-3102	30	5.28 (1.21)	5.22 (1.15)	-0.05 (0.09)	-0.05	-1.20 to 0.80

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	4.90 (1.28)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	4.90 (1.28)	5.00 (1.31)	0.10 (0.06)	0.10	-0.90 to 1.20
Week 8						
MK-3102/MK-3102	66	4.90 (1.28)	5.22 (1.32)	0.32 (0.07)	0.35	-0.70 to 1.80
Week 12						
MK-3102/MK-3102	66	4.90 (1.28)	5.08 (1.28)	0.18 (0.08)	0.10	-1.20 to 2.00
Week 24						
MK-3102/MK-3102	65	4.90 (1.29)	5.22 (1.26)	0.32 (0.09)	0.30	-1.10 to 2.00
Week 28						
MK-3102/MK-3102	65	4.90 (1.29)	5.35 (1.39)	0.45 (0.09)	0.40	-1.30 to 2.50
Week 36						
MK-3102/MK-3102	64	4.87 (1.29)	5.19 (1.31)	0.32 (0.08)	0.25	-1.20 to 1.80
Week 52						
MK-3102/MK-3102	64	4.87 (1.29)	5.00 (1.24)	0.13 (0.08)	0.10	-1.20 to 1.80

Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	5.12 (0.99)	-	-	-	-
Week 28						
Placebo/MK-3102	32	5.14 (1.00)	5.36 (1.14)	0.22 (0.09)	0.25	-1.00 to 1.20
Week 36						
Placebo/MK-3102	33	5.12 (0.99)	5.37 (0.97)	0.25 (0.09)	0.20	-0.90 to 1.40
Week 52						
Placebo/MK-3102	33	5.12 (0.99)	5.32 (0.97)	0.20 (0.13)	0.00	-1.50 to 1.70

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	4.72 (1.23)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	4.72 (1.23)	5.04 (1.40)	0.31 (0.06)	0.30	-0.80 to 1.50
Week 8						
MK-3102/MK-3102	65	4.72 (1.23)	5.26 (1.44)	0.54 (0.08)	0.50	-0.70 to 3.20
Week 12						
MK-3102/MK-3102	64	4.75 (1.22)	5.11 (1.38)	0.36 (0.08)	0.25	-0.80 to 1.90
Week 24						
MK-3102/MK-3102	63	4.74 (1.23)	5.32 (1.49)	0.58 (0.09)	0.50	-1.00 to 3.00
Week 28						
MK-3102/MK-3102	63	4.74 (1.23)	5.34 (1.55)	0.59 (0.10)	0.60	-1.10 to 2.80
Week 36						
MK-3102/MK-3102	61	4.76 (1.25)	5.34 (1.56)	0.58 (0.10)	0.50	-0.70 to 3.30
Week 52						
MK-3102/MK-3102	60	4.76 (1.26)	5.19 (1.50)	0.43 (0.10)	0.40	-1.00 to 3.40

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	5.05 (1.24)	-	-	-	-
Week 28						
Placebo/MK-3102	33	5.05 (1.24)	5.44 (1.29)	0.39 (0.12)	0.40	-1.00 to 1.70
Week 36						
Placebo/MK-3102	33	5.05 (1.24)	5.32 (1.26)	0.27 (0.10)	0.20	-0.90 to 1.50
Week 52						
Placebo/MK-3102	32	5.03 (1.25)	5.33 (1.19)	0.31 (0.13)	0.20	-1.00 to 2.10

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	4.98 (1.12)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	4.98 (1.12)	5.25 (0.98)	0.27 (0.08)	0.20	-1.60 to 1.50
Week 8						
MK-3102/MK-3102	67	4.98 (1.12)	5.41 (1.17)	0.43 (0.09)	0.50	-1.30 to 2.20
Week 12						
MK-3102/MK-3102	67	4.98 (1.12)	5.42 (1.20)	0.44 (0.08)	0.30	-0.90 to 2.20
Week 24						
MK-3102/MK-3102	67	4.98 (1.12)	5.61 (1.24)	0.63 (0.10)	0.60	-1.70 to 2.70
Week 28						
MK-3102/MK-3102	67	4.98 (1.12)	5.64 (1.22)	0.66 (0.09)	0.70	-1.10 to 2.80
Week 36						
MK-3102/MK-3102	67	4.98 (1.12)	5.65 (1.25)	0.67 (0.09)	0.70	-0.70 to 3.60
Week 52						
MK-3102/MK-3102	65	4.99 (1.13)	5.44 (1.28)	0.45 (0.08)	0.40	-1.30 to 1.70

C Confidential

Summary of Change from Baseline by Week in Urate (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	5.31 (1.42)	-	-	-	-
Week 28						
Placebo/MK-3102	28	5.31 (1.42)	5.46 (1.48)	0.15 (0.09)	0.05	-0.60 to 1.20
Week 36						
Placebo/MK-3102	28	5.31 (1.42)	5.50 (1.46)	0.19 (0.10)	0.00	-0.70 to 1.40
Week 52						
Placebo/MK-3102	28	5.31 (1.42)	5.50 (1.44)	0.19 (0.10)	0.30	-0.80 to 0.90

C Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	140.63 (1.78)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	140.63 (1.78)	141.26 (1.90)	0.63 (0.16)	1.00	-4.00 to 6.00
Week 8						
MK-3102/MK-3102	125	140.62 (1.78)	141.04 (1.62)	0.42 (0.14)	0.00	-3.00 to 4.00
Week 12						
MK-3102/MK-3102	124	140.64 (1.78)	141.37 (1.77)	0.73 (0.15)	1.00	-3.00 to 5.00
Week 24						
MK-3102/MK-3102	122	140.66 (1.79)	141.08 (1.81)	0.43 (0.16)	0.00	-4.00 to 4.00
Week 28						
MK-3102/MK-3102	122	140.66 (1.79)	141.00 (1.83)	0.34 (0.16)	0.00	-5.00 to 4.00
Week 36						
MK-3102/MK-3102	118	140.68 (1.81)	140.55 (1.84)	-0.13 (0.16)	0.00	-4.00 to 4.00
Week 52						
MK-3102/MK-3102	112	140.71 (1.78)	140.91 (1.80)	0.20 (0.17)	0.00	-5.00 to 4.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	140.75 (1.53)	-	-	-	-
Week 28						
Placebo/MK-3102	62	140.75 (1.53)	140.97 (1.77)	0.18 (0.20)	0.00	-5.00 to 3.00
Week 36						
Placebo/MK-3102	61	140.77 (1.54)	140.61 (1.90)	-0.18 (0.26)	-0.50	-5.00 to 4.00
Week 52						
Placebo/MK-3102	56	140.82 (1.56)	141.11 (1.61)	0.24 (0.23)	0.00	-3.00 to 4.00

C Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	140.06 (2.00)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	140.06 (2.00)	140.78 (1.94)	0.72 (0.20)	1.00	-3.00 to 7.00
Week 8						
MK-3102/MK-3102	65	140.06 (2.00)	140.49 (1.91)	0.43 (0.20)	0.00	-2.00 to 5.00
Week 12						
MK-3102/MK-3102	62	140.05 (2.03)	140.69 (1.78)	0.65 (0.21)	1.00	-4.00 to 4.00
Week 24						
MK-3102/MK-3102	61	140.13 (1.94)	140.87 (2.22)	0.74 (0.23)	1.00	-3.00 to 5.00
Week 28						
MK-3102/MK-3102	61	140.13 (1.94)	140.67 (1.98)	0.54 (0.25)	1.00	-4.00 to 4.00
Week 36						
MK-3102/MK-3102	61	140.13 (1.94)	140.41 (2.55)	0.28 (0.23)	1.00	-6.00 to 3.00
Week 52						
MK-3102/MK-3102	59	140.22 (1.90)	140.31 (2.28)	0.08 (0.22)	0.00	-5.00 to 3.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	140.87 (1.52)	-	-	-	-
Week 28						
Placebo/MK-3102	31	140.87 (1.52)	140.90 (1.80)	0.03 (0.28)	0.00	-3.00 to 3.00
Week 36						
Placebo/MK-3102	31	140.87 (1.52)	140.65 (1.50)	-0.23 (0.28)	0.00	-4.00 to 4.00
Week 52						
Placebo/MK-3102	30	140.90 (1.54)	140.30 (2.00)	-0.60 (0.27)	-1.00	-4.00 to 3.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	139.91 (1.86)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	139.91 (1.86)	140.73 (1.61)	0.82 (0.20)	1.00	-3.00 to 4.00
Week 8						
MK-3102/MK-3102	66	139.91 (1.86)	140.62 (1.75)	0.71 (0.20)	1.00	-3.00 to 5.00
Week 12						
MK-3102/MK-3102	66	139.91 (1.86)	140.83 (1.96)	0.92 (0.22)	1.00	-4.00 to 5.00
Week 24						
MK-3102/MK-3102	65	139.92 (1.87)	140.82 (1.58)	0.89 (0.20)	1.00	-2.00 to 5.00
Week 28						
MK-3102/MK-3102	65	139.92 (1.87)	140.86 (1.53)	0.94 (0.19)	1.00	-2.00 to 5.00
Week 36						
MK-3102/MK-3102	64	139.94 (1.88)	140.23 (1.73)	0.30 (0.22)	0.00	-4.00 to 4.00
Week 52						
MK-3102/MK-3102	64	139.94 (1.88)	140.59 (1.80)	0.66 (0.18)	1.00	-3.00 to 4.00

C Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	141.09 (1.23)	-	-	-	-
Week 28						
Placebo/MK-3102	32	141.13 (1.24)	140.88 (1.36)	-0.25 (0.21)	0.00	-3.00 to 1.00
Week 36						
Placebo/MK-3102	33	141.09 (1.23)	140.55 (1.79)	-0.55 (0.27)	0.00	-4.00 to 2.00
Week 52						
Placebo/MK-3102	33	141.09 (1.23)	141.00 (1.56)	-0.09 (0.30)	0.00	-4.00 to 2.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	140.43 (1.64)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	140.43 (1.64)	140.80 (1.68)	0.37 (0.21)	0.00	-4.00 to 4.00
Week 8						
MK-3102/MK-3102	65	140.43 (1.64)	140.72 (1.52)	0.29 (0.20)	0.00	-3.00 to 4.00
Week 12						
MK-3102/MK-3102	64	140.42 (1.65)	141.13 (1.57)	0.70 (0.23)	0.00	-3.00 to 5.00
Week 24						
MK-3102/MK-3102	63	140.44 (1.65)	141.13 (1.88)	0.68 (0.22)	1.00	-3.00 to 5.00
Week 28						
MK-3102/MK-3102	63	140.44 (1.65)	140.98 (1.60)	0.54 (0.22)	1.00	-3.00 to 4.00
Week 36						
MK-3102/MK-3102	61	140.46 (1.67)	140.75 (1.93)	0.30 (0.24)	0.00	-4.00 to 4.00
Week 52						
MK-3102/MK-3102	60	140.45 (1.68)	140.65 (2.04)	0.20 (0.24)	0.00	-5.00 to 5.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	141.48 (1.92)	-	-	-	-
Week 28						
Placebo/MK-3102	33	141.48 (1.92)	141.12 (1.83)	-0.36 (0.26)	0.00	-3.00 to 3.00
Week 36						
Placebo/MK-3102	33	141.48 (1.92)	140.85 (1.91)	-0.64 (0.30)	0.00	-5.00 to 2.00
Week 52						
Placebo/MK-3102	32	141.44 (1.93)	141.38 (1.81)	-0.06 (0.29)	0.00	-3.00 to 4.00

C Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	140.31 (1.77)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	140.31 (1.77)	140.94 (2.05)	0.63 (0.20)	0.00	-2.00 to 4.00
Week 8						
MK-3102/MK-3102	67	140.31 (1.77)	140.82 (1.82)	0.51 (0.18)	1.00	-3.00 to 4.00
Week 12						
MK-3102/MK-3102	67	140.31 (1.77)	141.07 (1.58)	0.76 (0.19)	1.00	-3.00 to 5.00
Week 24						
MK-3102/MK-3102	67	140.31 (1.77)	141.07 (1.88)	0.76 (0.22)	1.00	-3.00 to 6.00
Week 28						
MK-3102/MK-3102	67	140.31 (1.77)	140.93 (1.89)	0.61 (0.23)	1.00	-3.00 to 4.00
Week 36						
MK-3102/MK-3102	67	140.31 (1.77)	140.69 (1.97)	0.37 (0.26)	0.00	-4.00 to 6.00
Week 52						
MK-3102/MK-3102	65	140.31 (1.79)	140.71 (1.88)	0.40 (0.18)	0.00	-3.00 to 4.00

Confidential

Summary of Change from Baseline by Week in Sodium (mEq/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	140.79 (1.87)	-	-	-	-
Week 28						
Placebo/MK-3102	28	140.79 (1.87)	140.79 (1.73)	0.00 (0.27)	0.00	-4.00 to 2.00
Week 36						
Placebo/MK-3102	28	140.79 (1.87)	140.07 (1.72)	-0.71 (0.34)	-1.00	-4.00 to 3.00
Week 52						
Placebo/MK-3102	28	140.79 (1.87)	140.75 (1.53)	-0.04 (0.35)	0.00	-3.00 to 4.00

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	4.30 (0.36)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	4.30 (0.36)	4.36 (0.34)	0.06 (0.03)	0.05	-0.80 to 1.00
Week 8						
MK-3102/MK-3102	125	4.30 (0.36)	4.35 (0.31)	0.05 (0.03)	0.00	-0.90 to 0.90
Week 12						
MK-3102/MK-3102	124	4.30 (0.37)	4.35 (0.35)	0.05 (0.03)	0.00	-0.90 to 0.90
Week 24						
MK-3102/MK-3102	122	4.30 (0.37)	4.24 (0.34)	-0.06 (0.03)	-0.05	-0.90 to 1.50
Week 28						
MK-3102/MK-3102	122	4.30 (0.37)	4.27 (0.36)	-0.03 (0.03)	0.00	-0.90 to 1.00
Week 36						
MK-3102/MK-3102	118	4.29 (0.37)	4.27 (0.30)	-0.02 (0.02)	0.00	-0.80 to 0.60
Week 52						
MK-3102/MK-3102	112	4.30 (0.37)	4.24 (0.33)	-0.06 (0.03)	-0.10	-0.80 to 0.80

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	4.28 (0.31)	-	-	-	-
Week 28						
Placebo/MK-3102	62	4.28 (0.31)	4.26 (0.31)	-0.02 (0.03)	0.00	-0.70 to 0.60
Week 36						
Placebo/MK-3102	61	4.28 (0.31)	4.36 (0.36)	0.06 (0.04)	0.05	-0.60 to 1.00
Week 52						
Placebo/MK-3102	56	4.30 (0.31)	4.28 (0.30)	-0.03 (0.04)	0.00	-0.80 to 0.80

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	4.28 (0.30)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	4.28 (0.30)	4.35 (0.35)	0.07 (0.04)	0.10	-0.70 to 0.70
Week 8						
MK-3102/MK-3102	65	4.28 (0.30)	4.36 (0.36)	0.08 (0.04)	0.10	-0.50 to 0.90
Week 12						
MK-3102/MK-3102	62	4.29 (0.31)	4.35 (0.41)	0.07 (0.04)	0.00	-0.60 to 1.00
Week 24						
MK-3102/MK-3102	61	4.30 (0.28)	4.30 (0.37)	-0.00 (0.05)	0.00	-0.90 to 1.10
Week 28						
MK-3102/MK-3102	61	4.30 (0.28)	4.29 (0.29)	-0.01 (0.04)	-0.10	-0.70 to 0.60
Week 36						
MK-3102/MK-3102	61	4.30 (0.28)	4.25 (0.28)	-0.05 (0.04)	-0.10	-0.80 to 0.70
Week 52						
MK-3102/MK-3102	59	4.31 (0.28)	4.22 (0.33)	-0.09 (0.04)	-0.10	-0.60 to 0.70

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	4.22 (0.30)	-	-	-	-
Week 28						
Placebo/MK-3102	31	4.22 (0.30)	4.24 (0.29)	0.02 (0.06)	0.00	-0.80 to 1.00
Week 36						
Placebo/MK-3102	31	4.22 (0.30)	4.25 (0.28)	0.03 (0.05)	0.00	-0.50 to 0.60
Week 52						
Placebo/MK-3102	30	4.22 (0.30)	4.24 (0.29)	0.02 (0.06)	0.10	-0.80 to 0.60

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	4.38 (0.35)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	4.38 (0.35)	4.41 (0.31)	0.03 (0.04)	0.05	-0.60 to 1.10
Week 8						
MK-3102/MK-3102	66	4.38 (0.35)	4.38 (0.32)	0.01 (0.04)	0.00	-0.70 to 1.00
Week 12						
MK-3102/MK-3102	66	4.38 (0.35)	4.35 (0.30)	-0.02 (0.04)	0.00	-0.80 to 0.70
Week 24						
MK-3102/MK-3102	65	4.38 (0.35)	4.28 (0.28)	-0.10 (0.04)	-0.10	-0.90 to 0.70
Week 28						
MK-3102/MK-3102	65	4.38 (0.35)	4.30 (0.27)	-0.08 (0.04)	-0.10	-0.70 to 0.60
Week 36						
MK-3102/MK-3102	64	4.38 (0.35)	4.29 (0.29)	-0.09 (0.04)	-0.10	-0.90 to 0.40
Week 52						
MK-3102/MK-3102	64	4.38 (0.35)	4.27 (0.32)	-0.11 (0.04)	-0.10	-1.20 to 0.50

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	4.17 (0.25)	-	-	-	-
Week 28						
Placebo/MK-3102	32	4.17 (0.25)	4.26 (0.31)	0.09 (0.05)	0.10	-0.60 to 0.70
Week 36						
Placebo/MK-3102	33	4.17 (0.25)	4.33 (0.42)	0.16 (0.07)	0.10	-0.50 to 2.00
Week 52						
Placebo/MK-3102	33	4.17 (0.25)	4.32 (0.38)	0.15 (0.06)	0.10	-0.70 to 0.90

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	4.28 (0.30)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	4.28 (0.30)	4.33 (0.33)	0.06 (0.04)	0.10	-0.70 to 1.30
Week 8						
MK-3102/MK-3102	65	4.28 (0.30)	4.39 (0.34)	0.11 (0.04)	0.10	-0.70 to 0.90
Week 12						
MK-3102/MK-3102	64	4.28 (0.30)	4.34 (0.39)	0.06 (0.04)	0.05	-0.70 to 1.30
Week 24						
MK-3102/MK-3102	63	4.28 (0.30)	4.25 (0.34)	-0.03 (0.03)	0.00	-0.60 to 0.70
Week 28						
MK-3102/MK-3102	63	4.28 (0.30)	4.25 (0.32)	-0.03 (0.04)	0.00	-0.90 to 0.80
Week 36						
MK-3102/MK-3102	61	4.28 (0.30)	4.29 (0.39)	0.01 (0.04)	0.00	-0.50 to 0.70
Week 52						
MK-3102/MK-3102	60	4.28 (0.30)	4.25 (0.29)	-0.03 (0.04)	0.00	-0.80 to 0.50

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	4.22 (0.37)	-	-	-	-
Week 28						
Placebo/MK-3102	33	4.22 (0.37)	4.29 (0.32)	0.07 (0.06)	0.10	-1.10 to 0.80
Week 36						
Placebo/MK-3102	33	4.22 (0.37)	4.17 (0.37)	-0.05 (0.07)	0.00	-1.30 to 0.50
Week 52						
Placebo/MK-3102	32	4.22 (0.37)	4.22 (0.35)	-0.00 (0.05)	-0.05	-0.50 to 0.60

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	4.23 (0.37)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	4.23 (0.37)	4.38 (0.38)	0.15 (0.04)	0.20	-0.60 to 0.80
Week 8						
MK-3102/MK-3102	67	4.23 (0.37)	4.34 (0.33)	0.11 (0.04)	0.10	-0.70 to 0.70
Week 12						
MK-3102/MK-3102	67	4.23 (0.37)	4.36 (0.40)	0.12 (0.04)	0.10	-0.70 to 1.00
Week 24						
MK-3102/MK-3102	67	4.23 (0.37)	4.18 (0.28)	-0.06 (0.04)	0.00	-0.70 to 0.80
Week 28						
MK-3102/MK-3102	67	4.23 (0.37)	4.25 (0.36)	0.01 (0.04)	-0.10	-0.90 to 0.90
Week 36						
MK-3102/MK-3102	67	4.23 (0.37)	4.28 (0.36)	0.05 (0.04)	0.10	-0.70 to 0.80
Week 52						
MK-3102/MK-3102	65	4.24 (0.37)	4.19 (0.32)	-0.04 (0.04)	-0.10	-0.70 to 0.60

C Confidential

Summary of Change from Baseline by Week in Potassium (mEq/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	4.24 (0.35)	-	-	-	-
Week 28						
Placebo/MK-3102	28	4.24 (0.35)	4.28 (0.34)	0.04 (0.05)	0.00	-0.50 to 0.60
Week 36						
Placebo/MK-3102	28	4.24 (0.35)	4.29 (0.36)	0.04 (0.05)	0.10	-0.60 to 0.60
Week 52						
Placebo/MK-3102	28	4.24 (0.35)	4.23 (0.47)	-0.01 (0.07)	0.00	-0.60 to 1.20

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	101.79 (2.22)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	101.79 (2.22)	102.28 (2.02)	0.48 (0.20)	0.00	-7.00 to 7.00
Week 8						
MK-3102/MK-3102	125	101.78 (2.22)	102.85 (2.30)	1.06 (0.21)	1.00	-6.00 to 6.00
Week 12						
MK-3102/MK-3102	124	101.81 (2.22)	103.08 (2.27)	1.27 (0.21)	1.00	-6.00 to 7.00
Week 24						
MK-3102/MK-3102	122	101.83 (2.21)	103.10 (2.25)	1.27 (0.22)	1.00	-5.00 to 8.00
Week 28						
MK-3102/MK-3102	122	101.83 (2.21)	103.59 (2.22)	1.76 (0.21)	2.00	-4.00 to 7.00
Week 36						
MK-3102/MK-3102	118	101.85 (2.21)	103.34 (2.18)	1.49 (0.21)	1.00	-3.00 to 8.00
Week 52						
MK-3102/MK-3102	112	101.90 (2.20)	102.46 (1.98)	0.55 (0.20)	1.00	-5.00 to 6.00

Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	102.57 (2.01)	-	-	-	-
Week 28						
Placebo/MK-3102	62	102.57 (2.01)	103.44 (2.13)	0.82 (0.28)	1.00	-4.00 to 6.00
Week 36						
Placebo/MK-3102	61	102.57 (2.03)	103.18 (2.33)	0.57 (0.30)	1.00	-5.00 to 7.00
Week 52						
Placebo/MK-3102	56	102.73 (1.88)	102.61 (2.01)	-0.18 (0.30)	0.00	-5.00 to 6.00

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	100.95 (2.62)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	100.95 (2.62)	101.83 (2.32)	0.88 (0.31)	1.00	-3.00 to 8.00
Week 8						
MK-3102/MK-3102	65	100.95 (2.62)	101.68 (2.42)	0.72 (0.33)	0.00	-5.00 to 9.00
Week 12						
MK-3102/MK-3102	62	100.94 (2.67)	101.56 (2.48)	0.63 (0.33)	1.00	-7.00 to 9.00
Week 24						
MK-3102/MK-3102	61	101.02 (2.61)	102.69 (2.38)	1.67 (0.33)	2.00	-6.00 to 7.00
Week 28						
MK-3102/MK-3102	61	101.02 (2.61)	103.31 (2.30)	2.30 (0.34)	2.00	-5.00 to 10.00
Week 36						
MK-3102/MK-3102	61	101.02 (2.61)	102.98 (2.72)	1.97 (0.32)	2.00	-5.00 to 8.00
Week 52						
MK-3102/MK-3102	59	101.12 (2.59)	102.24 (2.35)	1.12 (0.33)	1.00	-4.00 to 8.00

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	102.39 (2.08)	-	-	-	-
Week 28						
Placebo/MK-3102	31	102.39 (2.08)	104.03 (2.02)	1.65 (0.30)	1.00	-1.00 to 5.00
Week 36						
Placebo/MK-3102	31	102.39 (2.08)	103.48 (2.00)	1.10 (0.33)	1.00	-2.00 to 4.00
Week 52						
Placebo/MK-3102	30	102.50 (2.01)	102.17 (1.98)	-0.33 (0.34)	0.00	-4.00 to 3.00

Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	100.79 (2.33)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	100.79 (2.33)	101.77 (2.26)	0.98 (0.27)	1.00	-4.00 to 5.00
Week 8						
MK-3102/MK-3102	66	100.79 (2.33)	101.65 (1.78)	0.86 (0.24)	1.00	-4.00 to 5.00
Week 12						
MK-3102/MK-3102	66	100.79 (2.33)	101.89 (2.33)	1.11 (0.26)	1.00	-3.00 to 7.00
Week 24						
MK-3102/MK-3102	65	100.80 (2.35)	102.97 (1.98)	2.17 (0.27)	2.00	-2.00 to 6.00
Week 28						
MK-3102/MK-3102	65	100.80 (2.35)	103.54 (2.08)	2.74 (0.28)	2.00	-2.00 to 8.00
Week 36						
MK-3102/MK-3102	64	100.83 (2.35)	102.92 (2.21)	2.09 (0.31)	2.00	-4.00 to 8.00
Week 52						
MK-3102/MK-3102	64	100.83 (2.35)	102.25 (1.94)	1.42 (0.22)	1.00	-3.00 to 5.00

Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	102.48 (1.87)	-	-	-	-
Week 28						
Placebo/MK-3102	32	102.44 (1.88)	103.41 (1.95)	0.97 (0.30)	1.00	-3.00 to 4.00
Week 36						
Placebo/MK-3102	33	102.48 (1.87)	103.48 (2.24)	1.00 (0.35)	1.00	-3.00 to 5.00
Week 52						
Placebo/MK-3102	33	102.48 (1.87)	102.06 (1.78)	-0.42 (0.41)	0.00	-7.00 to 4.00

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	101.52 (2.25)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	101.52 (2.25)	102.12 (2.25)	0.60 (0.23)	1.00	-3.00 to 4.00
Week 8						
MK-3102/MK-3102	65	101.52 (2.25)	102.05 (2.20)	0.52 (0.24)	0.00	-4.00 to 4.00
Week 12						
MK-3102/MK-3102	64	101.50 (2.26)	102.48 (2.48)	0.98 (0.26)	1.00	-4.00 to 5.00
Week 24						
MK-3102/MK-3102	63	101.51 (2.28)	103.24 (2.59)	1.73 (0.32)	2.00	-4.00 to 6.00
Week 28						
MK-3102/MK-3102	63	101.51 (2.28)	103.00 (2.35)	1.49 (0.27)	2.00	-4.00 to 6.00
Week 36						
MK-3102/MK-3102	61	101.62 (2.21)	103.52 (2.13)	1.90 (0.26)	2.00	-4.00 to 6.00
Week 52						
MK-3102/MK-3102	60	101.60 (2.23)	102.52 (2.10)	0.92 (0.28)	1.00	-4.00 to 5.00

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	103.30 (1.91)	-	-	-	-
Week 28						
Placebo/MK-3102	33	103.30 (1.91)	104.21 (2.04)	0.91 (0.31)	1.00	-3.00 to 5.00
Week 36						
Placebo/MK-3102	33	103.30 (1.91)	103.55 (1.99)	0.24 (0.35)	0.00	-4.00 to 4.00
Week 52						
Placebo/MK-3102	32	103.28 (1.94)	102.97 (1.80)	-0.31 (0.39)	-1.00	-5.00 to 5.00

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	101.49 (2.34)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	101.49 (2.34)	102.13 (2.31)	0.64 (0.22)	0.00	-3.00 to 6.00
Week 8						
MK-3102/MK-3102	67	101.49 (2.34)	102.24 (2.43)	0.75 (0.23)	1.00	-4.00 to 4.00
Week 12						
MK-3102/MK-3102	67	101.49 (2.34)	102.25 (2.48)	0.76 (0.27)	1.00	-4.00 to 6.00
Week 24						
MK-3102/MK-3102	67	101.49 (2.34)	103.12 (2.48)	1.63 (0.29)	2.00	-4.00 to 7.00
Week 28						
MK-3102/MK-3102	67	101.49 (2.34)	103.85 (2.47)	2.36 (0.28)	2.00	-3.00 to 7.00
Week 36						
MK-3102/MK-3102	67	101.49 (2.34)	103.24 (2.59)	1.75 (0.31)	2.00	-5.00 to 7.00
Week 52						
MK-3102/MK-3102	65	101.52 (2.35)	102.22 (2.48)	0.69 (0.24)	1.00	-6.00 to 5.00

C Confidential

Summary of Change from Baseline by Week in Chloride (mEQ/L) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	102.54 (2.81)	-	-	-	-
Week 28						
Placebo/MK-3102	28	102.54 (2.81)	103.96 (2.46)	1.43 (0.37)	2.00	-3.00 to 6.00
Week 36						
Placebo/MK-3102	28	102.54 (2.81)	103.18 (2.37)	0.64 (0.34)	1.00	-3.00 to 3.00
Week 52						
Placebo/MK-3102	28	102.54 (2.81)	102.75 (2.17)	0.21 (0.62)	1.50	-7.00 to 6.00

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	9.15 (0.34)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	9.15 (0.34)	9.15 (0.31)	0.00 (0.03)	0.00	-1.00 to 0.70
Week 8						
MK-3102/MK-3102	125	9.15 (0.34)	9.14 (0.35)	-0.01 (0.03)	0.00	-0.80 to 0.80
Week 12						
MK-3102/MK-3102	124	9.15 (0.33)	9.11 (0.32)	-0.04 (0.03)	0.00	-0.90 to 1.00
Week 24						
MK-3102/MK-3102	122	9.15 (0.34)	9.03 (0.38)	-0.11 (0.03)	-0.10	-1.00 to 0.80
Week 28						
MK-3102/MK-3102	122	9.15 (0.34)	9.12 (0.36)	-0.03 (0.03)	0.00	-0.90 to 0.90
Week 36						
MK-3102/MK-3102	118	9.15 (0.33)	9.17 (0.33)	0.02 (0.03)	0.00	-0.90 to 0.80
Week 52						
MK-3102/MK-3102	112	9.15 (0.34)	9.16 (0.32)	0.01 (0.03)	0.00	-0.70 to 0.80

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	9.06 (0.27)	-	-	-	-
Week 28						
Placebo/MK-3102	62	9.06 (0.27)	9.10 (0.30)	0.04 (0.03)	0.10	-0.60 to 0.70
Week 36						
Placebo/MK-3102	61	9.06 (0.28)	9.10 (0.29)	0.04 (0.04)	0.00	-0.60 to 0.90
Week 52						
Placebo/MK-3102	56	9.05 (0.27)	9.13 (0.29)	0.07 (0.03)	0.00	-0.50 to 0.70

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	9.20 (0.32)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	9.20 (0.32)	9.24 (0.33)	0.04 (0.03)	0.00	-0.60 to 0.60
Week 8						
MK-3102/MK-3102	65	9.20 (0.32)	9.27 (0.29)	0.07 (0.04)	0.00	-0.80 to 0.90
Week 12						
MK-3102/MK-3102	62	9.19 (0.31)	9.21 (0.35)	0.02 (0.04)	0.00	-0.70 to 0.80
Week 24						
MK-3102/MK-3102	61	9.20 (0.30)	9.09 (0.33)	-0.12 (0.04)	-0.20	-0.90 to 0.70
Week 28						
MK-3102/MK-3102	61	9.20 (0.30)	9.13 (0.27)	-0.07 (0.04)	-0.10	-1.00 to 0.60
Week 36						
MK-3102/MK-3102	61	9.20 (0.30)	9.10 (0.29)	-0.10 (0.04)	-0.10	-0.90 to 0.80
Week 52						
MK-3102/MK-3102	59	9.20 (0.31)	9.16 (0.33)	-0.04 (0.04)	0.00	-0.70 to 0.70

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	9.07 (0.28)	-	-	-	-
Week 28						
Placebo/MK-3102	31	9.07 (0.28)	9.03 (0.30)	-0.04 (0.05)	-0.10	-0.60 to 0.60
Week 36						
Placebo/MK-3102	31	9.07 (0.28)	9.08 (0.32)	0.01 (0.05)	0.00	-0.50 to 0.40
Week 52						
Placebo/MK-3102	30	9.07 (0.29)	9.11 (0.33)	0.04 (0.04)	0.00	-0.30 to 0.60

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	9.22 (0.30)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	9.22 (0.30)	9.21 (0.27)	-0.01 (0.03)	0.00	-0.80 to 0.50
Week 8						
MK-3102/MK-3102	66	9.22 (0.30)	9.22 (0.30)	-0.00 (0.03)	0.00	-0.60 to 0.70
Week 12						
MK-3102/MK-3102	66	9.22 (0.30)	9.14 (0.31)	-0.08 (0.03)	-0.10	-0.80 to 0.40
Week 24						
MK-3102/MK-3102	65	9.22 (0.30)	9.08 (0.29)	-0.14 (0.03)	-0.10	-0.70 to 0.60
Week 28						
MK-3102/MK-3102	65	9.22 (0.30)	9.10 (0.29)	-0.12 (0.04)	-0.10	-1.00 to 0.40
Week 36						
MK-3102/MK-3102	64	9.21 (0.29)	9.19 (0.29)	-0.02 (0.03)	0.00	-0.70 to 0.60
Week 52						
MK-3102/MK-3102	64	9.21 (0.29)	9.17 (0.35)	-0.04 (0.03)	-0.10	-0.60 to 0.50

Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	9.14 (0.29)	-	-	-	-
Week 28						
Placebo/MK-3102	32	9.15 (0.29)	9.05 (0.30)	-0.10 (0.04)	-0.10	-0.50 to 0.40
Week 36						
Placebo/MK-3102	33	9.14 (0.29)	9.20 (0.31)	0.06 (0.04)	0.10	-0.40 to 0.40
Week 52						
Placebo/MK-3102	33	9.14 (0.29)	9.22 (0.31)	0.08 (0.04)	0.20	-0.40 to 0.50

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	9.25 (0.36)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	9.25 (0.36)	9.22 (0.32)	-0.03 (0.03)	0.00	-0.90 to 0.50
Week 8						
MK-3102/MK-3102	65	9.25 (0.36)	9.23 (0.34)	-0.02 (0.04)	-0.10	-0.70 to 0.80
Week 12						
MK-3102/MK-3102	64	9.26 (0.36)	9.14 (0.37)	-0.12 (0.04)	-0.10	-0.90 to 0.90
Week 24						
MK-3102/MK-3102	63	9.26 (0.36)	9.05 (0.37)	-0.21 (0.04)	-0.20	-1.10 to 0.60
Week 28						
MK-3102/MK-3102	63	9.26 (0.36)	9.16 (0.31)	-0.10 (0.04)	-0.10	-0.90 to 0.50
Week 36						
MK-3102/MK-3102	61	9.27 (0.36)	9.13 (0.38)	-0.13 (0.05)	-0.10	-1.10 to 0.60
Week 52						
MK-3102/MK-3102	60	9.27 (0.36)	9.19 (0.33)	-0.08 (0.04)	-0.10	-1.00 to 0.60

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	9.01 (0.33)	-	-	-	-
Week 28						
Placebo/MK-3102	33	9.01 (0.33)	9.02 (0.40)	0.01 (0.07)	0.00	-1.00 to 0.70
Week 36						
Placebo/MK-3102	33	9.01 (0.33)	9.07 (0.40)	0.06 (0.06)	0.10	-0.50 to 0.90
Week 52						
Placebo/MK-3102	32	8.99 (0.32)	9.07 (0.37)	0.08 (0.05)	0.10	-0.60 to 0.60

Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	9.16 (0.34)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	9.16 (0.34)	9.22 (0.36)	0.07 (0.03)	0.00	-0.70 to 0.80
Week 8						
MK-3102/MK-3102	67	9.16 (0.34)	9.20 (0.37)	0.04 (0.03)	0.10	-0.80 to 0.80
Week 12						
MK-3102/MK-3102	67	9.16 (0.34)	9.17 (0.35)	0.01 (0.03)	0.10	-0.60 to 0.70
Week 24						
MK-3102/MK-3102	67	9.16 (0.34)	9.05 (0.36)	-0.11 (0.04)	-0.10	-0.80 to 1.00
Week 28						
MK-3102/MK-3102	67	9.16 (0.34)	9.07 (0.36)	-0.09 (0.04)	-0.10	-0.70 to 0.80
Week 36						
MK-3102/MK-3102	67	9.16 (0.34)	9.13 (0.34)	-0.02 (0.04)	0.00	-0.70 to 0.60
Week 52						
MK-3102/MK-3102	65	9.16 (0.34)	9.15 (0.29)	-0.00 (0.03)	0.00	-0.70 to 0.50

C Confidential

Summary of Change from Baseline by Week in Calcium (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	9.00 (0.32)	-	-	-	-
Week 28						
Placebo/MK-3102	28	9.00 (0.32)	8.94 (0.29)	-0.06 (0.05)	-0.05	-0.60 to 0.30
Week 36						
Placebo/MK-3102	28	9.00 (0.32)	8.95 (0.32)	-0.05 (0.06)	-0.10	-0.50 to 0.60
Week 52						
Placebo/MK-3102	28	9.00 (0.32)	9.01 (0.30)	0.01 (0.07)	0.00	-0.80 to 0.70

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	3.26 (0.43)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	3.26 (0.43)	3.20 (0.44)	-0.06 (0.03)	-0.05	-1.00 to 0.70
Week 8						
MK-3102/MK-3102	125	3.26 (0.43)	3.22 (0.47)	-0.04 (0.03)	-0.10	-1.10 to 1.30
Week 12						
MK-3102/MK-3102	124	3.26 (0.43)	3.19 (0.45)	-0.07 (0.03)	-0.10	-0.90 to 1.70
Week 24						
MK-3102/MK-3102	122	3.27 (0.43)	3.28 (0.40)	0.01 (0.03)	0.00	-0.80 to 1.10
Week 28						
MK-3102/MK-3102	122	3.27 (0.43)	3.24 (0.44)	-0.03 (0.03)	0.00	-0.80 to 1.10
Week 36						
MK-3102/MK-3102	118	3.27 (0.43)	3.24 (0.42)	-0.03 (0.03)	0.00	-0.70 to 0.80
Week 52						
MK-3102/MK-3102	112	3.26 (0.43)	3.23 (0.44)	-0.03 (0.03)	0.00	-1.10 to 1.30

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	3.38 (0.46)	-	-	-	-
Week 28						
Placebo/MK-3102	62	3.38 (0.46)	3.38 (0.45)	-0.00 (0.04)	0.00	-0.70 to 0.60
Week 36						
Placebo/MK-3102	61	3.37 (0.46)	3.38 (0.47)	0.02 (0.04)	0.10	-0.80 to 1.00
Week 52						
Placebo/MK-3102	56	3.38 (0.44)	3.35 (0.46)	-0.03 (0.04)	0.00	-0.90 to 0.60

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	3.36 (0.42)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	3.36 (0.42)	3.30 (0.48)	-0.06 (0.05)	0.00	-0.90 to 0.60
Week 8						
MK-3102/MK-3102	65	3.36 (0.42)	3.30 (0.47)	-0.06 (0.05)	0.00	-0.90 to 0.60
Week 12						
MK-3102/MK-3102	62	3.36 (0.42)	3.31 (0.46)	-0.05 (0.05)	-0.10	-0.90 to 1.30
Week 24						
MK-3102/MK-3102	61	3.37 (0.41)	3.31 (0.43)	-0.06 (0.04)	-0.10	-0.70 to 0.70
Week 28						
MK-3102/MK-3102	61	3.37 (0.41)	3.30 (0.49)	-0.07 (0.05)	-0.10	-0.80 to 1.00
Week 36						
MK-3102/MK-3102	61	3.37 (0.41)	3.27 (0.47)	-0.10 (0.04)	-0.10	-0.80 to 0.80
Week 52						
MK-3102/MK-3102	59	3.36 (0.42)	3.22 (0.48)	-0.14 (0.05)	-0.20	-1.00 to 0.90

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	3.26 (0.43)	-	-	-	-
Week 28						
Placebo/MK-3102	31	3.26 (0.43)	3.20 (0.40)	-0.06 (0.07)	-0.10	-0.70 to 0.80
Week 36						
Placebo/MK-3102	31	3.26 (0.43)	3.22 (0.39)	-0.05 (0.06)	0.00	-0.80 to 0.60
Week 52						
Placebo/MK-3102	30	3.24 (0.42)	3.12 (0.36)	-0.13 (0.06)	-0.20	-0.90 to 0.60

Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	3.39 (0.42)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	3.39 (0.42)	3.27 (0.42)	-0.12 (0.04)	-0.10	-0.90 to 1.20
Week 8						
MK-3102/MK-3102	66	3.39 (0.42)	3.38 (0.41)	-0.01 (0.04)	0.00	-0.80 to 1.30
Week 12						
MK-3102/MK-3102	66	3.39 (0.42)	3.30 (0.43)	-0.08 (0.04)	-0.10	-1.00 to 1.10
Week 24						
MK-3102/MK-3102	65	3.39 (0.42)	3.35 (0.47)	-0.04 (0.04)	0.00	-1.00 to 0.80
Week 28						
MK-3102/MK-3102	65	3.39 (0.42)	3.31 (0.45)	-0.08 (0.04)	-0.10	-1.20 to 0.50
Week 36						
MK-3102/MK-3102	64	3.39 (0.43)	3.35 (0.46)	-0.04 (0.04)	-0.05	-0.70 to 0.70
Week 52						
MK-3102/MK-3102	64	3.39 (0.43)	3.34 (0.42)	-0.05 (0.04)	-0.10	-0.70 to 1.30

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	3.40 (0.46)	-	-	-	-
Week 28						
Placebo/MK-3102	32	3.41 (0.46)	3.38 (0.48)	-0.03 (0.07)	0.00	-0.90 to 1.30
Week 36						
Placebo/MK-3102	33	3.40 (0.46)	3.38 (0.52)	-0.01 (0.06)	0.10	-0.80 to 0.70
Week 52						
Placebo/MK-3102	33	3.40 (0.46)	3.46 (0.50)	0.06 (0.06)	0.10	-0.70 to 0.80

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	3.30 (0.44)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	3.30 (0.44)	3.23 (0.48)	-0.08 (0.04)	-0.10	-0.80 to 0.70
Week 8						
MK-3102/MK-3102	65	3.30 (0.44)	3.26 (0.46)	-0.04 (0.04)	0.00	-0.70 to 0.60
Week 12						
MK-3102/MK-3102	64	3.30 (0.44)	3.22 (0.46)	-0.08 (0.04)	-0.10	-0.80 to 0.90
Week 24						
MK-3102/MK-3102	63	3.29 (0.44)	3.23 (0.50)	-0.06 (0.06)	-0.10	-1.00 to 1.40
Week 28						
MK-3102/MK-3102	63	3.29 (0.44)	3.28 (0.46)	-0.02 (0.04)	0.00	-0.90 to 0.60
Week 36						
MK-3102/MK-3102	61	3.31 (0.43)	3.28 (0.53)	-0.03 (0.04)	0.00	-0.60 to 0.80
Week 52						
MK-3102/MK-3102	60	3.30 (0.43)	3.25 (0.48)	-0.05 (0.05)	-0.05	-0.90 to 0.80

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	3.24 (0.43)	-	-	-	-
Week 28						
Placebo/MK-3102	33	3.24 (0.43)	3.23 (0.45)	-0.01 (0.06)	0.00	-1.30 to 0.50
Week 36						
Placebo/MK-3102	33	3.24 (0.43)	3.13 (0.48)	-0.11 (0.06)	-0.10	-0.90 to 0.60
Week 52						
Placebo/MK-3102	32	3.26 (0.43)	3.21 (0.48)	-0.05 (0.07)	0.00	-0.90 to 0.90

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	3.34 (0.39)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	3.34 (0.39)	3.30 (0.41)	-0.04 (0.04)	-0.10	-0.90 to 0.60
Week 8						
MK-3102/MK-3102	67	3.34 (0.39)	3.26 (0.43)	-0.09 (0.04)	-0.10	-0.80 to 0.80
Week 12						
MK-3102/MK-3102	67	3.34 (0.39)	3.37 (0.42)	0.02 (0.04)	0.10	-0.80 to 0.90
Week 24						
MK-3102/MK-3102	67	3.34 (0.39)	3.32 (0.45)	-0.03 (0.05)	-0.10	-0.80 to 1.10
Week 28						
MK-3102/MK-3102	67	3.34 (0.39)	3.36 (0.47)	0.01 (0.05)	-0.10	-1.00 to 1.10
Week 36						
MK-3102/MK-3102	67	3.34 (0.39)	3.23 (0.45)	-0.12 (0.05)	-0.10	-1.00 to 1.00
Week 52						
MK-3102/MK-3102	65	3.34 (0.39)	3.36 (0.40)	0.01 (0.05)	0.00	-0.90 to 0.90

C Confidential

Summary of Change from Baseline by Week in Phosphate (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	3.49 (0.35)	-	-	-	-
Week 28						
Placebo/MK-3102	28	3.49 (0.35)	3.44 (0.35)	-0.05 (0.07)	-0.10	-0.70 to 0.70
Week 36						
Placebo/MK-3102	28	3.49 (0.35)	3.49 (0.37)	-0.00 (0.06)	0.10	-0.60 to 0.70
Week 52						
Placebo/MK-3102	28	3.49 (0.35)	3.44 (0.33)	-0.05 (0.06)	0.00	-0.60 to 0.50

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	198.12 (32.20)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	198.12 (32.20)	194.82 (32.00)	-3.30 (1.87)	-2.50	-95.00 to 56.00
Week 12						
MK-3102/MK-3102	124	198.00 (32.15)	191.55 (31.32)	-6.45 (1.91)	-6.00	-70.00 to 64.00
Week 24						
MK-3102/MK-3102	122	197.91 (32.40)	186.86 (28.63)	-11.05 (1.75)	-11.00	-92.00 to 42.00
Week 28						
MK-3102/MK-3102	122	197.91 (32.40)	188.98 (29.15)	-8.93 (1.99)	-8.50	-79.00 to 59.00
Week 52						
MK-3102/MK-3102	114	197.12 (32.99)	197.72 (31.72)	0.60 (2.27)	1.00	-89.00 to 75.00

Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	187.64 (24.55)	-	-	-	-
Week 28						
Placebo/MK-3102	62	187.64 (24.55)	185.95 (26.98)	-1.30 (2.42)	-5.00	-36.00 to 55.00
Week 52						
Placebo/MK-3102	56	186.84 (21.08)	189.50 (25.68)	2.25 (2.44)	3.00	-36.00 to 55.00

Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	201.68 (36.97)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	201.68 (36.97)	200.23 (35.66)	-1.45 (2.60)	1.00	-101.00 to 46.00
Week 12						
MK-3102/MK-3102	63	200.02 (36.05)	196.35 (33.92)	-3.67 (2.76)	-4.00	-109.00 to 39.00
Week 24						
MK-3102/MK-3102	61	201.41 (35.78)	191.36 (33.32)	-10.05 (2.91)	-9.00	-105.00 to 39.00
Week 28						
MK-3102/MK-3102	61	201.41 (35.78)	190.87 (33.22)	-10.54 (3.10)	-9.00	-89.00 to 47.00
Week 52						
MK-3102/MK-3102	59	202.25 (36.05)	195.83 (34.26)	-6.42 (3.00)	-5.00	-76.00 to 37.00

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	184.52 (24.47)	-	-	-	-
Week 28						
Placebo/MK-3102	31	184.52 (24.47)	175.55 (23.97)	-8.97 (2.38)	-6.00	-40.00 to 9.00
Week 52						
Placebo/MK-3102	31	184.52 (24.47)	182.55 (23.42)	-1.97 (4.07)	-3.00	-42.00 to 47.00

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	201.05 (31.82)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	201.05 (31.82)	194.39 (26.67)	-6.65 (2.17)	-3.00	-58.00 to 39.00
Week 12						
MK-3102/MK-3102	66	201.05 (31.82)	189.79 (28.28)	-11.26 (2.63)	-8.00	-71.00 to 37.00
Week 24						
MK-3102/MK-3102	65	200.89 (32.04)	185.60 (25.29)	-15.29 (2.50)	-13.00	-70.00 to 25.00
Week 28						
MK-3102/MK-3102	65	200.89 (32.04)	186.17 (27.97)	-14.72 (2.54)	-11.00	-85.00 to 25.00
Week 52						
MK-3102/MK-3102	64	200.77 (32.28)	193.09 (26.75)	-7.67 (2.61)	-5.50	-56.00 to 54.00

Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	185.61 (25.42)	-	-	-	-
Week 28						
Placebo/MK-3102	32	185.97 (25.74)	183.09 (29.56)	-2.88 (2.79)	-8.00	-27.00 to 38.00
Week 52						
Placebo/MK-3102	33	185.61 (25.42)	184.42 (30.17)	-1.18 (3.08)	-5.00	-51.00 to 32.00

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	205.72 (34.37)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	205.72 (34.37)	201.98 (34.67)	-3.74 (2.56)	-4.00	-59.00 to 55.00
Week 12						
MK-3102/MK-3102	64	205.95 (34.59)	200.84 (35.38)	-5.11 (2.91)	-6.00	-55.00 to 61.00
Week 24						
MK-3102/MK-3102	63	205.75 (34.83)	195.38 (34.14)	-10.37 (3.68)	-14.00	-59.00 to 117.00
Week 28						
MK-3102/MK-3102	63	205.75 (34.83)	198.40 (35.37)	-7.35 (4.32)	-10.00	-76.00 to 134.00
Week 52						
MK-3102/MK-3102	60	206.32 (35.09)	197.87 (37.89)	-8.45 (3.11)	-9.00	-54.00 to 43.00

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	191.79 (28.46)	-	-	-	-
Week 28						
Placebo/MK-3102	33	191.79 (28.46)	187.30 (27.25)	-4.48 (2.59)	-9.00	-32.00 to 32.00
Week 52						
Placebo/MK-3102	32	191.78 (28.91)	188.63 (27.56)	-3.16 (2.69)	-6.50	-37.00 to 46.00

C Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	205.72 (35.54)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	205.72 (35.54)	201.06 (38.30)	-4.66 (2.92)	-5.00	-65.00 to 50.00
Week 12						
MK-3102/MK-3102	67	205.72 (35.54)	200.96 (35.25)	-4.76 (3.04)	-1.00	-79.00 to 53.00
Week 24						
MK-3102/MK-3102	67	205.72 (35.54)	195.90 (35.39)	-9.82 (2.85)	-9.00	-81.00 to 39.00
Week 28						
MK-3102/MK-3102	67	205.72 (35.54)	196.03 (36.35)	-9.69 (2.98)	-8.00	-69.00 to 29.00
Week 52						
MK-3102/MK-3102	65	205.38 (35.89)	198.06 (40.08)	-7.32 (2.92)	-6.00	-70.00 to 63.00

Confidential

Summary of Change from Baseline by Week in Total Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	180.50 (31.85)	-	-	-	-
Week 28						
Placebo/MK-3102	28	180.50 (31.85)	175.68 (29.59)	-4.82 (3.33)	0.50	-45.00 to 21.00
Week 52						
Placebo/MK-3102	28	180.50 (31.85)	186.64 (29.29)	6.14 (3.29)	7.00	-39.00 to 38.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	57.44 (13.28)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	57.44 (13.28)	56.15 (12.80)	-1.29 (0.56)	-1.00	-16.00 to 27.00
Week 12						
MK-3102/MK-3102	124	57.19 (12.96)	53.96 (11.45)	-3.23 (0.60)	-3.00	-30.00 to 19.00
Week 24						
MK-3102/MK-3102	122	57.41 (12.94)	52.52 (11.50)	-4.89 (0.66)	-4.00	-33.00 to 17.00
Week 28						
MK-3102/MK-3102	122	57.41 (12.94)	54.42 (13.93)	-2.99 (0.71)	-3.00	-22.00 to 36.00
Week 52						
MK-3102/MK-3102	114	57.49 (13.17)	56.48 (13.71)	-1.01 (0.71)	-1.00	-20.00 to 26.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	53.52 (15.03)	-	-	-	-
Week 28						
Placebo/MK-3102	62	53.52 (15.03)	53.95 (15.44)	0.59 (0.78)	0.00	-21.00 to 19.00
Week 52						
Placebo/MK-3102	56	54.84 (15.13)	56.27 (15.81)	1.62 (0.78)	1.00	-13.00 to 21.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	56.60 (14.44)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	56.60 (14.44)	56.29 (14.25)	-0.31 (0.65)	0.00	-11.00 to 14.00
Week 12						
MK-3102/MK-3102	63	56.60 (14.55)	55.86 (14.42)	-0.75 (0.70)	-1.00	-12.00 to 16.00
Week 24						
MK-3102/MK-3102	61	56.84 (14.71)	52.87 (13.14)	-3.97 (0.66)	-3.00	-18.00 to 6.00
Week 28						
MK-3102/MK-3102	61	56.84 (14.71)	52.77 (12.62)	-4.07 (0.81)	-4.00	-21.00 to 8.00
Week 52						
MK-3102/MK-3102	59	56.83 (14.96)	55.36 (13.73)	-1.47 (0.76)	-1.00	-19.00 to 15.00

Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	52.71 (12.02)	-	-	-	-
Week 28						
Placebo/MK-3102	31	52.71 (12.02)	51.68 (11.50)	-1.03 (0.74)	0.00	-11.00 to 5.00
Week 52						
Placebo/MK-3102	31	52.71 (12.02)	53.87 (11.84)	1.16 (1.08)	2.00	-14.00 to 12.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	58.79 (15.82)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	58.79 (15.82)	57.35 (15.39)	-1.44 (0.81)	-2.00	-23.00 to 19.00
Week 12						
MK-3102/MK-3102	66	58.79 (15.82)	55.15 (13.18)	-3.64 (0.91)	-2.00	-26.00 to 18.00
Week 24						
MK-3102/MK-3102	65	58.55 (15.83)	52.77 (12.48)	-5.78 (1.05)	-5.00	-34.00 to 29.00
Week 28						
MK-3102/MK-3102	65	58.55 (15.83)	53.32 (13.05)	-5.23 (0.81)	-5.00	-31.00 to 13.00
Week 52						
MK-3102/MK-3102	64	58.67 (15.92)	57.92 (14.68)	-0.75 (0.76)	-1.00	-16.00 to 21.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	57.52 (17.12)	-	-	-	-
Week 28						
Placebo/MK-3102	32	58.00 (17.16)	56.94 (16.99)	-1.06 (0.78)	-1.00	-9.00 to 6.00
Week 52						
Placebo/MK-3102	33	57.52 (17.12)	58.67 (17.58)	1.15 (0.88)	2.00	-9.00 to 9.00

Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	61.14 (15.12)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	61.14 (15.12)	58.22 (14.11)	-2.92 (0.87)	-2.00	-27.00 to 17.00
Week 12						
MK-3102/MK-3102	64	61.34 (15.15)	58.45 (14.70)	-2.89 (1.18)	-3.00	-32.00 to 23.00
Week 24						
MK-3102/MK-3102	63	61.16 (15.20)	55.94 (13.12)	-5.22 (1.03)	-3.00	-27.00 to 10.00
Week 28						
MK-3102/MK-3102	63	61.16 (15.20)	56.73 (12.90)	-4.43 (1.16)	-4.00	-36.00 to 15.00
Week 52						
MK-3102/MK-3102	60	60.95 (14.85)	58.80 (14.20)	-2.15 (1.07)	-2.00	-33.00 to 20.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	58.18 (13.51)	-	-	-	-
Week 28						
Placebo/MK-3102	33	58.18 (13.51)	57.45 (13.09)	-0.73 (0.89)	-1.00	-12.00 to 10.00
Week 52						
Placebo/MK-3102	32	58.25 (13.72)	60.56 (14.53)	2.31 (1.20)	3.00	-12.00 to 16.00

Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	54.36 (11.84)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	54.36 (11.84)	52.85 (12.49)	-1.51 (0.73)	-2.00	-16.00 to 19.00
Week 12						
MK-3102/MK-3102	67	54.36 (11.84)	53.18 (12.69)	-1.18 (0.70)	-2.00	-14.00 to 12.00
Week 24						
MK-3102/MK-3102	67	54.36 (11.84)	50.45 (11.55)	-3.91 (0.75)	-4.00	-22.00 to 13.00
Week 28						
MK-3102/MK-3102	67	54.36 (11.84)	50.90 (11.90)	-3.46 (0.76)	-3.00	-16.00 to 17.00
Week 52						
MK-3102/MK-3102	65	54.46 (11.99)	52.95 (12.36)	-1.51 (0.89)	-2.00	-23.00 to 18.00

C Confidential

Summary of Change from Baseline by Week in HDL Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	53.07 (15.70)	-	-	-	-
Week 28						
Placebo/MK-3102	28	53.07 (15.70)	51.96 (13.04)	-1.11 (1.10)	0.00	-23.00 to 7.00
Week 52						
Placebo/MK-3102	28	53.07 (15.70)	57.11 (14.79)	4.04 (1.14)	5.00	-6.00 to 14.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	118.02 (26.88)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	118.02 (26.88)	115.24 (27.55)	-2.78 (1.44)	-2.50	-61.00 to 51.00
Week 12						
MK-3102/MK-3102	124	118.00 (27.09)	113.63 (26.89)	-4.37 (1.50)	-2.00	-58.00 to 44.00
Week 24						
MK-3102/MK-3102	122	117.71 (27.20)	113.25 (26.58)	-4.46 (1.53)	-3.00	-51.00 to 45.00
Week 28						
MK-3102/MK-3102	122	117.71 (27.20)	112.41 (27.13)	-5.30 (1.63)	-3.50	-48.00 to 42.00
Week 52						
MK-3102/MK-3102	114	117.10 (27.66)	121.93 (28.22)	4.83 (1.92)	5.00	-66.00 to 67.00

C Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	112.41 (22.89)	-	-	-	-
Week 28						
Placebo/MK-3102	62	112.41 (22.89)	112.45 (25.46)	0.21 (2.14)	-1.00	-50.00 to 33.00
Week 52						
Placebo/MK-3102	56	112.09 (22.04)	116.73 (24.19)	4.29 (2.11)	4.00	-26.00 to 55.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	119.74 (28.49)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	119.74 (28.49)	119.80 (31.23)	0.06 (2.02)	1.00	-55.00 to 53.00
Week 12						
MK-3102/MK-3102	63	118.84 (28.47)	118.00 (28.62)	-0.84 (2.38)	0.00	-61.00 to 57.00
Week 24						
MK-3102/MK-3102	61	119.84 (28.38)	117.52 (28.68)	-2.31 (2.36)	-2.00	-48.00 to 79.00
Week 28						
MK-3102/MK-3102	61	119.84 (28.38)	114.90 (27.13)	-4.93 (2.19)	-8.00	-50.00 to 46.00
Week 52						
MK-3102/MK-3102	59	120.53 (28.51)	123.39 (29.69)	2.86 (2.34)	3.00	-46.00 to 41.00

C Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	110.00 (21.70)	-	-	-	-
Week 28						
Placebo/MK-3102	31	110.00 (21.70)	104.26 (21.25)	-5.74 (1.61)	-7.00	-25.00 to 10.00
Week 52						
Placebo/MK-3102	31	110.00 (21.70)	111.77 (23.11)	1.77 (3.45)	1.00	-42.00 to 43.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	121.91 (24.52)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	121.91 (24.52)	116.85 (22.48)	-5.06 (1.89)	-5.00	-39.00 to 42.00
Week 12						
MK-3102/MK-3102	66	121.91 (24.52)	116.79 (23.93)	-5.12 (2.20)	-2.50	-52.00 to 37.00
Week 24						
MK-3102/MK-3102	65	121.92 (24.71)	115.20 (22.37)	-6.72 (2.39)	-5.00	-64.00 to 65.00
Week 28						
MK-3102/MK-3102	65	121.92 (24.71)	116.17 (23.93)	-5.75 (2.03)	-6.00	-55.00 to 29.00
Week 52						
MK-3102/MK-3102	64	121.64 (24.80)	121.34 (23.50)	-0.30 (2.40)	2.00	-50.00 to 71.00

C Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	108.73 (26.28)	-	-	-	-
Week 28						
Placebo/MK-3102	32	108.41 (26.64)	108.78 (30.53)	0.38 (2.85)	-3.50	-26.00 to 42.00
Week 52						
Placebo/MK-3102	33	108.73 (26.28)	111.91 (29.48)	3.18 (2.88)	7.00	-50.00 to 33.00

C Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	121.95 (28.74)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	121.95 (28.74)	118.91 (29.46)	-3.05 (2.04)	-4.00	-55.00 to 42.00
Week 12						
MK-3102/MK-3102	64	121.84 (28.95)	118.53 (30.83)	-3.31 (2.23)	-5.50	-40.00 to 40.00
Week 24						
MK-3102/MK-3102	63	121.68 (29.15)	119.51 (30.17)	-2.17 (3.13)	-6.00	-41.00 to 109.00
Week 28						
MK-3102/MK-3102	63	121.68 (29.15)	121.10 (31.31)	-0.59 (3.57)	-5.00	-61.00 to 114.00
Week 52						
MK-3102/MK-3102	60	122.65 (28.96)	122.63 (33.74)	-0.02 (2.38)	2.00	-34.00 to 41.00

C Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	111.03 (28.03)	-	-	-	-
Week 28						
Placebo/MK-3102	33	111.03 (28.03)	110.58 (25.62)	-0.45 (2.44)	-3.00	-23.00 to 32.00
Week 52						
Placebo/MK-3102	32	111.22 (28.46)	112.69 (28.06)	1.47 (2.45)	3.00	-29.00 to 32.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	126.37 (30.77)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	126.37 (30.77)	122.16 (33.27)	-4.21 (2.56)	-5.00	-59.00 to 45.00
Week 12						
MK-3102/MK-3102	67	126.37 (30.77)	123.78 (31.33)	-2.60 (2.45)	-1.00	-55.00 to 38.00
Week 24						
MK-3102/MK-3102	67	126.37 (30.77)	121.75 (31.42)	-4.63 (2.43)	-5.00	-59.00 to 34.00
Week 28						
MK-3102/MK-3102	67	126.37 (30.77)	122.37 (33.03)	-4.00 (2.47)	-3.00	-61.00 to 34.00
Week 52						
MK-3102/MK-3102	65	125.95 (31.14)	126.06 (33.84)	0.11 (2.41)	0.00	-45.00 to 42.00

Confidential

Summary of Change from Baseline by Week in LDL Cholesterol (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	108.39 (27.33)	-	-	-	-
Week 28						
Placebo/MK-3102	28	108.39 (27.33)	104.39 (29.94)	-4.00 (3.01)	-6.00	-35.00 to 36.00
Week 52						
Placebo/MK-3102	28	108.39 (27.33)	115.21 (29.85)	6.82 (2.45)	6.50	-20.00 to 31.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	126.33 (111.34)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	126.33 (111.34)	115.48 (63.09)	-10.84 (8.50)	-4.00	-893.00 to 259.00
Week 12						
MK-3102/MK-3102	124	127.29 (111.97)	125.91 (82.34)	-1.38 (8.09)	2.00	-651.00 to 534.00
Week 24						
MK-3102/MK-3102	122	126.85 (112.69)	124.70 (69.16)	-2.15 (9.25)	0.00	-894.00 to 360.00
Week 28						
MK-3102/MK-3102	122	126.85 (112.69)	134.35 (123.59)	7.50 (11.89)	-0.50	-925.00 to 911.00
Week 52						
MK-3102/MK-3102	114	123.39 (113.59)	117.74 (57.12)	-5.65 (9.92)	2.50	-970.00 to 133.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	124.18 (115.82)	-	-	-	-
Week 28						
Placebo/MK-3102	62	124.18 (115.82)	113.16 (83.27)	-11.31 (6.68)	-3.00	-242.00 to 117.00
Week 52						
Placebo/MK-3102	56	110.27 (76.62)	105.07 (53.90)	-5.69 (5.22)	3.00	-203.00 to 60.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	148.98 (133.79)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	148.98 (133.79)	129.86 (90.92)	-19.12 (10.37)	-3.00	-357.00 to 160.00
Week 12						
MK-3102/MK-3102	63	142.86 (124.91)	123.59 (101.59)	-19.27 (8.38)	-11.00	-367.00 to 157.00
Week 24						
MK-3102/MK-3102	61	142.56 (126.89)	123.98 (84.64)	-18.57 (11.60)	-5.00	-455.00 to 105.00
Week 28						
MK-3102/MK-3102	61	142.56 (126.89)	145.61 (132.97)	3.05 (15.14)	-2.00	-422.00 to 620.00
Week 52						
MK-3102/MK-3102	59	142.97 (129.03)	126.75 (111.71)	-16.22 (10.28)	-6.00	-355.00 to 210.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	131.32 (66.15)	-	-	-	-
Week 28						
Placebo/MK-3102	31	131.32 (66.15)	116.45 (48.08)	-14.87 (8.17)	-5.00	-156.00 to 66.00
Week 52						
Placebo/MK-3102	31	131.32 (66.15)	123.52 (56.00)	-7.81 (6.68)	2.00	-115.00 to 61.00

C Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	131.24 (139.61)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	131.24 (139.61)	114.65 (62.30)	-16.59 (11.49)	1.00	-664.00 to 81.00
Week 12						
MK-3102/MK-3102	66	131.24 (139.61)	105.06 (47.73)	-26.18 (14.11)	-4.00	-831.00 to 69.00
Week 24						
MK-3102/MK-3102	65	131.09 (140.69)	116.66 (53.05)	-14.43 (16.42)	-1.00	-923.00 to 178.00
Week 28						
MK-3102/MK-3102	65	131.09 (140.69)	110.09 (49.22)	-21.00 (15.35)	3.00	-888.00 to 112.00
Week 52						
MK-3102/MK-3102	64	130.80 (141.78)	114.39 (56.98)	-16.41 (16.43)	3.00	-954.00 to 72.00

C Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	118.03 (57.72)	-	-	-	-
Week 28						
Placebo/MK-3102	32	118.69 (58.52)	113.75 (59.56)	-4.94 (10.49)	-8.00	-186.00 to 118.00
Week 52						
Placebo/MK-3102	33	118.03 (57.72)	109.45 (54.51)	-8.58 (8.29)	-10.00	-119.00 to 104.00

C Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	119.42 (62.76)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	119.42 (62.76)	123.85 (60.78)	4.43 (5.31)	6.00	-110.00 to 120.00
Week 12						
MK-3102/MK-3102	64	119.31 (63.25)	121.63 (58.00)	2.31 (6.50)	1.50	-172.00 to 199.00
Week 24						
MK-3102/MK-3102	63	119.92 (63.57)	113.08 (47.33)	-6.84 (6.33)	1.00	-229.00 to 78.00
Week 28						
MK-3102/MK-3102	63	119.92 (63.57)	116.86 (50.43)	-3.06 (6.23)	-4.00	-199.00 to 102.00
Week 52						
MK-3102/MK-3102	60	119.37 (62.82)	110.30 (60.53)	-9.07 (7.09)	-3.50	-188.00 to 116.00

C Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	126.33 (78.38)	-	-	-	-
Week 28						
Placebo/MK-3102	33	126.33 (78.38)	112.97 (69.12)	-13.36 (6.30)	-8.00	-134.00 to 56.00
Week 52						
Placebo/MK-3102	32	126.38 (79.63)	105.63 (61.68)	-20.75 (9.58)	-16.50	-165.00 to 123.00

Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	139.60 (90.36)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	139.60 (90.36)	133.19 (115.45)	-6.40 (8.64)	-8.00	-160.00 to 347.00
Week 12						
MK-3102/MK-3102	67	139.60 (90.36)	133.40 (83.88)	-6.19 (6.76)	-3.00	-187.00 to 160.00
Week 24						
MK-3102/MK-3102	67	139.60 (90.36)	140.81 (112.87)	1.21 (10.03)	-4.00	-182.00 to 397.00
Week 28						
MK-3102/MK-3102	67	139.60 (90.36)	130.64 (77.38)	-8.96 (6.73)	-1.00	-137.00 to 170.00
Week 52						
MK-3102/MK-3102	65	139.40 (91.69)	132.74 (103.98)	-6.66 (8.86)	-4.00	-185.00 to 278.00

C Confidential

Summary of Change from Baseline by Week in Triglycerides (mg/dL) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	106.50 (67.43)	-	-	-	-
Week 28						
Placebo/MK-3102	28	106.50 (67.43)	107.61 (83.99)	1.11 (9.61)	-5.50	-99.00 to 222.00
Week 52						
Placebo/MK-3102	28	106.50 (67.43)	95.21 (48.95)	-11.29 (11.76)	-6.50	-279.00 to 65.00

Confidential

付録 2.7.4: 25　　バイタルサイン及び心電図検査項目のベースラインからの変化量
（安全性解析対象集団）
（P020、プラセボ対照期）

Confidential

Summary of Change From Baseline by Week in Weight (kg) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	66.75 (12.92)	-	-	-	-
Sitagliptin 50 mg	164	68.58 (13.69)	-	-	-	-
Placebo	82	64.87 (11.58)	-	-	-	-
Week 4						
MK-3102 25 mg	166	66.75 (12.92)	66.85 (12.93)	0.09 (0.08)	0.10	-2.80 to 3.00
Sitagliptin 50 mg	164	68.58 (13.69)	68.69 (13.80)	0.11 (0.09)	0.15	-5.70 to 5.60
Placebo	82	64.87 (11.58)	64.76 (11.69)	-0.11 (0.09)	-0.20	-2.00 to 1.50
Week 8						
MK-3102 25 mg	165	66.74 (12.96)	66.88 (13.02)	0.14 (0.10)	0.20	-3.60 to 4.40
Sitagliptin 50 mg	161	68.63 (13.73)	68.79 (13.83)	0.16 (0.10)	0.20	-3.20 to 5.70
Placebo	82	64.87 (11.58)	64.61 (11.66)	-0.26 (0.12)	-0.20	-4.60 to 1.80
Week 12						
MK-3102 25 mg	165	66.74 (12.96)	66.78 (12.96)	0.04 (0.12)	0.10	-5.60 to 6.80
Sitagliptin 50 mg	161	68.63 (13.73)	68.83 (13.89)	0.20 (0.10)	0.30	-4.40 to 5.70
Placebo	82	64.87 (11.58)	64.44 (11.57)	-0.42 (0.13)	-0.20	-4.10 to 1.60
Week 16						
MK-3102 25 mg	164	66.70 (12.98)	66.81 (13.07)	0.11 (0.13)	0.20	-7.00 to 8.80
Sitagliptin 50 mg	161	68.63 (13.73)	68.77 (13.81)	0.14 (0.12)	0.30	-4.70 to 6.60
Placebo	80	65.10 (11.63)	64.72 (11.68)	-0.38 (0.16)	-0.30	-5.50 to 2.00
Week 20						
MK-3102 25 mg	163	66.69 (13.02)	66.73 (13.14)	0.04 (0.15)	0.10	-6.40 to 9.20
Sitagliptin 50 mg	160	68.50 (13.67)	68.54 (13.78)	0.04 (0.13)	0.20	-5.20 to 6.20
Placebo	80	65.10 (11.63)	64.39 (11.77)	-0.70 (0.18)	-0.50	-6.40 to 1.80

Confidential

Summary of Change From Baseline by Week in Weight (kg) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 24						
MK-3102 25 mg	162	66.70 (13.06)	66.76 (13.23)	0.06 (0.17)	0.30	-8.50 to 8.70
Sitagliptin 50 mg	161	68.63 (13.73)	68.69 (13.80)	0.06 (0.13)	0.30	-5.30 to 6.40
Placebo	80	65.10 (11.63)	64.38 (11.74)	-0.72 (0.18)	-0.45	-7.10 to 1.90

C Confidential

Summary of Change From Baseline by Week in Diastolic Blood Pressure (mmHg) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	75.28 (8.22)	-	-	-	-
Sitagliptin 50 mg	164	76.66 (7.91)	-	-	-	-
Placebo	82	74.84 (7.93)	-	-	-	-
Week 4						
MK-3102 25 mg	166	75.28 (8.22)	74.64 (9.24)	-0.64 (0.44)	-0.90	-18.00 to 14.00
Sitagliptin 50 mg	164	76.66 (7.91)	75.60 (8.92)	-1.06 (0.45)	-1.00	-17.00 to 18.50
Placebo	82	74.84 (7.93)	75.13 (9.62)	0.29 (0.64)	0.70	-16.50 to 13.00
Week 8						
MK-3102 25 mg	165	75.20 (8.18)	74.61 (10.23)	-0.59 (0.50)	-0.50	-18.00 to 18.00
Sitagliptin 50 mg	161	76.75 (7.92)	76.58 (9.58)	-0.16 (0.52)	0.00	-17.00 to 21.00
Placebo	82	74.84 (7.93)	74.71 (9.31)	-0.13 (0.67)	0.00	-25.50 to 17.00
Week 12						
MK-3102 25 mg	165	75.20 (8.18)	74.22 (9.85)	-0.98 (0.46)	-1.00	-22.50 to 15.20
Sitagliptin 50 mg	161	76.75 (7.92)	75.85 (9.09)	-0.90 (0.50)	-0.50	-32.00 to 15.50
Placebo	82	74.84 (7.93)	74.41 (8.74)	-0.43 (0.62)	-0.50	-18.50 to 14.70
Week 16						
MK-3102 25 mg	164	75.19 (8.20)	74.26 (9.39)	-0.93 (0.45)	-0.65	-16.50 to 14.00
Sitagliptin 50 mg	161	76.75 (7.92)	75.62 (9.32)	-1.12 (0.50)	-1.50	-15.50 to 13.20
Placebo	80	74.80 (8.03)	74.16 (9.38)	-0.64 (0.63)	-0.90	-21.50 to 13.50
Week 20						
MK-3102 25 mg	163	75.21 (8.22)	74.44 (9.41)	-0.77 (0.50)	-1.00	-24.00 to 16.50
Sitagliptin 50 mg	160	76.79 (7.93)	75.08 (9.23)	-1.71 (0.49)	-2.00	-17.00 to 12.50
Placebo	80	74.80 (8.03)	73.83 (9.26)	-0.97 (0.71)	-1.25	-17.80 to 15.00

Confidential

Summary of Change From Baseline by Week in Diastolic Blood Pressure (mmHg) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 24						
MK-3102 25 mg	162	75.19 (8.25)	72.96 (9.17)	-2.23 (0.52)	-1.75	-20.00 to 14.00
Sitagliptin 50 mg	161	76.75 (7.92)	74.88 (9.34)	-1.86 (0.51)	-2.00	-16.50 to 22.00
Placebo	80	74.80 (8.03)	73.38 (9.88)	-1.42 (0.88)	-1.25	-28.50 to 23.00

Confidential

Summary of Change From Baseline by Week in Systolic Blood Pressure (mmHg) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	127.47 (12.63)	-	-	-	-
Sitagliptin 50 mg	164	128.13 (11.93)	-	-	-	-
Placebo	82	124.94 (12.75)	-	-	-	-
Week 4						
MK-3102 25 mg	166	127.47 (12.63)	126.72 (14.78)	-0.75 (0.78)	-0.25	-31.00 to 30.00
Sitagliptin 50 mg	164	128.13 (11.93)	126.11 (12.40)	-2.02 (0.70)	-1.00	-31.30 to 31.50
Placebo	82	124.94 (12.75)	124.76 (13.52)	-0.19 (0.91)	-0.40	-22.00 to 20.50
Week 8						
MK-3102 25 mg	165	127.36 (12.58)	124.92 (14.63)	-2.44 (0.76)	-2.50	-35.00 to 25.00
Sitagliptin 50 mg	161	128.13 (12.03)	126.99 (13.80)	-1.13 (0.84)	-0.50	-35.50 to 26.50
Placebo	82	124.94 (12.75)	125.24 (13.25)	0.30 (1.08)	1.00	-29.50 to 20.50
Week 12						
MK-3102 25 mg	165	127.36 (12.58)	124.70 (14.25)	-2.66 (0.78)	-3.00	-33.50 to 31.00
Sitagliptin 50 mg	161	128.13 (12.03)	126.52 (12.93)	-1.61 (0.75)	-1.50	-35.00 to 21.50
Placebo	82	124.94 (12.75)	122.74 (13.19)	-2.20 (1.03)	-1.75	-31.80 to 24.70
Week 16						
MK-3102 25 mg	164	127.38 (12.61)	124.67 (13.66)	-2.71 (0.75)	-2.50	-39.50 to 24.00
Sitagliptin 50 mg	161	128.13 (12.03)	125.14 (13.21)	-2.99 (0.74)	-2.80	-32.50 to 26.20
Placebo	80	124.65 (12.75)	124.01 (12.94)	-0.63 (1.02)	-0.65	-18.80 to 24.00
Week 20						
MK-3102 25 mg	163	127.34 (12.64)	125.34 (14.37)	-2.00 (0.80)	-2.00	-33.00 to 24.70
Sitagliptin 50 mg	160	128.21 (12.01)	124.80 (12.88)	-3.41 (0.77)	-3.50	-32.50 to 24.50
Placebo	80	124.65 (12.75)	122.28 (14.47)	-2.37 (1.12)	-2.00	-35.50 to 20.20

Confidential

Summary of Change From Baseline by Week in Systolic Blood Pressure (mmHg) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 24						
MK-3102 25 mg	162	127.27 (12.65)	123.58 (13.76)	-3.69 (0.77)	-2.25	-26.50 to 18.00
Sitagliptin 50 mg	161	128.13 (12.03)	125.46 (12.97)	-2.67 (0.75)	-3.00	-31.50 to 29.00
Placebo	80	124.65 (12.75)	121.59 (15.52)	-3.06 (1.34)	-3.25	-38.00 to 25.00

Confidential

Summary of Change From Baseline by Week in Pulse Rate (beats/min) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	70.68 (9.54)	-	-	-	-
Sitagliptin 50 mg	164	70.46 (9.11)	-	-	-	-
Placebo	82	71.19 (9.29)	-	-	-	-
Week 4						
MK-3102 25 mg	166	70.68 (9.54)	70.78 (9.24)	0.10 (0.48)	0.00	-16.50 to 18.50
Sitagliptin 50 mg	164	70.46 (9.11)	70.19 (9.14)	-0.27 (0.49)	-0.40	-24.30 to 16.70
Placebo	82	71.19 (9.29)	71.79 (10.02)	0.60 (0.65)	0.00	-14.00 to 14.00
Week 8						
MK-3102 25 mg	165	70.63 (9.54)	70.56 (9.45)	-0.07 (0.47)	0.50	-19.50 to 17.70
Sitagliptin 50 mg	161	70.55 (9.14)	70.45 (9.31)	-0.10 (0.49)	-0.50	-16.50 to 16.00
Placebo	82	71.19 (9.29)	71.22 (10.66)	0.03 (0.75)	-0.40	-13.50 to 21.00
Week 12						
MK-3102 25 mg	165	70.63 (9.54)	71.27 (10.15)	0.63 (0.49)	0.50	-17.80 to 31.00
Sitagliptin 50 mg	161	70.55 (9.14)	70.40 (8.87)	-0.15 (0.50)	-0.50	-19.30 to 21.00
Placebo	82	71.19 (9.29)	71.91 (10.16)	0.72 (0.65)	0.50	-10.50 to 16.00
Week 16						
MK-3102 25 mg	164	70.74 (9.48)	70.62 (9.68)	-0.12 (0.53)	-0.30	-20.50 to 23.00
Sitagliptin 50 mg	161	70.55 (9.14)	70.75 (9.27)	0.20 (0.56)	0.50	-24.30 to 21.20
Placebo	80	71.21 (9.38)	71.05 (10.23)	-0.16 (0.69)	0.00	-14.50 to 13.70
Week 20						
MK-3102 25 mg	163	70.72 (9.50)	70.40 (9.18)	-0.32 (0.51)	0.00	-19.80 to 19.70
Sitagliptin 50 mg	160	70.48 (9.13)	70.56 (9.30)	0.08 (0.53)	0.50	-19.00 to 21.00
Placebo	80	71.21 (9.38)	70.54 (10.08)	-0.67 (0.65)	-1.00	-15.50 to 11.00

C Confidential

Summary of Change From Baseline by Week in Pulse Rate (beats/min) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 24						
MK-3102 25 mg	162	70.68 (9.52)	70.93 (9.87)	0.24 (0.52)	-0.50	-14.50 to 17.00
Sitagliptin 50 mg	161	70.55 (9.14)	70.55 (8.95)	0.01 (0.50)	0.00	-22.30 to 18.50
Placebo	80	71.21 (9.38)	71.69 (9.66)	0.48 (0.66)	0.00	-18.00 to 14.00

Confidential

Summary of Change From Baseline by Week in Atrial Rate (beats/min) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	165	65.50 (10.60)	-	-	-	-
Sitagliptin 50 mg	164	65.11 (10.51)	-	-	-	-
Placebo	82	65.74 (9.13)	-	-	-	-
Week 24						
MK-3102 25 mg	165	65.50 (10.60)	65.63 (9.91)	0.13 (0.54)	0.00	-23.00 to 16.00
Sitagliptin 50 mg	164	65.11 (10.51)	65.29 (9.49)	0.18 (0.63)	0.00	-33.00 to 37.00
Placebo	82	65.74 (9.13)	64.88 (9.12)	-0.87 (0.75)	-1.00	-25.00 to 15.00

Confidential

Summary of Change From Baseline by Week in Ventricular Rate (beats/min) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	65.75 (11.08)	-	-	-	-
Sitagliptin 50 mg	164	65.10 (10.50)	-	-	-	-
Placebo	82	65.77 (9.16)	-	-	-	-
Week 24						
MK-3102 25 mg	166	65.75 (11.08)	65.83 (10.22)	0.08 (0.54)	0.00	-23.00 to 16.00
Sitagliptin 50 mg	164	65.10 (10.50)	65.29 (9.49)	0.19 (0.63)	0.00	-33.00 to 37.00
Placebo	82	65.77 (9.16)	64.88 (9.12)	-0.89 (0.75)	-1.00	-25.00 to 15.00

Confidential

Summary of Change From Baseline by Week in RR Interval (msec) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	929.72 (144.26)	-	-	-	-
Sitagliptin 50 mg	164	941.82 (149.70)	-	-	-	-
Placebo	82	924.57 (133.20)	-	-	-	-
Week 24						
MK-3102 25 mg	166	929.72 (144.26)	925.63 (135.37)	-4.08 (7.27)	-0.50	-309.00 to 245.00
Sitagliptin 50 mg	164	941.82 (149.70)	931.12 (134.30)	-10.70 (8.64)	-2.50	-690.00 to 259.00
Placebo	82	924.57 (133.20)	936.71 (135.34)	12.13 (10.52)	9.50	-243.00 to 269.00

Confidential

Summary of Change From Baseline by Week in PR Interval (msec) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	165.81 (21.11)	-	-	-	-
Sitagliptin 50 mg	164	166.39 (22.94)	-	-	-	-
Placebo	82	167.68 (22.63)	-	-	-	-
Week 24						
MK-3102 25 mg	166	165.81 (21.11)	167.01 (22.51)	1.20 (0.88)	0.00	-36.00 to 42.00
Sitagliptin 50 mg	163	166.15 (22.80)	167.72 (22.36)	1.58 (0.85)	0.00	-29.00 to 40.00
Placebo	82	167.68 (22.63)	168.11 (23.11)	0.43 (1.35)	0.00	-42.00 to 58.00

Confidential

Summary of Change From Baseline by Week in QRS Interval (msec) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	97.41 (12.60)	-	-	-	-
Sitagliptin 50 mg	164	97.14 (15.75)	-	-	-	-
Placebo	82	97.83 (15.02)	-	-	-	-
Week 24						
MK-3102 25 mg	166	97.41 (12.60)	97.49 (12.59)	0.08 (0.41)	0.00	-26.00 to 24.00
Sitagliptin 50 mg	164	97.14 (15.75)	96.98 (15.20)	-0.16 (0.56)	0.00	-63.00 to 22.00
Placebo	82	97.83 (15.02)	97.71 (15.85)	-0.12 (0.46)	0.00	-13.00 to 12.00

C Confidential

Summary of Change From Baseline by Week in QT Interval (msec) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	404.12 (29.15)	-	-	-	-
Sitagliptin 50 mg	164	403.88 (29.96)	-	-	-	-
Placebo	82	402.57 (28.93)	-	-	-	-
Week 24						
MK-3102 25 mg	166	404.12 (29.15)	402.40 (27.88)	-1.72 (1.44)	-2.00	-62.00 to 52.00
Sitagliptin 50 mg	164	403.88 (29.96)	402.85 (27.56)	-1.02 (1.77)	0.00	-124.00 to 50.00
Placebo	82	402.57 (28.93)	406.09 (29.34)	3.51 (2.05)	4.00	-41.00 to 56.00

C Confidential

Summary of Change From Baseline by Week in QRS Axis (degrees) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	37.72 (29.42)	-	-	-	-
Sitagliptin 50 mg	164	31.90 (36.04)	-	-	-	-
Placebo	82	34.28 (28.53)	-	-	-	-
Week 24						
MK-3102 25 mg	166	37.72 (29.42)	38.16 (28.30)	0.44 (0.81)	0.00	-36.00 to 79.00
Sitagliptin 50 mg	164	31.90 (36.04)	31.84 (32.36)	-0.06 (1.60)	-1.00	-81.00 to 206.00
Placebo	82	34.28 (28.53)	34.35 (28.09)	0.07 (1.04)	-1.00	-24.00 to 47.00

Confidential

Summary of Change From Baseline by Week in QTc Interval Bazett (msec) (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	166	421.16 (22.49)	-	-	-	-
Sitagliptin 50 mg	164	418.54 (27.61)	-	-	-	-
Placebo	82	420.22 (20.36)	-	-	-	-
Week 24						
MK-3102 25 mg	166	421.16 (22.49)	420.16 (22.45)	-1.00 (1.20)	-1.00	-56.00 to 56.00
Sitagliptin 50 mg	164	418.54 (27.61)	419.46 (25.54)	0.93 (1.44)	0.00	-48.00 to 63.00
Placebo	82	420.22 (20.36)	421.09 (20.74)	0.87 (1.61)	-0.50	-35.00 to 39.00

Confidential

付録 2.7.4: 26　　バイタルサイン及び心電図検査項目のベースラインからの変化量
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P015、プラセボ対照期）

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	65.03 (11.03)	-	-	-	-
Placebo	63	66.62 (13.78)	-	-	-	-
Week 4						
MK-3102 25 mg	126	65.03 (11.03)	65.35 (11.17)	0.32 (0.07)	0.20	-1.70 to 3.30
Placebo	63	66.62 (13.78)	66.56 (14.03)	-0.07 (0.11)	-0.20	-1.80 to 3.80
Week 8						
MK-3102 25 mg	125	64.99 (11.07)	65.44 (11.31)	0.45 (0.10)	0.30	-2.40 to 4.40
Placebo	63	66.62 (13.78)	66.42 (14.07)	-0.20 (0.13)	-0.20	-2.00 to 3.40
Week 12						
MK-3102 25 mg	124	65.11 (11.03)	65.49 (11.23)	0.38 (0.12)	0.25	-2.50 to 4.80
Placebo	63	66.62 (13.78)	66.18 (13.85)	-0.44 (0.14)	-0.50	-3.40 to 2.20
Week 16						
MK-3102 25 mg	123	65.05 (11.05)	65.33 (11.28)	0.28 (0.13)	0.10	-3.60 to 3.90
Placebo	63	66.62 (13.78)	65.92 (13.82)	-0.70 (0.15)	-0.90	-3.20 to 1.50
Week 20						
MK-3102 25 mg	122	64.85 (10.87)	65.12 (11.16)	0.27 (0.13)	0.10	-3.00 to 5.30
Placebo	62	66.38 (13.75)	65.44 (13.87)	-0.94 (0.17)	-0.95	-4.40 to 2.10
Week 24						
MK-3102 25 mg	122	64.85 (10.87)	65.11 (11.28)	0.26 (0.14)	0.10	-4.20 to 5.30
Placebo	62	66.38 (13.75)	65.39 (13.86)	-1.00 (0.19)	-0.95	-5.40 to 2.10

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	67.81 (13.34)	-	-	-	-
Placebo	34	69.04 (14.46)	-	-	-	-
Week 4						
MK-3102 25 mg	65	67.81 (13.34)	68.07 (13.48)	0.26 (0.10)	0.20	-1.50 to 3.00
Placebo	34	69.04 (14.46)	68.96 (14.29)	-0.08 (0.14)	-0.15	-1.70 to 1.50
Week 8						
MK-3102 25 mg	65	67.81 (13.34)	68.31 (13.70)	0.50 (0.15)	0.50	-2.60 to 4.40
Placebo	34	69.04 (14.46)	68.79 (14.19)	-0.25 (0.16)	-0.25	-2.60 to 1.50
Week 12						
MK-3102 25 mg	62	67.52 (13.17)	67.97 (13.54)	0.45 (0.17)	0.40	-2.90 to 4.50
Placebo	34	69.04 (14.46)	68.64 (14.14)	-0.40 (0.19)	-0.30	-2.90 to 1.80
Week 16						
MK-3102 25 mg	62	67.52 (13.17)	67.95 (13.58)	0.43 (0.21)	0.40	-2.90 to 5.40
Placebo	33	69.04 (14.69)	68.49 (14.29)	-0.55 (0.25)	-0.20	-4.00 to 1.70
Week 20						
MK-3102 25 mg	62	67.52 (13.17)	67.97 (13.77)	0.45 (0.23)	0.50	-3.70 to 4.40
Placebo	31	67.88 (13.07)	67.46 (12.99)	-0.42 (0.25)	-0.10	-3.50 to 1.50
Week 24						
MK-3102 25 mg	61	67.49 (13.28)	67.81 (13.65)	0.32 (0.21)	0.50	-4.40 to 3.60
Placebo	31	67.88 (13.07)	67.18 (13.30)	-0.70 (0.25)	-0.70	-4.50 to 2.80

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	69.15 (14.33)	-	-	-	-
Placebo	33	70.21 (12.06)	-	-	-	-
Week 4						
MK-3102 25 mg	66	69.15 (14.33)	69.25 (14.14)	0.10 (0.12)	0.15	-3.50 to 2.30
Placebo	33	70.21 (12.06)	69.85 (11.87)	-0.36 (0.17)	-0.30	-3.20 to 1.50
Week 8						
MK-3102 25 mg	66	69.15 (14.33)	69.30 (14.27)	0.15 (0.18)	0.40	-7.00 to 3.20
Placebo	33	70.21 (12.06)	69.70 (12.07)	-0.52 (0.25)	-0.40	-4.90 to 2.20
Week 12						
MK-3102 25 mg	66	69.15 (14.33)	69.13 (14.07)	-0.03 (0.21)	0.30	-6.50 to 3.00
Placebo	33	70.21 (12.06)	69.49 (12.18)	-0.72 (0.24)	-0.70	-3.90 to 1.80
Week 16						
MK-3102 25 mg	65	69.20 (14.44)	69.29 (14.35)	0.09 (0.19)	0.10	-5.60 to 3.60
Placebo	33	70.21 (12.06)	69.54 (12.59)	-0.67 (0.29)	-0.70	-3.50 to 3.20
Week 20						
MK-3102 25 mg	65	69.20 (14.44)	69.04 (14.25)	-0.16 (0.20)	-0.10	-5.40 to 3.20
Placebo	33	70.21 (12.06)	69.51 (12.65)	-0.70 (0.31)	-0.90	-3.80 to 2.60
Week 24						
MK-3102 25 mg	65	69.20 (14.44)	69.04 (14.17)	-0.17 (0.18)	-0.10	-5.40 to 2.10
Placebo	33	70.21 (12.06)	69.59 (12.55)	-0.62 (0.29)	-0.50	-3.70 to 3.20

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	71.96 (13.61)	-	-	-	-
Placebo	34	71.44 (12.70)	-	-	-	-
Week 4						
MK-3102 25 mg	65	71.96 (13.61)	72.26 (13.68)	0.30 (0.11)	0.20	-1.50 to 3.60
Placebo	34	71.44 (12.70)	71.52 (12.86)	0.07 (0.14)	0.00	-1.70 to 2.20
Week 8						
MK-3102 25 mg	65	71.96 (13.61)	72.51 (13.91)	0.56 (0.14)	0.30	-1.20 to 4.30
Placebo	33	70.81 (12.34)	71.21 (12.90)	0.40 (0.25)	-0.10	-1.50 to 4.40
Week 12						
MK-3102 25 mg	64	71.88 (13.70)	72.58 (14.11)	0.70 (0.17)	0.65	-2.80 to 4.00
Placebo	33	70.81 (12.34)	71.23 (12.86)	0.42 (0.27)	0.20	-2.20 to 4.40
Week 16						
MK-3102 25 mg	64	71.88 (13.70)	72.63 (14.07)	0.75 (0.18)	0.80	-3.80 to 5.00
Placebo	33	70.81 (12.34)	71.16 (13.07)	0.35 (0.28)	-0.10	-2.50 to 6.00
Week 20						
MK-3102 25 mg	63	72.12 (13.68)	72.63 (14.05)	0.51 (0.23)	0.40	-7.10 to 4.40
Placebo	33	70.81 (12.34)	71.22 (12.79)	0.41 (0.24)	0.10	-1.90 to 4.30
Week 24						
MK-3102 25 mg	63	72.12 (13.68)	72.81 (14.15)	0.70 (0.26)	0.70	-8.50 to 4.40
Placebo	33	70.81 (12.34)	71.37 (12.93)	0.56 (0.29)	0.30	-2.40 to 4.60

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	67.64 (12.78)	-	-	-	-
Placebo	32	65.15 (10.97)	-	-	-	-
Week 4						
MK-3102 25 mg	67	67.64 (12.78)	67.59 (12.79)	-0.05 (0.10)	0.00	-2.00 to 1.80
Placebo	32	65.15 (10.97)	65.10 (10.70)	-0.05 (0.14)	-0.05	-1.70 to 1.30
Week 8						
MK-3102 25 mg	67	67.64 (12.78)	67.69 (12.88)	0.05 (0.12)	0.00	-2.20 to 3.30
Placebo	32	65.15 (10.97)	64.82 (10.50)	-0.33 (0.22)	-0.20	-5.10 to 1.40
Week 12						
MK-3102 25 mg	67	67.64 (12.78)	67.73 (12.92)	0.09 (0.16)	0.10	-4.00 to 3.10
Placebo	30	64.57 (11.06)	63.97 (10.80)	-0.60 (0.18)	-0.35	-2.40 to 1.00
Week 16						
MK-3102 25 mg	67	67.64 (12.78)	67.87 (12.95)	0.23 (0.21)	0.40	-4.60 to 5.00
Placebo	30	64.57 (11.06)	63.99 (10.96)	-0.58 (0.23)	-0.30	-3.60 to 2.40
Week 20						
MK-3102 25 mg	67	67.64 (12.78)	67.88 (12.95)	0.24 (0.21)	0.20	-5.30 to 4.00
Placebo	29	64.34 (11.19)	63.33 (10.92)	-1.01 (0.23)	-0.90	-4.30 to 1.00
Week 24						
MK-3102 25 mg	67	67.64 (12.78)	67.72 (12.86)	0.09 (0.23)	0.00	-6.10 to 4.60
Placebo	29	64.34 (11.19)	63.16 (11.02)	-1.18 (0.25)	-1.20	-4.90 to 1.20

C Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	75.20 (7.88)	-	-	-	-
Placebo	63	74.23 (8.99)	-	-	-	-
Week 4						
MK-3102 25 mg	126	75.20 (7.88)	75.37 (8.67)	0.16 (0.50)	0.35	-13.50 to 13.00
Placebo	63	74.23 (8.99)	73.56 (8.52)	-0.68 (0.76)	-0.50	-19.00 to 10.20
Week 8						
MK-3102 25 mg	125	75.22 (7.91)	75.45 (8.59)	0.23 (0.50)	0.00	-15.00 to 18.00
Placebo	63	74.23 (8.99)	73.62 (9.00)	-0.61 (0.82)	-0.30	-22.00 to 9.20
Week 12						
MK-3102 25 mg	124	75.16 (7.91)	74.80 (8.98)	-0.36 (0.54)	-0.50	-20.50 to 13.70
Placebo	63	74.23 (8.99)	72.87 (9.81)	-1.36 (0.74)	-1.50	-18.50 to 9.50
Week 16						
MK-3102 25 mg	123	75.28 (7.83)	74.35 (8.27)	-0.93 (0.50)	-1.30	-14.30 to 13.00
Placebo	63	74.23 (8.99)	73.08 (9.91)	-1.15 (0.83)	-0.80	-18.50 to 11.50
Week 20						
MK-3102 25 mg	122	75.29 (7.86)	73.89 (8.47)	-1.40 (0.51)	-0.50	-19.50 to 14.00
Placebo	62	74.31 (9.04)	73.48 (10.20)	-0.83 (0.65)	-1.00	-16.50 to 10.50
Week 24						
MK-3102 25 mg	122	75.29 (7.86)	74.70 (9.57)	-0.59 (0.61)	-0.75	-20.00 to 16.00
Placebo	62	74.31 (9.04)	72.95 (9.68)	-1.36 (0.82)	0.00	-18.00 to 14.50

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	76.84 (8.27)	-	-	-	-
Placebo	34	76.16 (8.16)	-	-	-	-
Week 4						
MK-3102 25 mg	65	76.84 (8.27)	77.06 (8.47)	0.22 (0.64)	0.70	-13.80 to 13.50
Placebo	34	76.16 (8.16)	76.24 (10.53)	0.08 (1.11)	-0.50	-12.50 to 16.00
Week 8						
MK-3102 25 mg	65	76.84 (8.27)	77.06 (9.35)	0.22 (0.65)	-0.30	-12.50 to 14.20
Placebo	34	76.16 (8.16)	75.35 (10.00)	-0.80 (1.06)	-0.65	-16.00 to 12.70
Week 12						
MK-3102 25 mg	62	76.66 (8.06)	77.37 (9.11)	0.71 (0.73)	1.50	-12.00 to 12.20
Placebo	34	76.16 (8.16)	75.85 (9.71)	-0.30 (1.12)	-0.75	-12.50 to 16.00
Week 16						
MK-3102 25 mg	62	76.66 (8.06)	75.89 (9.44)	-0.77 (0.79)	0.00	-15.30 to 13.00
Placebo	33	76.28 (8.25)	73.24 (10.19)	-3.04 (1.18)	-1.00	-25.00 to 8.50
Week 20						
MK-3102 25 mg	62	76.66 (8.06)	75.89 (10.30)	-0.77 (0.86)	-0.50	-15.80 to 17.70
Placebo	31	76.35 (8.48)	74.35 (9.71)	-1.99 (1.25)	-0.50	-24.00 to 10.00
Week 24						
MK-3102 25 mg	61	76.57 (8.09)	75.48 (9.27)	-1.10 (0.72)	-1.00	-15.80 to 12.50
Placebo	31	76.35 (8.48)	75.39 (9.77)	-0.96 (1.01)	-0.50	-14.80 to 9.70

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	77.21 (7.79)	-	-	-	-
Placebo	33	77.26 (8.05)	-	-	-	-
Week 4						
MK-3102 25 mg	66	77.21 (7.79)	76.47 (8.55)	-0.74 (0.64)	-0.50	-13.00 to 12.50
Placebo	33	77.26 (8.05)	76.12 (8.41)	-1.14 (1.12)	0.00	-17.30 to 8.20
Week 8						
MK-3102 25 mg	66	77.21 (7.79)	76.36 (7.97)	-0.84 (0.75)	0.00	-15.00 to 15.50
Placebo	33	77.26 (8.05)	74.24 (8.05)	-3.02 (0.94)	-3.00	-14.80 to 9.00
Week 12						
MK-3102 25 mg	66	77.21 (7.79)	76.88 (8.62)	-0.33 (0.70)	0.00	-12.30 to 20.50
Placebo	33	77.26 (8.05)	75.21 (8.94)	-2.05 (1.11)	-1.00	-13.30 to 12.50
Week 16						
MK-3102 25 mg	65	77.09 (7.79)	76.28 (9.45)	-0.81 (0.90)	0.00	-20.30 to 22.50
Placebo	33	77.26 (8.05)	74.36 (7.69)	-2.90 (1.34)	-2.50	-15.50 to 16.70
Week 20						
MK-3102 25 mg	65	77.09 (7.79)	75.80 (8.81)	-1.29 (0.84)	-1.50	-16.00 to 22.50
Placebo	33	77.26 (8.05)	75.18 (6.05)	-2.08 (1.08)	-2.80	-13.80 to 15.70
Week 24						
MK-3102 25 mg	65	77.09 (7.79)	75.28 (9.02)	-1.81 (0.90)	-2.50	-15.50 to 20.50
Placebo	33	77.26 (8.05)	75.73 (6.41)	-1.53 (1.01)	-3.50	-11.00 to 12.70

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	74.63 (7.84)	-	-	-	-
Placebo	34	75.93 (7.82)	-	-	-	-
Week 4						
MK-3102 25 mg	65	74.63 (7.84)	74.77 (9.25)	0.14 (0.89)	0.00	-16.30 to 20.00
Placebo	34	75.93 (7.82)	76.26 (8.88)	0.34 (1.04)	1.00	-12.30 to 11.70
Week 8						
MK-3102 25 mg	65	74.63 (7.84)	74.29 (8.72)	-0.34 (0.78)	0.00	-12.80 to 15.00
Placebo	33	75.74 (7.87)	75.27 (8.11)	-0.47 (1.06)	-1.00	-12.50 to 13.50
Week 12						
MK-3102 25 mg	64	74.89 (7.60)	72.97 (8.11)	-1.92 (0.86)	-2.00	-23.00 to 15.70
Placebo	33	75.74 (7.87)	76.33 (8.61)	0.59 (0.87)	0.50	-9.00 to 11.50
Week 16						
MK-3102 25 mg	64	74.89 (7.60)	74.08 (9.69)	-0.81 (0.78)	0.00	-16.50 to 12.00
Placebo	33	75.74 (7.87)	76.21 (8.43)	0.47 (1.38)	0.70	-16.30 to 14.50
Week 20						
MK-3102 25 mg	63	75.02 (7.60)	73.37 (9.16)	-1.65 (0.77)	-1.80	-14.00 to 12.00
Placebo	33	75.74 (7.87)	73.39 (9.07)	-2.35 (1.03)	-1.50	-18.50 to 8.70
Week 24						
MK-3102 25 mg	63	75.02 (7.60)	72.95 (9.87)	-2.07 (0.97)	-1.50	-21.50 to 15.50
Placebo	33	75.74 (7.87)	74.58 (9.50)	-1.17 (1.14)	-2.80	-17.30 to 13.70

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	76.35 (7.67)	-	-	-	-
Placebo	32	73.96 (6.70)	-	-	-	-
Week 4						
MK-3102 25 mg	67	76.35 (7.67)	76.21 (9.21)	-0.14 (0.84)	0.50	-27.50 to 14.00
Placebo	32	73.96 (6.70)	73.41 (8.39)	-0.56 (1.02)	0.35	-14.80 to 9.20
Week 8						
MK-3102 25 mg	67	76.35 (7.67)	75.67 (8.40)	-0.68 (0.73)	0.00	-15.50 to 18.70
Placebo	32	73.96 (6.70)	73.34 (8.27)	-0.62 (0.83)	0.25	-10.00 to 9.20
Week 12						
MK-3102 25 mg	67	76.35 (7.67)	75.36 (9.19)	-0.99 (0.84)	-1.00	-22.50 to 17.00
Placebo	30	73.58 (6.73)	73.47 (8.34)	-0.11 (0.89)	0.00	-11.30 to 8.00
Week 16						
MK-3102 25 mg	67	76.35 (7.67)	75.30 (10.54)	-1.05 (0.80)	-0.80	-15.50 to 14.00
Placebo	30	73.58 (6.73)	72.70 (7.53)	-0.88 (1.03)	-1.80	-12.80 to 8.70
Week 20						
MK-3102 25 mg	67	76.35 (7.67)	74.36 (10.10)	-1.99 (0.88)	-2.50	-20.00 to 17.00
Placebo	29	73.38 (6.76)	71.34 (8.20)	-2.03 (1.00)	-3.00	-13.50 to 9.00
Week 24						
MK-3102 25 mg	67	76.35 (7.67)	72.48 (9.33)	-3.87 (0.88)	-3.00	-22.80 to 12.70
Placebo	29	73.38 (6.76)	71.07 (7.54)	-2.31 (0.95)	-3.50	-10.00 to 10.00

C Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	130.99 (13.04)	-	-	-	-
Placebo	63	127.77 (11.96)	-	-	-	-
Week 4						
MK-3102 25 mg	126	130.99 (13.04)	130.61 (14.23)	-0.37 (0.78)	-0.65	-33.00 to 23.00
Placebo	63	127.77 (11.96)	127.63 (12.38)	-0.13 (1.22)	-1.50	-21.30 to 27.00
Week 8						
MK-3102 25 mg	125	131.00 (13.09)	129.92 (13.65)	-1.08 (0.84)	-1.30	-23.00 to 21.00
Placebo	63	127.77 (11.96)	125.14 (13.26)	-2.63 (1.34)	-2.50	-42.30 to 24.50
Week 12						
MK-3102 25 mg	124	130.91 (13.10)	128.78 (14.13)	-2.12 (0.90)	-2.40	-21.50 to 31.00
Placebo	63	127.77 (11.96)	128.11 (13.14)	0.34 (1.05)	0.00	-17.50 to 17.50
Week 16						
MK-3102 25 mg	123	131.10 (12.98)	127.79 (13.62)	-3.31 (0.92)	-4.00	-27.50 to 26.70
Placebo	63	127.77 (11.96)	125.86 (16.11)	-1.91 (1.45)	-1.30	-32.50 to 32.00
Week 20						
MK-3102 25 mg	122	131.14 (13.03)	127.68 (13.65)	-3.46 (0.97)	-3.15	-35.00 to 29.00
Placebo	62	127.92 (12.00)	126.98 (14.39)	-0.93 (1.29)	0.10	-24.50 to 26.50
Week 24						
MK-3102 25 mg	122	131.14 (13.03)	128.20 (14.14)	-2.94 (0.87)	-3.50	-28.00 to 32.50
Placebo	62	127.92 (12.00)	125.24 (13.66)	-2.68 (1.32)	-1.75	-23.50 to 18.00

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	129.73 (12.83)	-	-	-	-
Placebo	34	127.92 (12.04)	-	-	-	-
Week 4						
MK-3102 25 mg	65	129.73 (12.83)	130.14 (14.48)	0.41 (1.23)	0.50	-20.30 to 28.70
Placebo	34	127.92 (12.04)	127.32 (15.34)	-0.60 (1.73)	-1.30	-18.50 to 26.00
Week 8						
MK-3102 25 mg	65	129.73 (12.83)	127.92 (14.31)	-1.80 (1.15)	-2.50	-18.50 to 20.70
Placebo	34	127.92 (12.04)	128.03 (11.99)	0.11 (1.64)	-0.15	-19.50 to 18.00
Week 12						
MK-3102 25 mg	62	129.78 (12.58)	128.95 (14.04)	-0.83 (1.28)	-0.15	-20.50 to 35.70
Placebo	34	127.92 (12.04)	125.09 (10.76)	-2.84 (1.81)	-1.05	-26.50 to 32.00
Week 16						
MK-3102 25 mg	62	129.78 (12.58)	126.44 (15.94)	-3.35 (1.36)	-1.65	-30.30 to 18.70
Placebo	33	128.16 (12.14)	123.36 (11.24)	-4.80 (1.77)	-3.30	-21.30 to 19.20
Week 20						
MK-3102 25 mg	62	129.78 (12.58)	127.94 (15.01)	-1.85 (1.38)	-1.00	-34.50 to 23.70
Placebo	31	127.95 (12.05)	123.97 (13.18)	-3.98 (2.02)	-3.80	-30.00 to 27.20
Week 24						
MK-3102 25 mg	61	129.53 (12.53)	127.54 (13.73)	-1.99 (1.19)	0.20	-22.30 to 16.00
Placebo	31	127.95 (12.05)	123.23 (14.33)	-4.72 (2.06)	-4.30	-31.30 to 13.70

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	129.46 (11.29)	-	-	-	-
Placebo	33	128.34 (11.42)	-	-	-	-
Week 4						
MK-3102 25 mg	66	129.46 (11.29)	127.91 (14.16)	-1.55 (1.20)	-1.90	-42.50 to 18.70
Placebo	33	128.34 (11.42)	127.94 (15.22)	-0.40 (1.89)	2.00	-26.50 to 17.20
Week 8						
MK-3102 25 mg	66	129.46 (11.29)	126.39 (12.70)	-3.07 (1.10)	-1.00	-25.50 to 18.50
Placebo	33	128.34 (11.42)	122.91 (11.80)	-5.43 (1.67)	-4.50	-23.80 to 14.70
Week 12						
MK-3102 25 mg	66	129.46 (11.29)	127.14 (13.09)	-2.33 (1.16)	-3.00	-22.80 to 27.00
Placebo	33	128.34 (11.42)	123.00 (12.03)	-5.34 (1.93)	-4.30	-32.00 to 14.70
Week 16						
MK-3102 25 mg	65	129.42 (11.38)	124.92 (12.69)	-4.50 (1.26)	-4.00	-44.80 to 20.00
Placebo	33	128.34 (11.42)	122.30 (11.93)	-6.03 (1.74)	-6.50	-28.00 to 17.70
Week 20						
MK-3102 25 mg	65	129.42 (11.38)	125.08 (13.75)	-4.34 (1.29)	-3.00	-34.00 to 20.00
Placebo	33	128.34 (11.42)	123.76 (10.05)	-4.58 (1.82)	-6.30	-27.80 to 17.50
Week 24						
MK-3102 25 mg	65	129.42 (11.38)	126.08 (13.78)	-3.34 (1.27)	-4.00	-25.80 to 26.50
Placebo	33	128.34 (11.42)	125.09 (10.44)	-3.25 (1.45)	-4.30	-17.50 to 18.20

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	129.83 (11.64)	-	-	-	-
Placebo	34	131.90 (10.79)	-	-	-	-
Week 4						
MK-3102 25 mg	65	129.83 (11.64)	128.95 (13.54)	-0.87 (1.46)	-0.50	-37.80 to 41.50
Placebo	34	131.90 (10.79)	132.18 (12.89)	0.27 (1.58)	0.85	-16.00 to 14.50
Week 8						
MK-3102 25 mg	65	129.83 (11.64)	127.60 (13.10)	-2.23 (1.20)	-2.50	-27.00 to 19.50
Placebo	33	132.01 (10.94)	130.18 (9.75)	-1.82 (1.38)	-2.00	-21.30 to 15.70
Week 12						
MK-3102 25 mg	64	130.07 (11.56)	127.22 (11.38)	-2.85 (1.33)	-3.25	-25.50 to 19.20
Placebo	33	132.01 (10.94)	131.61 (12.46)	-0.40 (1.76)	-1.00	-29.30 to 19.20
Week 16						
MK-3102 25 mg	64	130.07 (11.56)	126.66 (12.50)	-3.42 (1.28)	-3.65	-26.80 to 17.20
Placebo	33	132.01 (10.94)	127.33 (10.61)	-4.67 (2.00)	-4.00	-32.30 to 23.00
Week 20						
MK-3102 25 mg	63	130.03 (11.65)	128.21 (11.96)	-1.83 (1.19)	-0.50	-21.50 to 21.70
Placebo	33	132.01 (10.94)	124.73 (11.76)	-7.28 (1.87)	-3.50	-37.50 to 13.00
Week 24						
MK-3102 25 mg	63	130.03 (11.65)	125.14 (14.50)	-4.89 (1.43)	-3.30	-27.50 to 16.20
Placebo	33	132.01 (10.94)	129.82 (13.76)	-2.19 (1.72)	-3.00	-22.30 to 14.00

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	127.47 (10.31)	-	-	-	-
Placebo	32	123.14 (10.39)	-	-	-	-
Week 4						
MK-3102 25 mg	67	127.47 (10.31)	127.40 (13.71)	-0.07 (1.26)	1.50	-24.50 to 32.50
Placebo	32	123.14 (10.39)	119.88 (10.79)	-3.27 (1.54)	-2.50	-23.50 to 10.00
Week 8						
MK-3102 25 mg	67	127.47 (10.31)	127.18 (12.03)	-0.29 (1.16)	-1.00	-19.00 to 20.50
Placebo	32	123.14 (10.39)	121.91 (14.61)	-1.24 (1.65)	-2.00	-18.00 to 28.50
Week 12						
MK-3102 25 mg	67	127.47 (10.31)	126.27 (11.67)	-1.20 (1.20)	-1.80	-23.50 to 27.00
Placebo	30	123.05 (10.50)	121.43 (12.29)	-1.62 (1.67)	-0.75	-24.50 to 12.00
Week 16						
MK-3102 25 mg	67	127.47 (10.31)	124.18 (14.31)	-3.29 (1.31)	-2.50	-32.00 to 21.50
Placebo	30	123.05 (10.50)	119.73 (11.94)	-3.32 (1.60)	-4.00	-28.00 to 12.70
Week 20						
MK-3102 25 mg	67	127.47 (10.31)	124.28 (12.88)	-3.19 (1.26)	-3.00	-29.50 to 21.00
Placebo	29	122.92 (10.66)	118.41 (11.94)	-4.50 (1.66)	-4.00	-25.00 to 18.50
Week 24						
MK-3102 25 mg	67	127.47 (10.31)	121.15 (13.45)	-6.32 (1.41)	-6.00	-30.50 to 34.00
Placebo	29	122.92 (10.66)	116.07 (10.42)	-6.85 (1.84)	-6.00	-26.00 to 11.50

C Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	71.31 (10.06)	-	-	-	-
Placebo	63	71.20 (9.37)	-	-	-	-
Week 4						
MK-3102 25 mg	126	71.31 (10.06)	71.32 (10.56)	0.01 (0.49)	0.00	-16.00 to 13.00
Placebo	63	71.20 (9.37)	71.38 (8.61)	0.18 (0.73)	-0.30	-16.00 to 13.00
Week 8						
MK-3102 25 mg	125	71.30 (10.10)	71.97 (10.66)	0.67 (0.58)	0.00	-15.00 to 30.00
Placebo	63	71.20 (9.37)	70.76 (10.68)	-0.44 (0.72)	-0.80	-11.00 to 19.00
Week 12						
MK-3102 25 mg	124	71.40 (10.07)	71.45 (10.68)	0.05 (0.64)	0.00	-35.00 to 19.50
Placebo	63	71.20 (9.37)	70.83 (9.96)	-0.38 (0.72)	-1.50	-10.00 to 13.20
Week 16						
MK-3102 25 mg	123	71.35 (10.10)	71.84 (10.87)	0.49 (0.64)	0.00	-19.00 to 26.70
Placebo	63	71.20 (9.37)	70.54 (10.78)	-0.67 (0.84)	-1.30	-20.00 to 17.50
Week 20						
MK-3102 25 mg	122	71.23 (10.06)	70.43 (9.58)	-0.80 (0.59)	-0.25	-24.00 to 14.70
Placebo	62	71.28 (9.43)	69.81 (9.88)	-1.47 (0.72)	-1.40	-20.00 to 7.70
Week 24						
MK-3102 25 mg	122	71.23 (10.06)	69.89 (10.26)	-1.35 (0.61)	-1.00	-30.00 to 20.00
Placebo	62	71.28 (9.43)	69.68 (12.76)	-1.60 (0.85)	-2.00	-25.50 to 19.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	71.19 (9.37)	-	-	-	-
Placebo	34	72.62 (10.02)	-	-	-	-
Week 4						
MK-3102 25 mg	65	71.19 (9.37)	71.43 (10.86)	0.24 (0.87)	0.00	-21.50 to 28.70
Placebo	34	72.62 (10.02)	73.12 (10.13)	0.50 (1.37)	0.00	-17.80 to 21.70
Week 8						
MK-3102 25 mg	65	71.19 (9.37)	72.08 (10.25)	0.89 (0.83)	0.50	-21.50 to 18.00
Placebo	34	72.62 (10.02)	72.59 (12.37)	-0.03 (1.34)	-0.25	-16.50 to 19.00
Week 12						
MK-3102 25 mg	62	71.08 (9.49)	72.61 (11.89)	1.53 (0.94)	0.50	-12.00 to 33.00
Placebo	34	72.62 (10.02)	72.26 (10.82)	-0.36 (1.70)	-0.25	-25.80 to 22.50
Week 16						
MK-3102 25 mg	62	71.08 (9.49)	72.81 (10.76)	1.73 (0.93)	1.85	-17.50 to 21.00
Placebo	33	72.55 (10.17)	73.36 (9.75)	0.82 (1.24)	0.00	-13.50 to 19.00
Week 20						
MK-3102 25 mg	62	71.08 (9.49)	72.81 (10.69)	1.73 (0.69)	2.00	-18.80 to 14.50
Placebo	31	72.71 (10.40)	72.13 (11.19)	-0.58 (1.23)	0.00	-16.50 to 11.00
Week 24						
MK-3102 25 mg	61	70.80 (9.31)	70.98 (10.15)	0.18 (0.83)	-0.30	-15.50 to 19.00
Placebo	31	72.71 (10.40)	71.74 (10.23)	-0.97 (1.52)	-1.30	-16.50 to 16.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	71.71 (7.04)	-	-	-	-
Placebo	33	70.39 (9.26)	-	-	-	-
Week 4						
MK-3102 25 mg	66	71.71 (7.04)	72.53 (7.38)	0.82 (0.69)	0.95	-12.30 to 14.00
Placebo	33	70.39 (9.26)	70.33 (10.34)	-0.05 (1.04)	-1.30	-11.80 to 15.00
Week 8						
MK-3102 25 mg	66	71.71 (7.04)	72.41 (9.42)	0.70 (1.04)	0.10	-17.00 to 43.00
Placebo	33	70.39 (9.26)	70.91 (10.50)	0.52 (1.45)	-1.50	-23.30 to 17.00
Week 12						
MK-3102 25 mg	66	71.71 (7.04)	73.20 (8.17)	1.48 (0.82)	1.00	-17.80 to 18.00
Placebo	33	70.39 (9.26)	69.55 (9.75)	-0.84 (1.22)	-1.00	-18.00 to 17.00
Week 16						
MK-3102 25 mg	65	71.74 (7.10)	73.80 (8.09)	2.06 (0.80)	2.20	-13.50 to 20.70
Placebo	33	70.39 (9.26)	70.33 (10.72)	-0.05 (1.24)	-1.00	-14.50 to 12.50
Week 20						
MK-3102 25 mg	65	71.74 (7.10)	72.82 (9.14)	1.08 (0.94)	0.20	-12.00 to 32.00
Placebo	33	70.39 (9.26)	70.79 (10.78)	0.40 (1.15)	-0.30	-9.30 to 17.50
Week 24						
MK-3102 25 mg	65	71.74 (7.10)	71.65 (8.92)	-0.09 (0.77)	-0.30	-17.80 to 19.70
Placebo	33	70.39 (9.26)	70.15 (10.52)	-0.24 (1.09)	0.00	-12.80 to 12.50

Confidential